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Abstract 
Human African Trypanosomiasis (HAT) and Animal African Trypanosomiasis (AAT) are 
neglected tropical diseases that pose a huge socioeconomic and health burden in poorer 
countries in sub-Saharan Africa. The causative agents of these diseases are the Trypanosoma 
brucei (T. brucei) spp., kinetoplastid parasites that is transmitted by tsetse flies (Diptera 
Glossina). Drugs against HAT and nagana are toxic, species and in nagana, host specific. With 
reports of emerging resistance to current drugs, it is essential to identify novel drug targets 
against T. brucei. This thesis focuses on identifying and characterising regulating proteins of 
ADP-ribosylation factors (ARFs) in T. brucei. ARFs are small GTPase binding proteins that 
have been shown to be essential in bloodstream form T. brucei. However the T. brucei ARFs 
share a high level of sequence identity with human ARFs, thus making them unsuitable as 
drug targets. Guanine nucleotide exchange factors (GEFs) and GTPase activating proteins 
(GAPs) regulate the activity of ARFs and have been shown to have highly diverse protein 
sequences. A total of 3 putative ARF GEFs and 4 putative ARF GAPs were identified in 
bloodstream form T. brucei by bioinformatics RNA interference (RNAi) cell lines were 
successfully generated for two GEFs and two GAPs in Lister 427 bloodstream form T. brucei. 
Tetracycline-induced knockdown was used to demonstrate that TbGEF3 is essential for 
viability of bloodstream form T. brucei. A decrease in cell growth was observed from 24 hours 
post RNAi, correlating with a decrease in cell cycle progression and an increase in cell death. 
The ‘BigEye’ phenotype could also be seen from 24 hours post RNAi, and cells were identified 
to have an endocytosis defect. These results combined with low level of sequence similarities 
at the essential ARF binding regions of TbGEF3 demonstrated that TbGEF3 may be a potential 
drug target. The TbGEF3 RNAi cells were used to assess the sensitivity of suramin, a drug 
taken up via endocytosis, in the presence of a partial endocytosis defect. Cells incubated in 
tetracycline for 24 hours prior to drug treatment had a reduced sensitivity to suramin  compared 
to cells grown in the absence of tetracycline. The Pathogen Box set of compounds was 
screened for molecules with activity against T. brucei parasites. Identified hit compounds were 
used in preliminary studies to initiate development of an assay to distinguish compounds that 
are taken up via endocytosis. In summary, the putative ARF-regulating protein TbGEF3 has 
been shown to be essential for viability in T. brucei and has promise as a potential drug target. 
Further work is required in order to validate the use of the TbGEF3 RNAi line as a drug 
screening tool. 
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Chapter 1 – Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
1.1 Neglected tropical diseases and Trypanosomatidae 
Neglected tropical diseases (NTDs) are defined as diseases affecting tropical and subtropical 
countries that are associated with poverty and limited health services (Molyneux et al., 2017). 
More than one billion people suffer from the burden of NTDs, with 500,000 deaths and 57 
million disability adjusted life years (DALYs) per year (Garchitorena et al., 2017). Parasites, 
eukaryotic organisms that complete part or all of their life cycles within a host organism, are  
causative agents of many of the NTDs (Goater et al., 2013). Parasitic diseases often present 
non-specific symptoms and commonly affect the most marginalised populations in developing 
countries, leading to high morbidity and mortality (Piperaki and Tassios, 2016).  
The Trypanosomatidae family are a diverse family of protozoan parasites that contribute to 
considerable morbidity and mortality (Malvy and Chappuis, 2011, de Clare Bronsvoort et al., 
2010, Kaufer et al., 2017). Since the discovery and documentation of trypanosomatids in 
insects by Burnett in 1851 and the establishment of the first genera by Kent in 1880, 
trypanosomatids were further redefined into their genera during the mid-1960s by Hoare and 
Wallace. These latter definitions were based on specific morphotypes and life cycles, 
establishing the taxonomic system of Trypanosomatidae with which we are familiar (Maslov et 
al., 2013).  
Trypanosomatidae are a family of flagellated parasites that belong to the class Kinetoplastida, 
which are identified by the presence of a DNA-containing region known as the kinetoplast in 
their single large mitochondrion. Although Trypanosomatidae are predominantly monoxenous 
parasites, those that are restricted to one host; several genera of Trypanosomatidae, such as 
Leishmania, Trypanosoma and Phytomonas require two hosts for their lifecycle (dixenous). 
The dixenous Trypanosomatidae, particularly those with a vertebrate host, are of huge medical 
and economic importance as causative agents of important human and animal diseases. 
These Trypanosomatidae are from the genus Trypanosoma and Leishmania and account for 
more than 900 vertebrate-infecting species, with Trypanosoma totalling about 600 of these 
  
3 
species (Stuart et al., 2008, Molinari and Moreno, 2018, Maslov et al., 2013, Kaufer et al., 
2017, Podlipaev, 2001). 
Parasites from the Trypanosoma genera include Trypanosoma brucei (T. brucei) and 
Trypanosoma cruzi (T. cruzi) which cause African Trypanosomiasis and American 
Trypanosomiasis (Chagas disease) respectively; whilst infection from parasites of the 
Leishmania genera results in various clinical forms of leishmaniasis (Smith et al., 2007, 
Simpson et al., 2006, Simpson et al., 2004, De Gaudenzi et al., 2011, Kaufer et al., 2017). This 
work will primarily focus on the dixenous parasite T. brucei.  
 
1.1.1 African Trypanosomiasis 
1.1.1.1 Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT) is a neglected tropical disease (NTD) that is also 
commonly known as sleeping sickness (Njamnshi et al., 2017, Cordon-Obras et al., 2015). 
Two subspecies of T. brucei are causative agents of HAT: T. b. gambiense and T. b. 
rhodesiense (Kennedy, 2019). These two subspecies of T. brucei are genetically and 
morphologically related, however they differ in clinical features, including epidemiology, 
transmission and geographical distribution (Keating et al., 2015, Büscher et al., 2017). HAT 
affects 36 countries in sub-Saharan Africa from the latitude of 14° north to 29° south of the 
equator, this geographical distribution is known as the tsetse belt due to their transmission 
being influenced by their primary host and vectors, the tsetse flies (Diptera Glossina) (Cayla 
et al., 2019, Kennedy, 2019). 
T. b. gambiense is endemic to West and Central Africa, with the highest prevalence found in 
poor rural populations of the least developed countries in these regions (Figure 1.1). The 
parasite is responsible for causing the chronic form of HAT, which can last months or even 
years. T. b. gambiense has been traditionally considered as an anthroponosis, meaning that 
humans are the single main reservoir for this parasite. However recent studies have identified 
  
4 
T. b. gambiense infections in domestic animals such as dogs, pigs and cattle (N’Djetchi et al., 
2017, Büscher et al., 2017, Umeakuana et al., 2019). 
 
 
Figure 1.1. Distribution of Human African Trypanosomiasis in Africa. Map showing the 
countries affected by T. b. gambiense and T. b. rhodesiense (Fevre et al., 2008). 
 
In contrast, the zoonotic subspecies T. b. rhodesiense is responsible for the acute form of HAT 
which is more common in Eastern and Southern Africa, where infected wild reservoir hosts 
such as warthogs and buffaloes as well as cattle are found. HAT caused by T. b. rhodesiense 
can be fatal within a year or less if left untreated (Muchiri et al., 2015, Kennedy, 2019). Although 
both of these parasites are found in the same continent, it should be noted that there is 
currently little to no overlap between the endemic areas, T. b. gambiense affecting around 24 
out of the 37 countries that are affected by HAT (Figure 1.1); with Uganda being the only 
country that is endemic to both T. b. gambiense and T. b. rhodesiense, albeit in geographically 
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distinct areas (Franco et al., 2018, Keating et al., 2015, Kimuda et al., 2018). Approximately 
98% of HAT cases occur in West and Central Africa due to infection with T. b. gambiense; 
compared to the 2% of cases caused by T. b. rhodesiense that are found in both domestic and 
wilderness areas (Cordon-Obras et al., 2015, Rock et al., 2015, Capewell et al., 2011).  
Human African Trypanosomiasis (HAT) is characterised by a chronic disease caused by T. b. 
gambiense and an acute disease caused by T. b. rhodesiense, with both forms of the disease 
having two clinical stages (Muchiri et al., 2015, Checchi et al., 2015). The haemolymphatic or 
first stage corresponds to the proliferation of the trypanosomes within the host’s blood and 
lymphatic systems, and is often undiagnosed (Büscher et al., 2017). HAT caused by T. b. 
gambiense presents with irregular symptoms such as fever, fatigue, headaches, pruritus and 
arthralgia; since these symptoms are nonspecific the patients could often be misdiagnosed for 
other tropical diseases such as malaria and filariasis (Simarro et al., 2008, Chappuis et al., 
2005). In contrast to this, HAT caused by T. b. rhodesiense presents with feverish illness from 
1 to 3 weeks post infection and the illness progresses more rapidly than the T. b. gambiense 
illness (Chappuis et al., 2005, Kennedy and Rodgers, 2019). In some cases the presence of 
symptoms often goes largely unobserved, for instance the visibility of skin rashes are more 
prominent on European patients than those with darker skin. The presence of a chancre is 
also more commonly identified in European patients, particularly those infected with T. b. 
rhodesiense, than in African patients with the same infection (Chappuis et al., 2005). 
The final stage of HAT is known as the late or second stage, in which the parasites have 
successfully penetrated the blood-brain barrier and invaded the central nervous system (CNS) 
(Checchi et al., 2015, Kennedy and Rodgers, 2019). In this stage the patient experiences 
neurological symptoms such as sleep, sensory and motor abnormalities and body wasting, 
eventually leading to coma and even death if left untreated (Muchiri et al., 2015, Chappuis et 
al., 2005, Kennedy, 2008). The time taken to develop into the clinical second stage of the 
disease is dependent on the Trypanosoma brucei subspecies; in T. b. gambiense this can take 
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from several months to several years whilst in T. b. rhodesiense this can occur within 6 months 
of infection (Chappuis et al., 2005). 
The importance of disease control and the negative impact of HAT were largely recognised in 
the 1930s during the colonial administration (Simarro et al., 2008). Routine screening and 
treatment as well as the follow-up of individuals led to a large decrease in HAT transmission 
in the 1960s (Figure 1.2) (Legros et al., 2002, Simarro et al., 2008, Gubler, 1998). Conflicts 
and emergence of independence in many of the HAT-endemic countries resulted in a reduction 
in human and financial resources to combat the disease (Legros et al., 2002, Simarro et al., 
2008, Gubler, 1998), leading to a re-emergence of HAT cases in the 1980s. It was estimated 
that 57 million people lived in high T. b. gambiense risk areas in 1998. This figure rises to 
around 60 million people at high risk of HAT when combined with T. b. rhodesiense (Chappuis 
et al., 2005, Kennedy, 2019). 
 
 
Figure 1.2. Total number of new cases of HAT reported to the World Health Organisation 
from 1940-2013. Through routine screening and treatments the number of HAT cases 
reported was significantly reduced in the 1960s and late 2000s. (Franco et al., 2014). 
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The World Health Organisation (WHO) report from 1998 suggested that around 20,000 to 
25,000 people have been infected with HAT in that year, however there is a possibility that 
these figures may have been significantly higher than 300,000 considering that only 3 to 4 
million people were actually under surveillance (Legros et al., 2002, Chappuis et al., 2005, 
Smith et al., 1998). Through concern expressed by WHO in 1995, outreach activities, 
production and distribution of free drugs, a 68% decrease in HAT cases from 1995 to 2006 
was reported (Simarro et al., 2008). With continued effort from WHO outreach activities and 
pharmaceutical companies, the number of cases dropped below 10,000 in 2009 and below 
6,228 in 2013 (Holmes, 2014, Simarro et al., 2011). HAT was also highlighted in The London 
Declaration on Neglected Tropical Diseases, with a target set to reduce the number of T. b. 
gambiense case to less than 1 new case/10,000 population at risk globally by 2020 and to zero 
incidences by 2030 through the use of frequent screening and outreach activities. The number 
of HAT cases in 2016 had dropped to 2,184, suggesting that the initiative to eliminate the HAT 
cases by 2030 may be within reach (Figure 1.3) (Rock et al., 2015, Kennedy, 2019, Franco et 
al., 2018). 
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Figure 1.3. Number of reported HAT cases per year from 2000-2016. Through outreach 
activities and frequent screening the number reported HAT cases dropped to 2,184 per year. 
The green lines show the WHO Roadmap to HAT elimination milestones, highlighting that 
elimination of HAT by 2030 is within reach (Franco et al., 2018). 
 
1.1.1.2 Animal African Trypanosomiasis  
Although initiatives to eliminate HAT have led to significant reduction in the number of reported 
cases in sub-Saharan Africa since 1995, Animal African Trypanosomiasis or nagana as it is 
commonly known is still a prevalent infectious disease that threatens livestock such as cattle, 
sheep and goats (Morrison et al., 2016). The economic impact of nagana remains very high. 
Nagana contributes to the death of three million animals per year, leading to loss of meat and 
milk production as well as rendering a quarter of Africa unsuitable for livestock farming. The 
total loss due to nagana and its vector is estimated to be around billions of US dollars annually. 
This places a huge socioeconomic burden for poorer countries in sub-Saharan Africa (Giordani 
et al., 2019, Meyer et al., 2018, Morrison et al., 2016). 
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Nagana infection is characterised by chronic anaemia, anorexia, lethargy and overall decline 
in production and condition; resulting in lower yield of milk and stillborn offspring (Batista et al., 
2011, de Clare Bronsvoort et al., 2010). This infection is caused by the third subspecies of T. 
brucei, T. b. brucei as well as Trypanosoma congolense (T. congolense) and Trypanosoma 
vivax (T. vivax) (de Clare Bronsvoort et al., 2010, Majekodunmi et al., 2013).  As with HAT 
infections, T. b. brucei, T. congolense and T. vivax are transmitted by tsetse flies, making 
nagana endemic to sub-Saharan Africa. However the ability of T. vivax to develop directly into 
epimastigotes within insect proboscis means that T. vivax is also able to be transmitted by 
other insects. As a result of this, T. vivax has been able to spread outside of the ‘tsetse belt’ in 
sub-Saharan Africa and into Northern Africa and South America (Figure 1.4) (Jackson et al., 
2015, Morrison et al., 2016).  
 
 
Figure 1.4 Geographical distribution of T. vivax and T. congolense infection. T. 
congolense infections are endemic to sub-Saharan Africa (tsetse belt) whilst T. vivax infections 
are endemic to sub-Saharan Africa, Northern Africa and South America (Morrison et al., 2016) 
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1.1.2 Life cycle 
1.1.2.1 Establishing infection in host 
In order to develop novel control methods for Trypanosoma brucei, it is important to understand 
the life cycle of these parasites. As dixenous parasites, all three subspecies of Trypanosoma 
brucei share a life cycle between two different hosts (Figure 1.5). The parasites have an insect 
vector, the tsetse fly (Diptera Glossina) which is required for the transmission of these parasites 
(Rock et al., 2015, Muchiri et al., 2015, Cordon-Obras et al., 2015, Ahmed et al., 2015, Siegel 
et al., 2010). Insect borne parasites undergo life cycle stage differentiation due to changes in 
temperature, pH and other factors (Dean et al., 2009). This is also true for trypanosomes: 
undergoing differentiation during their life cycle within mammalian host and tsetse flies as an 
immune evasion mechanism. The Trypanosoma brucei parasites are transmitted to mammals 
from tsetse flies during a blood meal, during this stage the infective metacyclic trypomastigotes 
present in the tsetse salivary glands are transferred to the mammalian host via dermal 
connective tissue (Figure 1.5.A) (Mitashi et al., 2015, Albisetti et al., 2015, Keating et al., 2015).  
During the transmission of the parasites to the host tissues, a local immune reaction occurs 
which result in the development of a ‘chancre’. The appearance of this painful skin ulceration 
usually occurs between 5 to 15 days after the first bite by tsetse flies and is more common in 
T. b. rhodesiense infections than T. b. gambiense (Kennedy, 2013, Caljon et al., 2016). From 
the dermal connective tissues, the metacyclic trypomastigotes transform into the bloodstream 
form trypomastigotes (Figure 1.5.B). These parasites are able to travel to other target sites 
within the body, such as blood capillaries, tissue fluids and cerebrospinal fluids (Kennedy, 
2013, Fenn and Matthews, 2007, Vickerman, 1985, Breidbach et al., 2002). Interestingly, 
Capewell et al (2016) identified the presence of T. brucei in skin in undiagnosed patients, 
suggesting that the skin may represent an anatomical reservoir for T. brucei infections 
(Capewell et al., 2016). 
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Figure 1.5. Trypanosoma brucei life cycle. (A) Ingestion of blood by tsetse initiates the 
infection in host. (B) Metacyclic trypomastigotes differentiate into bloodstream form 
trypomastigotes. (C) Another blood meal re-establishes infection in tsetse flies. (D) The stumpy 
trypomastigotes differentiate into procyclic trypomastigotes in tsetse midgut. T. b. rhodesiense 
and T. b. gambiense causes infect humans whilst T. b. brucei infect livestock and wild animals. 
(Büscher et al., 2017). 
 
1.1.2.2 Parasite stages within the mammalian host 
Once the trypomastigotes have reached their target sites, they start to multiply. Single copy 
organelles such as kinetoplast, nucleus, flagellum, basal body and Golgi that are present in 
trypomastigotes are duplicated and segregated in a precise order in order to produce viable 
progeny (Hammarton, 2007, Jones et al., 2014). This process of duplication and segregation 
of single copy organelles is referred to as binary fission and is tightly regulated by specific 
protein kinases (Hammarton, 2007, Jones et al., 2014). Similar to the mammalian cell cycles 
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which are regulated by cyclin-dependent kinases (CDKs) and their cyclins, Trypanosoma 
brucei cells also contain 11 CDKs known as cdc2-related kinases (CRKs) and 10 cyclins 
(CYCs). A number of CRKs have been shown to be involved in specific stages of cell cycle; 
for example RNA interference (RNAi) of CYC2 resulted in the arrest of preparation stage of 
cell division (G1/G0) (Hammarton, 2007, Hu et al., 2016). Another example of CRKs 
involvement in Trypanosoma brucei was demonstrated by Hammarton et al. (2003); RNAi of 
CYC6 showed the absence of mitotic process in the parasite and growth arrest in not only the 
bloodstream form but also in the procyclic trypomastigotes, the insect infective form of 
Trypanosoma brucei (Hammarton et al., 2003). 
Bloodstream form trypomastigotes are characterised as elongated cells with post-nuclear 
kinetoplast and flagellum along the side of the cell, a form which is commonly termed as the 
‘slender’ form (Figure 1.5.B). Upon increased parasitaemia, the slender form trypomastigotes 
undergo a morphological change into the ‘stumpy’ form. These cells have characteristic 
shortened flagellum, a large digestive vacuole, elaborated mitochondrion and the kinetoplast 
positioned at the posterior end of the cell (Zimmermann et al., 2017, Jones et al., 2014). 
The mechanism by which morphological changes occur in trypomastigotes has been 
investigated by Vasella et al. (1997). They identified that an increase in parasite density in the 
host triggers the stumpy inducing factor, a density sensing mechanism that triggers the arrest 
of G0/G1 phase of cell cycle (Vassella et al., 1997, Rojas and Matthews, 2019). It should be 
noted that the slender to stumpy form transition does not occur due to the host immune 
response. This was highlighted by studies with irradiated mice which were unable to produce 
antibodies against T. brucei infection but still showed the presence of stumpy form 
trypomastigotes, rather the transition of slender to stumpy form may be triggered as a means 
to establish a stable host-parasite relationship (Vassella et al., 1997).  
Stumpy forms are unable to proliferate due to the G0/G1 arrest or to undergo antigenic 
variation. This means that the parasite will either be transmitted back into the tsetse flies during 
their next blood meal or be cleared by macrophage phagocytosis (Fenn and Matthews, 2007, 
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Silvester et al., 2017). The stumpy form expresses enzymes associated with the citric acid 
cycle and electron transport system, which are not needed in the slender form since the 
abundance of glucose present in mammalian host means that the protozoan parasites are able 
to generate ATP with the aid of glycolysis, whereas amino acids are the principle energy source 
in tsetse flies (Brems et al., 2005, Breidbach et al., 2002, Milne et al., 1998). 
 
1.1.2.3 Parasite stages within the insect vector 
Stumpy form trypomastigotes are ingested by tsetse flies during their blood meal from an 
infected mammalian host, thus initiating an infection in the vector (Figure 1.5.C). Once these 
parasites have entered the tsetse fly midgut, they undergo differentiation into procyclic 
trypomastigotes around two to three days after infection (Figure 1.5.D). This differentiation is 
characterised by morphological changes; cells becoming elongated and the expansion and 
branching of the mitochondrion is observed. Metabolic and antigenic changes are also 
observed in these cells. The kinetoplast that was in the posterior position of the cell in stumpy 
form trypomastigotes is relocated to the anterior position of the nucleus (Silvester et al., 2018, 
Crozier et al., 2018). In a similar manner to metacyclic trypomastigotes, procyclic 
trypomastigotes are also able to multiply via binary fission in order to produce epimastigotes 
(Brems et al., 2005, Kennedy, 2013, Breidbach et al., 2002, Urwyler et al., 2007). 
Approximately 1-2 weeks after the initial infection in the tsetse fly midgut, procyclic 
trypomastigotes migrate to the salivary glands of the fly and differentiate into epimastigotes 
which contains a prenuclear kinetoplast and can also undergo asymmetric division (Kennedy, 
2013, Urwyler et al., 2007, Rotureau et al., 2012). These epimastigotes attach themselves 
tightly to the epithelial cells that are lined along the salivary gland lumen (Vickerman, 1985, 
Tetley et al., 1987, Urwyler et al., 2007). This attachment arises due to the branching dendritic 
outgrowths in the flagellum (flagellipodia) that wrap around the microvilli present in the 
epithelial cells and form junctional complexes (Vickerman, 1985, Tetley et al., 1987).  
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The epimastigotes undergo differentiation into metacyclic trypomastigotes through binary 
fission, a differentiation process which occurs in several stages (Zhang et al., 2019). Firstly the 
epimastigotes differentiate into the premetacyclic trypomastigotes. In this stage the 
trypomastigotes are still attached to the epithelial cells, however a reduction of size in the 
flagellipodia is observed. The premetacyclic form still retains the branched mitochondrion and 
has the capacity to undergo binary fission like the epimastigotes, however this binary fission is 
assumed to be brief (Tetley et al., 1987, Sharma et al., 2009). At a specific point, the 
premetacyclic trypomastigotes cease binary fission and start developing into the coated 
metacyclic trypomastigotes that are unattached to the epithelial cells, with the kinetoplast back 
in the posterior position of the cell. These metacyclic trypomastigotes in the salivary glands of 
the tsetse fly are ready to be transmitted to the host, thus starting the human stage lifecycle of 
Trypanosoma brucei. This process of procyclic trypomastigotes to the infective metacyclic 
trypomastigotes maturation in tsetse flies takes approximately 20-30 days (Urwyler et al., 2007, 
Kennedy, 2013, Fenn and Matthews, 2007, Tetley and Vickerman, 1985). The arrest of binary 
fission at the G0/G1 phase of stumpy form trypomastigotes in mammals and metacyclic 
trypomastigotes in the tsetse salivary glands is a way of pre-adapting the parasite to life in a 
new host (Figure 1.6), whilst the slender form trypomastigotes and the procyclic 
trypomastigotes in tsetse flies are the infective phase of the parasite (Hammarton et al., 2003, 
Hammarton, 2007). 
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Figure 1.6. Illustration of procyclic form T. brucei cell structure and replication process. 
(A) The G1 phase cell with a single copy of key organelles. (B) Probasal body maturation takes 
place, a new flagellum extends and attaches to the old flagellum by flagella connector. (C) 
New flagellum extends to roughly full length of the old flagellum and kinetoplast segregates, 
marking the start of mitosis. (D) Cytokinesis is initiated from the anterior end of the cell to the 
posterior end, resulting in two new cells  
 
1.1.3 Immune evasion 
1.1.3.1 Surface coat proteins in the bloodstream form  
T. brucei are extracellular in nature, not entering host cells at any point of their life cycles, 
which means that the parasites are continually exposed to the host’s immune responses (Pays 
and Vanhollebeke, 2009, Quintana et al., 2018). The long-lasting chronic infection caused by 
Trypanosoma brucei is due to their ability to evade the host’s immune response with the aid of 
variant surface glycoprotein (VSG). These 55 kDa homodimeric glycoproteins are the major 
component of the dense coat that covers the entire cell. With around 107 copies of VSGs 
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present, only one VSG is expressed at the surface of the cell at a time and are replaced as the 
host immune system produces antibodies against them; ensuring that a small percentage of 
the parasite survive and re-establish the population (Quintana et al., 2018, Shimogawa et al., 
2015, Tiengwe et al., 2016). T. brucei also internalises and recycles VSGs from the surface 
via the flagellar pocket, recycling the entire surface VSGs in approximately 12 minutes 
(Engstler et al., 2007). This clearance of VSGs from the cell surface enables T. brucei to 
maintain chronic infection in host by also clearing anti-VSG immunoglobulins  (Engstler et al., 
2007, Engstler et al., 2004).  
The VSGs are dimeric with each monomer consisting of a 350-400 residue N terminal domain 
that is hypervariable and one or two 30-70 residue C terminal domains that are conserved and 
buried within the coat. The covalent link of the C terminus domain to a 
glycophosphatidylinositol (GPI) anchor ensures that the VSGs are stable on the outer surface 
of the coat of trypanosomes (Figure 1.7) (Berriman et al., 2005, Chattopadhyay et al., 2005, 
Moreno et al., 2019). The location of the expressed VSG gene is found in the metacyclic 
expression site (MES) or the bloodstream expression site (BES) depending on whether the 
parasite is located in the salivary glands of tsetse flies or in mammalian host respectively 
(Vanhamme et al., 2001, Stanne and Rudenko, 2010). VSG gene switching in T. brucei occurs 
due to coding gene expression changes. The long polycistronic units of BES contain around a 
dozen of expression site associated genes (ESAGs) and end with telomeric repeats, with the 
last gene of BES being the VSG (Berriman et al., 2005, Vanhamme et al., 2001). Since there 
are about 20 to 30 BESs depending on the subspecies and 1000 VSGs found in trypanosomes, 
they can either switch between the BESs by in situ activation/inactivation or replace the VSG 
by homologous recombination (Hertz-Fowler et al., 2008, Becker et al., 2004).  
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Figure 1.7. VSG and the structure of GPI anchor from bloodstream form T. brucei. The 
covalent link of the conserved C domain to GPI ensures that VSGs are stable on the surface 
of T. brucei coat. (Hong and Kinoshita, 2009) 
 
1.1.3.2 Surface coat proteins in the procyclic form 
The surface coat of Trypanosoma brucei undergoes changes depending on the stage of the 
life cycle. Unlike bloodstream form trypomastigotes that express VSGs in order to avoid the 
host immune response, procyclic trypomastigotes in tsetse flies express a different cell surface 
glycoprotein coat called procyclins, also known as procyclic acidic repetitive protein (PARP) 
(Milne et al., 1998, Acosta-Serrano et al., 2001). Shedding of VSGs takes around 4 hours after 
the parasites have been ingested by tsetse fly and to reach maximum level of procyclin 
expression in a single cell takes 12-16 hours post ingestion by the tsetse flies (Roditi et al., 
1989). The shedding of VSGs in procyclic form occurs due to the activity of two identified 
enzymes, the GPI-phospholipase C (GPI-PLC) and a metalloprotease T. brucei major surface 
protease B (TbMSP-B). These enzymes cleave the VSGs close to its GPI anchor, by the C 
terminal domain. MSP-B expression is induced once the differentiation to procyclic form 
commences and this enzyme continues to be expressed in procyclic form trypomastigotes. In 
contrast to this, GPI-PLC expression is downregulated during the differentiation into procyclic 
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form that induces MSP-B expression, but is accessible to the parasite surface (Fenn and 
Matthews, 2007, Urwyler et al., 2007, Grandgenett et al., 2007).  
 
 
Figure 1.8. Schematic representation of EP and GPEET procyclin expressed in procyclic 
T. brucei trypomastigotes. EP and GPEET procyclins vary in amino acid repeats at the C-
terminal. (Acosta-Serrano et al., 1999) 
 
Two major forms of procyclins are expressed in procyclic trypomastigotes, with each form 
varying in the type of amino acid repeats present in their C-terminal (Figure 1.8). The EP 
procyclins consist of Glu-Pro repeats whilst the GPEET procyclins consist of Gly-Pro-Glu-Glu-
Thr repeats. These procyclins serve as a barrier against proteases and other immune defences 
in the tsetse fly (Urwyler et al., 2007, Acosta-Serrano et al., 2001, Vassella et al., 2009). Each 
of the EP and GPEET procyclins are expressed at different periods of the infection 
establishment in tsetse fly midgut. During the early phases of procyclic infection (within 24 
hours), GPEET are mainly expressed whilst traces of EP are found. This however changes 7 
days post infection as GPEET expression halts and EP1 and EP3 expression is detected 
(Urwyler et al., 2007, Liniger et al., 2004). Like the VSGs, the procyclins are also attached to 
the surface coat via GPI anchors at the C terminal domain and they also have a basic lysine 
rich N-terminal domain and a highly conserved signal peptide (Liniger et al., 2004, Shimogawa 
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et al., 2015). VSGs that are downregulated in the procyclic form trypomastigotes are 
reacquired during the metacyclic phase in the tsetse salivary glands (Tetley et al., 1987, Barry 
et al., 1998); however the VSGs expressed by the metacyclic trypomastigotes are of a limited 
repertoire (Pays et al., 1989). There are 27 repertoires of VSGs known as the metacyclic VSGs 
(M-VSGs) that are differentially expressed by each metacyclic trypomastigotes in the salivary 
glands in order to prepare for mammalian immune response (Casas-Sánchez et al., 2018).  
Activation of the M-VSGs follows the same basic principles as the bloodstream form VSGs. 
However unlike the bloodstream form VSGs that are activated by the polycistronic BESs, the 
metacyclic VSGs are activated by the monocistronic MESs (Ramey-Butler et al., 2015). 
 
1.1.4 Host immune response 
1.1.4.1 Trypanosome lytic factors 
As an innate defence against T. brucei infections, humans and several primates express 
trypanosome lytic factors (TLFs) in serum (Capewell et al., 2011, Symula et al., 2012). Laveran 
and Mesnil (1912) first noted that normal human serum had the capacity to lyse T. brucei 
(Vanhamme and Pays, 2004), while the presence of two types of TLFs was later described by 
Hawkings et al. (1973) (Tetley and Vickerman, 1985). Two types of TLFs have now been 
identified in humans. The first TLF (TLF1) is a 500 kDa subset of high density lipoprotein (HDL) 
that consists of apolipoprotein A-I (apoA-I), haptoglobin-related protein (Hpr), apolipoprotein 
L-I (Apol1), human cathelicidin antimicrobial peptide (hCAP18), glycosylphosphatidylinositol-
specific phospholipase D (GPI-PLD), apolipoprotein A-II and paraoxonase (Molina-Portela et 
al., 2008, Drain et al., 2001). Intriguingly Hpr, a heterodimeric protein with over 90% amino 
acid sequence identity to Haptoglobin and consisting of an -subunit and a -subunit bound 
by disulfide bond, is not found in any other HDLs, being exclusive to trypanolytic HDLs only 
(Drain et al., 2001, Raper et al., 2001). The second TLF identified is the TLF2, which is a 1000 
kDa protein complex that is not rich in lipid and consists of apoA-I, Hpr, Apol1, hCAP18, GPI-
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PLD and immunoglobulin M (Molina-Portela Mdel et al., 2005, Drain et al., 2001, Raper et al., 
2001). 
Lysis of T. brucei by TLF1 is achieved by binding onto the receptors found on the cell surface 
of trypanosomes; TLF1 is then endocytosed through the aid of coated pits where it is then 
targeted to the trypanosome lysosome (Drain et al., 2001). Binding of TLF1 to the flagellar 
pocket of trypanosomes occur with the help of ligands, which have been identified as ApoA-I 
and Hpr; Hpr binding to the haptoglobin-haemoglobin receptor (Figure 1.9). This means that 
there are two potential routes for TLF1 to enter the trypanosomes (Capewell et al., 2011, Raper 
et al., 2001, Currier et al., 2018). Although little is known about TLF2 uptake and mode of 
action, it has been suggested that TLF2 may be endocytosed by an uncharacterised potent 
mechanism or could also use ApoA-I as a mechanism of entry into T. brucei cellular pathway 
(Figure 1.9); this is mainly due to the fact that haptoglobin-haemoglobin complex competitively 
inhibits the uptake of TLF1 whilst the uptake of TLF2 is not hindered (Capewell et al., 2011, 
Uzureau et al., 2013, Currier et al., 2018).  
 
Figure 1.9. TLF1 and TLF2 pathways of entry into T. brucei. The composition of TLF1 and 
TLF2 are also highlighted (Vanhollebeke and Pays, 2010) 
  
21 
1.1.4.2 Mechanism of T. brucei lysis in host 
Initially it was assumed that after the uptake of TLF1 to the lysosome, the difference in pH 
triggers peroxidase activity and causes membrane destruction, ultimately leading to 
trypanosome auto-digestion (Molina Portela et al., 2000, Smith et al., 1995). However del Pilar 
Molina-Portela et al. (2000) found this to be inconclusive since their investigation on both TLF1 
and TLF2 found that no peroxidative mechanism appears to be involved in TLF mediated lysis 
of trypanosomes (Molina Portela et al., 2000). Instead del Pilar Molina-Portela et al. (2005) 
demonstrated in their study that TLF1 induces formation of cation permeable pores in T. brucei 
membranes, thus resulting in the disruption of membrane potential and leading to osmotically 
driven swelling, which eventually results in the lysis of trypanosomes (Molina-Portela Mdel et 
al., 2005).  
Primarily it was assumed that the lytic component of HDLs is the ApoA-I, but this was 
discounted since patients with Tangier disease (where levels of HDLs and ApoA-I are 
undetectable) still retained the trypanolytic activity (Pays and Vanhollebeke, 2009, Raper et 
al., 2001). One possible explanation to this may be due to the fact that patients with Tangier 
disease also exhibited low levels of haptoglobin. As a natural TLF1 inhibitor, the level of 
haptoglobin found in normal human serum correlates to the variation of trypanolytic activity in 
an individual (Drain et al., 2001, Raper et al., 2001). This would mean that patients with Tangier 
disease will have limited TLF1 inhibitory effect as opposed to normal human serum due to the 
low levels of haptoglobin present in the serum. The inhibitory effect of haptoglobin however 
appears to be only limited to TLF1, since Raper et al. (1996) identified that TLF2 activity was 
not inhibited in the presence of haptoglobin  (Raper et al., 1996). This may suggest that TLF2 
might actually be the predominant trypanolytic factor in normal human serum. 
Immunodepletion studies with anti- immunoglobulin M in normal human serum revealed an 
80% decrease in trypanolytic activity, further supporting the hypothesis that TLF2 might be the 
main trypanolysis factor (Raper et al., 2001). This may suggest that TLF2 might actually be the 
predominant trypanolytic factor in normal human serum. 
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Immunodepletion studies with anti- immunoglobulin M in normal human serum revealed an 
80% decrease in trypanolytic activity, further supporting the hypothesis that TLF2 might be the 
main trypanolysis factor (Raper et al., 2001). Haptoglobins are known to bind to haemoglobins 
with high affinity in order to form haptoglobin-haemoglobin (Hp-Hb) complexes (Molina Portela 
et al., 2000).The VSGs of Trypanosoma brucei exhibit receptors for Hp-Hb termed TbHpHbR. 
Trypanosomes are able to incorporate heme to hemoproteins via endocytosis of Hp-Hb, which 
is necessary for their survival (Pays and Vanhollebeke, 2009, Hardwick et al., 2014). Hpr is 
also capable of binding to haemoglobin to form Hpr-Hb complex, which in turn can also bind 
to the TbHpHbR on Trypanosoma brucei. Binding of Hpr-Hb complex that is also part of the 
TLF1 complex allows TLF1 to be endocytosed into the parasite. Once inside the parasite, the 
Bcl2-like protein – Apol1 is trafficked to the lysosome compartments. The change in pH triggers 
a pH mediated conformational change in Apol1, which in turn causes lysis of the parasite 
through swelling and rupture. Apol1 has been shown to be involved in selective ion movement 
via interaction with the lysosome membrane (Hardwick et al., 2014, Higgins et al., 2013).  
 
1.1.4.3 Trypanolysis evasion by T. b. rhodesiense 
Trypanolysis is the mechanism which prevents T. b. brucei from being infective to humans, 
enabling effective lysis of T. b. brucei. However, T. b. gambiense and T. b. rhodesiense are 
able to avoid lysis induced by normal human serum and thus effectively infect humans 
(Capewell et al., 2011, Hardwick et al., 2014). T. b. rhodesiense is able to evade lysis by TLF1 
through the serum-resistance associated (SRA) proteins. These SRA proteins are members 
of the VSGs, sharing several structural and sequence homologies, such as the similarity in the 
carboxy-terminal domain structure except for two substitutions at the second subdomain. 
VSGs and SRAs share similar amino-terminal domain, except for the deletion of approximately 
100 amino acids in SRAs (Oli et al., 2006, Stephens and Hajduk, 2011, Stijlemans et al., 2016). 
The localisation of SRAs and the location of interaction with TLFs within T. b. rhodesiense 
have been extensively studied. Initially it was assumed that the localisation of SRAs was 
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exclusively at the lysosome, where it would interact with the Apol1 and inhibit its pH mediates 
trypanolytic activity. However a study by Bart et al. (2015) using monoclonal antibodies as 
markers has identified that approximately 50% of SRA proteins are localised at the 
trypanosome lysosome, whilst the other SRA proteins are distributed to other parts of the 
parasite via the endocytic pathway (Bart et al., 2015). Interestingly Bart et al. (2015)  found 
that SRAs were absent from the flagellar pocket (Bart et al., 2015).  
Co-localisation of SRA proteins and TLFs was reported to occur at the small cytosolic vesicles, 
and it could be speculated that the interaction between SRAs and TLFs would likely occur at 
these small vesicles (Oli et al., 2006). Lecordier et al. (2009) speculated that the mechanism 
of SRA interacting with Apol1 in order to inhibit trypanolysis seem to involve coiled-coil binding 
of SRA to a C-terminal -helical region of Apol1. Mutation and deletion of the Apol1 C-terminal 
resulted in the reduced interaction of SRA with Apol1 whilst the Apol1 still maintained its pore 
forming activity in vitro and in transgenic mice (Lecordier et al., 2009).  
The importance of SRA in resistance to trypanolytic factors was highlighted by several studies 
involving T. b. brucei, which lacked the SRA gene. Xong et al. (1998) transfected the insect 
specific procyclic T. b. brucei with SRA and then measured the generated bloodstream form 
transformants both in vitro and in mice. They identified that the lysis of the control group 
occurred after 10 hours whilst the transfected group was unaffected, even 22 hours post 
exposure to normal human serum (Xong et al., 1998). This was further supported by Oli et al. 
(2006), where similar transfection of SRA into bloodstream form T. b. brucei was sufficient to 
induce resistance to TLFs in parasite lines (Oli et al., 2006). A study by Szempruch et al (2016) 
has highlighted the possibility that SRA can be transferred from T. b. rhodesiense to T. b. 
brucei via membranous nanotubes originating from flagellar membrane. This could mean that 
resistance in T. b. brucei can be established, thus enabling them to infect humans (Szempruch 
et al., 2016). 
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1.1.4.4 Trypanolysis evasion by T. b. gambiense 
While there is strong evidence of T. b. rhodesiense resistance to trypanolytic HDLs being 
conferred via SRA proteins, this is not the case for T. b. gambiense, in which SRA genes have 
not been found. Little is known about the mechanism of T. b. gambiense resistance to TLF1 
(Kieft et al., 2010, Capewell et al., 2011). T. b. gambiense is divided into two genetically distinct 
groups: the dominant group 1 form which is different to T. b. brucei and T. b. rhodesiense, and 
the less common group 2 which resembles T. b. brucei and has the capacity to lose resistance 
to normal human serum during serial passage in rodents (Kieft et al., 2010, Barrett et al., 2003). 
The group 1 T. b. gambiense is distinguishable from the group 2 T. b. gambiense by the 
conserved single nucleotide polymorphism of the T. brucei haptoglobin-haemoglobin receptor 
(TbHpHbR), causing a reduction of TLF1 uptake (Kieft et al., 2010, Capewell et al., 2011, 
Capewell et al., 2013). Kieft et al. (2010) demonstrated that by reducing the expression of T. 
b. brucei haptoglobin-haemoglobin receptor genes, a resistance to TLF1 was induced that 
corresponded to the resistance that was observed in group 1 T. b. gambiense. Thus Kieft et 
al. (2010) highlighted the significance of reduced TbHpHbR expression in T. b. gambiense as 
a mechanism of resistance to normal human serum (Kieft et al., 2010). Although this may 
explain the resistance to trypanolytic event in human serum by TLF1, it does not clearly explain 
as to why T. b. gambiense is still able to resist trypanolysis by TLF2. This gives rise to the 
question on whether group 1 T. b. gambiense interacts with Apol1 in both TLF1 and TLF2 
(Capewell et al., 2011).  
The discovery of a 47 kDa VSG like protein termed T. gambiense-specific glycoprotein 
(TgsGP) in 2001 by Berberof et al. (Berberof et al., 2001) brought forward a possibility of 
resistance mechanism of group 1 T. b. gambiense. To demonstrate the possibility of the 
involvement of TgsGP in trypanolysis resistance, Berberof et al. conducted a transfection of T. 
b. brucei with TgsGP. This however did not demonstrate a resistance in the transfected 
parasites, implying that other mechanisms might be working alongside TgsGP in group 1 T. b. 
gambiense (Berberof et al., 2001). At the time of the study, despite their attempts Berberof et 
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al. were not able to demonstrate TgsGP involvement in group 1 T. b. gambiense resistance, 
due both to the unsuccessful efforts to delete the gene and the failure to induce resistance in 
the transfected T. b. brucei expressing TgsGP (Capewell et al., 2013, Berberof et al., 2001). 
In 2013 this study was revisited by Capewell et al. (2013), who successfully deleted TgsGP in 
group 1 T. b. gambiense, resulting in sensitivity to TLF1, Apol1 and human serum. TgsGP 
complementation lines, i.e. knockout parasites in which TgsGP was reintroduced, also showed 
resistance; concluding that TgsGP may be an essential component to normal human serum 
resistance by T. b. gambiense (Capewell et al., 2013).  
The importance of TgsGp N-terminal domain structure in normal human serum resistance was 
identified by Uzureau et al. (2013); they identified the presence of -helical and -sheet 
hydrophobic linker between the two N-terminal domain helices in TgsGP (Uzureau et al., 
2013). Disruption of the -sheet hydrophobicity was observed to have affected the function 
and localisation of TgsGP, whilst a change in the -helix hydrophobicity does not appear to 
have an effect since the disruption of the hydrophobic character of -helix in TgsGP did not 
affect TgsGP’s activity (Uzureau et al., 2013). Although little is known about the mechanism of 
resistance of the least common group 2 T. b. gambiense, it has been identified that the group 
2 T. b. gambiense are superficially similar to T. b. rhodesiense in exhibition of a variable human 
serum resistance phenotype (Capewell et al., 2011). Unlike the group 1 T. b. gambiense, group 
2 does not exhibit avoidance to TLF uptake, instead being dependent on a separate 
mechanism to neutralise the lysis effect of the internalised Apol1 (Capewell et al., 2011, 
Symula et al., 2012). Initially it was speculated that the mechanism of neutralising Apol1 in 
group 2 T. b. gambiense occurs with the aid of TgsGP, however the presence of TgsGP in 
group 2 T. b. gambiense as well as the other two Trypanosome brucei subspecies have not 
been identified, implying that the TgsGP may be exclusive to only group 1 T. b. gambiense 
(Capewell et al., 2013). The complex mechanism of host immune evasion by T. brucei spp. 
makes targeting these parasites and eradicating them a complicated process. 
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1.1.5 Diagnosis 
Diagnosis of HAT is critical in order to identify infected individuals and properly administer the 
necessary treatment in order to minimise transmission. Diagnosis is usually based on a 
combination of clinical and investigative data (Kennedy, 2019). Key to diagnosis is the 
geographical location of the infection, as T. b. gambiense and T. b. rhodesiense endemic 
regions do not overlap except in some regions of Uganda (Figure 1.1) (Keating et al., 2015, 
Kennedy, 2008). However, since non-specific symptoms such as fever can easily be mistaken 
for other tropical diseases such as malaria, it is crucial to perform clinical testing to establish 
the type of infection in patients before administrating drugs (Kennedy, 2019, Büscher et al., 
2017). Diagnosis of haemolymphatic stage T. brucei often involves testing patient samples by 
microscopy, demonstrating the presence of the parasite in the peripheral blood using stained 
thick or thin films. Although this method could be used to diagnose T. b. rhodesiense infection 
due to their permanent presence in the blood, this method is not ideal to use to detect the 
presence of T. b. gambiense infection as few parasites are present in the blood in this latter 
subspecies, varying around 100 trypanosomes/mL to 10,000 trypanosomes/mL (Kennedy, 
2019, Bonnet et al., 2015). Microscopy can also be used to detect the presence of parasites 
in fluid taken from the cervical lymph nodes (CLNs) (Bonnet et al., 2015). 
Card agglutination trypanosomiasis test (CATT) is used to diagnose T. b. gambiense. This 
serological test is cheap, practical and relatively quick to perform and has been used widely 
since its development in 1978 (Kennedy, 2019, Bonnet et al., 2015). CATT involves the 
detection of T. b. gambiense specific antibodies (LiTAT 1.3 antigen) in the patient’s blood. A 
drop of blood is mixed with a drop of reagent and shaken for 5 minutes and the result can be 
visualised easily with the naked eye (Bonnet et al., 2015). Although this test has good 
specificity, there is a risk of false negatives, especially amongst patients that are infected with 
trypanosomes that do not express the LiTAT 1.3 genes (Bonnet et al., 2015, Büscher et al., 
2017). In order to accurately determine the stage of the infection and avoid inappropriate 
treatment, it is important to identify the presence of trypanosomes in the CNS (Kennedy, 2004, 
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Kennedy, 2008). This is achieved by lumbar puncture and examination of the cerebrospinal 
fluid (CSF) and by determining pleocytosis, analysis of white blood cell (WBC) and protein 
concentration (Bonnet et al., 2015, Kennedy, 2019).  
An additional method of diagnosing trypanosome infection is the detection of chancre 
formation; however the formation of chancre is more common in T. b. rhodesiense infection 
than that of T. b. gambiense, therefore any infection by T. b. gambiense is likely to be ignored 
using this method. To further complicate this, European patients are more likely to exhibit 
chancre than African patients (Kennedy, 2013). Biological markers could also be considered 
as a method of diagnosing different T. brucei subspecies infection. It is already known that 
CATT test incorporates the T. b. gambiense LiTAT 1.3 antigen, however there are other strain 
specific markers that could be used as a biomarker. In the case of T. b. rhodesiense, 
identification of SRA proteins in T. b. gambiense and T. b. brucei by Gibson et al. (2002) 
yielded negative results, suggesting that this protein is exclusive to only T. b. rhodesiense 
(Gibson et al., 2002). In the same manner, Gibson et al. (2010) studied the presence of TgsGP 
in group 1 and 2 T. b. gambiense as well as the other Trypanosoma brucei subspecies and 
noted that TgsGP is conserved in group 1 throughout all of its endemic regions, whereas 
TgsGP-like genes were present in some group 2 and other Trypanosoma brucei subspecies 
(Gibson et al., 2010). 
Other rapid diagnosis tests (RDTs) have been developed for T. b. gambiense. These RDTs 
partly test for the same antigens that are tested in CATT. The SD Bioline HAT (Standard 
Diagnostics, Yongin, South Korea); a lateral flow immunochromatography introduced in 2012, 
the HAT Sero-Strip; a dipstick test, and the HAT Sero-K-SeT test (Coris BioConcept, 
Gembloux, Belgium); a lateral flow device introduced in 2013 all test for the presence of T. b. 
gambiense antigens LiTAT 1.3 and LiTAT 1.5. All three of these RDTs have shown T. b. 
gambiense antigens (Boelaert et al., 2018, Bisser et al., 2016, Büscher et al., 2017). These 
RDTs fully comply with the ASSURED criteria (Affordable, Sensitive, Specific, User-friendly, 
Rapid and robust, Equipment free and Deliverable to end-users). This means that they can be 
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used in countries with lack of electricity or laboratory infrastructure (Büscher et al., 2017). 
However the use of CATT and RDTs are not always 100% specific, especially when disease 
prevalence is low. For example, with a specificity of 98% and prevalence of 0.1%; the predicted 
positive value is 4.5% (Büscher et al., 2017). 
DNA amplification can be used to stage HAT disease. The loop-mediated isothermal 
amplification (LAMP) technique amplifies specific parasite DNA sequence from blood, CSF, 
saliva or urine samples. This technique has high specificity and sensitivity, and can be used in 
countries with minimal laboratory equipment (Bonnet et al., 2015, Njiru et al., 2017). 
 
1.1.6 Treatments for HAT 
Antigenic variation of the Variable Surface Glycoproteins (VSGs) of the human infective T. b. 
gambiense and T. b. rhodesiense means that creating an effective vaccine for these parasites 
is very challenging (Baker and Welburn, 2018, Jones and Avery, 2015). There are currently 
five clinically approved drugs available to combat African trypanosomiasis, of which three of 
these were developed over 50 years ago and the newest one was recently registered for use 
against T. b. gambiense. These five drugs are both species and stage specific, administered 
after the diagnosis of the T. brucei infection (Baker and Welburn, 2018). 
 
1.1.6.1 Suramin 
The first clinically approved drug to be used against trypanosome infection was suramin 
(Figure 1.10.2), manufactured by Bayer; this colourless drug is a sulfonated naphthylamine 
that was first used in 1922 to treat trypanosomiasis cases in field (Babokhov et al., 2013). This 
drug has been used to successfully treat the early phase of T. b. rhodesiense infection and 
remains the drug of choice against early phase T. b. rhodesiense infection (Baker and Welburn, 
2018). Being a highly soluble drug, suramin can be administered intravenously via injection 
but since it is unable to cross the blood-brain barrier, it is not effective against the late phase 
  
29 
infection (Wiedemar et al., 2018). Suramin has the capability to bind strongly to serum proteins 
including LDLs; this gives suramin a very long half-life of 44-54 days in humans (Bacchi, 2009). 
Since suramin is bound to LDLs, it is endocytosed within the flagella pocket of the parasite; 
once inside the parasite, suramin is shown to inhibit glycolytic enzymes as well as other 
enzymes involved in a range of pathways such as pyruvate kinase (Wiedemar et al., 2018, 
Thomas et al., 2018, Baker and Welburn, 2018). Although suramin inhibits glycolytic enzymes, 
this inhibition is assumed to be slow since the trypanocidal action of the drug has been 
observed to be slow (Bacchi, 2009, Fairlamb, 2003). The activity of suramin is enhanced by 
ornithine (Thomas et al., 2018).  
The pleotropic effect of suramin might explain why cases of suramin resistance in human 
pathogenic trypanosomes are rare. However resistance to suramin has been described in 
animal pathogenic trypanosomes (Wiedemar et al., 2018, Barrett et al., 2007). The side effects 
of suramin administration range from mild to life-threatening, these can be divided into 
immediate side effects such as vomiting, shock and nausea; or delayed reactions such as 
kidney damage, exfoliative dermatitis, haemolytic anaemia, jaundice, agranulocytosis and 
severe diarrhoea (Fairlamb, 2003, Thomas et al., 2018). 
 
1.1.6.2 Pentamidine 
Pentamidine (Figure 1.10.1) is a water soluble aromatic diamidine manufactured by Aventis, 
which has been used against trypanosomes since the 1930s (Baker and Welburn, 2018). Since 
this drug is found to be very effective against early phase T. b. gambiense infection as opposed 
to T. b. rhodesiense infection, it is considered as a drug of choice against early phase T. b. 
gambiense infection (Schmidt et al., 2018, Thomas et al., 2018). The current dosing of this 
drug requires 7-10 intramuscular injections, however alternative dosing for this drug is also 
being considered (Bacchi, 2009, Barrett et al., 2007). Pentamidine is taken up by the 
adenine/adenosine P2 transporter as well as high-affinity pentamidine transporter 1 (HAPT1) 
and low-affinity pentamidine transporter 1 (LAPT1) (Munday et al., 2014, Song et al., 2016). 
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Once within the parasite, pentamidine promotes cleavage of kinetoplast DNA by binding to the 
minor groove, which leads to the development of dyskinetoplastic cells (Bacchi, 2009, Thomas 
et al., 2018). Resistance to this drug occurs due to the deletion and loss-of-function mutation 
to the TbAT1 gene that is responsible for encoding the P2 transporter. However trypanosomes 
are still able to take up the drug with the aid of the HAPT1 and LAPT1 transporters (Barrett et 
al., 2007, Baker and Welburn, 2018). The loss of both P2 and HAPT1 has been associated 
with greatly reduced uptake of pentamidine and potential resistance (Baker and Welburn, 
2018). T. brucei aquaglyceroporin 2 (TbAQP2), a major intrinsic protein, has been shown to 
increase the affinity of pentamidine uptake. Munday et al (2014) examined melarsoprol and 
pentamidine cross resistance T. brucei strains and identified deletion or rearrangements of 
TbAQP2 (Munday et al., 2014).  Interestingly reintroduction of TbAQP2 into melarsoprol-
pentamidine cross resistant T. brucei strains reinstated HAPT1 functions but not P2 
transporters (Munday et al., 2014). Intravenous administration of pentamidine causes 
hypotensive reaction, therefore the drug is administered intramuscularly, but even then the 
side effects of this drug can be fatal. Side effects include kidney, liver and pancreas damage, 
with pancreatic damage having the potential to lead to diabetes (Babokhov et al., 2013). 
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Figure 1.10. Drugs against Human African Trypanosomiasis (HAT). Current (1-5) and new 
(6 and 7) drugs used to treat HAT. 
 
1.1.6.3 Melarsoprol 
Melarsoprol is an arsenical drug manufactured by Aventis (Figure 1.10.5), and was introduced 
in 1949 (Babokhov et al., 2013, Baker and Welburn, 2018). This drug is used to treat the late 
stage T. b. gambiense and T. b. rhodesiense infection and is often administered as 2-4 series 
of three intravenous injections daily or as a single daily injection for 10 days (Fairlamb and 
Horn, 2018). Although the mechanism of melarsoprol action is not fully understood, it was 
noted that trypanosomes undergo rapid lysis after the administration of this drug. The inhibition 
of pyruvate kinase and other pathways involved in glycolysis has been attributed to this rapid 
lysis of trypanosomes (Thomas et al., 2018, Fairlamb and Horn, 2018). As with pentamidine, 
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Melarsoprol is also taken up by the trypanosomes via the P2 transporter, therefore exposing 
the parasite to cross-resistance (Nok, 2003, Baker et al., 2013) and identification of 
trypanosomes resistant to melarsoprol identified nine mutations in the TbAT1 gene (Nok, 2003, 
Munday et al., 2014). As melarsoprol is insoluble in water, it needs to be dissolved in propylene 
glycol before being administered intravenously. Administration by this route is very painful and 
often destroys veins after several doses (Fairlamb and Horn, 2018, Baker and Welburn, 2018). 
Side effects include vomiting, peripheral neuropathy, arthralgia, abdominal colic and 
thrombophlebitis. 5-10% of cases involving melarsoprol administration to patients developed 
serious reactive encephalopathy, of which 50% will die.  (Babokhov et al., 2013, Fairlamb and 
Horn, 2018).  
 
1.1.6.4 Eflornithine 
The fourth clinically approved drug for HAT is eflornithine (Figure 1.10.4); this drug is 
manufactured by Aventis and is the drug of choice for late stage T. b. gambiense infection 
(Kansiime et al., 2018, Baker and Welburn, 2018). Although not a trypanocidal drug, 
eflornithine is known to irreversibly inhibit ornithine carboxylase, an enzyme involved in the 
polyamine biosynthetic pathway (Thomas et al., 2018, Kansiime et al., 2018). In 2009 the use 
of eflornithine with another drug called nifurtimox (Figure 1.10.3) as a combination therapy 
(Nifurtimox-Eflornithine combination therapy; NECT) was introduced to the WHO Essential 
Medicines List to target late stage T. b. gambiense infection. This new treatment option is 
cheaper and easier to administer to patients compared eflornithine monotherapy, requiring 
only 14 intravenous infusions over 7 days as opposed to 56 infusions over 14 days (Yun et al., 
2010, Bacchi, 2009, Kansiime et al., 2018). Bloodstream form trypanosomes exposed to 
Eflornithine show arrested proliferation and transform into the stumpy form, which are then 
killed by the host immune system (Baker and Welburn, 2018, Thomas et al., 2018). The 
disadvantages of this drug are cost of production and difficulty in administration; patients are 
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given four daily infusions for 7-14 days and each infusion requires 400mg kg-1 of eflornithine 
(Babokhov et al., 2013).  
 
1.1.6.5 Fexinidazole 
Due to the increased cost of production, serious side effects and emerging resistance to 
existing clinically approved drugs against HAT, there has been a rise in research for alternative 
treatment against HAT that are easy to use and effective (Mesu et al., 2018). This has recently 
led to the discovery of fexinidazole (Figure 1.10.7), a nitroimidazole that was discovered during 
a proactive compound mining approach (Torreele et al., 2010). Fexinidazole is a drug that can 
be used to treat the haemolymphatic and meningoencephalitic stages of HAT and is 
administered orally. Phase II and phase III clinical trial on patients with late stage T. b. 
gambiense HAT demonstrated 91% success rate 18 months post treatment with fexinidazole 
versus 98% success rate with NECT. The overall results demonstrate that fexinidazole is an 
effective and safe oral drug for treatment against HAT compared to NECT and has now been 
registered for use (Mesu et al., 2018, Pollastri, 2018, Chappuis, 2018). 
 
1.1.6.6 New treatments 
Research into other potential drugs against HAT has led to the development of Benzoxaborole 
(SCYX-7158). SCYX-7158 showed potency in curing mice infected with late stage T. brucei 
infection 7 days post oral administration at a dose of 25 mg/kg. SCYX-7158 is currently 
awaiting phase III clinical trials (Figure 1.10.6) (Jacobs et al., 2011, Mäser et al., 2012, 
Steketee et al., 2018). Other possible drugs that can be used to treat HAT are microtubule 
stabilising drugs; these drugs are primarily used for cancer chemotherapy, however the 
potential to treat other diseases such as diseases of CNS have been highlighted in several 
studies. One such study demonstrated the use of Paclitaxel, a microtubule stabilising drug to 
inhibit the replication of T. brucei (Monti et al., 2018, Lama et al., 2012).  
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1.1.7 Treatments for nagana 
Animal African Trypanosomiasis (nagana) contributes to considerable loss of livestock and 
profit, rendering approximately 25% of arable land mass unsuitable for farming livestock and 
costing Africa billions of US dollars annually. The current drugs against nagana are diminazene 
aceturate (Berenil); an aromatic diamidine, homidium (Ethidium); a phenanthridine and 
isometamidium (Samorin); a phenanthridine-aromatic amidine (Giordani et al., 2019, Büscher 
et al., 2019, Delespaux and de Koning, 2007).  
1.1.7.1 Diminazene aceturate 
Diminazene aceturate is administered to cattle as a therapeutic agent and is the first-line 
treatment against nagana due to its low relative cost, availability and trypanocidal effect. 
Diminazene aceturate binds to kinetoplast DNA via interacting with adenine-thymine base 
pairs rather than intercalating, this interaction inhibits RNA primer synthesis, resulting in 
inhibition of kDNA replication due to accumulation of replicating intermediates (Tsegaye et al., 
2015, Delespaux and de Koning, 2007). Due to diminazene aceturate being cleared rapidly 
post administration, it has been assumed that resistance to this drug may not been widespread. 
However since this drug is taken up by the P2 transporter in T. brucei, resistant to diminazene 
aceturate due to loss of activity in P2 transporter have been documented (Tsegaye et al., 2015, 
Delespaux and de Koning, 2007). 
 
1.1.7.2 Isometamidium and homidium 
Isometamidium was first synthesised by coupling homidium and diminazene aceturate. This 
drug alongside Homidium are administered to cattle as a prophylactic and therapeutic drug. 
Although homidium and isometamidium are localised differently inside trypanosomes; 
Isometamidium being concentrated in the kinetoplast whilst homidium is spread throughout the 
cell, both of these drugs interact by intercalating between DNA base pairs and inhibiting nucleic 
acid synthesis as well as causing the inhibition of RNA and DNA polymerases (Tsegaye et al., 
2015, Delespaux and de Koning, 2007, Anene et al., 2001). As with diminazene aceturate, 
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both homidium and isometamidium are taken up by trypanosomes through the P2 transporters; 
thus deletion or loss-of function mutation to the P2 transporter gene TbAT1 results in cross 
resistance to both of these drugs (Anene et al., 2001, Delespaux and de Koning, 2007, 
Tsegaye et al., 2015, Geerts et al., 2001, Gysin et al., 2018).  
 
Although there has been great success due to the introduction of fexinidazole as a new 
treatment for HAT, there is always the threat of parasites developing resistance. This issue 
coupled with the rising resistance to drugs against nagana means that research into new 
methods of Human African Trypanosomiasis and Animal African Trypanosomiasis treatment 
should remain a priority. The ADP-ribosylation factors (ARFs) are known to have important 
roles in T. brucei and may be promising targets, either directly or indirectly, for new 
therapeutics against T. brucei spp. infection. 
 
1.2 ADP-ribosylation factors 
1.2.1 ADP-ribosylation factor and ARF-like proteins 
1.2.1.1 What are ADP-ribosylation factors? 
ADP-ribosylation factors (ARFs) are small guanine nucleotide binding proteins (approximately 
20kDa) that belong to the Ras superfamily of GTPases. However ARFs lack the C-terminal 
isoprenylation and carboxymethylation regions that are present in other members of the Ras 
GTPase superfamily (Morgan et al., 2015, Guadalupe et al., 2018, Muthamilarasan et al., 
2016). These proteins were originally identified due to their ability to act as cofactors to 
stimulate cholera toxin ADP-ribosyltransferase activity (Kahn and Gilman, 1984). ARFS have 
been found in all studied eukaryotic organisms to date and are highly conserved at the amino 
acid level (Nie et al., 2003).  
Six ARF isoforms have been identified in mammals; these isoforms are divided into three 
classes depending on their gene organisation and primary sequence (Nie et al., 2003, Chun 
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et al., 2008). The class I ARFs consist of ARFs that are localised mainly in the Golgi apparatus 
(Yorimitsu et al., 2014, Myers and Casanova, 2008). Although little is known about Class II 
ARFs, it was generally concluded that class I and class II ARFs are localised in the same area, 
Golgi apparatus (Hosoi et al., 2018). Live cell imaging techniques by Chun et al. (2008) 
identified that class I ARFs and class II ARFs also localised at the ER-Golgi intermediate 
compartment (ERGIC) (Chun et al., 2008). ARF6 is the only member of class III ARF; unlike 
class I and II ARFs, ARF6 does not localise at the Golgi complex but instead is found primarily 
in the endosomes and plasma membrane (Nie et al., 2003, Chun et al., 2008, Myers and 
Casanova, 2008). As small guanine nucleotide binding proteins, ARFs exist as either the active 
GTP bound form or as the inactive GDP bound form, depending on the type of g-phosphate 
nucleotide bound. Cycling between the active and inactive forms is regulated by ARF 
regulators (Figure 1.11) (Kötting and Gerwert, 2004, Scheffzek and Ahmadian, 2005). 
 
 
Figure 1.11. Activation and inactivation of ARFs. ARFs are activated by guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs) (Nielsen et al., 2008). 
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1.2.1.2 ARF structure 
Although ARFs are members of the Ras superfamily, structurally they are more similar to 
heterotrimeric G protein  subunits than they are to other Ras like proteins, with the same size 
of approximately 20 kDa (Muthamilarasan et al., 2016, Moss and Vaughan, 1995). ARFs are 
made up of five -helices, six -strands and five highly conserved polypeptide (G) loops (Figure 
1.12). The functional activities of the small G-proteins occurs due to the G loops, making them 
an essential part of the ARFs (Serbzhinskiy et al., 2015, Paduch et al., 2001, Vetter and 
Wittinghofer, 2001). The nucleotide binding occurs due to the G1 loop (also referred to as the 
P loop) that is located between the 1 strand and the 2 helix (Serbzhinskiy et al., 2015, 
Paduch et al., 2001). The G2 loop that connects 1 helix and 2 strand contains a conserved 
threonine (Thr27) residue that is known to play a key role in Mg2+ ion binding. This region is 
more commonly referred to as the switch I region (Serbzhinskiy et al., 2015, Paduch et al., 
2001, Amor et al., 2001).  
In addition to the switch I region, ARFs also contain a switch II region that is made up of the 
G3 loop located at the N-terminus of the 2 helix; which provides residues for Mg2+ and -
phosphate binding (Figure 1.12.B) (Paduch et al., 2001, Amor et al., 2001). The interaction of 
ARFs with guanine nucleotides occurs due to the G4 and G5 loops, each of the G loops share 
a particular role in order to bind effectively (Serbzhinskiy et al., 2015). The lysine and aspartate 
residues present in G4 loops interact with the nucleotides whilst the G5 loop has a partial 
responsibility for guanine base recognition (Serbzhinskiy et al., 2015).  
The N-terminus of ARFs consists of an N-myristoylation site that is unique to this group of the 
small GTPase superfamily, followed by an amphipathic helix (Munro, 2005, Pasqualato et al., 
2002, Peurois et al., 2019). The N-myristoylation allows ARF to bind to the membrane 
depending on the nucleotide conformation. Thus in the GDP bound form the ARF is water 
soluble and in the GTP bound form the ARF becomes lipid soluble and is able to be inserted 
into membranes (Anders and Jurgens, 2008, Muthamilarasan et al., 2016).  
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Figure 1.12. Crystal structure of ARF1. Crystal structure shows 5 a-helices, 6 b-sheets and 
5 loops. (A) shows ARF1 in GDP bound conformation whilst (B) shows ARF1 in GTP bound 
conformation (Mossessova et al., 2003). 
 
1.2.1.3 ARF-like proteins 
The accidental discovery of an adjacent gene to Brahma gene in Drosophila melanogaster that 
encoded a protein related to mammalian ARFs led to the identification of ARF-like proteins 
(ARLs) (Munro, 2005, Tamkun et al., 1991). More than 20 ARLs have been identified in 
humans, leading to the conclusion that there are significantly more ARLs than ARFs in humans 
(Amor et al., 2001, Burd et al., 2004, Sharma et al., 2019). The contrast between sequence 
similarity and function of ARFs and ARLs helps to define the two groups of proteins (Amor et 
al., 2001), with ARLs sharing 40-60% of sequence homology with each other and the ARFs 
whilst lacking GTPase activity (Amor et al., 2001, Munro, 2005, Hanzal-Bayer et al., 2005). 
Structurally ARLs and ARFs are very similar, consisting of six -strands and five -helices 
(Burd et al., 2004); however x-ray crystallography of S. cerevisiae ARF2 and ARL1 by Amor 
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et al. (2001) revealed structural differences in the N terminus and its surrounding regions 
between the two proteins (Amor et al., 2001).  
 
1.2.1.4 Switch regions 
ARF consists of two highly conserved switch regions that are involved in the activation and 
inactivation of ARFs through binding to their respective regulators (Khan and Ménétrey, 2013). 
Binding of ARF regulators to the switch regions causes conformational changes to the switch 
regions. For examples the binding of guanine nucleotide exchange factors (GEFs) to the two 
switch regions contributes to structural changes in the ARF, this result in the inhibition of 
phosphate and metal ion binding (Vetter and Wittinghofer, 2001). Implication of the switch 
regions has also been demonstrated in several studies, the invariant glutamine found in the 
switch II region is shown to be involved in GTP hydrolysis; mutation of this glutamine to any 
other amino acids results in 50-fold reduction in GTP hydrolysis (Scheffzek and Ahmadian, 
2005, Geyer and Wittinghofer, 1997, Gideon et al., 1992). 
 
1.2.2 ARF functions 
1.2.2.1 Class I and class II ARFs 
Table 1.1 shows the localisation of different classes of ARFs in mammalian cell. The 
localisation of the ARFs may give an indication of their function within the cell. Of the three 
classes of ARFs, ARF1 and ARF6 have been most extensively characterised (Xie et al., 2016). 
Class I ARFs are implicated in a number of roles involving regulation of intracellular vesicular 
trafficking in the ER-Golgi and endosomal systems; this occurs at multiple stages of the 
secretory and lysosomal/vacuolar transport pathways (Xu and Scheres, 2005, Lee et al., 2002, 
Takeuchi et al., 2002). Through a series of in vitro ARF inhibition and assay studies conducted 
by Balch et al. in 1992 and Dascher and Balch in 1994, the significance of ARFs in vesicular 
trafficking between the endoplasmic reticulum and cis-Golgi was demonstrated (Balch et al., 
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1992, Dascher and Balch, 1994). Class I ARFs are involved in the formation of transport 
vesicles as well as the selection of transmembrane protein cargo from donor compartments in 
mammalian cells (Xu and Scheres, 2005, Donaldson and Jackson, 2000). Although less is 
known about class II ARF function it has been speculated that like class I ARFs, the class II 
ARFs are involved primarily in regulating vesicular trafficking between the Golgi and ER (Hsu 
et al., 2015).  
A number of studies have elucidated the functions of ARF1, a key member of class I ARFs, in 
eukaryotes. One of the functions of ARF1 is the recruitment of cytoplasmic coatomers to COPI-
coated vesicles (Arakel and Schwappach, 2018). Vesicle coated proteins such as COPI and 
COPII are ‘molecular machines’ that enable vesicle formation and selection of proteins and 
lipid cargo to be packaged (Arakel and Schwappach, 2018). The coats of non-clathrin-coated 
(COPI-coated) vesicles contain the protein complex: coatomers, which are membrane bound 
transport vesicle coating protein complex, and ARFs. Presley et al. (2002) identified that 
activated ARF1 recruits coatomers to the membrane and the coatomers remain associated 
with the membranes even when ARF1 is disassociated (Figure 1.13) (Stamnes and Rothman, 
1993, Presley et al., 2002). Within the Golgi stacks, these COPI-coated vesicles are involved 
in transport. In their study, Gu and Gruenberg (2000) showed that the endosomal pH is 
involved in the regulation of ARF1 binding to endosomal membranes, thus explaining the pH 
dependence of COPI binding to endosomes (Gu and Gruenberg, 2000).  
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Figure 1.13. COPI coat assembly model. The activation of ARF1 by ARF1GEF results in the 
recruitment of COPI coatomer by the activated ARF1. Vesicle buds once the formation of coat 
is complete. Hydrolysis of GTP bound ARF1 by ARF1GAP allows the ARF1 to dissociate from 
the complex. Adapted from (Kirchhausen, 2000). 
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Class Name Localisation Function References 
Class I ARF1 
ARF2 
ARF3 
Mainly in the 
Golgi apparatus 
and ERGIC 
Intracellular vesicle 
trafficking in ER-Golgi 
and endosomal 
systems. Coatomer 
recruitment 
Xu and Scheres (2005) 
Lee et al. (2002) 
Presley et al. (2002) 
 
Class II ARF4 
ARF5 
ERGIC and 
Golgi apparatus 
Regulating vesicle 
trafficking between ER 
and Golgi 
Hsu et al. (2015) 
Donaldson and 
Jackson (2000) 
Class III ARF6 Plasma 
membrane and 
endosome 
Actin cytoskeleton 
remodelling. Regulating 
secretion. Plasma 
membrane protein and 
endosomal recycling. 
Cell polarity. Cell 
migration 
Altschuler et al. (1999) 
Morgan et al. (2015) 
Zhang et al. (1999) 
Zhang et al. (1998) 
 
Table 1.1. Localisation and function of class I, II and III ARFs. 
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1.2.2.2 Class III ARFs 
ARF6 is found exclusively in the endosomal system and plasma membrane of mammalian 
cells (Table 1.1). The protein has been implicated in a number of diverse functional roles such 
as actin cytoskeletal remodelling, regulating secretion, plasma membrane protein and 
endosomal recycling, cell polarity and finally cell migration (Morgan et al., 2015, Hsu et al., 
2015, Donaldson and Jackson, 2000). The implication of ARF6 in macrophage phagocytosis 
was highlighted by Zhang et al. in 1998. They identified that expression in macrophages of 
mutant ARF6s that were defective in GTP hydrolysis caused inhibition of phagocytosis of 
erythrocytes that are coated with IgG. Interestingly, in this study  Zhang et al. demonstrated 
that ARF6 mutants that were defective in binding to GTP also contributed to inhibition of 
phagocytosis, suggesting that FcR mediated phagocytosis in macrophages requires guanine 
nucleotide cycling by ARF6 (Donaldson and Jackson, 2000, Zhang et al., 1999, Zhang et al., 
1998). 
 
1.2.2.3 ARLs 
The importance of ARL1 in regulating Golgi structure and function was highlighted in a study 
conducted by Lu et al. in 2001; overexpression of ARL1 mutant that is restricted to the GDP 
bound form resulted in the disassembly of the Golgi apparatus, whilst the overexpression of a 
mutant GTP-locked form of ARL1 caused the expansion of Golgi apparatus (Lu et al., 2001). 
ARL1 is also shown to be involved in various other cellular functions ranging from secretory 
trafficking, lipid droplet and salivary granule formation, and innate immunity and neuronal 
development (Yu and Lee, 2017).  
ARL2 involvement in native tubulin folding by interacting with tubulin folding Cofactor D has 
been highlighted by Bhamidipati et al. (2000). The destruction of tubulin and microtubules by 
overexpressed Cofactor D is averted by the expression of GDP-bound ARL2, which causes 
the down-regulation of GTPase activating protein activity in Cofactor D (Pasqualato et al., 
2002, Hanzal-Bayer et al., 2005, Bhamidipati et al., 2000). Sharer and Kahn (1999) identified 
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that ARL2 binds to a novel 19 kDa protein termed Binder of ARL Two (BART) (Sharer and 
Kahn, 1999). Both ARL2 and BART were later identified by Sharer et al. (2002) to be able to 
enter mitochondria, and together bind to adenine nucleotide transporter (Sharer et al., 2002).  
The function of ARL4 that are localised in the nucleus may be implicated during development; 
Lin et al. (2000) identified that mouse ARL4 is developmentally regulated during mouse 
embryogenesis (Pasqualato et al., 2002, Lin et al., 2000).  
Mutations in BBS3, the gene which encodes ARL6, has been implicated in Bardet-Biedl 
Syndrome (BBS), a heterogeneous human disorder characterised by the dysfunction of basal 
body and/or cilia (Wiens et al., 2010). The BBSome is an octameric complex of proteins of 
BBS, consisting of eight BBS proteins (Jin and Nachury, 2009, Jin et al., 2010, Kahn et al., 
2005). BBS3, one of the genes that are implicated in BBSome complex has also been identified 
to encode ARL6. This ARL6/BBS3 is absent in plants and fungi but highly conserved in ciliated 
organisms, thus suggesting a potential role in cilium biogenesis (Jin and Nachury, 2009, Jin et 
al., 2010, Price et al., 2012). Jin et al. (2010) identified that GTP-bound ARL6 is involved in the 
recruitment of BBSome onto the membranes, forming an electron dense coat. This recruited 
BBSome coat complex is involved in sorting membrane proteins to cilia, thus it could be 
speculated that the absence of ARL6/BBS3 could result in inhibited BBSome recruitment to 
the membrane, therefore leading to cilium biogenesis inhibition (Jin et al., 2010). The sorting 
of membrane proteins into cilia occurs via intraflagellar transport (IFT). Recruitment of 
BBSome acts as an adapter for membrane proteins and uses IFT to cycle through cilia 
(Wingfield et al., 2018). 
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1.3 ARF regulators 
1.3.1 Guanine nucleotide exchange factors 
ARFs exist as either the active GTP bound form or the inactive GDP bound form (Serbzhinskiy 
et al., 2015, Kötting and Gerwert, 2004). The cycling between the active and inactive forms of 
ARFs is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating 
proteins (GAPs) respectively (Jackson and Casanova, 2000). Under physiological conditions 
the exchange of GDP for GTP occurs very slowly (Jackson and Casanova, 2000); however 
the rate of GDP to GTP exchange is increased with the aid of GEFs, proteins that catalyse the 
dissociation of the GDP on ARFs, thus allowing GTP to associate with ARFs and become 
activated (Jackson and Casanova, 2000, Anders and Jurgens, 2008, Schmidt and Hall, 2002, 
Bhatt et al., 2016).  
Since their first discovery in 1992, the importance of GEFs and their diversity has been 
demonstrated in a number of studies that have been reviewed by Jackson and Casanova 
(Jackson and Casanova, 2000). Although the GEFs identified to date are very divergent to 
each other at the amino acid level, they share a region that is more highly conserved. This 200 
amino acid sequence is known as the Sec7 domain, due to a high degree of homology with 
the yeast Sec7p protein (Jackson and Casanova, 2000, Mansour et al., 1999). 14 human ARF 
GEFs were identified. These identified GEFs can be divided by their size and organisation into 
the low molecular weight and high molecular weight GEFs. The small molecular weight GEFs 
(<100 kDa) consist of CYTH, IQSEC and PSD subfamilies. These family of GEFs are the 
encoded by the pleckstrin-Sec7 domain genes (Mouratou et al., 2005, Sztul et al., 2019).  
The high molecular weight GEFs (>100 kDa) consists of GBF1; a GEF that is closely related 
to the yeast Gea1 and Gea2 proteins, and the Brefeldin A (BFA) sensitive ARFGEF 
subfamilies. These GEFs are closely related to yeast Sec7 (Le et al., 2013, Sztul et al., 2019). 
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1.3.1.1 ARF GEF structure 
Crystal structures of Cytohesin-1 and Cytohesis-2 helped determine the structure of GEFs. 
Both of these GEFs consist of an N terminal coiled-coil region, a C-terminal consisting of 
pleckstrin homology domain and a Sec7 domain (Mayer et al., 2001, Mossessova et al., 1998). 
The crystal structure Cytohesin-2 Sec7 region by Mossessova et al. (1998) at 2.2 Å resolutions 
identified the presence elongated 10 -helices with a distinctive hydrophobic groove (Beraud-
Dufour et al., 1998, Mossessova et al., 1998). To easier understand the structure of the Sec7 
domain, each of the 10 -helices is designated a letter (from A-J) (Beraud-Dufour et al., 1998). 
The distinct hydrophobic groove is made up of the hydrophobic residue present on F and G 
helices, making up the bottom of the groove. The two facing sides of the groove consist of the 
hydrophobic residue present on the H helix and the hydrophilic residue present on the F and 
G helices, forming a loop.  
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Figure 1.14. Structure of Cytohesin-2 Sec7 domain. (A) Schematic diagram of domains that 
are present in human Cytohesin-2. (B) Ribbon representation of human Cytohesin-2 Sec7 
domain. The seven -helices from the N-terminus are right-handed superhelix (A-G) against 
three C-terminal -helices. Areas in yellow represent the active site regions  (Mossessova et 
al., 1998) 
 
The Sec7 domain grooves of the GEFs interact with the switch I and II regions present in ARFs. 
Béraud-Dufour et al. (1998) identified the presence of a glutamic finger (Glu156) in the 
hydrophilic F-G loop of the Cytohesin-2 Sec7; they proposed that the Glu156 carboxyl group 
may interact with Mg2+(found in the switch regions), destabilising its co-ordinations with the -
phosphate of GDP and a strong steric and repulsive effect on the bound GDP, thus causing 
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the dissociation of GDP from ARF (Beraud-Dufour et al., 1998, Donaldson and Jackson, 2000, 
Jackson and Casanova, 2000, Goldberg, 1998). The F-G loop and the H helix are conserved 
in all members of the Sec7 family, suggesting that its mechanism of GDP dissociation may be 
similar in all GEFs. Through site directed mutagenesis studies, this region has been identified 
as the ARF interacting site has been demonstrated (Beraud-Dufour et al., 1998, Mossessova 
et al., 1998).  
 
1.3.1.2 GEF interaction with ARFs 
The activation of ARF1 by Sec7 through a positive feedback mechanism was demonstrated 
by Richardson et al. in 2012 (Richardson et al., 2012). Conformational changes in ARF is 
induced during the binding of GTP that are present in the cell, the conformational change of 
ARF was demonstrated by intrinsic fluorescent coincident changes (Kahn et al., 1991, Kahn 
and Gilman, 1986). This conformational change allows the N-myristoylated terminal of ARFs 
to be inserted into cellular membranes (Jackson and Casanova, 2000, Roth, 1999). 
Conformational changes also occur at the ARF switch regions, mediating the binding of GTP 
and GDP by tightly binding to -phosphate of GTP and weakly to GDP nucleotides (Pasqualato 
et al., 2001, Pasqualato et al., 2002).  
 
1.3.1.3 ARF GEF and Brefeldin A 
Brefeldin A (BFA) is a small hydrophobic lactone compound produced as a metabolite in toxic 
fungi. Addition of BFA to cells has dramatic effects on mammalian cells, causing rapid 
dissociation of protein from the Golgi complex as well as Golgi complex disassembly and 
redistribution of Golgi proteins to the endoplasmic reticulum, making it a potent secretion 
inhibitor (Myers and Casanova, 2008, Xu and Scheres, 2005, Ohashi et al., 2012). BFA 
selectively inhibits Golgi-associated ARF-GEF action in mammalian, plant and fungal cells, 
thereby inhibiting the activation of ARFs (Myers and Casanova, 2008, Yorimitsu et al., 2014, 
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Xu and Scheres, 2005, Ohashi et al., 2012). For instance the ARF1 function of COPI coat 
recruitment is inhibited when the ARF-GEF rate is inhibited by BFA (Xu and Scheres, 2005). 
BFA in particular targets the ARF-GDP-GEF intermediate, thus causing it to stabilise and in 
turn block the activation of the ARF cycle (Donaldson and Jackson, 2000). Mossessova et al. 
(2003) concluded from the crystal structure of GDP bound ARF1 with Sec7 and BFA complex 
that binding of BFA occurs at the protein-protein interface, inhibiting ARF1 conformational 
changes that are required for Sec7 domain to dislodge GDP molecule (Xu and Scheres, 2005, 
Peyroche et al., 1999, Mossessova et al., 2003). Although BFA inhibits ARF GEF function of 
large ARF GEFs,  BFA has little effect on the small molecular weight GEFs (Donaldson and 
Jackson, 2000). An example of this is when the function of ARF6 in membrane association is 
not affected by addition of BFA. This is because the GEF that activates the function of ARF6 
is PSD, a member of low molecular weight GEFs (Zhang et al., 1998). Similarly Cytohesin-2 is 
also not that sensitive to BFA, however it is interesting to note that the Sec7 domain of 
Cytohesin-2 is structurally similar to Gea2 (Chardin and McCormick, 1999, Goldberg, 1998).  
 
1.3.2 GTPase activating proteins 
The activated ARFs by GEFs are inactivated by GAPs, thus resulting in the cycling of ARFs 
within cells. Intrinsically the GTPase activity of ARFs are slow, however GAPs accelerate the 
GTPase activity; causing the hydrolysis of GTP to GDP and inorganic phosphate (Donaldson, 
2000, Scheffzek et al., 1997, Scheffzek and Ahmadian, 2005). 26 GAPs have been identified 
in humans, these identified GAPs all have ARFGAP domain in common, which is roughly 130 
amino acids in length. Besides this domain, the GAP family can be divided into 10 subgroups 
based on their domain structure and phylogenetic analysis. The 10 subgroups can be further 
classified into two groups depending on the position of the ARFGAP domains (Figure 1.15) 
(Campa and Randazzo, 2008, Kahn et al., 2008, Sztul et al., 2019).  
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Figure 1.15. Domains present in ARF GAPs. ARF GAPs can be divided into 10 subgroups 
based on their structure and domains; however all of the 10 subgroups have highly conserved 
ARF GAP domain. Adapted from (Campa and Randazzo, 2008). 
 
Through a series of in vitro analysis it was demonstrated that ARFGAP1, ASAP1 and ASAP2 
interacted with ARF1 and ARF5 more effectively than ARF6 whilst GIT1 showed no preference 
within these three ARFs (Donaldson, 2000, Jackson and Casanova, 2000, Randazzo et al., 
2000). Jackson et al. (2000) identified ACAP1 and ACAP2, two ARF6 GAPs. These two GAPs 
were found to be widely expressed in various cell lines and behaved in a similar manner to 
ASAP1, in the sense that overexpression lead to the inhibition of the formation of platelet-
derived growth factor (PDGF)-induced dorsal membrane ruffles in NIH 3T3 fibroblasts. Just as 
how ARFGAP1, ASAP1 and ASAP2 had greater affinity for interacting with ARF1 and ARF5, 
  
51 
in vitro study has shown that ACAP1 and ACAP2 had greater affinity to ARF6 than with ARF1 
or ARF5 (Jackson and Casanova, 2000). 
 
1.3.2.1 ARF GAP structure 
The crystal structure of human ARF1 and rat ARFGAP complex was determined at 1.95 Å by 
Goldberg (1999), from this crystal structure it was identified that the ARFGAP domain 
resembled a clenched fist; the “fingertips” consisting of -strands whilst the “palm” consisting 
of -helices, together these two regions forms a groove that serves as ARF1 binding site. The 
presence of Cys4 zinc finger with a characteristic CX2CX16CX2C motif was also observed, this 
region is nestled in an array of -helices and a -sheet and form the “knuckle” region that faces 
away from the protein-protein interface (Goldberg, 1999). Goldberg observed that the 
ARFGAP molecule binds to and stabilises the switch II region as well as the 3 helix in order 
to direct the ARF1 residues for catalysis. ARFGAP does not provide a catalytic arginine finger 
or any other amino acid side chains to the GTPase active site for GTP hydrolysis (Scheffzek 
and Ahmadian, 2005, Goldberg, 1999); instead Goldberg noted that the addition of coatomer 
to the reaction in in vitro GTPase assays increased the hydrolysis of GTP by almost 1000-fold 
(Goldberg, 1999). ARFGAP1 binding to ARF1 does not involve the switch I region, instead the 
switch I regions appears to bind to coatomer (Scheffzek and Ahmadian, 2005). It can be 
concluded that binding of coatomer to switch I region provides a catalytic residue such as 
arginine finger that aids in the hydrolysis of GTP (Scheffzek and Ahmadian, 2005, Goldberg, 
1999).  
Although the structure of ARFGAP1 with ARF1-GDP complex and interaction determined by 
Goldberg (1999) is invaluable in order to understand more about ARF GAP interactions, it 
should be noted that ARFGAP1 lacks the Ankyrin repeats at the C terminal as well as several 
other domains such as PH domains and SH3 domains that are present in several other 
subgroups of ARF GAPs (Campa and Randazzo, 2008, Goldberg, 1999, Sztul et al., 2019). 
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The PH domains bind to phosphatidylinositol (4,5)-bisphosphate and/or phosphatidylinositol 
(3,4,5)-trisphosphate which causes the activation of the catalytic ARFGAP domain (Robinson 
and Kanamarlapudi, 2017, Kahn and Lambright, 2015). The SH3 domain is involved in the 
binding of focal adhesion tyrosine kinase (Randazzo et al., 2000). The Ankyrin repeats are 
involved in protein-protein interactions and cargo binding (Chan et al., 2017, Bai et al., 2012). 
The lack of additional domains means that ARFGAP1 utilises a different interaction mechanism 
to the other ARF GAP subfamilies. 
To resolve this issue, Mandiyan et al. (1999) studied the crystal structure of PYK2-associated 
protein  (PAP) ARFGAP domain and the Ankyrin repeats at 2.1 Å resolutions. PAP 
(ASAP2) is one of the ARF GAPs that consists of the PH domain, Ankyrin repeats, SH3 domain 
and ARFGAP domain (Mandiyan et al., 1999, Sztul et al., 2019). Mandiyan et al. identified the 
presence of 3 -sheets flanked by 5 -helices, a Zn2+ ion coordinated by the CX2CX16-17CX2C 
sequence motifs and four Ankyrin repeats; it should be noticed that the structure of the 
ARFGAP domain is similar to that described by Goldberg (1999) (Goldberg, 1999, Mandiyan 
et al., 1999).  
Taking this into consideration, it can be assumed that all of the ARFGAP domains of the 
identified GAPs consists of zinc finger motif with the specific spacing of four Cysteines motifs 
(East and Kahn, 2011, Cukierman et al., 1995, Huber et al., 2002). In their study, Mandiyan et 
al. found that there is an overlap between the ARF1 and the third and fourth Ankyrin repeats. 
They concluded that either these Ankyrin repeats are dislodged or PAP undergoes extensive 
rearrangements before binding (Scheffzek and Ahmadian, 2005, Mandiyan et al., 1999). As 
opposed to the conclusions by Goldberg (1999), mutation studies on PAP revealed that 
mutation of Arg292 to lysine resulted in 10,000 fold decrease in GTP hydrolysis, suggesting 
that the invariant arginine maybe required for GTP hydrolysis by ARF GAPs in the other 
subfamilies (Scheffzek and Ahmadian, 2005, Goldberg, 1999, Mandiyan et al., 1999). 
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1.3.2.2 ARF GAP functions 
The cycling of GEFs and GAPs are important in regulating the function of ARF/ARLs. Previous 
studies had highlighted the functions of ARF GAPs and their importance for cellular functions. 
For example, Randazzo et al. (2000) demonstrated that the overexpression of ASAP1 caused 
focal adhesion morphology alteration and inhibited cell spreading of NIH 3T3 fibroblasts in vitro 
(Randazzo et al., 2000). The hydrolysis of ARF1-GTP by GAP causes the uncoating of coated 
vesicles; this is an important step before the vesicles fuse with the acceptor compartment 
(Mandiyan et al., 1999, Antonny et al., 1997). However, overexpression of ARFGAP1 causes 
redistribution of the entire Golgi complex to the endoplasmic reticulum and the release of COPI 
from Golgi membranes to cytosol (Mandiyan et al., 1999). The activity of GAPs have been 
demonstrated to be affected by several molecules within the cell, for example ARF GAP is 
highly dependent on Phosphatidylinositol 4,5-bisphosphate (PIP2) and are sensitive to 
phosphatidic acid (PA) and phosphatidylcholine (PC), stimulating and inhibiting ARF GAP 
activity respectively (East and Kahn, 2011, Randazzo and Kahn, 1994). The dependence of 
ARF GAP to PIP2 was further identified by Kam et al. (2000), they identified that activation of 
ASAP1 required PIP2 binding to the PH domain (Kam et al., 2000); minimum GAP activity can 
be observed in the presence of GAP mutants that lacked PH domain (Mandiyan et al., 1999). 
 
1.4 ARF regulating proteins as potential drug targets 
ARFs and their regulators have been the targets of interest for several diseases, most notably 
as a potential target for cancer (Ohashi et al., 2012). Ohashi et al (2012) identified BFA like 
inhibitor of ARF1-ARFGEF termed AMF-26. AMF-26 inhibited ARF1 activation and oral 
administration of AMF-26 saw complete regression of human breast cancer BSY-1 xenografts 
in vivo (Ohashi et al., 2012). ARFs and their regulators have also been connected to several 
genetic diseases. Mutations of IQSEC2 has been shown to cause nonsyndromic X-linked 
intellectual disability (Shoubridge et al., 2010). Similarly mutation of ARFGEF2 has been linked 
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to autosomal recessive periventricular heterotopia, a disorder that leads to severe 
malformation of the cerebral cortex (Jackson and Bouvet, 2014). 
There may be potential to target ARFs or their regulators in order to develop new therapeutics 
for African trypanosomiasis.  
 
1.4.1 RNA interference of T. brucei ARF/ARLs 
Several studies have been carried out on RNA interference (RNAi) of T. brucei ARFs and ARLs 
which have demonstrated the functions of ARFs and ARLs in bloodstream form T. brucei. Nine 
ARF/ARLs have previously been identified in T. brucei (Price et al., 2005b, Price et al., 2005a). 
Several tetracycline-inducible RNAi studies of the identified ARF/ARLs were carried out on 
bloodstream form T. brucei. The importance of ARL6 has been discussed in section 1.2.2.3. 
Mutation of BBS3/ARL6 is characterised by the dysfunction of basal body and/or cilia (Wiens 
et al., 2010). The flagellum in T. brucei is important for cell division, survival within the tsetse 
fly and immune evasion. However Price et al. (2012) demonstrated through RNAi of ARL6 that 
although RNAi of ARL6 leads to significant shortening of flagellum, the RNAi did not affect the 
viability of the bloodstream form T. brucei (Hemsworth et al., 2013, Price et al., 2012).  
In contrast to this however, RNAi of ARL1 and ARF1 lead to significant levels of T. brucei cell 
death.  ARL1 in T. brucei is only expressed during the mammalian bloodstream form stage, 
where it localises to the Golgi apparatus of the parasite; RNAi of ARL1 in this stage of T. brucei 
life cycle resulted in parasite cell death between 24 and 48 hours post RNAi. Prior to cell death, 
the depletion of ARL1 caused Golgi structure disintegration and delay in exocytosis of GPI 
anchored VSGs, presence of multiple flagella, nuclei and vesicles; this demonstrated the 
importance of ARL1 in T. brucei viability (Price et al., 2005b, Price et al., 2005a).  
ARF1 in T. brucei is localised to the Golgi apparatus, inhibition of the ARF by RNAi has 
demonstrated increased cell death in T. brucei. RNAi of ARF1 in bloodstream form T. brucei 
resulted in lethal phenotypes and cell division decreasing by 24 hours post induction, the 
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phenotypes included development of cells with multiple nuclei and abnormal morphology such 
as the “BigEye” large vacuole morphology. Although the morphology of the parasite was 
affected, electron microscopy and immunofluorescence assay of the Golgi matrix marker 
showed that the Golgi was intact (Price et al., 2007b). Interestingly overexpression of ARF1 in 
bloodstream form T. brucei proved to be lethal to the parasite, contributing to Golgi to lysosome 
transport defect (Price et al., 2007b). In contrast to what was observed in the knockdown of 
ARF1 in bloodstream form T. brucei; knockdown of ARF1 in the procyclic form T. brucei does 
not affect endocytosis, particularly the fluid phase endocytosis of dextran. However RNAi of 
ARF1 in procyclic form T. brucei did affect the lysosome, resulting in an enlarged lysosome 
without any significant impairment in protein degradation (Price et al., 2007a).  
The involvement of ARL2 in T. brucei cytokinesis function was demonstrated by RNAi and 
overexpression study in bloodstream form T. brucei. RNAi of ARL2 in T. brucei resulted in a 
severe cytokinesis defect due to the inhibition of formation and ingression of cleavage furrows, 
the overexpression of C-terminally myc-tagged ARL2 also showed the same results as the 
RNAi but overexpression of untagged ARL2 did not affect the parasite. Although inhibited cell 
division was observed by 24 hours post induction; the parasites themselves were still viable, 
demonstrating a cytostatic effect rather than a cytotoxic effect (Price et al., 2010b). 
These studies have demonstrated that ARFs and ARLs found in T. brucei are important in 
essential cellular functions and targeting these proteins as a novel therapeutic target could 
lead to parasite death. However a major problem with targeting ARF/ARLs is the fact that they 
share a high level of protein sequence identity with ARF/ARL sequences from other species, 
particularly humans (Table 1.2). Multiple sequence alignment showed that identified T. brucei 
ARF/ARLs and human ARF/ARLs have high level of sequence identity at the GDP/GTP - and 
- phosphate binding site, which is also essential for GEF binding. Other sites that had high 
level of sequence identity include the switch II region that interacts with GTP, and the NKXD 
region where GTP magnesium and - phosphate binding occurs (Price et al., 2007b, Price et 
al., 2005b).  
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Inhibiting the function of ARF/ARLs would likely require inhibitors to bind to one of these highly 
conserved site. However this may lead to complications since drugs inhibiting T. brucei 
ARF/ARLs functions by binding to the highly conserved regions could also potentially target 
human ARF/ARLs as well. Alternative potential therapeutic targets that could be exploited are 
the ARF regulators. Considering the overall sequence divergence of both GEFs and GAPs 
and the complications of overexpression or mutation of these regulators (Xu and Scheres, 
2005, Mandiyan et al., 1999, Antonny et al., 1997), targeting ARF regulating proteins as novel 
drug targets against T. brucei and potentially other kinetoplastids could prove to be effective. 
 
Gene Human homologue  Similarity (%) Size (kDa) 
TbARL1 ARL1 53% 20.7 
TbARL2 ARL2 63% 20.7 
TbARL3A ARL3 48% 19.9 
TbARL3B ARL3 59% 21.9 
TbARL3C ARL3 42% 20.0 
TbARL6 ARL6 43% 20.0 
TbARLX ARL1 45% 21.0 
TbARF1 ARF1 75% 20.6 
TbARF2 ARF4 57% 21.2 
 
Table 1.2. ARF/ARLs in T. brucei and their homologue to human ARF/ARLs. The high 
percentage of similarity between T. brucei ARF/ARLs and human ARF/ARLs makes finding a 
suitable drug target complicated. Adapted from: (Price et al., 2005b). 
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1.5 Aims 
The overall aim of this study is to determine whether regulating proteins of ARFs are suitable 
as drug targets against T. brucei. To achieve this aim, the following objectives will be 
addressed: 
1. Identify ARF regulator protein orthologues in T. brucei 
Bioinformatics will be used to identify the orthologues of ARF GEFs and GAPs in the T. brucei 
genome. 
 
2. Generate RNAi expressing cell lines 
Tetracycline inducible RNAi constructs will be generated and transfected into bloodstream 
form T. brucei to generate stable cell lines. 
 
3. Determine whether regulating proteins are essential 
The effect of knockdown of specific ARF regulators on cell growth will be determined by 
counting the number of cells at a range of time points. Changes in morphology will be assessed 
using immunofluorescent and electron microscopy. Extraction of RNA at different time points 
post-induction of RNAi will be carried out and the change in gene expression will be determined 
using real-time PCR. 
 
4. In addition to studying ARF regulators as drug targets, transgenic cell lines exhibiting 
endocytosis defect will be evaluated as research tools to investigate drug uptake 
Transgenic cell lines that can be induced to express endocytosis defect will be used to identify 
if compounds from open-access libraries that are effective against T. brucei are taken up via 
endocytosis. 
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Chapter 2 – Materials and Methods 
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2.1 Materials 
Unless specified, all plasticware and glassware were purchased from the following companies: 
Greiner Bio-One (Solingen, Germany), Star Lab (Milton Keynes, UK), Eppendorf (Cambridge, 
UK) and VWR International (Lutterworth, UK). Pathogen Box compound library was provided 
by Medicines for Malaria Ventures (MMV) (https://www.mmv.org/mmv-open/pathogen-box - 
accessed: Feb 2020). Parasite culture was carried out in a Health and Safety Executive 
approved Category III cell culture facility under a Specified Animal Pathogens Order (SAPO) 
licence.  
 
2.1.1 Laboratory equipment 
The following list of equipment were used during experimental work described in this thesis: 
3520 Advance bench pH meter Jenway (Cole-Palmer) (Stone, UK) 
AMAXA® Nucleofector® Lonza (Basel, Switzerland) 
Discovery Comfort Pipettes HTL Lab Solutions (Warszawa, Poland) 
EVOS FL Cell Imaging System Thermo Fisher Scientific (Loughborough, UK) 
G:BOX F3 Syngene (Cambridge, UK) 
GloMax® Multi Detection System Promega Corporation (Southampton, UK) 
Guava EasyCyte 6-2L flow cytometer Merck Millipore (Watford, UK) 
Magnetic Stirrers VWR International (Lutterworth, UK) 
NanoDropTM 1000 Spectrophotometer Thermo Fisher Scientific (Loughborough, UK) 
PowerPacTM Basic Power Supply Bio-Rad Laboratories (Watford, UK) 
PTC-2000 Gradient Thermal Cycler Bio-Rad Laboratories (Watford, UK) 
StepOne Plus Real-Time System Thermo Fisher Scientific (Loughborough, UK) 
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2.1.2 Chemicals and reagents 
Chemicals and reagents were sourced as follows: 
Thermo Fisher Scientific (Gibco®) 
(Loughborough, UK) 
Heat inactivated Foetal Bovine Serum; HMI-
9 powder; L-glutamine (4 mM); PrestoBlue®; 
Concanavalin A; dNTPs; KOD Hot Start 
DNA polymerase; MgSO4; PowerUpTM 
SYBR® Green; RNAseOUT Recombinant 
Ribonuclease inhibitor; Image-iTTM FX 
Signal enhancer; 1X PBS; Loading buffer 
(X5); ProLongTM Diamond Antifade 
Mountant; SOC medium; Voorheis’ modified 
PBS (vPBS) – PBS supplemented with 10 
mM glucose and 46mM sucrose 
Sigma-Aldrich (Merck) (Watford, UK) 2-mercaptoethanol; Ethidium bromide; LB 
Broth (Miller); LB Broth with Agar (Lennox); 
Sodium bicarbonate; Tris-Acetate-EDTA; 
Methylene blue (0.01% in 1X TAE); 
Paraformaldehyde; Propidium Iodide 
VWR International (Lutterworth, UK) Chloroform; Methanol; TritonTM X-100; 
Ethanol 
Lonza (Basel, Switzerland) SeaKem® Agarose; Sodium acetate (3M) 
Bioline (London, UK) TRIsureTM; 1kb+ Hyperladder 
New England BioLabs (Hitchin, UK) Taq Polymerase; Quick-Load® 2-Log DNA 
Ladder;  
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2.1.3 Kits 
AmbionTM DNAse Kit  Thermo Fisher Scientific (InvitrogenTM) 
(Loughborough, UK) 
Omniscript® RT kit Qiagen (Hilden, Germany) 
QIAprep® Spin Miniprep kit Qiagen (Hilden, Germany) 
QIAquick® Gel Extraction kit Qiagen (Hilden, Germany) 
T4 DNA ligase kit New England BioLabs (Hitchin, UK) 
TOPO® TA Cloning® kit Thermo Fisher Scientific (InvitrogenTM) 
(Loughborough, UK) 
 
 
2.1.4 Media 
HMI-9 medium 1.8 g/L HMI-9 powder, 0.036 M NaHCO3, 10% 
heat inactivated tetracycline free Foetal Bovine 
Serum, 100 U/mL Penicillin & 100 g/mL 
Streptomycin, 4 mM L-glutamine, 5.72 mM 2-
Mercaptoethanol, 
LB medium 25 g/L LB Broth (Miller), 1 L dH2O, autoclaved 
for sterilisation and antibiotics added once LB 
medium has cooled down to 50°C 
LB-Agar with ampicillin medium 35 g/L LB Broth (Lennox), 1 L dH2O 
Autoclaved for sterilisation, 100 g/mL 
ampicillin added once LB-Agar has cooled 
down to 50°C 
Cryo medium for T. brucei  20% glycerol in HMI-9 medium 
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2.1.5 Oligonucleotides 
Name Sequence 
TbGAP1 (For) 5’-CCGCCGATCTAGACGCGTGGAAGC-3’ 
TbGAP1 (Rev) 5’-CCGAACCCCTTTTTCTCTAGACCACCACC-3’ 
TbGAP2 (For) 5’-CCGGTCTAGATCGGTCAGCAGGTA-3’ 
TbGAP2 (Rev) 5’-GCATTGGGTGTCTAGAAGAGATCATCTATG-3’ 
TbGAP3 (For) 5’-GGATGCCCGTCTAGACCGTG-3’ 
TbGAP3 (Rev) 5’-CGTACCACTCTAGAGGTGTCCAC-3’ 
TbGAP4 (For) 5’-GGAACTTCTAGACAATCAACGGGC-3’ 
TbGAP4 (Rev) 5’-CTGCTCTAGAAGTGTCTTGCGCC-3’ 
TbGEF1 (For) 5’-GGTCCGAGAGACCTTCTAGAGGTGATGAAG-3’ 
TbGEF1 (Rev) 5’-CAACTACGCACATGTTGTTGCTCTAGAGGG-3’ 
TbGEF2 (For) 5’-TGAGAGCAGTAGCCGTCTAGATGCCCC-3’ 
TbGEF2 (Rev) 5’-CCTGCATCCTGGACGACTCTAGAGCAC-3’ 
TbGEF3 (For) 5’-GCAGGGAGTCTAGAGACGCTGG-3’ 
TbGEF3 (Rev) 5’-CCAGCTCTAGAGTTAGCATCATCAGG-3’ 
TbGEF3 ORF (For) 5’-ATGGAGGCTCTCCTGCGGTC-3’ 
TbGEF3 ORF (Rev) 5’-CTACAGCCACATGCATTCCGGTG-3’ 
TbGEF3 qPCR (For) 5’-ATGTGTCGCAGTACCGTTTC-3’ 
TbGEF3 qPCR (Rev) 5’-AACTCCATTTCAGCCTGTCG-3’ 
TbGAP1 sequencing 5’-GTCAAAACGGCTCCACTGG-3’ 
TbGAP4 sequencing 5’-TACGAGGCGCATCTTCCTAA-3’ 
TbGEF1 sequencing 5’-CCAAAGGTCGTGAAGCAACA-3’ 
TbGEF2 sequencing 5’-CTCCCGCGAGTTTTGACTTC-3’ 
TbGEF3 sequencing 5’-GGAGTGTTGGTTACCACTGGA-3’ 
 
 
  
63 
2.2 Methods 
2.2.1 Bioinformatics 
2.2.1.1 Identification of T. brucei regulator genes 
Literature and NCBI database searches (http://www.ncbi.nlm.nih.gov/ - accessed: Oct 2015) 
were used to identify ARF GEFs and GAPs that are present in humans. Known names and 
accession numbers as well as the presence of the Sec7 and ARFGAP domains were used to 
identify human ARF GEFs and GAPs. Protein sequences for the identified GEFs and GAPs 
were acquired from NCBI database. BLAST search using the human GEFs and GAPs protein 
sequences were carried out on TriTrypDB website (Aslett et al., 2010) to identify possible 
orthologues in T. brucei Lister 427 strain. Possible orthologues in T. brucei genome with the 
lowest e-values were selected. Catalytic domain search on TriTrypDB was then carried out on 
the selected T. brucei orthologues to support the possibility that the selected genes were those 
of the ARF regulators. The presence of Sec7 domain and ARFGAP domain in the identified T. 
brucei orthologues confirmed the validity of the genes. Reverse BLAST search on the identified 
T. brucei orthologues was carried out on the NCBI database to further ensure the identified 
orthologues were ARF regulators.  
 
2.2.1.2 Sequence alignment 
Identified human and T. brucei ARF GEF and GAP amino acid sequences were aligned using 
Uniprot Align software tool (http://www.uniprot.org/align/ - accessed: Oct 2015). The 
percentage identity between pairs of human and T. brucei ARF regulators was also determined 
using this software tool. Sequence alignments on the T. brucei GEFs and GAPs was carried 
out against each subfamily of their respective human ARF regulators and the average 
percentage identity for each subfamily was obtained. 
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2.2.1.3 Domain and Structural analysis 
Domains present in each of the identified human and T. brucei ARF GEF and GAP amino acid 
sequences were determined using the online software SMART: sequence analysis (Schultz et 
al., 1998, Letunic et al., 2015). Schematic representation of the domains were obtained for 
each of the human ARF regulator subfamilies and for each of the T. brucei GEFs and GAPs. 
In order to carry out structural analysis the T. brucei GEFs and GAPs were analysed on Phyre2 
(http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index – accessed: May 2018) (Kelley 
et al., 2015) software to generate PDB files on predicted structures. The generated PDB files 
were opened on PyMOL Molecular Graphics System, Version 2.0 supplied by Schrödinger, 
LLC and the predicted structures for each of the T. brucei GEFs and GAPs were analysed. 
Structural similarities were also determined on PyMOL. 
 
2.2.1.4 Prediction of protein localisation 
Localisation of the identified T. brucei GEFs and GAPs were predicted using TrypTag resource 
(http://tryptag.org/ - accessed: March 2018) (Dean et al., 2017). BLASTP of the identified T. 
brucei GEFs and GAPs protein sequence on TriTrypDB identified closest homologues in 
TREU927 cell lines. Accession numbers obtained from the TREU927 cell lines were used to 
identify localisation of T. brucei GEFs and GAPs in T. brucei. 
 
2.2.1.5 Identification of putative orthologues in other kinetoplastids 
Presence of identified T. brucei GEF and GAP orthologues in other kinetoplastids was 
determined for each T. brucei GEFs and GAPs. Accession number search for each T. brucei 
GEFs and GAPs on TriTrypDB identified orthologue group number for each gene. The 
identified orthologue group numbers were searched on OrthoMCL to identified parasites with 
the same orthologue groups. Kinetoplastid group was selected as a search criteria and 
respective orthologues of T. brucei GEFs and GAPs were identified in other kinetoplastids. 
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2.2.2 General Methods 
2.2.2.1 Gel electrophoresis 
2.2.2.1.1 Ethidium bromide gel 
Separation of DNA based on their size was carried out using 1.5% (w/v) Agarose gel, unless 
otherwise stated. Powdered SeaKem® LE Agarose (Lonza) was dissolved in Tris-Acetate-
EDTA running buffer (40 mM Tris-Acetate, 1 mM EDTA, pH 8.0) containing 12.5 pg/mL 
ethidium bromide, and allowed to set at room temperature. The gel was transferred to 
electrophoresis tank containing Tris-Acetate-EDTA buffer and DNA samples mixed with 
loading dye were loaded onto the gel. 2 log ladder (New England BioLabs) was also loaded 
onto the gel as markers. The loaded gel was run for 60 minutes at 90V on (PowerPacTM Basic 
Power Supply, Bio-Rad Laboratory). The finished gel was viewed under ultra violet (UV) light 
on G:BOX F3 (Syngene) using the GENEsys (v1.2.8.0) software and images were captured. 
 
2.2.2.1.2 Methylene blue gel 
A 1.5% (w/v) Agarose gel was prepared for gel extraction of DNA. Powdered SeaKem® LE 
Agarose (Lonza) was dissolved in Tris-Acetate-EDTA running buffer (40 mM Tris-Acetate, 1 
mM EDTA, pH 8.0) without ethidium bromide, and allowed to set at room temperature. The gel 
was transferred to an electrophoresis tank containing Tris-Acetate-EDTA buffer and DNA 
samples mixed with loading dye were loaded onto the gel. Quick-Load® Purple 2-log ladder 
(New England Biolabs) was also loaded onto the gel as markers. The loaded gel was run for 
60 minutes at 90V on (PowerPacTM Basic Power Supply, Bio-Rad Laboratories). The finished 
gel was incubated overnight at 4°C in 0.01% methylene blue/1X TAE as described previously 
(Soto and Draper, 2012). 
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2.2.2.2 Gel extraction and DNA purification 
Gel extraction was carried out using the QIAquick® Gel Extraction kit (Qiagen) on methylene 
blue stained Agarose gel. All extraction steps were performed as stated in the manufacturer’s 
handbook (QIAquick® Spin handbook). DNA enzymatic purification was carried out following 
the same kit and handbook as the gel extraction. All steps for the enzymatic purification were 
followed as stated in the handbook. 
 
2.2.2.3 NanoDropTM Spectrophotometry 
DNA concentration was determined using NanoDropTM 1000 Spectrophotometer (Thermo 
Scientific). Loading of the samples and concentration measurement was carried out as stated 
in the user’s manual and all results were analysed using the NanoDropTM 1000 (v3.7) software. 
 
2.2.3 Molecular cloning 
2.2.3.1 Generation of RNAi constructs 
2.2.3.1.1 Amplification of GEFs and GAPs for RNAi cloning 
A suitable RNAi region from nucleic acid sequences for each of the T. brucei GEFs and GAPs 
were selected using the software RNAit – RNAi target selection for Trypanosome genomes 
(https://dag.compbio.dundee.ac.uk/RNAit/ - accessed: Nov 2018).  Primers were designed for 
TbGAP1, TbGAP2, TbGAP3, TbGAP4, TbGEF1, TbGEF2 and TbGEF3 (see section 2.1.5) 
with XbaI restriction site on the 5’ and 3’ ends of the RNAi region to enable cloning into P2T7Ti 
RNAi vector. The designed primers were generated by Eurofins MWG Operon (Ebersberg, 
Germany). Gradient PCR was used to amplify the RNAi region of T. brucei GEFs and GAPs 
from T. brucei genomic DNA. 20 L reaction consisting of 1X KOD Hot Start DNA polymerase 
buffer (Novagen), 0.04 units KOD Hot Start DNA polymerase (Novagen), 0.4 mM dNTPs, 3 
mM MgSO4, 0.6 M forward and reverse primers, and water was prepared for each of the 
genes. The PCR cycle was initiated on a Peltier Thermal Cycler PTC-200 (Bio-Rad 
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Laboratories) for 35 cycles (Table 2.1). A restriction digest was carried out with XbaI enzyme 
(Thermo Fisher Scientific FastDigest) on the P2T7TbARL6 vector (Price et al., 2012) and 
purified amplified PCR products. The digested plasmid vectors were treated with Alkaline 
Phosphatase (Thermo Scientific FastAP). The reaction was set up as stated in the 
manufacturer’s handbook and 1 g vector DNA was used per reaction (Thermosensitive 
Alkaline Phosphatase). The reagents were incubated at 37°C for 10 minutes followed by 
termination of the reaction at 75°C for 5 minutes. Alkaline Phosphatase treated vector and 
XbaI digested inserts were ligated using T4 DNA ligase kit (New England Biolabs). The 
protocol for ligation was adapted from the manufacturer’s handbook (NEB Ligation Protocol 
with T4 DNA Ligase). Approximately 97.85 ng vector and 73.5 ng insert was added to 1.5 L 
10X T4 DNA ligase buffer with 10 mM ATP and 1 L T4 DNA ligase enzyme, water was added 
to make a final volume of 15 L. The reaction was left at room temperature for 10 minutes.  
 
Gradient PCR cycle 
Step Temperature Time Repeats 
Initialisation 95°C 2 minutes 
34 
Denaturation 95°C 20 seconds 
Annealing 55-65°C 20 seconds 
Elongation 70°C 1 minute 
Final elongation 70°C 10 minutes N/A 
Cycle end 4°C ∞ N/A 
 
Table 2.1. Gradient PCR cycle. Table detailing the steps and number of cycles used for 
gradient PCR 
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2.2.3.1.2 Transformation 
Ligated products were transformed into One Shot® TOP10 Chemically Competent E. coli 
(Invitrogen). 3 L of ligated product was added to the competent cells and kept in ice for 30 
minutes. This was then heat shocked at 42°C for 45 seconds and then placed in ice 
immediately for 2 to 3 minutes. 200 L of SOC medium was added to the cells and incubated 
at 37°C for 1 hour. 150 L of SOC-competent cells were plated onto LB-ampicillin (ampicillin 
concentration of 100 g/mL) agar plates and incubated at 37°C overnight. 6 colonies were 
transferred into 5ml LB-ampicillin liquid medium and incubated at 37°C overnight with shaking. 
 
2.2.3.1.3 Plasmid miniprep preparation 
Plasmid DNA was isolated and purified from selected colonies grown overnight in LB-ampicillin 
liquid medium using QIAprep® Spin Miniprep kit (Qiagen). All miniprep steps were carried out 
as recommended by the manufacturer. The purified plasmid DNAs were subjected to 
restriction digest using XbaI and the products were then separated on a gel electrophoresis in 
order to validate the presence of inserts. Successfully ligated and transformed plasmid DNAs 
were selected and sent for sequencing by Eurofins MWG Operon (Ebersberg, Germany). List 
of primers used for sequencing are provided in section 2.1.5.  
 
2.2.3.2 TOPO® cloning 
2.2.3.2.1 Design of Oligonucleotides for TOPO® cloning 
The open reading frame (ORF) for T. brucei GEF3 was amplified from T. brucei genomic DNA 
using KOD DNA polymerase (Novagen). Specific primers were designed for TbGEF3 (section 
2.1.5) and gradient PCR was used to amplify the ORF following the same procedure as 
described in section 2.2.3.1.1. 
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2.2.3.2.2 3’ A-overhangs addition 
Addition of 3’ A-overhangs reaction was conducted as follows: 100 ng/L PCR products, 5 L 
Taq Polymerase buffer (New England BioLabs), 1 L 10 mM dNTPs, 0.5 U/L Taq Polymerase 
(New England BioLabs) and 3 L water was added together and incubated at 72C for 10 
minutes. 
 
2.2.3.2.3 TOPO® TA® Cloning® 
TOPO® cloning reaction was set up using the TOPO® TA® Cloning® kit (Invitrogen). All steps 
were carried out as stated by the manufacturer (Invitrogen) and 0.5 g PCR products were 
used for this reaction. The products of the TOPO cloning reaction was transformed into One 
Shot® TOP10 Chemically Competent E. coli. (Invitrogen) as stated above and grown in LB-
ampicillin (100 g/mL) overnight. A restriction digest was carried out with EcoRI enzyme 
(Thermo Scientific FastDigest) on 1 g purified plasmid DNA samples extracted from individual 
clones. Reaction mixes were incubated for 10 minutes at 37°C and then viewed by gel 
electrophoresis. 
 
2.2.4 Transfection of T. brucei 
2.2.4.1 Parasite culture 
T. brucei bloodstream form (BSF) strain Lister 427 (Single Marker) was maintained as 
described (Wirtz et al., 1999) in HMI-9 media with 2 g/mL GeneticinTM (Gibco, Thermo Fisher 
Scientific) and incubated at 37°C with 5% CO2. This strain stably expresses a phage derived 
T7 RNA polymerase and tetracycline repressor. HMI-9 media consisted of 1.8 g/L HMI-9 
powder (custom made by Gibco, Thermo Fisher Scientific), 0.036 M NaHCO3 (Sigma-Aldrich), 
10% heat inactivated tetracycline free Foetal Bovine Serum (Gibco, Thermo Fisher Scientific), 
100 U/mL Penicillin & 100 g/mL Streptomycin (Gibco, Thermo Fisher Scientific), 4 mM L-
glutamine (Gibco, Thermo Fisher Scientific) and 5.72 mM 2-Mercaptoethanol (Sigma-Aldrich). 
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2.2.4.2 Preparation of DNA for Transfection 
RNAi constructs were subjected to restriction digest by NotI enzyme (Thermo Scientific 
FastDigest). The digested products were purified using enzymatic purification kit (Qiagen). NotI 
digested plasmid DNA was further purified and concentrated via ethanol precipitation. A 1/10 
volume of 3M sodium acetate (AccuGene®, Lonza) and 2 volumes of 100% ethanol were 
added to the plasmid DNA samples. The solution was then incubated at -20°C for 30 minutes 
and then centrifuged at 14,500 g for 10 minutes. Supernatant was discarded and the plasmid 
DNA samples were washed with 1 mL 70% ethanol. This was then centrifuged 14,500 g for 10 
minutes and most of the supernatant was removed. 
 
2.2.4.3 Transfection 
Mid-log phase T. brucei BSF strain parasites were transfected with the NotI digested P2T7Ti-
TbGAP/GEF plasmid as described (Price et al., 2005b). AMAXA® Human T cell Nucleofector 
kit (Lonza) was used to perform the transfection. 2X107 mid log-phase T. brucei BSF strain 
parasites were centrifuged at 800 g for 10 minutes and supernatant was discarded. The 
parasites were re-suspended in 10 mL 1X PBS and centrifuged at 800 g for 10 minutes and 
the majority of the supernatant was discarded. Parasites were transferred to a 1.5 mL 
microtube. The microtube was centrifuged at 1,990 g for 5 minutes and all supernatant was 
removed. Parasites were resuspended in T-cell nucleofection solution (Lonza) (100 L per 
transfection). The suspension was transferred to the NotI digested DNA sample, then 
transferred to AMAXA® cuvettes and nucleofection was performed using an AMAXA® 
nucleofector device (programme X-001) (Lonza). The nucleofected parasites were transferred 
to HMI-9 media and incubated at 37°C with 5% CO2. 
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2.2.5 Induction of RNAi 
RNAi of the transfected bloodstream form Lister 427 T. brucei was induced by adding 1 g/mL 
tetracycline (Sigma-Aldrich). The density of the parasites was determined by counting the 
number of parasites using a haemocytometer. The phenotype of the induced parasites were 
also observed every 24 hours post addition of the tetracycline using light microscopy. Parasites 
with a density of 5X104/mL were grown in 10 mL HMI-9 medium (with neomycin) in two sets of 
triplicates. Tetracycline was added to one set of the experimental triplicates. 
 
2.2.6 Quantification of gene expression following RNAi 
2.2.6.1 Design of Oligonucleotides for qPCR 
Primers for qPCR (section 2.1.5) were designed utilising the Primer 3 software 
(http://frodo.wi.mit.edu/ - accessed: May 2019) and the Beacon Designer Free Edition software 
(http://free.premierbiosoft.com/ - accessed: May 2019) and all standard parameters were used 
as stated (Thornton and Basu, 2011). 
 
2.2.6.2 RNA extraction 
Total RNA was extracted from mid-log phase BSF T. brucei following incubation in 1 g/mL 
tetracycline for a range of time points. The extraction of RNA was performed using TRIsureTM 
(Bioline) and all steps were followed as stated in the manufacturer’s handbook. The parasites 
were centrifuged at 800 g for 10 minutes and the supernatant was discarded. The parasites 
were then re-suspended in 45 mL PBS and centrifuged at 800 g for 10 minutes and the 
supernatant was then discarded. Parasites were resuspended in 100 L PBS and transferred 
to a nuclease-free microtube. 1 mL TRIsureTM (Bioline) was added to the suspension and 
incubated at room temperature for 5 minutes. 200 L chloroform was added to the microtube, 
mixed vigorously for 15 seconds and incubated at room temperature for 3 minutes. The 
samples were centrifuged at 12,000 g for 15 minutes at 4°C. The aqueous upper phase was 
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transferred to new microtube, 500 L isopropanol was added and mixed. The samples were 
then incubated at room temperature for 10 minutes, followed by centrifugation at 12,000 g for 
15 minutes at 4°C. The supernatant was removed and the pellet was washed by adding 75% 
ethanol and vortexing briefly. The solution was then centrifuged at 7500 g for 5 minutes at 4°C 
and the supernatant was removed. The pellet was air-dried and then re-suspended in 30 L 
nuclease free water. 
 
2.2.6.3 DNAse treatment 
The extracted RNA samples were subjected to DNase treatment using the DNase kit (Ambion), 
using 4 g RNA, 5 L 1X DNase buffer, 0.04 U/L DNase I enzyme and 5 L inactivation 
buffer. All procedures were carried out as stated in the manufacturer’s handbook. 
 
2.2.6.4 Reverse transcription 
Reverse transcription was carried out on the DNase treated samples using the Omniscript® 
RT kit (Qiagen), Oligo dT (Qiagen) and RNaseOUTTM Recombinant Ribonuclease Inhibitor 
(Invitrogen). A 40 L reaction containing 4 g of RNA was set up following the procedures 
stated in the manufacturer’s handbook. 
 
2.2.6.5 Quantitative Polymerase Chain Reaction 
qPCR reactions were set up as stated in the Universal SYBR® Green Quantitative PCR 
Protocol (Sigma-Aldrich). A master mix consisting of PowerUPTM SYBR® Green master mix 
(Applied Biosystems), DNA template, 0.3 M forward and 0.3 M reverse primers were 
prepared with nuclease-free water to make 25 L reagent per well. 25 l reagents were 
aliquoted into each well and the qPCR run was performed using StepOne Plus Real-Time 
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System (Thermo Fisher Scientific) (programme detailed in Table 2.2). Results were analysed 
with StepOne Software v2.3 (Thermo Fisher Scientific) and Excel. 
 
qPCR cycle 
Step Temperature Time Repeats 
UDG activation 50°C 2 minutes Hold 
Dual-Lock DNA 
Polymerase 
95°C 2 minutes Hold 
Denature 95°C 15 seconds 
40 
Anneal/Extend  60°C 1 minute 
Dissociation curve 
Step Ramp rate Temperature Time 
1 1.6°C/second 95°C 15 seconds 
2 1.6°C/second 60°C 1 minute 
3 0.15°C/second 95°C 15 seconds 
 
Table 2.2. qPCR cycle and dissociation curve steps. Table detailing the steps, number of 
cycles and temperature used for qPCR. A dissociation curve was used to determine the 
specificity of the qPCR. 
 
2.2.7 Microscopy 
2.2.7.1 Indirect immunofluorescence 
Log-phase BSF parasites (1x107/mL) were harvested by centrifugation at 800 g for 10 minutes. 
BSF cells were washed in Voorheis’ modified PBS (vPBS; PBS supplemented with 10mM 
glucose and 46mM sucrose) and fixed for 1 hour on ice in 4% (w/v) paraformaldehyde. Fixed 
cells were washed and adhered to poly-lysine microscope slides for 20 minutes at room 
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temperature in humid chamber. The cells were then permeabilised with 0.1% (w/v) Triton-X 
100 in PBS for 10 minutes (Allen et al., 2003). Image-iTTM FX Signal Enhancer (Invitrogen) 
signal enhancer was added to the slides and incubated at room temperature for 1 hour. A 
primary mouse monoclonal antibody 1 (TAT1) against T. brucei -tubulin (1:200, a gift from 
Keith Gull) and a primary anti-rabbit monoclonal antibody against paraflagellar rod protein 1 
(PFR1) (1:200) (Hemsworth et al., 2013) were added to the slides and incubated for 1 hour at 
room temperature. Unbound primary antibodies were washed off with PBS. Alexa Fluor 488 
and 594 conjugated secondary antibodies (1:250, Invitrogen) were added to the slides and 
incubated at room temperature for 1 hour. Unbound secondary antibodies were washed off 
with PBS and 5 g/mL DAPI was added to all cells. Cells were incubated at room temperature 
for 5 minutes and washed with PBS. ProLongTM Diamond Antifade Mounting (Invitrogen) 
medium was added to the slides and sealed with coverslips. All samples were visualised by 
fluorescence microscopy using EVOS FL Cell Imaging System (Life Technologies). 
 
2.2.7.2 Transmission Electron Microscopy (TEM) 
Log-phase BSF parasites (2x107 cells/mL) were washed three times in serum free HMI9 media 
and once in PBS. Samples were then processed for TEM by Meg Stark (Technology Facility, 
Department of Biology, University of York) using methods described previously (Price et al., 
2007a). Images were viewed with a Tecnai 12 BioTwin (FEI) at 120 kV and images were 
acquired using SIS MegaView III digital camera. 
 
2.2.8 Flow cytometry 
2.2.8.1 Propidium iodide flow cytometry 
Mid-log phase BSF parasites were incubated for 0 to 72 hours in the presence of 1 g/mL 
tetracycline. 1x107 cells were harvested by centrifugation at 1000 g for 10 minutes at 4°C and 
washed in PBS and prepared for propidium iodide flow cytometry as described previously 
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(Ibrahim et al., 2011). 10 ng/mL RNase A (Thermo Fisher Scientific) was added to each 
samples and tubes were incubated in 37°C for 2 hours. 10 ng/mL propidium iodide (Sigma-
Aldrich) was then added to the samples and the tubes were further incubated for 45 minutes 
at 37°C. Samples were processed on a Guava EasyCyte 6-2L flow cytometer (Merck Millipore) 
and 20,000 events were counted per sample. The flow cytometer was calibrated before each 
use as described in the manufacturer’s protocol. InCyte software (Merck Millipore) was used 
to analyse the data. 
 
2.2.8.2 Live/Dead flow cytometry  
Mid-log phase BSF parasites (1x107 cells) induced at different time points with 1 g/mL 
tetracycline were harvested by centrifugation for 10 minutes at 800 g, washed with PBS and 
resuspended in 1 mL PBS. 1 L of Live/Dead Fixable Red Dead Stain (Thermo Fisher 
Scientific) was added to the samples and incubated for 30 minutes at 20°C in dark. The 
samples were centrifuged at top speed for 20 seconds (Labnet PrismTM Microcentrifuge) and 
resuspended in 1 mL 4% (w/v) paraformaldehyde, these were then incubated at room 
temperature in dark for 15 minutes. The samples were washed in PBS by centrifugation at 800 
g for 10 minutes and resuspended in 1 mL PBS. Flow cytometry was carried out using Guava 
EasyCyte 6-2L flow cytometer (Merck Millipore) and 20,000 events were counted per sample, 
InCyte software (Merck Millipore) was used to analyse the data. 
 
2.2.9 Concanavalin A endocytosis assay 
Log-phase BSF parasites (1x107 cells) were harvested by centrifugation at 800 g for 10 
minutes and resuspended in 1 mL serum free HMI9/1% BSA. Samples were incubated at 4°C, 
12°C or 37°C for 45 minutes. 25 g/mL Concanavalin A (Alexa FluorTM 488 Conjugate, Thermo 
Fisher Scientific) was added to each samples and the samples were further incubated for 1 
hour at temperatures as before. The samples were washed in Voorheis’ modified PBS (vPBS; 
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PBS supplemented with 10 mM glucose and 46 mM sucrose) and resuspended in 0.5 mL 
vPBS. 0.5 mL 6% (w/v) paraformaldehyde was added and the samples were incubated at 4°C 
for 1 hour. The samples were washed and resuspended in 1 mL PBS. The samples were then 
prepared for an indirect immunofluorescence assay as previously described in section 2.7.1. 
Rabbit anti-TbRab5A against T. brucei early endosomes (1:100, a gift from Mark Field, 
Department of Pathology, University of Cambridge, UK) and mouse anti-P67 against T. brucei 
lysosomes (1:100, a gift from Jay Bangs, Department of Medical Microbiology and 
Immunology, Madison, WI, USA) were used on samples incubated at 12°C and 37°C 
respectively. The primary antibodies were detected using Alexa Fluor 488 and 594 conjugated 
secondary antibodies (1:250, Invitrogen). All samples were visualised by fluorescence 
microscopy using EVOS FL Cell Imaging System (Life Technologies). 
 
2.2.10 Drug Screening 
2.2.10.1 Determination of IC50 of tetracycline in T. brucei lines 
The IC50 of tetracycline in P2T7-GEF3 cell lines was identified in order to determine a suitable 
concentration of tetracycline for inducing a non-lethal defect in endocytosis. 2-fold dilutions of 
tetracycline with concentrations ranging from 1 g/mL to 7.63 pg/mL were prepared in HMI-9 
media. 100 L of the prepared dilutions were dispensed into each well of the 96 well plate in 
triplicates, 100 L of log-phase BSF P2T7-GEF3 T. brucei (1x105 cells) were added to each 
dilutions. Positive (Amphotericin B) and negative (water) controls were also included in all 
plates. The plates were incubated for 48 hours in 37°C with 5% CO2. PrestoBlue® (Thermo 
Fisher Scientific) was added to a dilution of 1:10 per well and plates were incubated in the dark 
for 3 hours in 37°C with 5% CO2. Plates were read on a Promega GloMax® Multi Detection 
System (ex/em = 525/580-640 nm). Percentage viability was calculated as described 
previously (Berry et al., 2018). The data were analysed using GraphPad Prism7 to determine 
the half maximal inhibitory concentration (IC50) of tetracycline.  
  
77 
Percentage viability for all drug screening experiments were calculated as described by Berry 
et al. 2018:  
 
 
Figure 2.1. Percentage viability formula. s = mean value for samples, (+) = mean of 
negative control, (-) = mean of positive control (Amphotericin B) (Berry et al., 2018). 
 
2.2.10.2 Determination of IC50 of suramin in T. brucei lines 
2-fold dilutions of suramin were prepared in HMI-9 medium with concentrations ranging from 
1mM to 1.95M as described previously (Bruhn et al., 2015). 100 L of the dilutions were 
dispensed into each well of the 96 well plate in triplicates. 100 L of log-phase BSF P2T7-
GEF3 T. brucei (1x105 cells) were added to each well containing the dilutions. Positive 
(Amphotericin B) and negative (water) controls were also included in all plates. The plates 
were incubated for 48 hours in 37°C with 5% CO2. PrestoBlue® (Thermo Fisher Scientific) was 
added to a dilution of 1:10 per well and plates were incubated in the dark for 3 hours in 37°C 
with 5% CO2. Plates were read on a Promega GloMax® Multi Detection System (ex/em = 
525/580-640 nm). Percentage viability was calculated as described previously (Berry et al., 
2018). The data were analysed using GraphPad Prism7 to determine the half maximal 
inhibitory concentration (IC50) of suramin. 
 
2.2.10.3 MMV Pathogen Box 
The Pathogen Box consisting of 400 drug like compounds against neglected tropical diseases 
was obtained from Medicines for Malaria Venture (MMV). The compounds were dissolved in 
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dimethyl sulfoxide (DMSO) at a concentration of 10 M and further diluted to a concentration 
of 1 M in HMI-9 media. Each compound was added to the well at a final concentration of 1 
M and 10 M in duplicates. 100 L of log-phase wild type BSF T. brucei (1x105 cells) was 
added to each well. Positive (Amphotericin B) and negative (DMSO) controls were also 
included in all plates. The plates were incubated for 48 hours in 37°C with 5% CO2. 
PrestoBlue® (Thermo Fisher Scientific) was added to a dilution of 1:10 per well and plates 
were incubated in dark for 3 hours in 37°C with 5% CO2. Plates were read on a Promega 
GloMax® Multi Detection System (ex/em = 525/580-640 nm). The percentage viability was 
calculated as described previously (Berry et al., 2018) and data was analysed using GraphPad 
Prism7. Percentage viability of 5% or below compared to the diluent only control (DMSO) was 
identified as a positive hit. IC50 of the positive hits was carried out as described in section 
2.2.10.2. 
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Chapter 3 – Identification and 
functional prediction of ARF 
regulators in T. brucei using 
bioinformatics 
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3.1 Introduction 
Since the discovery of ADP-ribosylation factors (ARFs) in the 1980s for their ability to act as 
cofactors to stimulate cholera toxin ADP-ribosyltransferase activity (Kahn and Gilman, 1984, 
Enomoto and Gill, 1980), ARFs have been extensively studied and documented, resulting in 
the identification of these proteins in all studied eukaryotic organisms to date (Nie et al., 2003). 
The identified ARFs have been shown to be highly conserved throughout eukaryotic evolution 
(Nie et al., 2003, Li et al., 2004, Muthamilarasan et al., 2016, Serbzhinskiy et al., 2015). This 
was further shown by Price et al. through amino acid sequence analysis of the 9 identified T. 
brucei ARF/ARLs against closest homologues of human ARF/ARLs, finding the level of 
similarities to range from 43% to 75% (Price et al., 2005b, Price et al., 2005a).  
Knockdown studies on T. brucei ARF/ARLs using a tetracycline inducible RNAi system have 
demonstrated the potential roles of ARF/ARLs in bloodstream form T. brucei. Previous studies 
have demonstrated that ARL6 may be involved in maintaining flagellum length since RNAi of 
ARL6 led to shortening of the flagellum length (Price et al., 2012). Price et al demonstrated the 
potential roles of ARF1 and ARL1 in T. brucei endocytosis and trafficking. RNAi of ARF1 and 
ARL1 in bloodstream form T. brucei led to increase in lethal phenotypes and cell death (Price 
et al., 2007b, Price et al., 2005a, Price et al., 2005b). These studies have highlighted that many 
of these proteins are essential for T. brucei viability. However the high level of amino acid 
similarity between T. brucei and human ARF/ARLs suggest that targeting T. brucei ARF/ARLs 
may inadvertently target human ARF/ARLs; thus possibly leading to adverse side effects for 
the host (Müller and Hemphill, 2016). 
Guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) regulate 
the activity of ARF/ARLs. GEFs aid in the dissociation of GDP and association of GTP to 
ARF/ARLs, resulting in their activation. GAPs on the other hand aid in the hydrolysis of GTP 
into GDP that are bound to ARF/ARLs, thus leading to their inactivation (Scheffzek and 
Ahmadian, 2005, Jackson and Casanova, 2000). Previous studies have demonstrated that the 
overexpression or mutation of these regulators affects the function of ARFs, thus disrupting 
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cellular functions; highlighting the essential nature of these regulating proteins. Unlike 
ARF/ARLs, GEFs and GAPs are highly diverse at the amino acid level, with the highly 
conserved regions being the Sec7 and ARFGAP catalytic domains respectively (Jackson and 
Casanova, 2000, Pocognoni et al., 2018, Kahn et al., 2008). Therefore this high level of 
diversity found in these ARF/ARL regulating proteins could possibly make them drug targets 
against T. brucei. 
 
3.1.1 Aims 
The aim of this chapter is to use bioinformatics tools to identify T. brucei GEFs and GAPs, to 
find the level of homology with human GEFs and GAPs at both the sequence and structural 
level, and to explore protein localisation using existing datasets. 
Additionally this chapter also aims to identify orthologues in other kinetoplastids. While T. 
brucei are extracellular parasites, not entering host cells at any point of their life cycles, the 
related kinetoplastids T. cruzi and Leishmania spp. have intracellular stages in the host. This 
difference in localisation environment may lead to alteration in functions of GEFs and GAPs or 
the absence of members of these groups of regulating proteins. 
 
3.2 Methods 
Bioinformatics tools were used to identify T. brucei ARF GEFs and GAPs, as well as to analyse 
the structure and see if it would be possible to determine their interactions and functions. 
The methods used in this chapter are as follows: 
3.2.1 Protein BLAST 
Literature and NCBI database searches were used to identify human GEFs and GAPs 
(https://www.ncbi.nlm.nih.gov/ - accessed: Oct 2015). BLAST searches (BLASTP) using the 
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protein sequences of human GEFs and GAPs were used to identify possible homologues in 
the T. brucei genome database (https://tritrypdb.org/tritrypdb/ - accessed: Oct 2015). 
 
3.2.2 Sequence alignment 
Amino acid sequence alignment was used to determine regions of sequence similarity between 
human and T. brucei GEFs and GAPs. The amino acid sequences for T. brucei and human 
GEFs and GAPs were aligned using UniProt sequence alignment (Clustal Omega) 
(www.https://uniprot.org/align/ - Oct 2015). 
 
3.2.3 Domain analysis 
Visualisation and analysis of the domains present in T. brucei GEFs and GAPs was carried 
out using Simple Modular Architecture Research Tool (SMART) (http://smart.embl-
heidelberg.de/ - accessed: June 2017). The same was done for all human GEFs and GAPs, 
and the domain composition was compared between the two species. 
 
3.2.4 Structural analysis 
The structure of identified T. brucei GEFs and GAPs was determined with the aid of structure 
prediction tool; Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index – 
accessed: May 2018). The predicted structures for both human and T. brucei ARF regulators 
were analysed on PyMOL Molecular Graphics System, Version 2.0 supplied by Schrödinger, 
LLC. 
 
3.2.5 Protein localisation 
Subcellular localisation of the identified T. brucei GEFs and GAPs was searched using 
TrypTag (http://tryptag.org/ - accessed: March 2018),  a protein localisation resource (Dean et 
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al., 2017). The same was done for previously identified T. brucei ARF/ARLs. The Human 
Protein Atlas (www.proteinatlas.org – accessed: April 2019) was used to the search for existing 
datasets to explore subcellular localisation of human GEFs and GAPs. 
 
3.2.6 Putative orthologues of T. brucei ARF regulators in other kinetoplastids 
Putative orthologues of T. brucei GEFs and GAPs in other kinetoplastids was determined with 
the aid of OrthoMCL (https://orthomcl.org/orthomcl/ - accessed: April 2019). Orthologue groups 
for the T. brucei GEFs and GAPs were identified and searched for in other kinetoplastids such 
as Trypanosoma cruzi and Leishmania spp. 
 
3.3 Results 
3.3.1 Identification of T. brucei GEFs and GAPs 
Literature and gene sequence searches were carried out using the National Center for 
Biotechnology Information (NCBI) protein database (https://www.ncbi.nlm.nih.gov/protein/ - 
accessed: Oct 2015) to identify human ARF regulators and their protein sequences.  26 human 
ARF GAP genes were identified. The 26 human ARF GAPs were classified according to their 
subfamilies (Appendix 1): ARFGAP, ADAP, SMAP, GIT, ASAP, ACAP and ARAP; based on 
their protein-protein interaction domains (Sztul et al., 2019). 14 human ARF GEF genes were 
also identified (Appendix 2). The GEF genes were also classified into their subfamilies 
according to their protein-protein interacting domains and size. These are: CYTH, GBF, 
ARFGEF, PSD and IQSEC (Sztul et al., 2019).  
Protein sequences for each human GEFs and GAPs were obtained. BLASTP was carried out 
using the protein sequences on TriTrypDB (release 42), a collective genomic database on 
Trypanosomatidae (Aslett et al., 2010), to identify similar proteins in T. brucei Lister 427 strain. 
BLASTP results identified 9 T. brucei genes which are potential orthologues to more than one 
human ARF GAP genes. Four T. brucei GAP genes that had the lowest e-values (no higher 
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than 1e-5) were selected for further analysis (Table 3.1). Similarly BLASTP results identified 
three T. brucei genes which are potential orthologues to more than one human ARF GEF 
genes. The three identified T. brucei GEF genes had e-values that were no higher than e-5 
(Table 3.1). 
To check that the identified T. brucei genes are orthologues to human ARF regulators, a 
reverse BLAST was executed. Reverse BLAST results confirmed that the identified T. brucei 
genes did correspond to their correct orthologues in humans. The T. brucei genes that came 
up on BLAST searches but were not selected were also subjected to reverse BLAST search. 
Results showed that these genes did not correspond to any ARF orthologues in humans. 
The four T. brucei ARF GAPs were assigned names: TbGAP1 (Tb427tmp.244.2540), TbGAP2 
(Tb427tmp.01.0920), TbGAP3 (Tb427tmp.01.6060). The same was done to the three T. brucei 
ARF GEFs: TbGEF1 (Tb427.08.1840), TbGEF2 (Tb427.04.2200) and TbGEF3 
(Tb427tmp.01.7610). 
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Accession number 
Assigned 
name 
Size (amino 
acids)/ kDa 
Highest 
similarities (%) 
Regulator 
similar to 
Tb427tmp.244.2540 TbGAP1 417/46.16 19 ARFGAP3 
Tb427tmp.01.0920 TbGAP2 291/31.68 20 ADAP1 
Tb427tmp.01.6060 TbGAP3 306/33.98 20 ARFGAP1 
Tb427.03.5300 TbGAP4 275/31.24 14 SMAP2 
 
Tb427.08.1840 TbGEF1 2054/225.09 15 GBF1 
Tb427.04.2200 TbGEF2 1666/183.63 15 ARFGEF2 
Tb427tmp.01.7610 TbGEF3 1046/117.05 14 IQSEC1 
 
Table 3.1. Homologues of ARF GEFs and GAPs in T. brucei. BLASTP was performed on 
amino acid sequences of human ARF GAPs to identify homologs in T. brucei. BLASTP results 
yielding e-values lower than 1e-5 were selected, and four putative T. brucei GAPs and three 
putative T. brucei GEFs with the lowest e-values were selected for further analysis. Amino acid 
sequence analysis was carried out on the identified T. brucei GEFs and GAPs against all 
known human GEFs and GAPs. The highest percentage of similarities for each of the putative 
T. brucei ARF regulators are shown.  
 
3.3.2 Structural and sequence similarities 
3.3.2.1 Amino acid sequence alignment 
In order to use ARF regulators as novel drug targets against T. brucei, a low level of sequence 
identity between the human and T. brucei ARF regulators would be preferable. UniProt 
sequence alignment (Clustal Omega) tool was used to determine the level of amino acid 
sequence identity between the identified human ARF regulators and T. brucei ARF regulators, 
as well as to identify regions of similarity between the two regulators. 
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Amino acid sequences of the 26 identified human ARF GAPs were aligned with each of the 
amino acid sequences of the 4 identified T. brucei GAPs. Percentage of similarities was 
obtained from UniProt sequence alignment (Clustal Omega) tool for each of the 4 T. brucei 
GAPs against the 26 human ARF GAPs. The same was done with the amino acid sequences 
of the 14 identified human ARF GEFs and the amino acid sequences of each of the 3 identified 
T. brucei GEFs.  Percentage of similarities of amino acid sequences between human and T. 
brucei ARF regulators demonstrated the high level of diversity of these regulators between the 
two species.  
BoxShade was used to highlight regions of amino acid sequence similarity between identified 
T. brucei GEFs and human GEFs post multiple sequence alignment (Figure 3.1). Further 
analysis of the similar amino acid sequences showed that the identical regions were the highly 
conserved Sec7 catalytic domains present in all GEFs. The regions marked by red and blue 
lines above and below the sequences are the ARF binding sites that are formed from the 
hydrophobic and hydrophilic residues present on F and G helices (red lines), and the 
hydrophobic residue present on the H helix (blue lines); forming a loop (Pai, 1998).  
The same was done for T. brucei GAPs and human GAPs using BoxShade (Figure 3.2). 
Analysis of the identical amino acid regions revealed them to be the highly conserved ARFGAP 
catalytic domains that are present in GAPs. The characteristic Cys4 zinc finger present in 
ARFGAP domains are highlighted by the red lines above and below the sequences.  
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Figure 3.1. Multiple sequence alignment of T. brucei and human GEFs. Partial sequence 
from multiple sequence alignment of human and T. brucei GEFs. Regions of similarities were 
depicted using BoxShade. Amino acids shaded black are identical, whilst amino acids shaded 
grey display similar properties. Regions highlighted by red and blue lines represent the ARF 
binding sites of GEFs. The asterisks (*) and dots (.) under the sequence indicate completely 
conserved and highly conserved amino acids. 
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Figure 3.2. Multiple sequence alignment of T. brucei and human GAPs. Partial sequence 
from multiple sequence alignment of human and T. brucei GAPs. Regions of similarities were 
depicted using BoxShade. Amino acids shaded black are identical, whilst amino acids shaded 
grey display similar properties. The region highlighted by red lines represent the Cys4 Zinc 
finger motif that is characteristic of ARFGAP domain. The asterisks (*) and dots (.) under the 
sequence indicate completely conserved and highly conserved amino acids. 
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3.3.2.2 Domain prediction 
The Simple Modular Architecture Research Tool (SMART) was used to identify and analyse 
domains that are present in identified human and T. brucei ARF regulators. SMART is a web 
resource that allows the identification and analysis of protein domains once a protein sequence 
has been inputted (Letunic and Bork, 2017, Letunic et al., 2015). Schematic representation of 
protein domains were generated for all subfamilies of human ARF GEFs and GAPs using 
obtained protein sequences (Figure 3.3 & 3.4), and for all identified T. brucei GEFs and GAPs 
(Figure 3.5).  
SMART analysis identified the presence of pleckstrin homology (PH) domain in CYTH, PSD 
and IQSEC subfamilies of human GEFs (Figure 3.3), PH domains are involved in binding of 
phosphatidylinositol to membranes and other proteins such as  subunits of trimeric G-
proteins (Wang et al., 1994). Interestingly the human ARFGEF and GBF subfamilies lacked 
the PH domain (Figure 3.3). SMART analysis also revealed the presence of the Sec7 catalytic 
domain in all human GEFs as expected. 
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Figure 3.3. Schematic representation of domains present in human ARF GEF subfamilies. Simple Modular Architecture Research Tools 
(SMART) analysis was used to get schematic representation of CYTH (A), GBF (B), ARFGEF (C), PSD (D) and IQSEC (E) subfamilies of ARF 
GEFs. All of the ARF GEF subfamilies except for ARFGEF and GBF contained a pleckstrin homology (PH) domain. The pink regions depict low 
complexity regions, and the green regions depict coiled coil regions. 
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Figure 3.4. Schematic representation of domains present in human ARF GAP subfamilies. Simple Modular Architecture Research Tools 
(SMART) analysis was used to get schematic representation of ARFGAP (A), ADAP (B), SMAP (C), GIT (D), ASAP (E), ACAP (F), AGAP (G) 
and ARAP (H) subfamilies. The presence of pleckstrin homology (PH) domains, ankyrin repeats (ANK), Spa2 homology domains (GIT), Scr 
homology 3 (SH3) domains, sterile alpha motif (SAM) and RhoGAP domains are also depicted. The pink regions depict low complexity regions, 
and the green regions depict coiled coil regions.
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SMART analysis of human GAPs revealed the presence of ARFGAP catalytic domain in all of 
the identified ARF GAPs. The schematic representation in Figure 3.4 showed that the ADAP, 
ASAP, ACAP, AGAP and ARAP subfamilies had PH domains similarly to the GEFs. 
Additionally to the PH domains, the human ARF GAPs also contained other functional 
domains. Ankyrin repeat (ANK) domains are present in the GIT, ASAP, ACAP and AGAP 
subfamilies. Scr homology 3 (SH3) domains, sterile alpha motif (SAM) were only present in 
ASAP and ARAP subfamilies respectively. Ankyrin repeat (ANK) domains and Scr homology 
3 (SH3) domains are domains that are required for protein-protein interactions and protein 
bindings respectively (Bork, 1993, Mayer, 2001), whereas the sterile alpha motif (SAM) is 
involved in cell-cell initiated signal transduction mediation (Schultz et al., 1997). The GIT 
domains are Spa2 homology domains that interact with binding proteins (Kim et al., 2003). The 
ARFGAP and SMAP subfamilies of the human GAPs only consisted of the ARFGAP catalytic 
domain (Figure 3.4). 
Analysis of identified T. brucei GEFs and GAPs using SMART tool revealed the presence of 
Sec7 and ARFGAP domains respectively (Figure 3.5), confirming the possibility that the 
identified T. brucei GEFs and GAPs could be homologues to human ARF regulators. Domain 
analysis also showed that the identified T. brucei GEFs and GAPs are similar to ARFGEF and 
GBF subfamilies, and ARFGAP and SMAP subfamilies respectively.  
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Figure 3.5. Schematic representation of identified T. brucei ARF regulators. Simple Modular Architecture Research Tools (SMART) analysis 
was used to identify the domains present in TbGAP1 (A), TbGAP2 (B), TbGAP3 (C), TbGAP4 (D), TbGEF1 (E), TbGEF2 (F) and TbGEF3 (G). 
The pink regions depict low complexity regions, and the green regions depict coiled coil regions. 
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3.3.2.3 Structure prediction and analysis 
Amino acid sequence analysis in section 3.3.2.1 showed the diversity between identified 
human and T. brucei ARF regulators at the amino acid sequence level. Section 3.3.2.2 
conversely highlighted the similarities between domains in human ARF regulators and T. 
brucei ARF regulators. Therefore, structural analysis was carried out in order to identify 
structural similarities between human and identified T. brucei ARF regulators. 
The structures of identified T. brucei GEFs and GAPs were predicted by analysis of amino acid 
sequences on Phyre2, a web-based protein structure prediction service (Kelley et al., 2015). 
Phyre2 structural prediction results revealed that 30% - 45% of the whole sequence was 
covered at 100% confidence for T. brucei GAPs, whilst only 10% - 18% of the whole sequence 
was covered at 100% confidence for T. brucei GEFs. This means that 30% - 45% of T. brucei 
GAPs, and 10% - 18% of T. brucei GEFs had true homology to the template used by Phyre2 
software. 
Phyre2 generated Protein Data Bank (PDB) files for the identified T. brucei GEFs and GAPs. 
The PDB files were used to predict 3D structures using PyMOL Molecular Graphics System, 
Version 2.0 Schrödinger, LLC. Predicted 3D structures for T. brucei GAPs identified the 
presence of -helices and -sheets for TbGAP1, TbGAP3 and TbGAP4 (Figure 3.6). TbGAP2 
however only consisted of -helices, lacking the -sheets that could be seen in the other T. 
brucei GAPs (Figure 3.6). The overall structure of TbGAP1, TbGAP3 and TbGAP4 also differed 
in the number of -helices and -sheets. TbGAP1 consisted of 5 -helices and 3 -sheets, 
TbGAP3 consisted of 5 -helices and 2 -sheets, whilst TbGAP4 consisted of 6 -helices and 
3 -sheets. 
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Figure 3.6. Predicted structure of T. brucei GAPs. Phyre2 was used to predict the structure 
of identified T. brucei GAPs and 3D structural analysis was carried out on PyMOL Molecular 
Graphics System. The predicted structures of TbGAP1 (A), TbGAP3 (C) and TbGAP4 (D) 
revealed the presence of -helices and -sheets characteristic of the ARFGAP domain. 
TbGAP2 (B) is predicted to only consists of -helices. 
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Figure 3.7. Predicted structure of T. brucei GEFs. Phyre2 was used to predict the structure 
of identified T. brucei GEFs and 3D structural analysis was carried out on PyMOL Molecular 
Graphics System. The predicted structure of TbGEF1 (A), TbGEF2 (B) and TbGEF3 (C) 
demonstrates the presence of 10 -helices that correlates to the Sec7 domain in GEFs. 
TbGEF3 however consists of two additional small -helices. 
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Figure 3.8. Structural alignment of T. brucei GEFs and GAPs with human CYTH and 
ARFGAP subfamily. Structural alignment was carried out on PyMOL Molecular Graphics 
System to identify structural homology of TbGEF1 (A), TbGEF2 (B) and TbGEF3 (C) against 
CYTH1. The same was done for TbGAP1 (D), TbGAP2 (E), TbGAP3 (F) and TbGAP4 (G) 
against ARFGAP3. RMS values obtained from structural alignment signified the level of 
homology between the structures. Structures depicted in red are predicted T. brucei structures. 
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Predicted 3D structures of identified T. brucei GEFs on PyMOL Molecular Graphics System 
showed the presence of -helices for all of the T. brucei GEFs. The predicted structure of 
TbGEF1 and TbGEF2 consisted of 10 -helices whilst TbGEF3 consisted of 12 -helices 
(Figure 3.7). Unlike the predicted structures of T. brucei GAPs, the T. brucei GEFs lacked -
sheets.  
Structural alignments on all of the predicted structures for T. brucei GEFs against all available 
structure of human GEFs from RCSB Protein Data Bank was carried out on PyMOL Molecular 
Graphics System (Figure 3.8.A-C). The same was done for the predicted structures of all T. 
brucei GAPs against all available structures of human GAPs (Figure 3.8.D-G). The structural 
alignment for each T. brucei ARF regulator against their respective human ARF regulators 
gave a Root Mean Square (RMS) value. A RMS value closest to 0 suggests the two protein 
structures are similar, whilst a larger RMS value suggest that the two protein structure are not 
similar. 
RMS values from structural alignment for each T. brucei GEFs and GAPs against all available 
human GEFs and GAPs showed high level of structural similarities between the identified T. 
brucei GEFs and human CYTH1 and CYTH2 (Table 3.2). Human CYTH3 had the least level 
of structural similarities with T. brucei GEFs, despite being part of the CYTH subfamily. This 
may be due to CYTH3 being a protein structure in solution whilst CYTH1 and CYTH2 were 
crystal protein structures. 
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Human GEF TbGEF1 TbGEF2 TbGEF3 
CYTH1 0.900 0.860 0.918 
CYTH2 0.763 0.827 0.625 
CYTH3 6.258 9.786 14.078 
ARFGEF2 1.171 1.167 1.729 
ARFGEF1 1.845 1.796 2.106 
IQSEC2 1.881 1.926 3.244 
IQSEC1 1.622 1.539 1.692 
 
Table 3.2. RMS values of the three identified T. brucei GEFs. Structural alignment of the 
three identified T. brucei GEFs against identified human GEFs was carried out on PyMOL 
Molecular Graphics System. RMS values closer to zero signified the similarities of the 
compared structures (coloured in green). 
 
In contrast to the RMS values for GEFs above, the RMS values for each T. brucei GAP against 
all available human GAPs showed a varying level of structural similarities (Table 3.3). All of 
the T. brucei GAPs were structural similar to SMAP2. TbGAP1 and TbGAP3 were structurally 
similar to ARFGAP subfamily and ADAP1, with TbGAP1 also being structural similar to ACAP1 
whilst TbGAP3 being structurally similar to AGAP3. TbGAP2 is structurally similar to ADAP1 
and SMAP1, whilst TbGAP4 is structurally similar to ASAP3 and ACAP1.  
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Table 3.3. RMS values of the four identified T. brucei GAPs. Structural alignment of the 
four identified T. brucei GAPs against identified human GAPs was carried out on PyMOL 
Molecular Graphics System. RMS values closer to zero signified the similarities of the 
compared structures (coloured in green). 
 
 
 
 
 
 
 
Human GAP TbGAP1 TbGAP2 TbGAP3 TbGAP4 
ARFGAP3 0.854 1.070 0.777 4.218 
ARFGAP1 0.327 1.093 0.338 1.006 
ARFGAP2 0.802 1.392 0.751 2.858 
ASAP3 1.015 1.133 7.604 0.328 
ACAP1 0.815 1.188 1.391 0.681 
AGAP3 11.145 9.145 0.537 12.703 
ARAP1 4.406 2.836 3.401 4.504 
ADAP1 0.718 0.968 0.889 1.279 
SMAP1 1.042 0.203 1.070 1.283 
SMAP2 0.683 0.839 0.718 0.783 
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3.3.3 Prediction of protein localisation 
The interactions and functions of GEFs and GAPs are influenced by their subcellular 
localisation (Donaldson and Jackson, 2011). Therefore, determining the localisation of the T. 
brucei GEFs and GAPs using available resources could give indications about their functions 
within T. brucei. The subcellular localisation of the identified T. brucei ARF regulators was 
predicted with the aid of TrypTag, a T. brucei protein localisation resource with data on proteins 
in the T. brucei genome tagged with mNeonGreen tag at N and/or C terminals (Dean et al., 
2017). TrypTag resources are currently only available for the procyclic form pleomorphic 
TREU927 T. brucei cell lines; as opposed to the bloodstream form Lister 427 T. brucei cell 
lines used in this research. In order to obtain localisation data on the identified T. brucei ARF 
regulators from TrypTag, TREU927 homologues were identified through BLASTP and 
accession numbers were used to obtain data on localisation of T. brucei GEF and GAP 
homologues (Table 3.4). Localisation results gave data for N terminal tagging and C terminal 
tagging for the identified T. brucei ARF regulators (Figure 3.9). The localisation data of 
identified T. brucei ARF GEFs and GAPs were compared to the known localisation data of 
human ARF GEFs and GAPs (Appendix 1 and 2) with the aid of The Human Protein Atlas 
(www.proteinatlas.org – accessed: April 2019), a spatial map of human proteome (Thul et al., 
2017, Uhlen et al., 2010).  
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Figure 3.9. Predicted localisation of TbGEFs and TbGAPs in T. brucei. Simplified schematic representation of T. brucei showing (1) nucleus, 
(2) kinetoplast, (3) mitochondria, (4) endosomes, (5) Golgi, (6) lysosomes, (7) flagellar pocket and (8) flagellum. The predicted localisation of 
TbGEFs and TbGAPs are represented as stars for C terminal tagged data and crosses for N terminal tagged data. 
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Localisation data for the TREU927 homologues of the identified T. brucei GEFs showed that 
TbGEF1 was localised to the nucleolus and endosomes. TbGEF2 was localised to the 
endosomes, cytoplasm and hook complex, and TbGEF3 to the cytoplasm and flagellar pocket 
(Table 3.4). This data suggests that the homologues of the identified T. brucei GEFs may be 
implicated in endocytic pathways. The hook complex is a cytoskeletal structure located at the 
flagellar pocket neck and is thought to be involved in endocytosis at the flagellar pocket; the 
subcellular localisation of TbGEF3 (Perry et al., 2018, Albisetti et al., 2017). The similarities of 
the subcellular localisation of TbGEF2 and TbGEF3 may suggest that these two GEFs may be 
involved in a similar function or could be interacting with the same ARF/ARLs present in T. 
brucei. Comparison of the subcellular localisation of human GEFs against identified T. brucei 
GEFs showed that the human ARFGEF, GBF and IQSEC subfamilies shared the same 
subcellular localisation as TbGEF2 and TbGEF3; at the cytoplasm (Yamaji et al., 2000, Mazaki 
et al., 2012, Someya et al., 2001). These similarities in localisation could mean that TbGEF2 
and TbGEF3 may be implicated in a similar function as well. Interestingly TbGEF1 is shown to 
be localised at the nucleolus as well. This subcellular localisation is also shared by ARFGEF1 
(Padilla et al., 2004), suggesting that TbGEF1 and ARFGEF1 may have a similar function or 
could be interacting with similar ARF/ARL homologues.  
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Accession number 
(Lister 427) 
Accession 
number 
(TREU927) 
Assigned 
name 
N terminus 
tagging 
C terminus 
tagging 
Tb427tmp.244.2540 Tb927.9.15490 TbGAP1 N/A Endosome 
Tb427tmp.01.0920 Tb927.11.9180 TbGAP2 
Endosome 
Cytoplasm 
Flagellum 
Cytoplasm 
Endosome 
Tb427tmp.01.6060 Tb927.11.14460 TbGAP3 
Golgi 
Cytoplasm 
Endosome 
Cytoplasm 
Tb427.03.5330 Tb927.3.5330 TbGAP4 Endosome 
Endosome 
Nucleolus 
 
Tb427.08.1840 Tb927.8.1840 TbGEF1 Nucleolus Endosome 
Tb427.04.2200 Tb927.4.2200 TbGEF2 Endosome 
Hook complex 
Cytoplasm 
Tb427tmp.01.7610 Tb927.11.15970 TbGEF3 
Cytoplasm 
Flagellar 
pocket 
Cytoplasm 
 
Table 3.4. Localisation of T. brucei ARF regulators determined through TrypTag. 
Homologs of the Lister 427 T. brucei ARF regulators were identified in TREU927 cell lines and 
accession numbers were used to identify localisation with the aid of TrypTag Trypanosome 
protein localisation resource. 
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Similar to T. brucei GEFs, the localisation data for the TREU927 homologues of the identified 
T. brucei GAPs highlighted the different subcellular localisation for each T. brucei GAP. 
TbGAP1 was localised to the endosomes; TbGAP2 was localised to cytoplasm, flagellum and 
endosomes; TbGAP3 was localised to endosomes, cytoplasm and Golgi apparatus; whilst 
TbGAP4 was localised to endosomes and nucleolus (Table 3.4). All of the T. brucei GAPs 
were localised to the endosomes; suggesting that they are implicated in the endocytic pathway 
similar to T. brucei GEFs. TbGAP2 and TbGAP3 were localised to the cytoplasm, a subcellular 
localisation that is also shared by the human ADAP, SMAP, GIT, ASAP, AGAP and ARAP 
subfamilies (Hanck et al., 2004, Kon et al., 2008, Hasegawa et al., 2012). TbGAP3 is also 
localised at the Golgi apparatus, similar to the ARFGAP and ARAP subfamilies (Santy and 
Casanova, 2002, Parnis et al., 2006). The similarities in subcellular localisation between T. 
brucei GAPs and human GAP subfamilies may suggest that they share similar functions and 
interactions. Interestingly TbGAP2 was the only identified T. brucei GAP that was shown to be 
localised to the flagellum. This may suggest that TbGAP2 could be interacting with the same 
ARF/ARLs that TbGEF2 and TbGEF3 might be interacting with. 
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Accession 
number 
Assigned 
name 
N terminus tagging C terminus tagging 
Tb927.9.13680 ARF1 
Cytoplasm, Flagellum, 
Nuclear lumen 
Flagellar pocket, 
Endosome 
Tb927.9.7650 ARF2 
Cytoplasm, Flagellum, 
Nuclear lumen 
N/A 
Tb927.7.6230 ARF3 
Cytoplasm, Flagellum, 
Nuclear lumen 
N/A 
Tb927.9.7230 ARL1B 
Cytoplasm, Flagellum, 
Nuclear lumen 
Cytoplasm, Flagellum, 
Nuclear lumen, Endosome 
Tb927.10.4250 ARL2 N/A Cytoplasm 
Tb927.3.3450 ARL3A N/A 
Axoneme, Basal body, 
Cytoplasm, Nucleus 
Tb927.10.8580 ARL3B N/A Cytoplasm 
Tb927.6.3650 ARL3C 
Cytoplasm, Basal body, 
Flagellum, Nuclear lumen 
Cytoplasm, Nucleus, 
Flagellum, Basal body 
Tb927.8.5060 ARL6 
Cytoplasm, Flagellum, 
Nucleoplasm 
Cytoplasm, Flagellum, 
Nucleoplasm, Basal body 
 
Table 3.5. Localisation of T. brucei ARF/ARLs were determined through TrypTag. 
Homologs of the ARF/ARLs identified by Price et al. (2005) were identified in TREU927 cell 
lines and accession numbers were used to identify localisation with the aid of TrypTag 
Trypanosome protein localisation resource. 
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The function of ARF/ARLs are tightly regulated by GEFs and GAPs, initiating and terminating 
ARF/ARL activities respectively (Jackson and Casanova, 2000). Extensive studies on human 
ARF/ARLs and their regulators have identified the relationship and localisation of these 
proteins. Price et al. had identified 9 ARF/ARLs in T. brucei in their previous work (Price et al., 
2005b). In order to understand the relationship between the identified T. brucei ARF regulators 
and the identified ARF/ARLs by Price et al. (2005), the subcellular localisation of the 9 T. brucei 
ARF/ARLs were identified with the use of TrypTag (Figure 3.10). Accession numbers of the 9 
T. brucei ARF/ARLs were used to obtain protein sequences. BLASTP was then executed to 
find TREU927 homologues of the 9 ARF/ARLs. Accession numbers of the TREU927 
homologues were used to determine the localisation of the ARF/ARLs on TrypTag database. 
Localisation data for N terminus and C terminus tagging was obtained (Table 3.5). 
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Figure 3.10. Predicted localisation of ARF/ARLs in T. brucei. Simplified schematic representation of T. brucei showing (1) nucleus, (2) 
kinetoplast, (3) mitochondria, (4) endosomes, (5) Golgi, (6) lysosomes, (7) flagger pocket and (8) flagellum. Triangles represent ARF/ARLs. The 
predicted localisation of ARF/ARLs based on C terminus tagging is shown. 
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N terminus and C terminus tagging of the proteins showed that the ARF/ARLs are localised 
mainly to the cytoplasm, flagellum/components of the flagellum and nucleus (Table 3.5). All of 
the identified ARF/ARLs shared a subcellular localisation with TbGEF2, TbGEF3, TbGAP2 and 
TbGAP3 at the cytoplasm. 7 out of the 9 T. brucei ARF/ARLs were shown to be localised to 
the flagellum or components of the flagellum (Table 3.5). These ARF/ARLs may be regulated 
by TbGEF2, TbGEF3 and TbGAP3 due to their subcellular localisation being components of 
the flagellum as well. Similarly 7 out of the 9 T. brucei ARF/ARLs were also localised to 
components of the nucleus, a subcellular localisation that is shared by TbGEF1 and TbGAP4. 
Figure 3.11 shows a simplified schematic representation of ARF/ARL and identified T. brucei 
regulators and their predicted subcellular localisation.  
 
The researchers who performed the TrypTag project recognise the limitations of using mutant 
forms of the proteins to determine their localisation. They used gene ontology and localisation 
modifiers to determine locations of proteins when necessary (Dean et al., 2017). Additionally, 
the N terminus tagging of T. brucei ARF/ARLs shown in Table 3.5 may not represent an 
accurate localisation data since N terminal myristoylation is required for ARF/ARL functions 
(Padovani et al., 2013, Liu et al., 2009). 
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Figure 3.11. Predicted localisation of ARF/ARLs, TbGEFs and TbGAPs in T. brucei. Simplified schematic representation of T. brucei showing 
(1) nucleus, (2) kinetoplast, (3) mitochondria, (4) endosomes, (5) Golgi, (6) lysosomes, (7) flagger pocket and (8) flagellum. Triangles represent 
ARF/ARLs. Lightning and crosses represent TbGEF/TbGAPs according to C terminal and N terminal tagging data respectively.
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3.3.4. Putative orthologues of T. brucei ARF regulators in other Kinetoplastids 
Unlike T. cruzi or Leishmania spp., T. brucei are extracellular in all stages of their life cycle 
(Pays and Vanhollebeke, 2009), being constantly exposed to host’s immune response. The 
differences in pH, availability of nutrients and composition in extracellular and intracellular 
environment as well as exposure to host immune response means that parasites have to adapt 
differently depending on their environment (Dean et al., 2009, Quintana et al., 2018). This 
difference in localisation and therefore adaptation in T. brucei and other kinetoplastids may 
results in changes in protein functions or lack of a particular protein. Presence of ARF/ARLs 
and their regulators have been identified previously by Price et al. (Price et al., 2005b) and in 
section 3.3.1, the identified T. brucei GEFs and GAPs amino acid sequences will be used to 
identify orthologues of these proteins in other intracellular kinetoplastids. 
Accession number searches were carried out on each of the identified T. brucei ARF GEFs 
and GAPs on TriTrypDB. Orthologue group (OG) numbers were obtained from the database 
search for each of the gene. A search on the obtained OG numbers for each of the ARF 
regulators was carried out on OrthoMCLDB, a public database containing orthologue groups 
based on the OrthoMCL algorithm (Chen et al., 2006). OrthoMCLDB identified orthologues of 
T. brucei GEFs and GAPs in L. braziliense, L. infantum, L. major, L. mexicana, T. b. 
gambiense, T. congolense, T. cruzi and T. vivax (Table 3.6). However TbGEF3 and TbGAP3 
did not generate orthologues in T. cruzi (marked as red on the table), suggesting that the 
functions of these proteins may not be implicated in T. cruzi cellular pathways. There is also a 
possibility that orthologues of the TbGEF3 and TbGAP3 are significantly different on amino 
acid sequence level in T. cruzi, thus not identified in the searches on TriTrypDB. 
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Multiple amino acid sequence alignment was carried out for each orthologue groups in order 
to identify any regions of similarities the ARF regulators share between the kinetoplastid 
species (Appendix 3 - 8). Sequence alignment showed that the ARF regulators for each 
orthologue groups were highly conserved at the catalytic Sec7 and ARFGAP domains (Figure 
3.12). Other than the catalytic domains, the sequence alignment showed that many of the 
orthologues consisted of highly conserved regions (Appendix 3 - 8); suggesting that the ARF 
regulators might function similarly in other kinetoplastid species. 
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Figure 3.12. Multiple sequence alignment of orthologues. Partial multiple sequence of (A) 
TbGEF1 and (B) TbGAP1. The highly conserved regions shown are the Sec7 and ARFGAP 
catalytic domains in GEFs and GAPs respectively. Regions of similarities were depicted using 
BoxShade. Amino acids shaded black are identical, whilst amino acids shaded grey display 
similar properties. 
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3.4. Discussion 
This chapter aimed to identify T. brucei GEFs and GAPs using literature searches and 
bioinformatics tools. 26 human ARF GAPs and 14 human ARF GEFs were identified with the 
aid of literature searches and gene searches on NCBI database. BLASTP of the identified 
human ARF regulator protein sequences identified orthologues in T. brucei, 4 ARF GAPs and 
3 ARF GEFs with the lowest e-values were selected for further analysis. 
 
3.4.1 TbGEFs and TbGAPs are highly conserved at the catalytic domains on amino 
acid and structural level 
In order to use ARF regulators as novel drug targets against T. brucei, a low level of sequence 
identity between human and T. brucei ARF regulators would be ideal. This is so that inhibitors 
binding to essential functional regions of T. brucei ARF regulators would not be able to bind to 
and affect human ARF regulators with as great affinity. UniProt sequence alignment (Clustal 
Omega) of the identified T. brucei GEFs and GAPs against humans ARF GEFs and GAPs in 
section 3.3.2.1 revealed overall low levels of sequence identity. This result is a contrast to the 
results observed by Price et al., who identified high levels of sequence identity between the 9 
T. brucei ARF/ARLs and their closest human homologues that was identified by them (Price 
et al., 2005b). This suggests that there is a high level of diversity amongst human and T. brucei 
ARF regulators compared to the ARF/ARLs identified by Price et al. (2005).  
Multiple protein sequence alignment showed that the Sec7 and ARFGAP domains in T. brucei 
ARF regulators and human ARF regulators were very similar at the amino acid sequence level. 
The Sec7 and ARFGAP catalytic domains are highly conserved and present in ARF GEFs and 
GAPs in all studied eukaryotes to date (Pocognoni et al., 2018, Arakel et al., 2020). Figure 3.1 
showed that the ARF binding site present in GEFs are very conserved at amino acid level in 
two of the three identified T. brucei GEFs. Although TbGEF3 appears to have the ARF binding 
motifs, the amino acid sequence of that region does not appear to share high levels of identity 
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with the other GEFs. This would mean that targeting the ARF binding region in TbGEF3 via 
inhibitors may not inadvertently target ARF binding regions in human GEFs. Although the 
catalytic domains in the other T. brucei GEFs and GAPs appear to be conserved at the amino 
acid level, there is a possibility for these domains to have ARF/ARL binding specificity 
(Panethymitaki et al., 2006). It may also be possible to exploit selectivity pockets and any 
possible secondary structure differences to specifically target T. brucei ARF regulators (Spinks 
et al., 2015). Domain and structural analysis were carried out in order to identify any differences 
that can be exploited. 
Domain analysis on human and identified T. brucei GEFs using SMART resource in section 
3.3.2.2 highlighted the lack of PH domains in all T. brucei GEFs. Out of the five human ARF 
GEF subfamilies that was analysed in section 3.3.2.2, only CYTH, PSD and IQSEC subfamilies 
contained PH domains. Like the identified T. brucei GEFs, the ARFGEF and GBF subfamilies 
also lacked PH domains. This correlates with previous studies that highlighted the differences 
between small molecular weight GEFs and high molecular weight GEFs. Small molecular 
weight GEFs such as CYTH, PSD and IQSEC subfamilies contain PH domains whilst the high 
molecular weight GEFs such as ARFGEF and GBF subfamilies lacked the PH domains 
(Meissner et al., 2018, Jackson and Casanova, 2000).  
The PH domains are involved in binding of specific phosphatidylinositol to membranes and 
other proteins such as  subunits of trimeric G-proteins (Wang et al., 1994, Roy et al., 2016). 
In small molecular weight GEFs, the PH domains are required for regulating GEF activity. For 
example the PH domain in CYTH subfamily inhibit the association of Sec7 domain to ARF-
GDP, however the binding of phosphatidylinositol (3,4,5)-trisphosphate and ARF6-GTP to the 
PH domain confers PH domain rearrangement and recruitment of CYTH subfamilies to the 
plasma membrane. This recruitment and release of autoinhibition allows CYTH to associate 
with ARF1/6-GDP, thus enabling the GEF activity (Roy et al., 2016, Lee et al., 2015). In 
contrast to the PH domain activity in CYTH subfamilies, the PH domain in PSD subfamilies act 
as a negative feedback loop for the association of ARF-GDP to Sec7 domain. Binding of ARF6-
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GTP to the PH domain caused the inhibition of PSD Sec7 catalytic activity with ARF1 and 
ARF6 (Padovani et al., 2014). Unlike the PH domain functions in CYTH and PSD subfamilies, 
the PH domain in IQSEC subfamilies bind to phosphatidylinositol (4,5)-bisphosphate and 
increase the association of ARF-GDP to the Sec7 catalytic domain by forming part of the 
catalytic interface with IQSEC (Roy et al., 2016, Jian et al., 2012).  
Although the high molecular weight GEFs lack PH domains, they are still able to interact with 
ARFs through different mechanisms, albeit not fully understood. Functional studies on yeast 
SEC7, closest homology to human ARFGEF subfamily, identified the Homology Downstream 
of Sec7 (HDS1) domain that is involved in regulating the activation and membrane recruitment 
of yeast SEC7 similarly to the PH domains. HDS1 domains act as an inhibitor to SEC7, 
preventing the association of yeast SEC7 with ARF-GDP. However in the presence of ARF1-
GTP, the HDS1 domain activates the catalytic Sec7 domain in yeast SEC7 as well as the 
recruitment of yeast SEC7 to Trans Golgi Network (TGN); thus enabling the yeast SEC7 to 
associate with ARF-GTP found in the TGN (Richardson et al., 2012, Richardson and Fromme, 
2012). The GBF subfamily also contain the HDS1 domain, however unlike the yeast 
SEC7/ARFGEF interaction of HDS1 domain, the GBF HDS1 domain is implicated in GBF 
recruitment to Golgi through binding of phosphatidylinositol (4,5)-bisphosphate, 
phosphatidylinositol 3-phosphate or phosphatidylinositol 4-phosphate (Meissner et al., 2018). 
BLAST search on TriTrypDB identified the presence of PH domains in other proteins in T. 
brucei, suggesting that the lack of PH domains seen in section 3.3.2.2 may have been due to 
the absence of PH domains in T. brucei genome. The lack of PH domains in section 3.3.2.2 
may also indicate that the identified GEFs are close homologues to high molecular weight 
GEFs such as ARFGEF and GBF subfamilies. High molecular weight GEFs are classified as 
GEFs that are above 100 kDa (Shinotsuka et al., 2002b). The calculated molecular weight of 
the identified T. brucei GEFs in Table 3.1 are shown to be above 100 kDa, further supporting 
the possibility of the identified GEFs to be close homologues to human ARFGEFs and GBF. 
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ARFGEF1, ARFGEF2, ARFGEF3 and GBF1 regulate the activities of ARF1, ARF2, ARF5 and 
ARF6; being involved in vesicle trafficking and coating (Boal and Stephens, 2010, Li et al., 
2003, Shinotsuka et al., 2002a, Zhao et al., 2006, Szul et al., 2007). The domain similarities 
between these human GEFs and identified T. brucei GEFs may suggest that T. brucei GEFs 
could have a similar function, implicated in vesicle trafficking.  
Similar to T. brucei ARF GEFs, the T. brucei ARF GAPs only consisted of the catalytic 
ARFGAP domains; lacking the PH domains, ANK domains, SH3 domains, SAM and GIT 
domains. This trait is also shared by ARFGAP and SMAP subfamilies of human GAPs. Domain 
analysis of the other 6 human GAP subfamilies in section 3.3.2.2 revealed the presence of a 
variety of domains in different subfamilies.  
Similar to the human small molecular weight GEFs, the PH domain in GAPs are involved in 
the activation of catalytic ARFGAP domain through binding of specific phosphatidylinositol. 
The PH domain in ASAP subfamily initiates the catalytic activity of ARFGAP domain through 
the binding of phosphatidylinositol (4,5)-bisphosphate, however this activation mechanism has 
yet to be established (Kahn and Lambright, 2015, Luo et al., 2008). The binding of 
phosphatidylinositol (3,4)-bisphosphate and/or phosphatidylinositol (3,4,5)-trisphosphate by 
the C terminal PH domain in ADAP subfamily triggers the recruitment of ADAP to the plasma 
membrane. The other PH domain present in ADAP only binds to phosphatidylinositol (3,4,5)-
trisphosphate (Stricker and Reiser, 2014, Robinson and Kanamarlapudi, 2017). Similar to the 
ASAP subfamily, the binding of phosphatidylinositol (4,5)-bisphosphate to the PH domains 
present in ACAP subfamilies activates the catalytic ARFGAP domain. However the PH domain 
in ACAP is also implicated in oligomerization and bending of membrane (Shi et al., 2012, Chan 
et al., 2017). PH domain present in AGAP subfamily are very similar to PH domains present in 
ADAP subfamily, initiating the activation of the catalytic ARFGAP domain in AGAP by binding 
to phosphatidylinositol (3,4)-bisphosphate and/or phosphatidylinositol (3,4,5)-trisphosphate, 
however AGAP2 GAP activity is stimulated more strongly by the binding of phosphatidylinositol 
(3,4,5)-trisphosphate to the PH domain (Nie et al., 2002, Nie et al., 2005). The PH domain in 
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AGAP1 and AGAP2 are also involved in the binding of adapter protein 3 (AP3) and adapter 
protein 1 (AP1) respectively. These adapter proteins are clathrin associated complexes that 
are required for ARF vesicle formation (Nie et al., 2005, Park and Guo, 2014). A unique feature 
of the ARAP subfamily is the presence of 5 PH domains. These PH domains bind to specific 
phosphatidylinositol in order to activate the catalytic ARFGAP domain (Segeletz et al., 2018, 
Campa et al., 2009). 
The ANK domains in GAPs do not activate the ARFGAP catalytic activity directly, however 
they are important for the function of GAPs through interacting with other proteins and 
molecules. The ANK domains that are present in ASAP has been hypothesised to aid in lipid 
binding to PH domain (Luo et al., 2008), whilst the three ANK domains present in ACAP are 
involved in cargo binding to ACAP (Chan et al., 2017, Bai et al., 2012). AGAP ANK domains 
are hypothesised to function similarly to the ASAP subfamily ANK domains. The ANK domains 
present in GIT subfamily are involved in binding to endosomes (Hoefen and Berk, 2006).  
The other domains present in human GAPs are also involved in various functions that indirectly 
aid in GAP activities. The SH3 domain present near the C terminal of ASAP is involved in the 
binding of focal adhesion tyrosine kinase (Randazzo et al., 2000). The SAM domain in ARAP 
subfamily interacts with SHIP2, a SH2 containing inositol 5-phosphatase. The binding of 
phosphatidylinositol initiates GAP activity in ARAP GAPs, however the binding of SHIP2 via 
SAM domain is hypothesised to induce a negative feedback in ARAP through 
dephosphorylation of specific phosphatidylinositol, thus deactivating the GAP functions of 
ARAP (Raaijmakers et al., 2007, Leone et al., 2009). Another unique feature of ARAP 
subfamily is the presence of RhoGAP domain as well as the ARFGAP domain. This means 
that ARAP subfamily can regulate ARF proteins and Rho GTP-binding proteins. However the 
RhoGAP domain in ARAP2 is inactive, suggesting that ARAP1 and ARAP3 might be the only 
members of the ARAP subfamily that can regulate ARF and Rho GTP-binding proteins (Miura 
et al., 2002). The GIT domains (also known as Spa2 homology domain) present in GIT 
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subfamily of ARF GAPs bind to p21 activated kinase interacting exchange factors (Hoefen and 
Berk, 2006, Webb et al., 2006).  
The ARFGAP and SMAP subfamilies of human GAPs lacked the PH, ANK, GIT, SAM and 
SH3 domains that were described above. Instead these GAP subfamilies are hypothesised to 
initiate the ARFGAP activity through a mechanism that is not fully understood. Previous studies 
have identified the SMAP subfamily role in clathrin dependent endocytosis (Tanabe et al., 
2005) whilst ARFGAP2 and ARFGAP3 initiate uncoating via binding to coatomer (Shiba et al., 
2011, Beck et al., 2009). ARFGAP1 on the other hand is implicated in the COPI complex (Bai 
et al., 2011). The lack of additional domains in identified T. brucei GAPs may suggest that the 
T. brucei GAPs may also be implicated in similar functions as ARFGAP and SMAP subfamilies. 
The results of domain similarities observed in section 3.3.2.2 may suggest that the T. brucei 
GEFs may function similarly to the human ARFGEF and GBF subfamilies. The same can be 
hypothesised for T. brucei GAPs and the human ARFGAP and SMAP subfamilies. However, 
protein functional studies and domain interaction studies need to be carried out in order to 
confirm this hypothesis since a generalisation could not be made with the available data. An 
example of experiment that can be used to identify domains in the T. brucei GEFs and GAPs 
would be analysis of crystal structures. Mossessova et al. (1998), Goldberg (1999) and 
Mandiyan et al. (1999) all studied crystal structures of GEFs and GAPs in order to identify 
domains that are present (Mossessova et al., 1998, Mandiyan et al., 1999, Goldberg, 1999). 
Other techniques that can be used include NMR and mass spectrometry. 
As no previous data were available on T. brucei ARF regulators or their structures, Phyre2 was 
utilised to predict the structure of the identified ARF regulators (Kelley et al., 2015). However 
Phyre2 predicted 30% - 45% of the whole sequence at 100% confidence for T. brucei GAPs 
and 10% - 18% of the whole sequence at 100% confidence for T. brucei GEFs. Phyre2 protein 
structure prediction occurs with the aid of pre-existing templates of homologous proteins 
structures. The lack of structural data available on T. brucei ARF regulators may have resulted 
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in Phyre2 software predicting the highly conserved catalytic Sec7 and ARFGAP domains with 
100% confidence. 
Visualisation and analysis of the Phyre2 predicted structure on PyMOL Molecular Graphics 
System, Version 2.0 in section 3.3.2.3 highlighted the structural differences between T. brucei 
GEFs and GAPs. All of the identified T. brucei GEFs were predicted to have -helices 
structure, with TbGEF1 and TbGEF2 consisting of 10 -helices and TbGEF3 consisting of 12 
-helices (Figure 3.7). The identified T. brucei GAPs on the other hand were predicted to have 
-helices and -sheets structures, albeit with differences in the number of -helices and -
sheets present in each identified T. brucei GAP (Figure 3.6). 
Mandiyan et al. (1999) described the crystal structure of PAP ARFGAP domain in their study. 
They identified the presence of 3 -sheets flanked by 5 -helices and a Zn2+ ion coordinated 
by the CX2CX16-17CX2C sequence motifs. This structure was similar to the structure observed 
by Goldberg (1999) in rat ARFGAP (Mandiyan et al., 1999, Goldberg, 1999), suggesting that 
the ARFGAP domain has a conserved structure. The -sheets flanked by -helices motif can 
also be observed in the predicted structures for the identified T. brucei GAPs: TbGAP1, 
TbGAP3 and TbGAP4 as described above. The predicted structure of TbGAP1 is very similar 
to the ARFGAP structure observed by Mandiyan et al. (1999). Although TbGAP3 and TbGAP4 
consisted of the -sheets flanked by -helices motif, TbGAP3 consisted of 2 -sheets flanked 
by 5 -helices whilst TbGAP4 consisted of 3 -sheets flanked by 6 -helices. The similarities 
between the predicted structures of T. brucei GAP and the PAP ARFGAP domain observed 
by Mandiyan et al. suggests that the predicted structure of the T. brucei GAPs by Phyre2 could 
have been the ARFGAP domain. This may also explain the 30% - 45% of the whole sequence 
being predicted at 100% confidence since the ARFGAP domain is made up of 130 amino acids 
and are highly conserved (Frigerio et al., 2007, Schlacht et al., 2013).  
Structural alignment of predicted T. brucei GAP structures with all available human GAP 
structures from RCSB Protein Data Bank identified various degrees of structural similarities 
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amongst the T. brucei GAPs. TbGAP1 was identified to be structurally similar to ARFGAP1, 
SMAP2 and ADAP1. TbGAP3 was structurally similar to ARFGAP1, AGAP3, ADAP1 and 
SMAP2. TbGAP4 was structurally similar to ASAP3 and ACAP1. Despite TbGAP2 not 
consisting of the -sheets flanked by -helices motif, structural alignment showed that TbGAP2 
was structurally similar to ADAP1, SMAP1 and SMAP2. The protein structure of human 
ARFGAP1, SMAP2, ASAP3, ACAP1 and ADAP1 showed the crystal structure ARFGAP 
domain, whilst the protein structure of SMAP1 is shown to be the ARFGAP domain in solution. 
The high level of structural similarities of these ARFGAP domain structure to predicted 
structure of identified T. brucei GAPs highlights the possibility of the predicted structure of T. 
brucei GAPs being the conserved ARFGAP domain. An interesting observation to be made is 
the structural similarity of TbGAP3 to AGAP3 crystal structure of Ras like domain. This 
structural similarity is not shared by the other identified T. brucei GAPs, suggesting that 
TbGAP3 may also exhibit regulatory effect on Ras-like GTPase proteins in a similar 
mechanism to human ARAP subfamilies. Despite the presence of Ras-like GTPase proteins, 
T. brucei does not express true members of the Ras GTPases (Field, 2005). 
Similar to the ARFGAP domains, the Sec7 catalytic domain present in ARF GEFs are also 
highly conserved with a 200 amino acid sequence (Jackson and Casanova, 2000, Mansour et 
al., 1999). The structure of ARNO (Cytohesin-2) Sec7 domain was determined at 2.2 Å 
resolution by Mossessova et al. (1998) who showed that the Sec7 domain is made up 10 -
helices, 7 N-terminal -helices that form a right handed superhelix and 3 C-terminal -helices 
(Mossessova et al., 1998). The Sec7 domain also consisted of a distinctive hydrophobic 
groove, which was later identified to contain a glutamic finger by Béraud-Dufour et al. (1998). 
Béraud-Dufour et al. proposed that this glutamic finger in the hydrophobic groove may interact 
with the Mg2+ found in the switch regions of the ARFs (Beraud-Dufour et al., 1998). Similar 
structure was observed for the predicted structures of the three identified T. brucei GEFs as 
describes above. The predicted structures for TbGEF1 and TbGEF2 were identical to the 
structure studied by Mossessova et al. (1998), consisting of 10 -helices. Although the 
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predicted structure for TbGEF3 consists of the -helices motif as described by Mossessova et 
al. (1998) and Béraud-Dufour et al. (1998), TbGEF3 also contains additional 2 -helices. The 
similarities between the predicted T. brucei GEF structures by Phyre2 and the Sec7 domain of 
ARNO described by Mossessova et al. (1998) suggest that Phyre2 successfully predicted the 
Sec7 domain that are present in the identified T. brucei GEFs. This is further supported by the 
percentage of sequence covered by Phyre2. Phyre2 predicted 10% - 18% of the whole 
sequence at 100% confidence for T. brucei GEFs. The Sec7 domain is 200 amino acids long 
whilst the whole T. brucei GEF sequences are 1046 – 2054 amino acids long, correlating to 
the percentage covered at 100% confidence by Phyre2. 
The structural alignment of predicted T. brucei GEFs against all available human GEFs on 
PyMOL Molecular Graphics System, Version 2.0 showed that all three of the identified T. brucei 
GEFs were structurally more similar to CYTH1 and CYTH2 than the other GEF protein 
structures. However the proteins structures of CYTH1 and CYTH2 on the RCSB Protein Data 
Bank are crystal structures of the Sec7 domain, suggesting that the high level of structural 
similarities was due to the highly conserved Sec7 domain. An interesting observation that can 
be made from the RMS values for structural alignment in section 3.3.2.3 is the low level of 
structural similarities between ARFGEF1 crystal structure of Sec7 domain and the identified T. 
brucei GEFs. The ARFGEF subfamily were shown to have similar domain composition as the 
identified T. brucei GEFs, lacking the PH domain. The low level of structural similarities may 
suggest that despite T. brucei GEFs not having the PH domain, they could function similarly 
to the CYTH subfamily. However further functional studies and protein interaction studies need 
to be carried out in order to give a conclusive answer. 
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3.4.3 Predicted protein localisation of TbGEFs and TbGAPs may not be accurate in 
bloodstream form T. brucei 
The prediction of subcellular localisation of proteins using bioinformatics can aid in the 
understanding of their relationship and function (Pang et al., 2019). Previous studies on human 
ARFs and their regulators have identified their subcellular localisation, the relationships 
between the ARF and their regulators, as well as their functions. Although Price et al. identified 
9 ARF/ARLs in T. brucei, there is a lack of information available on the relationship between 
ARF/ARLs and their regulators as well as the subcellular localisation of the regulators. TrypTag 
was used in order to identify the subcellular localisation of the identified T. brucei GEFs and 
GAPs. 
TrypTag is a T. brucei protein localisation resource that has data on proteins that are tagged 
with mNeonGreen tag at N and/or C terminals (Dean et al., 2017). The current data available 
on TrypTag is based on the procyclic form of T. brucei that are found in the tsetse midgut as 
opposed to the mammalian infectious bloodstream form T. brucei on which this thesis will be 
focusing. The difference in environment during trypanosome life cycle results in T. brucei 
adapting accordingly. For example the bloodstream form T. brucei relies on glucose that are 
present in the mammalian blood in order for metabolism to occur, whilst the procyclic form T. 
brucei adapts to use amino acids such as proline and threonine for metabolism (Millerioux et 
al., 2018). The rate of endocytosis has also been shown to be different, with bloodstream form 
T. brucei having a higher rate of metabolism than compared to the procyclic form T. brucei 
(Natesan et al., 2011). The procyclic and bloodstream form T. brucei express proteins 
differentially. Procyclic form T. brucei express surface glycoproteins called procyclic acidic 
repetitive proteins (PARPs) that aids in the immune evasion (Castillo-Acosta et al., 2017). The 
bloodstream form T. brucei on the other hand expresses antigenic variant surface 
glycoproteins (VSGs) that enable the parasite to evade host immune response and establish 
a chronic infection (Castillo-Acosta et al., 2017, Kolev et al., 2018). 
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Endocytosis occurs at the flagellar pocket via coated vesicles in bloodstream for T. brucei. 
Interestingly these coated vesicles are absent in procyclic form T. brucei, instead relying on 
cysteine-rich acidic transmembrane proteins (CRAM). The absence of coated vesicles 
suggests that the functions of ARF/ARLs and their regulators may also differ in the procyclic 
form (Liu et al., 2000, Qiao et al., 2006). This could mean that the localisation data obtained 
from TrypTag on T. brucei ARF/ARLs and their regulators in section 3.3.3 may not always be 
applicable to protein localisation in bloodstream form T. brucei. Tagging identified T. brucei 
GEFs and GAPs as well as the 9 ARF/ARLs using fluorescent marker proteins in bloodstream 
form T. brucei may aid in accurate identification of localisation in bloodstream form T. brucei. 
TrypTag tags proteins using mNeonGreen, a monomeric 26 kDa fluorescent protein (Stockmar 
et al., 2018). mNeonGreen is tagged at the N terminus and C terminus of the protein. 
ARF/ARLs are small GTPases (~22 kDa) that are myristoylated at the N terminus, this N-
myristoylation allows the ARF/ARLs to associate to the membrane during activation (Padovani 
et al., 2013, Liu et al., 2009). Tagging of mNeonGreen at the N terminus would inhibit 
myristoylation at the N terminus, thus affecting the function and localisation of the ARFs. With 
this in mind, I focused primarily on the localisation data for C terminus tagged proteins. The 
large size of mNeonGreen in comparison to ARF/ARLs may also affect the function of 
ARF/ARLs as well as their interactions with GEFs and GAPs in T. brucei. 
Localisation data in section 3.3.3 highlighted the localisation of TREU927 homologues of T. 
brucei GEFs and GAPs, as well as the 9 identified ARF/ARLs. TrypTag data showed that some 
of the ARF/ARLs and identified regulators were localised at the same place in T. brucei. 
However this localisation data does not provide information on which ARF/ARLs interact with 
the identified T. brucei GEFs and GAPs. To overcome this disadvantage, protein-protein 
interaction studies using biotin identification (BioID) could be used. The identified T. brucei 
GEFs and GAPs can be fused with mutated version of E. coli biotin ligase (BirA*). Reactive 
bioAMP are readily released by BirA*, these bioAMP covalently interact with primary amines 
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present in proximity to BirA* fused proteins. The biotinylated proteins can then be isolated via 
streptavidin affinity purification and identified through mass spectrometry (Khan et al., 2018). 
 
3.4.5 Putative orthologues of T. brucei ARF regulators in other Kinetoplastids may 
have similar functions 
Kinetoplastids are parasites that are distinguished by the presence of kDNA. These parasites 
include Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. All three parasites have 
a lifecycle that takes place in both invertebrate host and vertebrate host (Filardy et al., 2018). 
However T. cruzi and Leishmania spp. are intracellular, infecting a wide range of cells and 
phagolysosomes of macrophages respectively (Salassa and Romano, 2018, Kohl et al., 2018), 
whilst T. brucei are exclusively extracellular (Pays and Vanhollebeke, 2009).  
OrthoMCL was used to check if orthologues of the identified T. brucei GEFs and GAPs are 
present in other kinetoplastids. Results in section 3.3.4 highlighted the presence of GEFs and 
GAPs orthologues in other kinetoplastids. Multiple sequence alignment of the T. brucei GEFs 
and GAPs and their orthologs in other kinetoplastids showed that majority of the sequences 
were similar on the amino acid level (Appendix 3 - 8). This suggests that the orthologues may 
function similarly. Orthologues of TbGEF3 and TbGAP3 were absent in T. cruzi, a possible 
explanation for this could be due to how T. cruzi undergoes endocytosis.  
The flagellar pocket, an invagination of the cell surface located where the flagellum exits is the 
site where endocytosis primarily occurs in kinetoplastids. Endocytosis in T. brucei is mediated 
by T. brucei clathrin heavy chain (TbCLH), with Morgan et al. (2001) identifying the correlation 
between TbCLH and endocytosis (Morgan et al., 2001). Clathrin dependent endocytosis in T. 
brucei was further proven by Allen et al. (2003) through RNAi studies. Showing that RNAi of 
TbCLH disrupted endocytosis and became lethal to bloodstream form T. brucei (Allen et al., 
2003). Similarly Leishmania utilises clathrin dependent endocytosis. Agarwal et al. (2013) 
identified that overexpression of Leishmania clathrin heavy chain (Ld-CHC) lead to enhanced 
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uptake of haemoglobin, whilst expression of clathrin hub fragment in Leishmania proved to be 
fatal (Agarwal et al., 2013, Rastogi et al., 2016). Interestingly T. cruzi exhibits clathrin 
dependent and independent endocytosis. Kalb et al. (2014) demonstrated that T. cruzi clathrin 
heavy chain (TcCHC) and light chain (TcCLC) were localised to the flagellar pocket and were 
utilised in endocytosis of albumin. However endocytosis of transferrin was cholesterol 
dependent and occurred at the cytostome/cytopharynx complex (Kalb et al., 2014). The 
cytostome/cytopharynx complex is located near the flagellar pocket, this complex consists of 
an opening in the membrane referred to as cytostome and a deep membrane invagination 
referred to as cytopharynx (Alcantara et al., 2017). Alcantara et al. (2014) stated that although 
T. cruzi utilises flagellar pocket for clathrin dependent endocytosis, the main site of endocytosis 
in T. cruzi is at the cytostome/cytopharynx complex via clathrin independent (Alcantara et al., 
2014).  
This difference in endocytosis in T. cruzi may explain the absence of TbGEF3 and TbGAP3 
orthologues. Section 3.3.3 identified the subcellular localisation of TREU927 homologues of 
TbGEF3 and TbGAP3 to be in flagellar pocket and flagellum respectively. The subcellular 
localisation of TbGEF3 and TbGAP3 could possibly mean that these two ARF regulators may 
be implicated in endocytic functions at the flagellar pocket. The preference of T. cruzi utilising 
cytostome/cytopharynx complex as the main site of endocytosis could have meant that T. cruzi 
may have adapted to avoid utilising the functions of TbGEF3 and TbGAP3 in the flagellar 
pocket and flagellum respectively. However the function of TbGEF3 and TbGAP3 could not be 
confirmed with the available data in this chapter. Protein-protein interactions studies described 
in section 3.4.3 and protein functional studies could give more insight into the function of 
TbGEF3 and TbGAP3. Likewise, assumptions could not be made for the orthologues of T. 
brucei GEFs and GAPs in other kinetoplastids. Further studies need to be carried in order to 
understand the specific functions of T. brucei GEFs and GAPs and their orthologues in other 
kinetoplastids. 
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3.5. Conclusions 
The main findings of this chapter are as follows: 
• Homologues of human ARF regulators were identified in T. brucei – BLASTP was used 
to identify 3 T. brucei GEFs and 4 T. brucei GAPs that were followed up for further 
analysis. 
• There is a high level of diversity between human and T. brucei ARF regulators on the 
amino acid level. 
• T. brucei GEFs and GAPs lacked additional protein-protein interaction domains that 
are present in many human GEFs and GAPs. 
• T. brucei GEFs and GAPs appear structurally similar to some human ARF regulator 
subfamilies. 
• T. brucei ARF regulators are predicted to be localised in the cytoplasm and endocytic 
pathways  
• Orthologues of TbGEF3 and TbGAP3 were absent in T. cruzi but present in Leishmania 
and Trypanosoma spp. 
 
In order to understand the function of the identified T. brucei GEFs and GAPs within 
bloodstream form T. brucei, the next stage of the investigation was to knockdown the 
expression of the identified T. brucei GEFs and GAPs using an inducible RNAi system. The 
observation of the effect of RNAi for each T. brucei GEFs and GAPs in bloodstream form T. 
brucei should highlight the essential GEFs and GAPs and their possible functions within 
bloodstream form T. brucei.  
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Chapter 4 – Identification of 
essential ARF regulators in 
bloodstream form T. brucei 
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4.1 Introduction 
Currently eight registered drugs are used to treat African Trypanosomiasis; suramin, 
pentamidine, melarsoprol, eflornithine and fexinidazole for Human African Trypanosomiasis 
(HAT); and diminazene aceturate, homidium and isometamidium against Animal African 
Trypanosomiasis i.e. nagana. These drugs are disease stage and T. brucei subspecies 
specific. As mentioned in Chapter 1 Section 1.1.7, the emergence of drug resistance, adverse 
side effects and low efficacy of these drugs means that research into alternative drug targets 
is essential (Moreno et al., 2019, Giordani et al., 2016, Baker and Welburn, 2018). An ideal 
drug target is defined by several rules including:: 1) absent in host or sufficiently different in 
order for specific targeting; 2) essential for  survival of the host-stage parasite; and 3) 
‘druggable’ (Ilari et al., 2018, Kandoi et al., 2015).  
A ‘druggable’ biological target is a molecule (usually a nucleic acid, peptides or proteins) that 
has the potential to bind to drugs which alter its biological functions (Hussein et al., 2017). A 
‘druggable’ target should also be able to have the capacity to change disease progression 
whilst having low impact on the modulation of physical conditions of the host (Kandoi et al., 
2015, Gashaw et al., 2011, Ilari et al., 2018). Previous studies on ARF/ARLs have identified 
inhibitors that can alter or inhibit their functions, demonstrating that ARF/ARLs could be used 
as a ‘druggable’ target (Benabdi et al., 2017). Moreover, RNAi induced knockdown of T. brucei 
ARF/ARLs has demonstrated that several of these ARF/ARLs are essential for T. brucei 
viability (Price et al., 2005b, Price et al., 2010b, Price et al., 2007b). However sequence 
alignment showed a high percentage of sequence similarity with T. brucei and human 
ARF/ARLs, especially at the essential binding sites (Price et al., 2005b, Price et al., 2005a). 
This high level of similarity between human and T. brucei ARF/ARLs may mean that inhibitors 
to the parasite proteins could also bind to human ARFs, contradicting the first rule for an ideal 
drug target. Therefore, ARF/ARLs may not be ideal drug targets against HAT. 
ARF/ARLs are regulated by guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs), activating and inactivating the ARF/ARLs respectively. In the 
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previous chapter, I identified three GEFs and four GAPs in T. brucei through BLASTP searches 
on known human ARF regulator protein sequences. However, amino acid sequence alignment 
to compare identified T. brucei and human ARF regulators showed a low level of overall 
sequence similarity, but the catalytic domains that regulate ARF functions were highly 
conserved; with the exception of TbGEF3. 
Bioinformatics analysis in the previous chapter identified the domain and structural similarities 
of T. brucei GEFs and GAPs to human GEFs and GAPs, as well as the possible localisation 
of these proteins in T. brucei. However due to lack of available data, bioinformatics analysis 
alone could not determine the functions of the GEFs and GAPs in T. brucei or identify which 
of these regulators are essential for bloodstream form T. brucei viability.  
Previous studies highlighting essential genes in T. brucei used tetracycline inducible RNAi 
systems to knock down the function of a particular gene (Alibu et al., 2005). RNAi is a gene 
expression knockdown mechanism that utilises small interfering RNAs (siRNAs) and 
microRNAs (miRNA) which are incorporated into the RNA-induced silencing complex (RISC), 
causing mRNA translation interference and knockdown of target gene (Fire et al., 1998, Ding 
et al., 2018). The same RNAi system was used to highlight the essential ARF/ARLs in 
bloodstream form T. brucei (Price et al., 2007b, Price et al., 2005b, Price et al., 2012).  
 
4.1.1 Aims 
The aim of the work described in this chapter was to identify which of the TbGEFs and TbGAPs 
are essential for the viability of bloodstream form T. brucei and to identify the effects of RNAi 
on these genes. 
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4.2 Methods 
Molecular laboratory techniques were used in order to generate and transfect RNAi constructs 
into bloodstream form T. brucei and then to identify the effect of GEF/GAP knockdowns on 
bloodstream form T. brucei viability and morphology. The methods used in this chapter are as 
follows: 
 
4.2.1 Selection and amplification of RNAi regions 
RNAi regions for each T. brucei GEFs and GAPs were selected and amplified using PCR with 
suitable XbaI restriction sites.  
 
4.2.2 Generation of RNAi constructs 
Amplified RNAi regions were ligated to the P2T7Ti vector and transformed into One Shot® 
TOP10 Chemically Competent E. coli. Plasmid DNA were then isolated and purified. 
 
4.2.3 Transfection 
RNAi constructs were subjected to restriction digest by NotI restriction enzyme and then 
purified via enzymatic purification. The linearised RNAi constructs were prepared for 
transfection and transfected into mid-log phase bloodstream form T. brucei. Transfected cells 
were incubated at 37°C with 5% CO2. 
 
4.2.4 Induction of RNAi 
RNAi of the transfected bloodstream form Lister 427 T. brucei was induced by adding 
tetracycline. The density of the parasites was determined by counting the number of parasites 
using a haemocytometer. 
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4.2.5 Propidium Iodide flow cytometry 
Mid-log phase bloodstream form Lister 427 T. brucei incubated in tetracycline at different time 
points were harvested and a propidium iodide flow cytometry was carried out. 
 
4.2.6 Live/Dead flow cytometry 
Mid-log phase bloodstream form Lister 427 T. brucei incubated in tetracycline at different time 
points were harvested and stained with Live/Dead Fixable Red Dead Stain. The sample were 
then processed using flow cytometry. 
 
4.2.7 Quantitative polymerase chain reaction (qPCR) 
Total RNA was extracted from mid-log phase bloodstream form T. brucei following induction 
of RNAi at different time points. cDNAs were generated from the RNA samples and a qPCR 
reaction was set up. 
 
4.2.8 Indirect immunofluorescent microscopy 
Log-phase bloodstream form T. brucei were harvested and processed for indirect 
immunofluorescent microscopy. Primary mouse monoclonal antibody 1 (TAT1) against T. 
brucei -tubulin and primary anti-rabbit monoclonal antibody against paraflagellar rod protein 
1 (PFR1) were used. 
 
4.2.9 Transmission Electron Microscopy (TEM) 
Log-phase bloodstream form T. brucei were harvested and processed for TEM. 
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4.2.10 Concanavalin A (Con A) endocytosis assay 
Log-phase bloodstream form T. brucei samples incubated at different time points in 
tetracycline were harvested and prepared for endocytosis assay. Concanavalin A was used to 
determine defects in endocytosis. 
 
4.3 Results 
4.3.1 Identification and amplification of RNAi regions 
In order to carry out RNAi of the identified T. brucei GEFs and GAP, a suitable RNAi region 
was identified for each of the genes using RNAit – target selection for Trypanosoma genomes 
(http://dag.compbio.dundee.ac.uk/RNAit/ - accessed: Nov 2018), a web-based tool for the 
identification of RNAi regions and primers in kinetoplastids. This was done to ensure that the 
possibility of cross or co-suppression was avoided between closely related genes (Redmond 
et al., 2003). The RNAi regions were then checked for possible presence of XbaI restriction 
sites using Webcutter 2.0 (http://www.firstmarket.com/cutter/cut2.html - accessed: Nov 2015).  
The selected regions for RNAi were amplified using Polymerase Chain Reaction (PCR) and 
visualised by agarose gel electrophoresis. Figure 4.1 shows the successful amplification of the 
RNAi regions from genes encoding six putative T. brucei ARF regulators. The seventh ARF 
regulator (TbGAP3) was not successfully amplified. New primers were designed but the 
amplification of GAP3 was still unsuccessful, therefore no further work was carried out on this 
putative regulator. 
The known size of the RNAi regions for each T. brucei GEFs and GAPs are as follows: TbGAP1 
– 397bp; TbGAP2 – 457bp; TbGAP3 – 398bp; TbGAP4 – 427bp; TbGEF1 – 469bp; TbGEF2 
– 503bp; and TbGEF3 – 483bp. These sizes were compared to the gel electrophoresis image 
of the amplified PCR products. The close proximity of the size of the PCR products to the 
known size of the RNAi region suggest that the amplification of the region was successful 
(Figure 4.1). 
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Figure 4.1. Amplification of T. brucei GEFs and GAPs RNAi regions. RNAi regions of (A) 
TbGAP1, (B) TbGAP2, (D) TbGAP4, (E) TbGEF1, (F) TbGEF2 and (G) TbGEF3 were 
amplified using PCR technique and visualised by agarose gel electrophoresis (1.5% agarose). 
Despite several attempts, amplification of (C) TbGAP3 was not successful. Quick-Load® 2-log 
DNA ladder (M) was used as marker. 
 
4.3.2 Generation of RNAi constructs and transfection 
The amplified RNAi regions of T. brucei ARF regulators were ligated into the P2T7Ti vector. 
The P2T7Ti RNAi system was used in this thesis to induce knockdown of identified T. brucei 
ARF regulators, since this system overcame the transient effect of other RNAi systems (Ngô 
et al., 1998). The P2T7Ti vector consists of two inverted repeat T7 promoters with a 
downstream Tet Operator (TetOP) (LaCount and Donelson, 2001). The transgenic 
bloodstream form T. brucei strain Lister 427 expresses Tet repressor (TetR) and T7 RNA 
Polymerase (Poon et al., 2012). The TetR binds to TetOP (Figure 4.2.B), which prevents the 
transcription of the RNAi region by T7 RNA Polymerase from the T7 promoter site (LaCount 
et al., 2000, Alibu et al., 2005). However addition of tetracycline prevents the binding of TetR 
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to TetOP (Figure 4.2.C), thus enabling transcription of the target RNAi region to occur. 
Transcription of the RNAi region produces dsRNAs that are then cleaved by TbDCL1 and 
TbDCL2 into small interfering RNAs (siRNAs). These siRNAs are incorporated into the RISC 
complex which induces gene knockdown (Shi et al., 2009). 
 
Figure 4.2. Schematic representation of the P2T7Ti vector and the function of the vector. 
The P2T7Ti vector consists of T7 promoters and Tet Operators (TetOP). Tet Repressors (TetR) 
present in the transgenic cell lines bind to TetOP preventing transcription of the target RNAi 
region (B). Addition of tetracycline prevents the binding of TetR to TetOP (C), thus allowing 
transcription to occur. 
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The available P2T7Ti vector was already ligated to TbARL6. Therefore a restriction digest using 
XbaI restriction enzyme was carried out in order to isolate the P2T7Ti vector. Successful 
digestion and isolation of the P2T7Ti vector was visualised using gel electrophoresis (Figure 
4.3). Amplified RNAi regions were also subjected to XbaI restriction digest prior to ligation in 
order to facilitate easier ligation.  
 
Figure 4.3. P2T7Ti vector digest. Visualisation of (A) restriction and (B) undigested P2T7-
ARL6 vector on 1.5% Agarose gel. Restriction digest was performed using XbaI restriction 
digest. Quick-Load® 2-Log DNA Ladder (M) was used as a marker. 
 
The ligated P2T7Ti-TbGEF/GAP plasmid was transformed into chemically competent E. coli in 
order to generate large quantities of recombinant DNA for transfection. Transformed E. coli 
cells were grown on agar with ampicillin. Recombinant plasmid DNA was purified from 
successfully grown E. coli colonies. In order to check the presence of RNAi inserts in the eluted 
recombinant DNA, the DNA samples were subjected to restriction digest with XbaI and then 
visualised on gel electrophoresis (Figure 4.4 and Figure 4.5). 
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Figures 4.4 and 4.5 showed that transformation of TbGAP1, TbGAP4, TbGEF1, TbGEF2 and 
TbGEF3 were successful due to the presence of large bands (>5000bp) indicating the P2T7Ti 
vector, and small bands (300bp to 5000bp) which indicates the presence of the inserts. Despite 
transformation of TbGAP2 producing ampicillin resistant E. coli colonies, the eluted 
recombinant DNA did not show presence of the TbGAP2 RNAi insert (Figure 4.5).  
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Figure 4.4. Visualisation of TbGEF RNAi inserts in P2T7Ti plasmid DNA. Plasmid DNAs were purified from transformed colonies and subjected 
to restriction digest using XbaI restriction enzyme. Digested products were visualised on 1.5% Agarose gels. Two separate bands in some 
colonies confirmed the presence of RNAi inserts for (1) TbGEF3, (2) TbGEF2 and (3) TbGEF1. 1kb+ Hyperladder (M) was used as a marker. 
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Figure 4.5. Visualisation of TbGAP RNAi inserts in P2T7Ti plasmid DNA. Plasmid DNAs were purified from transformed colonies and 
subjected to restriction digest using XbaI restriction enzyme. Digested products were visualised on 1.5% Agarose gels. Two separate bands in 
some colonies confirmed the presence of RNAi inserts for (1) TbGAP1 and (3) TbGAP4. No inserts were detected in colonies transfected with 
(2) TbGAP2. 1kb+ Hyperladder (M) was used as a marker. 
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The eluted recombinant DNA samples were subjected to restriction digest by NotI restriction 
enzyme in order to linearise the recombinant DNA. The samples were prepared for transfection 
and transfected into Lister 427 bloodstream form T. brucei. Transfected bloodstream form T. 
brucei were grown in HMI-9 media with the presence of phleomycin and neomycin at 37°C and 
5% CO2.  
Transfected cell lines will be referred to by their respective RNAi genes. Transfection of P2T7-
TbGAP1, P2T7-TbGAP4, P2T7-TbGEF2 and P2T7-TbGEF3 RNAi genes generated stable 
bloodstream form Lister 427 T. brucei cell lines that were taken forward for further studies. 
Three attempts were made at transfection of P2T7-TbGEF1 gene into bloodstream form Lister 
427 T. brucei, but despite attempts at growing 72 wells of transgenic cells, no wells generated 
stable cell lines from 24 hours post transfection. 
 
4.3.3 Effects of RNAi on parasite growth 
Three transfected cell lines from each TbGEFs and TbGAPs were randomly selected to identify 
the effect of RNAi of each gene on bloodstream form T. brucei growth. Transfected parasite 
cell lines were grown in selective HMI-9 media and RNAi was induced with the addition of 
tetracycline. The number of parasites were counted at 24 hours intervals for 72 hours. The 
same was done for control cultures for each of the TbGEF and TbGAP cell lines, which were 
grown in the absence of tetracycline. The effect of addition of tetracycline on wild type Lister 
427 bloodstream form T. brucei was also determined as a control to ensure that no effects 
were due to presence of the antibiotic alone. 
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Figure 4.6. RNAi effect on the growth of wild type and transgenic P2T7-TbGAP1 cell line. 
The effect of RNAi on (B) clone 1, (C) clone 2 and (D) clone 3 of the P2T7-TbGAP1 transgenic 
cell lines was studied at 24 hours interval. The effect of tetracycline on (A) wild type was also 
studied at 24 hours interval. *** = P ≤ 0.001; **** = P ≤ 0.0001. 
 
Parasite growth for clones from P2T7-TbGAP1 cell line shows that there were no significant 
differences in growth between the RNAi induced (red) and control group (blue) up until 72 
hours post RNAi (P ≤ 0.0001) (Figure 4.6). However clone 2 shows that there were slightly 
less parasite growth form 48 hours post RNAi (P ≤ 0.001). Tetracycline did not affect the growth 
of wild type bloodstream form T. brucei (Figure 4.6.A), therefore any results observed from 
addition of tetracycline could be considered as due to RNAi taking place. 
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Figure 4.7. RNAi effect on the growth of transgenic P2T7-TbGAP4 cell line. The effect of 
RNAi was studied in (A) clone 2, (B) clone 4 and (C) clone 6 of the transgenic P2T7-TbGAP4 
cell line at 24 hours interval. * = P ≤ 0.05; *** = P ≤ 0.001; **** = P ≤ 0.0001. 
 
As with the clones from P2T7-TbGAP1 cell line, the RNAi of clones from the P2T7-TbGAP4 
cell line did not appear affect the growth of bloodstream form T. brucei greatly until 72 hours 
post RNAi (Figure 4.7). However the growth of bloodstream form T. brucei from 48 hours post 
RNAi of TbGAP4 appears to significantly affect, albeit differently for each clone (P ≤ 0.05 – P 
≤ 0.0001). 
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Figure 4.8. RNAi effect on the growth of transgenic P2T7-TbGEF2 cell line. The RNAi 
effect in (A) clone 1, (B) clone 2 and (C) clone 3 from the transgenic P2T7-TbGEF3 cell line 
was studied at 24 hours interval. ** = P ≤ 0.01; **** = P ≤ 0.0001. 
 
The growth of different clones from the P2T7-TbGEF2 cell lines appear to be affected 
differently post RNAi (Figure 4.8). All clones appear to have significantly lower parasite growth 
from 48 hours post RNAi of TbGEF2. However, the RNAi effect on the growth of clone 2 
appears to be greater than in clone 1 and 3; P ≤ 0.0001 from 48 hours for clone 2 whilst clone 
1 and 3 had a P value of P ≤ 0.01 from 4 8 hours. 
 
 
  
144 
 
Figure 4.9. RNAi effect on the growth of transgenic P2T7-TbGEF3 cell line. The effect of 
RNAi on (A) clone 1, (B) clone 3 and (C) clone 6 of the P2T7-TbGEF3 transgenic cell line was 
studied at 24 hours interval. ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001. 
 
Parasite growth in the clones 3 and 6 from P2T7-TbGEF3 cell lines are shown to be greatly 
affected by the RNAi of TbGEF3 (Figure 4.9.B-C), with significantly lower parasite growth from 
48 hours post RNAi in clone 3 (P ≤ 0.0001) and from 24 hours post RNAi in clone 6 ( P ≤ 0.01). 
Clone 1 from P2T7-TbGEF3 cell line did not appear to have been affected by the RNAi of 
TbGEF3 to a greater extent than the other two clones. However there was still a significant 
difference in the growth from 48 hours post RNAi (P ≤ 0.001). 
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4.3.4 Quantification of gene expression 
The expression of clone 6 from P2T7-TbGEF3 was quantified at different time points post RNAi 
using qPCR. This is to ensure that the effect of TbGEF3 RNAi on bloodstream form T. brucei 
that can be observed from section 4.3.3 was due to reduced expression of TbGEF3.  
qPCR is a sensitive technique that is used to identify changes in gene expression (Panina et 
al., 2018). SYBR Green was used in this thesis to determine the changes in the expression of 
TbGEF3 post RNAi at 0, 4, 24 and 48 hour time points via qPCR. SYBR Green is an 
intercalating dye that binds to double stranded DNA to produce fluorescence. The intensity of 
the fluorescence can be used to determine the relative fold changes of the gene of interest’s 
expression (Cao and Shockey, 2012). Expression changes of the gene of interest is 
normalised against a housekeeping gene that is constituently expressed in the cells (Panina 
et al., 2018, Cao and Shockey, 2012). In this thesis -tubulin was used as a housekeeping 
gene in order to normalise the results obtained for TbGEF3. A standard curve was generated 
for TbGEF3 and -tubulin templates in order to assess the efficiency of the qPCR reaction 
(Svec et al., 2015). The R2 value generated from the standard curve gave a value closer 1 
(0.986 and 0.952 for TbGEF3 and -tubulin respectively) and qPCR efficiency of 90.198% - 
101.608%, confirming that the results observed were obtained at the best qPCR efficiency and 
the primers used for each gene worked optimally (Kuang et al., 2018). 
The differences in TbGEF3 relative expression across all time points was determined using 2-
ct method (Livak and Schmittgen, 2001), with the wild type as the control group. One-way 
ANOVA was used to determine the statistical significance of fold change of 4, 24 and 48 hours 
post RNAi compared to the 0 hour time point. 
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Figure 4.10. TbGEF3 Standard curve. Standard curve for TbGEF3 template was generated 
after preparing a series of templates with 10-fold dilution. StepOne Software Version 2.3 was 
used to analyse the R2 value, slope and efficiency percentage.  
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Figure 4.11. -tubulin Standard curve. Standard curve for -tubulin template was generated 
after preparing a series of templates with 10-fold dilution. StepOne Software Version 2.3 was 
used to analyse the R2 value, slope and efficiency percentage.   
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Figure 4.12 shows that compared to 0 hour time point, the expression of TbGEF3 was reduced 
from 4 hours post RNAi. The expression of TbGEF3 continued to be further reduced up until 
48 hours post RNAi. Although there was a reduced expression of TbGEF3 from 0 to 4 hour 
time point, the expression change was not big enough to be statistically significant. However 
the expression changes of TbGEF3 in 24 and 48 hour time points compared to 0 hours were 
statistically significant (P ≤ 0.05). This result confirms that the RNAi system used targeted the 
TbGEF3 gene in bloodstream form T. brucei. Therefore, this suggests that the reduced 
expression of TbGEF3 may have resulted in the observed changes in bloodstream form T. 
brucei growth in section 4.3.3. 
 
Figure 4.12. Relative expression change of TbGEF3 following RNAi. Expression change 
of TbGEF3 at 0, 4, 24 and 48 hours post RNAi was identified using qPCR. Fold changes were 
calculated using 2-CT method. Graph depicts results from TbGEF3 clone 6. 
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4.3.5 Flow cytometry 
4.3.5.1 Propidium iodide flow cytometry 
Propidium iodide flow cytometry was used to determine whether knockdown of the TbGEFs 
and TbGAPs caused any defects in bloodstream form T. brucei cell cycle progression. Mid-log 
phase bloodstream form T. brucei were harvested at 0, 4, 24 and 48 hours post RNAi and 
treated with RNAse A prior to staining with propidium iodide. The samples were processed 
and analysed on InCyte software (Merck Millipore). 
Propidium iodide is a small fluorescent intercalating agent that binds to DNA (Crowley et al., 
2016, de Silva Rodrigues et al., 2016). Cells with multiple nuclei or undergoing cell cycle will 
fluorescence differently compared to healthy cells with single nuclei due to the difference in 
propidium iodide binding to DNA. The number of nucleus present in a cell can be determined 
using flow cytometry. Samples stained with propidium iodide are rapidly passed in front of a 
laser and the changes in wavelength emitted by each cell is detected in flow cytometry (Dey, 
2018). T. brucei cells with defect in cytokinesis and containing multiple nuclei emit light at a 
different wavelength compared to healthy cells containing single nucleus. These results are 
collated and visualised in histograms. The number of peaks represents the number of nuclei 
present in each cell. A single peak corresponds to a single diploid nucleus (2C) whilst the 
subsequent peaks corresponding to the number of nuclei post mitosis (Price et al., 2010b). 
Wild-type bloodstream form T. brucei was used as a control sample to identify cell cycle 
progression using propidium iodide flow cytometry in normal cells prior to transfection of P2T7-
TbGEF/TbGAP plasmids. Data was collected from unstained wild type samples in order to 
eliminate false positives. Flow cytometry settings were adjusted so that unstained cells and 
background readings were avoided (Figure 4.13.A). As an intercalating agent, propidium iodide 
is able to bind to both DNA and dsRNA, this could lead to misleading data on cell cycle 
progression (Rieger et al., 2010). Two wild type samples were prepared in order to identify if 
samples with RNA present were significantly different to samples that were treated with RNAse 
A (Figure 4.13.B and C). 
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Figure 4.13. Propidium iodide flow cytometry of wild type bloodstream form T. brucei. 
Cell cycle progression in wild type bloodstream form T. brucei was determined using (A) no 
stain, (B) propidium iodide only and (C) propidium iodide with RNAse A. 
 
Figure 4.13. shows that samples that were not treated with RNAse A were not significantly 
different to samples treated with RNAse A. However the peaks indicating the number of DNA 
content present were more prominent in samples that had undergone RNAse A treatment. Two 
peaks can be observed that corresponds to a DNA content of 2C and 4C (Figure 4.13) 
The settings used for wild type samples were kept the same for transfected bloodstream form 
cell lines. The effect of cell cycle progression at different time points post RNAi was determined 
for the two TbGEFs and TbGAPs. The results show that all of the transfected cell lines had a 
DNA content similar to wild types: 2C and 4C, at 0 and 4 hours post RNAi (Figure 4.14 and 
Figure 4.15). This suggests that RNAi of TbGEFs and TbGAPs did not affect cell cycle 
progression during those time points. 
As expected from the growth curves, RNAi of TbGAP1 and TbGAP4 from 24 hour time points 
did not show any difference in the number of DNA content present in the cell population (Figure 
4.15). Similar results can be observed from RNAi of TbGEF2 (Figure 4.14.A). This suggests 
that RNAi of the TbGAPs and TbGEF2 does not affect bloodstream form T. brucei cell cycle 
progression, correlating with data from the growth curves. 
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 Flow cytometry data for TbGEF3 from 24 hours post RNAi showed that the cell population 
had a decrease in 2C cells, with significant decrease of 2C cell population observed in 48 hours 
post RNAi time point. The number of 4C population remained approximately the same at 24 
hours post RNAi of TbGEF3. However the 4C cell population decreased as well in the 48 hours 
post RNAi samples. A new cell population with a DNA content of 8C was observed from 24 
hours post RNAi. This population size increased in the 48 hours post RNAi samples. A rise in 
a new population containing DNA content of 16C can also be observed in the 48 hours post 
RNAi samples (Figure 4.14.B). 
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Figure 4.14. GEF RNAi effect on cell cycle progression in T. brucei. The effect of RNAi on cell cycle progression was identified in (A) P2T7-
TbGEF2 and (B) P2T7-TbGEF3 at 0, 4, 24 and 48 hour time points. The peaks were labelled according to their DNA content. 
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Figure 4.15. GAP RNAi effect on cell cycle progression in T. brucei. The effect of RNAi on cell cycle progression in (A) P2T7-TbGAP1 and 
(B) P2T7-TbGAP4 was identified at 0, 4, 24 and 48 hour time points. The peaks were labelled according to their DNA content.  
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4.3.5.2 Live/Dead flow cytometry 
Propidium iodide flow cytometry data in section 4.3.5.1 showed that RNAi of TbGAPs and 
TbGEF2 did not affect cell cycle progression, whilst RNAi of TbGEF3 led to an increase in a 
cell population with a DNA content of 8C and more. This suggested that RNAi against TbGEF3 
possibly had a cytostatic effect on bloodstream form T. brucei. However in order to asses if 
RNAi of TbGEF3 does have a cytostatic effect or if the results observed are caused by cell 
death (cytocidal), a Live/Dead flow cytometry was carried out. Live/Dead flow cytometry was 
carried out on TbGAP1, TbGAP4 and TbGEF2 to see if RNAi of these regulators have a 
cytocidal effect as well.   
Mid-log phase bloodstream form T. brucei were harvested at 0, 4, 24 and 48 hours post RNAi. 
The harvested cells were stained with Live/Dead Fixable Red Dead dye and the effect or RNAi 
was observed using Guava EasyCyte 6-2L flow cytometer (Merck Millipore) and on InCyte 
software (Merck Millipore). Live/Dead flow cytometry results for RNAi of TbGEFs and TbGAPs 
showed two distinct populations that were identified as live and dead cells. The two different 
populations were differentiated using gates and data for each population was analysed. One-
way ANOVA test was used to determine the statistical significance of population change at 
different time points post RNAi compared to 0 hours. 
Live/Dead flow cytometry results for TbGAP1 at different time points post RNAi showed that 
there was an increase in live cell population than compared to the dead cell population across 
the different time points (Figure 4.16). 97% of the cell population were live cells at all time 
points compared to 0.5 – 0.6% of the cell population being dead cells. Although there was a 
slight increase in dead cells at 48 hours post RNAi, the increase was not statistically significant 
and could not be concluded to be an effect of RNAi of TbGAP1 (Figure 4.20).  
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Figure 4.16. Live/Dead flow cytometry of P2T7-TbGAP1 post RNAi at different time 
points. P2T7-TbGAP1 cells were harvested at (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 
48 hours post RNAi of TbGAP1 and stained with Live/Dead Fixable Red Dead dye. Samples 
were processed by flow cytometry to differentiate between live and dead cells. 
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Live/Dead flow cytometry results showed that RNAi of TbGAP4 did not cause a significant 
increase in cell death (P > 0.05) similarly to the RNAi of TbGAP1. 94 – 97% of the cell 
population consisted of live cells whilst only 1 – 2% of the cell population consisted of dead 
cells at all of the time points post RNAi (Figure 4.17 and Figure 4.20). The same was observed 
for samples at different time points post RNAi of TbGEF2 (Figure 4.18). A high percentage of 
the cell population consisted of live cells (95 – 97%) at all time points post RNAi. Similarly to 
TbGAPs, RNAi of TbGEF2 resulted in only 1% dead cells in the population counted (Figure 
4.20). 
Live/Dead flow cytometry results for TbGEF3 at different time points post RNAi showed that 
changes in the live and dead cell population sizes from 48 hours post RNAi was clearly 
observable (Figure 4.19). The results show that RNAi of TbGEF3 did not cause immediate cell 
death since 93 – 94% of the cell population consisted of live cells from 0 to 24 hours post 
RNAi. A significant increase in dead cell population (P ≤ 0.0001) can be observed from 48 
hours post RNAi (Figure 4.20). 
 
 
 
 
 
 
 
 
 
 
  
157 
 
Figure 4.17. Live/Dead flow cytometry of P2T7-TbGAP4 post RNAi at different time 
points. P2T7-TbGAP4 cells were harvested at (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 
48 hours post RNAi of TbGAP4 and stained with Live/Dead Fixable Red Dead dye. Samples 
were processed by flow cytometry to differentiate between live and dead cells. 
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Figure 4.18. Live/Dead flow cytometry of P2T7-TbGEF2 post RNAi at different time 
points. P2T7-TbGEF2 cells were harvested at (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 
48 hours post RNAi of TbGEF2 and stained with Live/Dead Fixable Red Dead dye. Samples 
were processed by flow cytometry to differentiate between live and dead cells. 
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Figure 4.19. Live/Dead flow cytometry of P2T7-TbGEF3 post RNAi at different time 
points. P2T7-TbGEF3 cells were harvested at (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 
48 hours post RNAi of TbGEF3 and stained with Live/Dead Fixable Red Dead dye. Samples 
were processed by flow cytometry to differentiate between live and dead cells. 
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Figure 4.20. Live/Dead cell percentage at different time points post RNAi. The percentage 
of (A) Dead and (B) Live cells for each time point post RNAi of their respective GEFs and 
GAPs was analysed to determine the statistical significance between the two populations. **** 
= P ≤ 0.0001. 
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4.3.6. Microscopy 
4.3.6.1 Indirect immunofluorescent microscopy 
Immunofluorescent microscopy is a cell imaging technique that utilises fluorescent labelled 
antibodies to detect specific antigens in order to visualise target proteins or cell structures 
(Odell and Cook, 2013). This technique is further divided into two classes depending on the 
fluorophore tagged antibodies used. Direct immunofluorescent microscopy is a one-step 
staining procedure where the fluorophore tagged antibody binds directly to the antigen. In 
contrast to this, fluorophore tagged secondary antibodies and primary antibodies are utilised 
in indirect immunofluorescent microscopy. Primary antibodies bind to surface antigens, 
fluorophore tagged secondary antibodies then bind to the primary antibodies; enabling 
visualisation of target proteins or structures of the cell (Becheva et al., 2018, Mohan et al., 
2008).  
Indirect immunofluorescent microscopy was utilised in this project to visualise the cell structure 
of bloodstream form T. brucei at 0, 4, 24 and 48 hours post RNAi of TbGEFs and TbGAPs. 
Primary mouse monoclonal antibody 1 (TAT1) and primary anti-rabbit monoclonal antibody 
was used against T. brucei -tubulin and paraflagellar rod protein 1 (PFR1) respectively. Alexa 
Fluor 488 and 594 conjugated secondary antibodies were used to detect primary antibodies. 
The cell structure of bloodstream form T. brucei was visualised using EVOS FL Cell Imaging 
System (Life Technologies).  
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The cellular structure of T. brucei transfected with P2T7-TbGAP1 plasmid prior to RNAi (0 
hours) were similar to those of the infective wild type bloodstream form (Figure 4.21.A-B). This 
is characterised by the vermiform shape with tapered ends (highlighted by -tubulin in green) 
with a single flagellum along the length of T. brucei body (highlighted by PFR1 in red) (Ralston 
et al., 2009). The vermiform shape in transfected T. brucei was maintained across all time 
points post RNAi (Figure 4.21.C-E). This suggests that RNAi of TbGAP1 did not grossly affect 
the cellular structure of bloodstream form T. brucei. The same was observed for bloodstream 
form T. brucei transfected with P2T7-TbGAP4 and P2T7-TbGEF2 plasmids, following 
incubation in tetracycline (Figure 4.22 and Figure 4.23). 
 
 
 
 
 
 
 
  
163 
 
Figure 4.21. Indirect immunofluorescent microscopy of wild type bloodstream form T. 
brucei and PT27-TbGAP1. The cellular structure of (A) wild type, (B) 0 hours, (C) 4 hours, 
(D) 24 hours and (E) 48 hours post RNAi of TbGAP1 was studied. -tubulin is shown in 
(green), paraflagellar rod is shown in red, nucleus and kinetoplast is shown in blue. Scale bar 
= 10 m. 
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Figure 4.22. Indirect immunofluorescent microscopy of bloodstream form T. brucei 
post RNAi of TbGAP4. The cellular structure of (A) wild type, (B) 0 hours, (C) 4 hours, (D) 24 
hours and (E) 48 hours post RNAi of TbGAP4 was studied. -tubulin is shown in (green), 
paraflagellar rod is shown in red, nucleus and kinetoplast is shown in blue. Scale bar = 10 m 
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Figure 4.23. Indirect immunofluorescent microscopy of bloodstream form T. brucei 
post RNAi of TbGEF2. The cellular structure of (A) wild type, (B) 0 hours, (C) 4 hours, (D) 24 
hours and (E) 48 hours post RNAi of TbGEF2 was studied. -tubulin is shown in (green), 
paraflagellar rod is shown in red, nucleus and kinetoplast is shown in blue. Scale bar = 10 m. 
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Similar to the other T. brucei ARF regulators that were transfected into bloodstream form T. 
brucei, the cellular structure of T. brucei transfected with P2T7-TbGEF3 plasmid at 0 hours 
(before RNAi was induced) had a vermiform shape that is characteristic of the wild type 
bloodstream form T. brucei. This shape was retained up until 4 hours post RNAi of TbGEF3 
(Figure 4.24.A-B). However from 24 hours post RNAi, the shape of the bloodstream form T. 
brucei became circular (Figure 4.24.C-D) and resembled the BigEye phenotype that was 
described previously by Allen et al. (Allen et al., 2003).   
Since bloodstream form T. brucei transfected with P2T7-TbGEF3 demonstrated changes in 
cellular structure from 24 hours post RNAi. The numbers of circular and vermiform (slender) 
morphology present in the indirect immunofluorescent slides were counted for all time points 
post RNAi of TbGEF3. 100 cells were counted in total for each sample and the percentage 
was calculated for each morphology type across the different time points (Figure 4.25). The 
circular morphology present in the samples were assumed to be caused by an enlarged 
flagellar pocket and is termed as BigEye phenotype (Allen et al., 2003). However enlargement 
of the flagellar pocket could not be confirmed with the use of indirect immunofluorescent 
microscopy. 
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Figure 4.24. Indirect immunofluorescent microscopy of bloodstream form T. brucei. The 
cellular structure of (A) wild type, (B) 0 hours, (C) 4 hours, (D) 24 hours and (E) 48 hours post 
RNAi of TbGEF3 was studied. -tubulin is shown in (green), paraflagellar rod is shown in red, 
nucleus and kinetoplast is shown in blue. Scale bar = 10 m. 
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Figure 4.25. Number of BigEye and slender T. brucei cells at different time points post 
RNAi. The number of BigEye Vs slender morphology observed at different time points post 
RNAi of TbGEF3 was counted. 100 cells were counted for each time point sample and a 
percentage was calculated. ** = P ≤ 0.01, **** = P ≤ 0.0001. 
 
4.3.6.2 Transmission Electron Microscopy 
The circular morphology that was observed at different time points post RNAi of TbGEF3 in 
section 4.3.6.1 resembled the BigEye morphology. The BigEye morphology is characterised 
by the presence of enlarged flagellar pocket (Allen et al., 2003). However the presence of an 
enlarged flagellar pocket could not be determined clearly by indirect immunofluorescent 
microscopy. Transmission Electron Microscopy (TEM) was used in order to characterise 
changes in morphology in greater detail. 
Electron microscopy enables high resolution imaging of cellular structures and proteins 
(Schorb et al., 2017). This is achieved by utilising a beam of electrons instead of light to 
illuminate and record the image (McIntosh et al., 2017). There are two subclasses of electron 
microscopy, Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy 
(TEM). SEM looks at the surface of the sample, identifying structural abnormalities and shapes 
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of the sample. In contrast TEM provides informative two dimensional details on cellular 
ultrastructure (McIntosh et al., 2017).  
 Bloodstream form T. brucei at 0, 24 and 48 hours post RNAi of TbGEF3 were harvested and 
prepared for TEM. The prepared samples were kindly processed for TEM at Technology 
Facility, Department of Biology, University of York by Meg Stark. 
TEM enabled the visualisation of T. brucei ultrastructure at different time points post RNAi, 
and these results were compared to the wild type T. brucei ultrastructure. The cellular 
ultrastructure of wild type and 0 hours post RNAi samples were similar. Regular morphology 
of subpellicular microtubules, nucleus, paraflagellar rod and flagellum can be observed in both 
samples (Figure 4.26 and Figure 4.27). The cellular ultrastructure for samples that were 
subjected to RNAi for 24 hours were different to the wild type ultrastructure (Figure 4.28). The 
presence of nucleus and paraflagellar rod could not be visualised clearly in the 24 hours RNAi 
samples. Presence of a large vacuole can be observed and this was identified by TEM as the 
enlarged flagellar pocket. The vacuole was designated as the flagellar pocket due to the 
presence of an electron dense VSG coat on the membrane and the presence of flagellum 
bound to the membrane via flagellum attachment zone (Allen et al., 2003). Unfortunately cells 
in the 48 hours post RNAi samples lysed during processing and therefore TEM images could 
not be obtained. 
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Figure 4.26. Transmission Electron Microscopy of wild type bloodstream form T. brucei. 
The cellular ultrastructure of wild type bloodstream form T. brucei was determined. Visible 
components of the cells were labelled. MT; microtubules, PFR; paraflagellar rod, F; flagellum, 
and N; nucleus. Scale bars: Large image – 500 nm, small image – 1 m. 
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Figure 4.27. Transmission Electron Microscopy RNAi induced bloodstream form T. 
brucei. Samples from 0 hours post RNAi of TbGEF3 were analysed using TEM. Visible 
components of the cells were labelled. MT; microtubules, PFR; paraflagellar rod, F; flagellum, 
and N; nucleus. Scale bars: Large image – 500 nm, small image – 1 m. 
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Figure 4.28. Transmission Electron Microscopy RNAi induced bloodstream form T. 
brucei. Samples from 24 hours post RNAi of TbGEF3 were analysed using TEM. MT; 
microtubules, FP; flagellar pocket, F; flagellum; arrow indicate the electron dense VSG coat; 
and open bracket indicates the flagellar attachment zone. Scale bars: Large image – 500 nm, 
small image – 1 m. 
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4.3.7 Concanavalin A endocytosis assay 
Allen et al. (2003) demonstrated the correlation between endocytosis defect and the presence 
of BigEye morphology in bloodstream form T. brucei post RNAi of TbCLH (Allen et al., 2003). 
Price et al. (2007) also observed similar results post RNAi of TbARF1 (Price et al., 2007b). 
This suggests that the BigEye morphology observed in microscopy images post RNAi of 
TbGEF3 in section 4.3.6 may also hint to possible endocytosis defect. Receptor mediated and 
fluid phase endocytosis occurs at the flagellar pocket in T. brucei. Endocytosed components 
such as antibody bound VSGs are delivered to early endosomes (TbRab5A/B) and recycled 
to either recycling endosomes (TbRab11) or late endosomes (TbRab7). The VSG is then 
trafficked to the single lysosome where it is degraded (Umaer et al., 2018, Engstler et al., 
2004, Overath and Engstler, 2004). A defect in endocytosis would mean that lipids, solutes 
and receptor bound ligands would not be delivered to the endosomes; and would accumulate 
in the flagellar pocket instead.  
An endocytosis defect in Lister 427 bloodstream form T. brucei was identified by Allen et al. 
(2003) and Price et al. (2007) with the use of FITC-labelled Concanavalin A (Con A). Con A is 
a legume lectin that is readily taken up by bloodstream form T. brucei via endocytosis (Allen 
et al., 2003). At different temperatures Con A will be localised at different endocytic pathway 
components. At 4°C Con A is localised at the flagellar pocket where endocytosis occurs. At 
12°C Con A is taken deeper into the cell via endocytic pathways and localised to TbRab5A 
early endosomes. At 37°C Con A is further taken up to the lysosomes (Allen et al., 2003, 
Jeffries et al., 2001). TbRab5A endosomes and lysosomes (P67) were labelled with Rabbit 
anti-TbRab5A and mouse anti-P67 primary antibodies respectively, and Alexa Fluor 594 
secondary antibodies were used to detect the primary antibodies. This is to ensure that the 
localisation of Con A can be visualised and determined if they are in close proximity to the 
organelles. 
Figure 4.29 shows that Con A is present next to the kinetoplast, where the flagellar pocket is 
located. This suggests that Con A was taken up into the flagellar pocket and it remained 
  
174 
localised to the flagellar pocket for all time points post RNAi of TbGEF3 at 4°C as expected. 
There was an increase in number of cells from 48 hours post RNAi that did not have Con A 
present in their cells. This may suggest that there is an increase in the number of dead cells 
from 48 hours post RNAi. 
 
Figure 4.29. Endocytosis of Con A at 4°C. Endocytosis disruption was examined in T. brucei 
samples from (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 48 hours post RNAi of TbGEF3. 
FITC-labelled Con A (green) was used to detect endocytosis. Nucleus and kinetoplast are 
labelled in blue. Scale bar = 10 m. Images in the last column were magnified by 2.5 fold. 
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Figure 4.30. Endocytosis of Con A at 12°C. Endocytosis disruption was examined in T. 
brucei samples from (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 48 hours post RNAi of 
TbGEF3. FITC-labelled Con A (green) was used to detect endocytosis, TbRab5A are shown 
in red. Nucleus and kinetoplast are shown in blue. Scale bar = 10 m. Images in the last 
column were magnified by 2.5 fold. 
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At 12°C Con A is transported  to the early endosomes (labelled here by TbRab5A) (Allen et 
al., 2003). The localisation of TbRab5A was visualised by using rabbit anti-TbRab5A primary 
antibody and Alexa Fluor 594 secondary antibody. Figure 4.26 shows that TbRab5A can be 
visualised in multiple puncta in the cells at all time points post RNAi. However endocytosed 
Con A only partially co-localises with TbRab5A from 0 hours post RNAi to 4 hours post RNAi 
(Figure 4.30.A-B). Although Con A was present in the flagellar pocket of cells with BigEye 
morphology from 24 hours post RNAi, the Con A were not taken up further into TbRab5A 
(Figure 4.30.C-D). This shows endocytosis being compromised in cells from 24 hours post 
RNAi. 
Similar results were observed in cells incubated at 37°C with Con A. At 37°C, Con A is 
transported to the terminal endosomal compartment, the lysosome, a single organelle in 
trypanosomes (Allen et al., 2003). The localisation of the lysosome was visualised using 
mouse anti-P67 primary antibodies and Alexa Fluor 594 secondary antibodies. The cells from 
0 hours to 4 hours post RNAi showed that Con A was transported to compartments adjacent 
to the p67-stained lysosome (Figure 4.31.A-B). However, from 24 hours post RNAi, the cells 
started to exhibit BigEye morphology. This was accompanied by the lack of transport of Con 
A away from the flagellar pocket (Figure 4.31.C-D). This further suggests that an endocytosis 
defect is present in bloodstream form T. brucei cells that had undergone RNAi of TbGEF3 for 
24 hours or more. Interestingly around 60% of cells from 48 hours post RNAi of TbGEF3 
showed no presence of Con A signal (Figure 4.31.D). This may suggest that uptake into the 
flagellar pocket is compromised or that the cells from 48 hours post RNAi have died or lysed 
during the preparation of the endocytosis assay. This finding coincides with the live/dead flow 
cytometry data from section 4.3.5.2; where increase in cell death was observable from 48 
hours post RNAi of TbGEF3. 
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Figure 4.31. Endocytosis of Con A at 37°C. Endocytosis disruption was examined in T. 
brucei samples from (A) 0 hours, (B) 4 hours, (C) 24 hours and (D) 48 hours post RNAi of 
TbGEF3. FITC-labelled Con A (green) was used to detect endocytosis, P67 lysosomes are 
shown in red. Nucleus and kinetoplast are shown in blue. Scale bar = 10 m. Images in the 
last column were magnified by 2.5 fold. 
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4.4 Discussion 
This chapter aimed to identify which of the TbGEFs and TbGAPs were essential for 
bloodstream form T. brucei viability. This chapter also aimed to identify the effects of RNAi of 
TbGEFs and/or TbGAPs on growth and morphology of bloodstream form T. brucei, as well as 
identify any differences can be observed between the RNAi of TbGEFs and TbGAPs. Suitable 
RNAi regions were identified and amplified by PCR. RNAi constructs were generated and 
transfected into bloodstream form T. brucei for further analysis in order to analyse the effects 
of RNAi on bloodstream form T. brucei. 
 
4.4.1 Unsuccessful transfections may be due to a leaky inducible expression system 
RNAi is an ancient and ubiquitous mechanism of antiviral defence that utilises small interfering 
RNAs (siRNAs) and microRNAs (miRNA) produced from the cleavage of double stranded 
RNAs (dsRNA) by DICER, a ribonuclease (Saurabh et al., 2014, Fire et al., 1998, Ding et al., 
2018). The siRNAs and miRNAs are incorporated into the RNA-induced silencing complex 
(RISC). This results in the interference of mRNA translation, thus leading to gene expression 
knockdown (Saurabh et al., 2014, Fire et al., 1998, Ding et al., 2018). A functioning RNAi 
system was first demonstrated in T. brucei in 1998, making T. brucei the first protozoan 
parasites with an identified operational RNAi system (Kolev et al., 2011). The RNAi system in 
T. brucei utilises two DICER like homologues (TbDCL1 and TbDCL2) that synthesise siRNAs 
(Shi et al., 2006, Patrick et al., 2009). The synthesised siRNAs associates with the single 
argonaute protein present in T. brucei (TbAGO1), which is then incorporated into the RISC 
complex and induces gene knockdown via mRNA translation interference (Durand-Dubief and 
Bastin, 2003, Shi et al., 2004, Shi et al., 2009).  
Original RNAi studies in T. brucei involved transfection of dsRNA to induce knockdown of 
target mRNAs, however the effect of this knockdown was short and only present for one cell 
cycle (Ngô et al., 1998). To overcome the temporary effect of RNAi post transfection of dsRNA 
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in T. brucei, a tetracycline inducible RNAi system was introduced (discussed in detail in section 
4.3.2). RNAi regions of the identified T. brucei GEFs and GAPs were ligated to the tetracycline 
inducible RNAi system, transformed and grown on selective agar plates in order to generate 
large quantities of recombinant DNA (Rahimzadeh et al., 2016). The purified recombinant DNA 
were transfected into bloodstream form T. brucei. 
 Transfection can be broadly categorised into three types of techniques that can be used to 
introduce foreign nuclei acids into a cell; biological, chemical and physical transfection (Chow 
et al., 2016). Delivery of linear recombinant DNA into bloodstream form T. brucei was achieved 
by electroporation, a physical transfection technique, in this chapter. Electroporation technique 
was first demonstrated by Neumann et al. (1982) on mouse lyoma cells, who showed that 
electric impulses greatly increased intake of DNA into cells (Neumann et al., 1982). The 
duration, intensity and frequency of the electric impulse affected the efficiency of gene delivery 
into a cell (Heller et al., 2005). The electric impulse generates temporary permeability in the 
cell membrane, allowing DNA to enter the cell without damaging the cell (Kamimura et al., 
2011, Sugar and Neumann, 1984). 
Stable cell lines were grown post transfection of P2T7-TbGEF/GAP into Lister 427 
bloodstream form T. brucei. However transfection of P2T7-TbGEF1 into bloodstream form T. 
brucei did not yield stable transgenic cell lines from 24 hours post transfection despite 
numerous attempts. Previous studies have highlighted that transfection of the P2T7Ti vector 
sometimes caused ‘leaky’ expression in uninduced cells (LaCount et al., 2002). This leaky 
expression coupled with knockdown of an essential gene may have caused the rapid killing of 
bloodstream form T. brucei from 24 hours post transfection of P2T7-TbGEF1. Further 
evidence of leaky expression in transfected bloodstream form T. brucei was observed during 
light microscopy visualisation of the cells after transfection of TbGEF1. Uninduced transfected 
bloodstream form T. brucei exhibited phenotypes with large vacuole and sometimes multiple 
flagellum. The presence of large vacuoles in bloodstream form T. brucei is known as BigEye 
morphology, and has been known to be caused by enlarged flagellar pocket (Allen et al., 
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2003). Previous RNAi studies on T. brucei have identified the presence of BigEye morphology 
when RNAi was induced. An example of this is the study by Price et al. (2007), who 
demonstrated that inducing RNAi of ARF1 resulted in BigEye morphology in bloodstream form 
T. brucei (Price et al., 2007b).  
Alternative methods of gene knockdown systems in bloodstream form T. brucei are available 
for tightly controlled inducible expression of dsRNA for essential genes. The pTbFIX vectors 
consists of two transcription units. The RNAi of target gene is driven by inducible rRNA 
promoter containing two TetOPs and a downstream dicistronic unit that encodes TetR. The 
pTbFIX vector contains the sequence of interest and regulatory elements for gene silencing; 
thus this vector eliminates the need for pre-existing transgenic cell lines that can be 
transfected with the RNAi sequence (Niemirowicz et al., 2018). Niemirowicz et al (2018) 
successfully knocked down the expression of clathrin heavy genes in bloodstream form T. 
brucei using the pTbFIX vector (Niemirowicz et al., 2018). 
Another alternative inducible system is the glmS ribozyme based inducible gene expression 
system. The glmS ribozyme is inserted into the C-terminal of the gene of interest allele. The 
glmS acts as a self-cleaving riboswitch, which when inserted into the 5’-UTR or 3’-UTR of the 
gene of interest causes gene silencing in the presence of glucosamine 6-phosphate (Cruz‐
Bustos et al., 2018). Cruz-Bustos et al. had noted that the glmS ribozyme inducible system 
worked as effectively as the conventional RNAi system, minus the drawback from leaky 
expression (Cruz‐Bustos et al., 2018). The glmS ribozyme inducible system was used to 
knockdown the expression of TbVPS41 and compare the knockdown effect to RNAi 
knockdown system. Results showed that whilst knockdown of TbVPS41 was only effective for 
2 days, the knockdown of TbVPS41 using the glmS ribozyme inducible system remained 
stable (Cruz‐Bustos et al., 2018).  
Future work involving one of these gene knockdown techniques on TbGEF1 may provide a 
stable transfected cell line that can be further studied. 
  
181 
4.4.2 Identification of essential ARF regulators in bloodstream form T. brucei 
A tetracycline induced RNAi system has been used in this thesis to inhibit the expression of 
T. brucei GEFs and GAPs in bloodstream form T. brucei. Three clones were randomly 
selected from transgenic cell lines that were successfully transfected with TbGAP1, TbGAP4, 
TbGEF2 and TbGEF3; and the effect of RNAi on bloodstream form T. brucei growth was 
studied. RNAi of TbGEF3 was shown to have greatly affected the growth of bloodstream form 
T. brucei. Especially in clone 6 where the effect of RNAi of bloodstream form T. brucei growth 
can be observed from 24 hours post addition of tetracycline. This could possibly mean that 
TbGEF3 is essential for the viability of bloodstream form T. brucei. There was also a significant 
difference in parasite growth from 48 hours post RNAi of TbGEF2, suggesting that TbGEF2 
may also be essential in bloodstream form T. brucei. Although there was a significant 
difference in bloodstream form T. brucei growth post RNAi of TbGAP1 and TbGAP4, the 
differences were not as great as the effect of TbGEF3 RNAi.  
The effect of RNAi on parasite growth was not uniform in all clones of P2T7-TbGEF3 cell lines, 
with the same trend being observed in the P2T7-TbGAP1, P2T7-TbGAP4 and P2T7-TbGEF2 
cell lines. There is a possibility that the lack of difference in bloodstream form T. brucei growth 
observed in section 4.3.3 in some clones of the P2T7-TbGAP1, P2T7-TbGAP4, P2T7-
TbGEF2 and P2T7-TbGEF3 cell lines may be due to incomplete knockdown or lack of RNAi 
taking place. A qPCR can be used to analyse the expression of the TbGEF and TbGAP genes 
in order to determine if there was a partial knockdown or no RNAi taking place in some of the 
clones. 
Successful qPCR data was only obtained for clone 6 of TbGEF3 cell line. The data in section 
4.3.4 showed that the expression of TbGEF3 had reduced from 0 to 48 hours post RNAi. The 
change in TbGEF3 expression from 0 hour to 4 hours was not statistically significant. However, 
the expression of TbGEF3 in 24 hours and 48 hours post RNAi samples were significantly 
reduced compared to 0 hours post RNAi sample. qPCR on all clones for TbGEFs and TbGAPs 
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should be carried out in the future to determine if the differences in parasite growth observed 
was due to incomplete knockdown or no RNAi taking place. 
In order to determine if the lack of parasite growth observed in section 4.3.3 was due to 
increase in parasite death from 24 hours post RNAi of TbGEF3, a Live/Dead flow cytometry 
analysis was carried out using Live/Dead Fixable Red Dead Stain on clone 6 from P2T7-
TbGEF3 cell line. The same was done for clone 2 from P2T7-TbGAP1, clone 6 from P2T7-
TbGAP1 and clone 2 from P2T7-TbGEF2 cell lines. These clones showed the most significant 
differences in bloodstream form T. brucei, therefore they chosen for further analysis. 
All eukaryotic cell surfaces are covered by lipids and proteins, making up the plasma 
membrane. Cell death due to either apoptosis, necrosis or other factors lead to compromised 
plasma membrane (Zhang et al., 2018, Bridges et al., 2008). Live/Dead Fixable Red Dead 
dye reacts with amines present on the cell surface. The dye also reacts with free amines 
present inside membrane compromised dead cells. Thus the intensity of the fluorescent dye 
increases in plasma membrane compromised cells than compared to viable cells. Similar to 
propidium iodide flow cytometry, the samples stained with Live/Dead Fixable Red Dead dye 
are rapidly passed in front of a laser. Dead cells will emit stronger fluorescence than live cells. 
This difference in fluorescence data is collated and visualised in Dot plot graphs (Dey, 2018). 
Live/Dead flow cytometry data from section 4.3.5.2 showed that the RNAi of TbGAP1, 
TbGAP4 and TbGEF2 had similar results. Around 97% of the cell population were live for all 
three cell lines at all time points post RNAi. This suggests TbGAP1, TbGAP4 and TbGEF2 
may not be essential for the viability of bloodstream form T. brucei. Hence no effects were 
seen on the growth of bloodstream form T. brucei following the RNAi of their respective 
regulators.  
Similarly, RNAi of TbGEF3 data showed that there were no significant differences between 
live and dead cells from 0 to 24 hours post RNAi of TbGEF3. High percentage of the cell 
population (90-93%) consisted of live cells whilst 6-9% of the cell population were dead. 
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However an increase in dead cells was observed at 48 hours post RNAi, with 54% of the cell 
population being dead and 43% of the population being alive. This data suggests that RNAi 
of TbGEF3 does not cause rapid cell death, but cell death occurs slowly. 
Propidium iodide flow cytometry was then used in order to identify if the differences in parasite 
growth for each ARF regulator gene was due to defect in cell cycle progression, since RNAi 
of TbGEFS and TbGAPs did not cause cell death (or rapid cell death) that may explain the 
growth curve data seen in section 4.3.3.  
Like other eukaryotic cells, T. brucei undergoes a tightly regulated cell cycle. Broadly following 
the G0/G1, S, G2 and M phases of the cell cycle. However T. brucei consists of single copies 
of nucleus and kinetoplast (mitochondrial DNA), as well as other organelles and structures. 
These single copy organelles and structures are duplicated and segregated at particular 
phases of the cell cycle (Hammarton, 2007, Benz et al., 2017, Jakob et al., 2016). Kinetoplast 
replication and segregation occurs prior to nuclear replication and segregation, enabling T. 
brucei cells to progress from 1K1N (K refers to kinetoplast whilst N refers to nucleus) to 2K1N 
configuration. Nuclear division during mitosis progresses T. brucei cells to 2K2N configuration. 
Mitosis is followed by cytokinesis, leading to the formation of two daughter cells (Hammarton, 
2007, Benz et al., 2017). Previous studies have shown that cell cycle arrest and defect in 
cytokinesis in T. brucei is characterised by the presence of multiple nuclei, flagellar and 
abnormal morphology (Mudogo et al., 2018, Price et al., 2010b). The presence of multiple 
nucleus was examined in section 4.3.5.1 to determine if RNAi of TbGEFs and TbGAPs caused 
a cell cycle defect. 
Results in section 4.3.5.1 showed that all transfected cells lines prior to RNAi (0 hours) and 
wild type samples consisted of cells with DNA content of 2C and 4C. Normal bloodstream form 
T. brucei undergo cell division that lasts for approximately 8 hours in order to produces viable 
progeny. During the cell division the parasite transitions from G0/G1 phase of the cell cycle, 
where DNA content of 2C is present, to the G2 phase where DNA content of 4C is present 
(Hammarton, 2007, Peacock et al., 2014, Benz et al., 2017). This controlled cell division may 
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explain the presence of 2C and 4C DNA content in the 0 hours post RNAi and wild type 
samples. However defect in cytokinesis leads to T. brucei cells replicating without forming 
daughter cells, thus leading to multiple nucleus present in the cell and a DNA content of 8C or 
more (Jones et al., 2014).  
A normal cell population with DNA content of 2C and 4C was observed in all time points post 
RNAi of TbGAP1, TbGAP4 and TbGEF2. This suggests that RNAi of these genes has not 
affected the cell cycle progression in bloodstream form T. brucei. Although the 0 and 4 hours 
post RNAi of TbGEF3 samples showed that the cell population consisted of healthy cells with 
DNA content of 2C and 4C. The DNA content of TbGEF3 samples from 24 and 48 hours post 
RNAi showed a significant decrease in populations with DNA content of 2C. An increase in 
new populations with DNA contents of 8C and 16C can be observed in 24 and 48 hours post 
RNAi samples respectively. This suggest that a defect in cytokinesis is present in bloodstream 
form T. brucei from 24 hours post RNAi of TbGEF3. This may also suggest that TbGEF3 may 
be implicated in the function of cytokinesis and cell cycle progression in bloodstream form T. 
brucei, albeit at a lower level since RNAi did not affect cell cycle progression immediately.  
Propidium iodide flow cytometry result for TbGEF3 also coincides with the results observed in 
section 4.3.3, suggesting that defect in cell cycle progression contributed to lack of 
bloodstream form T. brucei growth; since cell cycle defect results in lack of healthy daughter 
cells being produced, thus leading to decrease in parasite growth. There is also a possibility 
that the high percentage of dead cells in 48 hours post RNAi may have been caused by 
accumulation of cells with cytokinesis defect dying from 48 hours post RNAi of TbGEF3. The 
gene expression change results observed in section 4.3.4 may also explain the morphological 
and physiological changes observed in bloodstream form T. brucei post RNAi of TbGEF3. The 
absence of significant expression changes in TbGEF3 at 4 hours post RNAi could mean that 
the function of TbGEF3 could have resumed without causing any effect on bloodstream form 
T. brucei, hence no changes in cell cycle progression or cell death was observed until 24 hours 
post RNAi. 
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GEFs and GAPs are known to interact with more than one ARF/ARLs in order to regulate their 
functions (Sztul et al., 2019). The lack of significant effect on bloodstream form T. brucei 
growth seen post RNAi of TbGAP1 and TbGAP4 may mean that more than one T. brucei 
GAPs may be interacting with the ARF/ARLs that are regulated by TbGAP1 and TbGAP4. 
Identification of the ARF/ARLs that interact with TbGAP1 and TbGAP4 using protein-protein 
interaction studies may identify other T. brucei GAPs or GEFs that interacts with their 
respective ARF/ARLs. Following this, a pairwise knockdown (Tu and Wang, 2005) of 
TbGAP1/4 and another regulator that interacts with the target ARF/ARLs may provide with 
additional information on the effect of multiple ARF regulators at the same time.  
 
4.4.3 TbGEF3 may be involved in endocytic pathways 
Propidium iodide and Live/Dead flow cytometry data in section 4.3.5 showed that RNAi of 
TbGEF3 causes a cell cycle defect in bloodstream form T. brucei as opposed to rapid parasite 
killing. Defect in cell cycle is characterised by the presence of multiple nucleus, flagellum and 
abnormal morphology in bloodstream form T. brucei (Mudogo et al., 2018, Price et al., 2010b). 
Mudogo et al. (2018) identified the presence of BigEye morphology in bloodstream form T. 
brucei that had partial cell cycle arrest (Mudogo et al., 2018). Indirect immunofluorescent 
microscopy was used to visualise the cell structure of bloodstream form T. brucei at different 
times points post RNAi of TbGEF3 in section 4.3.6.1 and to identify the presence of abnormal 
morphology. Indirect immunofluorescent microscopy was also used to visualise the cellular 
structures of bloodstream form T. brucei post RNAi of TbGAP1, TbGAP4 and TbGEF2. 
Microscopy images showed bloodstream form T. brucei having slender morphology termed 
vermiform from 0 to 4 hours post RNAi of TbGEF3 and in all time points for TbGAP1, TbGAP4 
and TbGEF2. This cell structure was similar to the wild type cell structure observed in section 
4.7.1 as well as the cell structure described in literature for wild type bloodstream form T. 
brucei (Pineda et al., 2018). Formation of bloodstream form T. brucei with circular morphology 
was observed from 24 hours to 48 hours post RNAi of TbGEF3. Previous studies on 
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bloodstream form T. brucei with circular morphology has been identified as the ‘BigEye’ 
morphology caused by enlarged flagellar pocket (Allen et al., 2003, Price et al., 2007b). 
However indirect immunofluorescent microscopy images did not clearly show the presence of 
a vacuole caused by enlarged flagellar pocket. TEM was used in order to identify if the cells 
with circular morphology that was observed in the indirect immunofluorescent microscopy. 
RNAi was induced at 0, 24 and 48 hour time points in bloodstream form T. brucei. However 
only 0 and 24 hours samples were successfully processed for TEM. Unfortunately 48 hour 
time point RNAi sample did not survive transportation for TEM processing. TEM images in 
section 4.3.6.2 showed that wild type and 0 hours post RNAi T. brucei cells had similar cellular 
structure with visible microtubules, flagellum, paraflagellar rod and nucleus. This suggest that 
transfection of P2T7-TbGEF3 did not cause any cellular changes in T. brucei.  
The presence of an enlarged vacuole in T. brucei cellular structure from 24 hours post RNAi 
can be observed in section 4.3.6.2. The enlarged structure was identified as the flagellar 
pocket. The flagellar pocket is a small invagination in the plasma membrane from where the 
proximal end of the flagellum emerges. Flagellar pocket is also the site where endocytosis and 
exocytosis takes place in bloodstream form T. brucei (Field and Carrington, 2009, Langousis 
and Hill, 2014). Enlarged flagellar pocket was first described by Allen et al. (2003), who 
identified the presence of BigEye morphology post RNAi of TbCLH (T. brucei clathrin heavy 
chain) in bloodstream form T. brucei (Allen et al., 2003). Allen et al. also noted a severe defect 
in endocytosis in cells with an enlarged flagellar pocket, suggesting that BigEye morphology 
is characterised by absence of endocytosis in bloodstream form T. brucei (Allen et al., 2003). 
Price et al. (2007) also identified a decrease in endocytosis post RNAi of TbARF1 in 
bloodstream form T. brucei (Price et al., 2007b). This may mean that the T. brucei cells 
exhibiting BigEye morphology post RNAi of TbGEF3 may also have an endocytosis defect. 
Endocytosis was investigated in the cell lines using FITC-labelled Concanavalin A (Con A), a 
legume lectin that is readily taken up by bloodstream form T. brucei via receptor-mediated 
endocytosis (Allen et al., 2003). Data in section 4.3.7 shows that Con A was further 
  
187 
endocytosed into TbRab5A and P67 lysosomes at 12°C and 37°C respectively at 0 and 4 
hours post RNAi of TbGEF3. Interestingly Con A did not localise to TbRab5A and P67 
lysosomes at their respective temperatures from 24 hours post RNAi of TbGEF3. This 
demonstrates defect in endocytosis in samples with BigEye morphology. 
Around 60% of T. brucei cells in the 48 hours post RNAi of TbGEF3 samples consisted of cells 
with no visible presence of Con A in the flagellar pocket or other organelles. This may be due 
to the severity of endocytosis and cell cycle defect. Live/Dead flow cytometry data from section 
4.3.5.2 showed that there was an increase in cell death at 48 hours post RNAi of TbGEF3. 
There is also a possibility that the stress of preparation of samples for the endocytosis assay 
may have killed cells that had severe endocytosis defects. Endocytosis assay on the 48 hours 
post RNAi time point was carried out four time and the same results was seen across all 
samples at that particular time point. Further investigation needs to be carried out in order to 
determine if lack of Con A presence in cells is due to endocytosis defect or cell death. 
 
4.5 Conclusions 
The main findings of this chapter are as follows: 
• TbGEF3 is essential for bloodstream form T. brucei viability. RNAi of TbGEF3 
negatively affects the growth, morphology and cell cycle of bloodstream form T. brucei. 
• RNAi of TbGEF3 may have a cytostatic than cytocidal effect on bloodstream form T. 
brucei. An increase in cell death can observed from 48 hours post RNAi of TbGEF3, 
however a defect in cell cycle progression can be observed from 24 hours post RNAi 
of TbGEF3. This suggests that a cell cycle defect could be the cause of the cell death 
that was observed in Live/Dead flow cytometry. 
• BigEye morphology could be seen from 0 hours post RNAi of TbGEF3 – leaky 
expression system of the P2T7Ti vector meant that expression of BigEye morphology 
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could be seen in samples prior to RNAi induction. However the number BigEye 
morphology increased from 24 hours post RNAi of TbGEF3. 
• Receptor-mediated endocytosis of Con A was compromised in bloodstream form T. 
brucei following TbGEF3 knockdown. 
• Knockdown of TbGAP1, TbGAP4 and TbGEF2 does not appear to affect the growth, 
morphology or cellular functions of bloodstream form T. brucei. Further work need to 
be carried out to confirm the effect of TbGAP1, TbGAP4 and TbGEF2 knockdown. 
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Chapter 5 – Exploring the use of T. 
brucei GEF3 RNAi cell line in drug 
discovery 
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5.1 Introduction 
The rise in resistance to existing drugs means that new tools to identify potent drugs against 
Neglected Tropical Diseases (NTDs) are of high importance (Molyneux et al., 2017). Field 
reports have identified a rise in resistance to two out of the five current drugs against Human 
African Trypanosomiasis (HAT) and the three current drugs against Animal African 
Trypanosomiasis (nagana) (Fairlamb and Horn, 2018, Giordani et al., 2016). These drugs are 
pentamidine and melarsoprol, against HAT; and diminazene aceturate, homidium and 
isometamidium, against nagana. All five of these drugs are taken up into the T. brucei spp. via 
TbAT1/P2 transporters. Resistance to these drugs have been established in T. brucei spp. 
due to loss-of-function mutations and deletion of the TbAT1 gene that encodes the P2 
transporters (Fairlamb and Horn, 2018). Additionally, deletion or rearrangement of T. brucei 
aquaglyceroporin 2 (TbAQP2) has been shown to induce resistance to pentamidine via 
HAPT1 transporters (Munday et al., 2014).  
Initiatives into drug discovery against HAT and data mining approach of previously identified 
compounds led to the rediscovery of fexinidazole, a 5-nitroimidazole derivative that is 
registered as an oral treatment against late stage T. b. gambiense infection (Mesu et al., 2018, 
Torreele et al., 2010). Fexinidazole and nifurtimox are both nitroaromatic compounds, and the 
activation of these drugs in T. brucei requires reductive activation via nitroreductase (NTR). 
Single point mutations and deletion in NTR were shown to induce cross resistance to both 
nifurtimox and fexinidazole (Wyllie et al., 2015, Deeks, 2019). This suggests that there might 
be a possibility of T. b. gambiense undergoing mutation that could lead to resistance to the 
newly registered fexinidazole.  
Suramin is a drug that is used to treat early stage T. b. rhodesiense infection in humans. As a 
large highly charged molecule, suramin is unable to diffuse through the cell membrane 
(Wiedemar et al., 2019). This means that suramin entry into T. brucei spp. occurs via a highly 
specific endocytic pathway that involves bloodstream stage specific invariant surface 
glycoprotein ISG75 and variant surface glycoproteins (Thomas et al., 2018, Wiedemar et al., 
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2018). Despite suramin being used as a drug against HAT for over 50 years, there has been 
no reports of resistance to suramin by human infective T. brucei spp. (Wiedemar et al., 2018). 
However there have been limited reports of suramin resistance in animal pathogenic 
trypanosomes such as T. evansi (Wiedemar et al., 2018). The lack of widespread resistance 
to suramin in HAT suggests that drugs taken up by endocytosis mechanism may be less likely 
to induce resistance in parasites. 
There are two main types of early drug discovery techniques that can be used to screen and 
identify potential compounds against T. brucei spp. These are the target-based screening and 
the phenotypic screening approaches. In the target-based screening approach, an essential 
target molecule within T. brucei is identified and studied, and compounds that are 
hypothesised to interact with the target molecule and inhibit its functions are tested in order to 
identify potential drugs. The phenotypic screening on the other hand utilises a library of 
compounds which are tested against T. brucei, and positive hits are further studied in order to 
identify their mechanism of action (Lage et al., 2018, Croston, 2017, Brown and Wobst, 2019).  
It is essential during the drug discovery process to test hit compounds to prevent development 
of drugs for which there are existing or potential mechanisms of cross-resistance in T. brucei; 
for example any identified drug compounds that are taken up into T. brucei spp. via TbAT1/P2 
transporters. However, we hypothesise that compounds that are taken up via endocytosis in 
T. brucei spp. may have reduced potential for development of resistance in parasites. 
The Pathogen Box provided by Medicines for Malaria Ventures (MMV) 
(https://www.mmv.org/mmv-open/pathogen-box – accessed: Feb 2020; Geneva, Switzerland) 
consists of 400 molecules that have been shown to have inhibitory activity against pathogens 
causing a range of infectious diseases including: toxoplasmosis, tuberculosis, neosporosis, 
malaria, leishmaniasis and trypanosomiasis (Machicado et al., 2019, Duffy et al., 2017). 
In Chapter 4, I identified transgenic Lister 427 bloodstream form T. brucei cell lines that 
exhibited endocytosis defects following RNAi knockdown of TbGEF3. In this chapter, a 
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TbGEF3 RNAi cell line will be used to develop an assay for identifying compounds in the 
Pathogen Box that are taken up via endocytosis in bloodstream form T. brucei and not by 
transporter proteins. 
 
5.1.1 Aims 
The aim of this chapter is to test whether transgenic Lister 427 bloodstream form T. brucei cell 
lines that have an endocytosis defect due to RNAi knockdown of TbGEF3, can be used to 
identify compounds that are taken up via endocytosis. The Pathogen Box open access source 
of compounds will be used as a proof of principle. 
 
5.2 Methods 
The following methods were used to determine drug compounds that are taken up via 
endocytosis:  
 
5.2.1 Determination of IC50 of tetracycline 
The IC50 value of tetracycline was identified using concentrations ranging from 1 g/mL to 7.63 
pg/mL. These concentrations were tested on bloodstream form P2T7-GEF3 T. brucei and 
Lister 427 bloodstream form wild type T. brucei. PrestoBlue® was used to measure parasite 
viability by reading fluorescence after 48 hours. 
 
5.2.2 Determination of IC50 of suramin 
The IC50 value of suramin was identified using concentrations ranging from 1 M to 1.95 nM. 
These concentrations were tested on bloodstream form P2T7-GEF3 T. brucei and Lister 427 
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bloodstream form wild type T. brucei. PrestoBlue® was used to measure parasite viability by 
reading fluorescence after 48 hours. 
 
5.2.3 Determination of IC50 of diminazene aceturate 
The IC50 value of diminazene aceturate was identified using concentrations ranging from 1 
g/mL to 7.63 ng/mL. These concentrations were tested on bloodstream form P2T7-GEF3 T. 
brucei and Lister 427 bloodstream form wild type T. brucei. PrestoBlue® was used to measure 
parasite viability by reading fluorescence after 48 hours. 
 
5.2.4 MMV Pathogen Box 
Compounds from the Pathogen Box (MMV) were prepared at 10 M and 1 M concentration 
in HMI-9 media. Compounds were tested on Lister 427 bloodstream form wild type T. brucei. 
PrestoBlue® was used to measure parasite viability by reading fluorescence. 
 
5.2.5 Determination of IC50 of Pathogen Box compounds 
The IC50 value of 20 compounds that had positive activity against Lister 427 bloodstream form 
wild type T. brucei at 1 M concentration was carried out. Concentrations ranging from 1 M 
to 7.63 pM was used. These concentrations were tested on Lister 427 bloodstream form wild 
type T. brucei. PrestoBlue® was used to measure parasite viability by reading fluorescence 
after 48 hours. 
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5.3 Results 
5.3.1 Identifying the IC50 of tetracycline, suramin and diminazene aceturate in 
transgenic lines of T. brucei 
Tetracycline induced RNAi of TbGEF3 in bloodstream form T. brucei was shown to induce an 
endocytosis defect in Chapter 4. However data in that chapter also showed that tetracycline 
induced RNAi of TbGEF3 caused a cell cycle defect and increase in cell death. Viable cells 
with a partial endocytosis defect would be desirable to test for compounds that are taken up 
into bloodstream form T. brucei via endocytosis. This means that the concentration of 
tetracycline used in Chapter 4 to induce RNAi of TbGEF3 would not be ideal for the 
experiments in this chapter, since RNAi will also lead to widespread cell death. This chapter 
aimed to identify a suitable concentration of tetracycline that can induce endocytosis defect 
whilst maintaining a stable cell line.   
Suramin and diminazene aceturate are drugs that are taken up via endocytosis and P2 
transporters, respectively. Disruption of endocytosis in bloodstream form T. brucei has 
previously been shown to affect sensitivity to suramin. Wiedemar et al. (2019) identified that 
expression of variant surface glycoprotein (VSGSur) in bloodstream form T. b. brucei resulted 
in increased suramin resistance. Suramin strongly binds to low density lipoproteins prior to 
endocytosis, however the expression of VSGSur strongly impaired low density lipoprotein (LDL) 
endocytosis; thus causing increased drug resistance (Wiedemar et al., 2019). This study 
suggests that suramin can be used as an indicator of a defect in endocytosis, which could 
therefore be used to identify drugs that are taken up by endocytosis. As a drug taken up by 
P2 transporters into T. brucei spp., diminazene aceturate sensitivity should not be directly 
affected by an endocytosis defect. For this reason, diminazene aceturate was used in this 
chapter as a control; since this drug should kill the parasites regardless of an endocytosis 
defect. 
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5.3.1.1 IC50 of suramin and diminazene aceturate 
Sensitivity to suramin in wild type Lister 427 bloodstream form T. brucei and all clones of the 
transgenic P2T7-TbGEF3 T. brucei cell lines was determined in the absence of tetracycline 
(i.e. RNAi not induced). The half maximal effective concentration (IC50) of suramin was 
obtained for wild type and all clones of the transgenic cell line (Table 5.1). 
Figure 5.1 shows the IC50 curves for suramin for all of the clones from P2T7-TbGEF3 cell lines 
and the wild type samples. 
 
 
  
Figure 5.1. IC50 for suramin in transgenic T. brucei cell lines. Half maximal inhibitory 
concentration for suramin was determined for (A) wild type T. brucei, (B) clone 1, (C) clone 3 
and (D) clone 6 of the transgenic P2T7-TbGEF3 cell line (n = 3) 
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The IC50 values for wild type and all clones of TbGEF3 cell line are presented in Table 5.1. 
The data in Table 5.1 shows that wild type, clone 1 and clone 3 from the P2T7-TbGEF3 
transgenic cells had similar sensitivity to suramin. However clone 6 from the P2T7-TbGEF3 
cell line had a higher sensitivity to suramin, as highlighted by the lower IC50 value. The 95% 
confidence interval could not be accurately determined. Increasing additional dilution points to 
determine the sensitivity of suramin in wild type and transgenic cells may provide a more 
accurate measurement of IC50 (Paolini et al., 2010).  
 
Sample IC50 of suramin (nM) 
Wild type 27.12 
Clone 1 25.39 
Clone 3 ~28.77 
Clone 6 22.82 
 
Table 5.1. IC50 of suramin in transgenic T. brucei lines. The IC50 of suramin was determined 
for wild type bloodstream form T. brucei and all clones of the P2T7-TbGEF3 transgenic cell 
line. The IC50 value calculated using GraphPad Prism v.8.2. 
 
Diminazene aceturate sensitivity in wild type Lister 427 bloodstream form T. brucei was 
identified using 18 serial drug dilutions. The same was done for clone 6 of the P2T7-TbGEF3 
transgenic cell line.  
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Figure 5.2. IC50 of diminazene aceturate in transgenic cell lines. Data points for different 
concentrations of diminazene aceturate was plotted and the IC50 for diminazene aceturate was 
calculated for (A) wild type and (B) clone 6 of TbGEF3 cell line using GraphPad prism (n = 3). 
The IC50 of diminazene aceturate in wild type and clone 6 of the transgenic cell line was 
calculated, Table 5.2 shows that the IC50 for wild type and clone 6 of the transgenic cell line 
were 7.287 nM and 9.281 nM respectively.  
 
Sample 
IC50 of diminazene 
aceturate (nM) 
95% confidence interval 
(nM) 
Wild type 7.287 6.320 – 8.396 
Clone 6 9.281 8.606 – 10.010 
 
Table 5.2. IC50 values for diminazene aceturate in transgenic T. brucei cell line. The IC50 
value for diminazene aceturate was identified in wild type and clone 6 of the P2T7-TbGEF3 
cells. IC50 calculated using GraphPad Prism v.8.2. 
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5.3.1.2 IC50 of tetracycline 
The sensitivity of tetracycline in wild type Lister 427 bloodstream form T. brucei and clone 6 
of the transgenic P2T7-TbGEF3 cell line was identified in order to determine whether there 
were differences in sensitivity to tetracycline. The sensitivity of tetracycline in wild type and 
transgenic cell lines were also determined to confirm that tetracycline did not affect cell growth 
in wild type T. brucei, as demonstrated in Chapter 4 Section 4.3.3. Sensitivity to tetracycline 
was also identified in clone 1 and 3. This is because work described in Chapter 4 Section 4.3.3 
also showed that clone 1 did not have any morphological or physiological differences post 
addition of tetracycline, whilst clone 3 exhibited both morphological and physiological 
difference from 48 hours post addition of tetracycline.  
Wild type and clone 1 were used as a negative control to test sensitivity to tetracycline, since 
both cell samples are not expected to have any differences in parasite growth in the presence 
of this antibiotic.  
A serial drug dilution of tetracycline was carried out and incubated with the cell samples for 48 
hours. Viability of the cells was then measured using PrestoBlue® (fluorescence). Figure 5.3 
shows that wild type and clone 1 of the transgenic P2T7-TbGEF3 cell line did not show 
sensitivity to tetracycline (Figure 5.3.A-B), whilst both clones 3 and 6 from the transgenic 
P2T7-TbGEF3 cell line showed a dose response curve (Figure 5.3.C-D).  
The IC50 of tetracycline could not be calculated for wild type and clone 1 because the highest 
tetracycline concentration used (1 g/mL) did not cause cell death. However clone 3 and clone 
6 had an IC50 of 0.3959 ng/mL and 0.4132 ng/mL respectively (Table 5.3).  
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Sample IC50 of tetracycline (ng/mL) 
95% confidence interval 
(ng/mL) 
Clone 3 0.3959 0.2850 – 0.5272 
Clone 6 0.4132 0.3107 – 0.5240 
 
Table 5.3. IC50 of tetracycline in transgenic T. brucei cell line. Tetracycline IC50 was 
calculated in clone 3 and 6 of the P2T7-TbGEF3 cell line using GraphPad Prism v.8.2. 
 
 
Figure 5.3. IC50 of tetracycline for the transgenic TbGEF3 cell lines. IC50 of tetracycline 
was determined for (A) wild type bloodstream form T. brucei, as well as (B) clone 1, (C) clone 
3 and (D) clone 6 of the TbGEF3 cell lines (n = 3). 
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5.3.2. Identifying the potency of suramin on transgenic T. brucei in the presence of 
tetracycline 
5.3.2.1 Identifying optimum tetracycline concentration 
The addition of tetracycline at a high concentration was shown to affect the growth of clone 6 
from the transgenic P2T7-TbGEF3 cell line in Chapter 4, which led to increased cell death 
from 48 hours post addition of tetracycline. However to successfully test compounds for their 
mechanism of uptake, a tetracycline concentration that induces endocytosis defect in the 
transgenic cell line without killing the parasites was needed. 
The IC50 of tetracycline was calculated as 0.4132 ng/mL. A range of concentrations above and 
below the calculated IC50 of tetracycline was then used to identify an optimum concentration 
of tetracycline that can be used to induce an endocytosis defect without compromising the 
parasites viability. The range of tetracycline concentration tested was between 0.1 ng/mL and 
0.5 ng/mL. 
Similarly a range of concentrations above and below the IC50 of suramin was used. This was 
primarily done in order to avoid over-saturation of suramin in the cell samples, thus leading to 
increased cell death which can be interpreted as false negative results.  
In the first experiment, tetracycline and suramin were added at the same time to the 
bloodstream form cells. The plates were incubated for 48 hours and the viability was 
determined using PrestoBlue®. Figure 5.4 shows the results observed after 48 hours 
incubation. Cells incubated in tetracycline concentrations between 0.1 ng/mL and 0.25 ng/mL 
had only 10 – 20% of viable cells at the lowest suramin concentration. The percentage of 
viable cells decreased when suramin concentration was increased, and likewise the 
percentage of viable cells at lower suramin concentration decreased as the concentration of 
tetracycline increased (Figure 5.4). 
The work presented in Chapter 4 highlighted that the endocytosis defect in transgenic cell 
lines was evident from 24 hours post-induction of RNAi. Adding tetracycline and suramin at 
  
201 
the same time results in a very high death rate as the parasites are taking up suramin via 
endocytosis before the tetracycline-induced endocytosis defect can develop. 
To ensure that cells had an endocytosis defect before the addition of suramin, the cultures 
were incubated at different concentrations of tetracycline for 24 hours. Suramin was then 
added and the plates were further incubated for 48 hours. As a control, samples of cells were 
incubated in medium only for the extra 24 hours. This was done in order to ensure that any 
changes in the results were due to the endocytosis defect and not due to the additional 
incubation time. 
Results show that at lower concentrations of suramin, the cells incubated in the lowest 
concentrations of 0.1 ng/mL and 0.15 ng/mL of tetracycline had a similar percentage of viability 
as the control group with no tetracycline. However as the suramin concentration increased, 
the percentage of viable cells in the 0.1 ng/mL and 0.15 ng/mL tetracycline groups were 
greater than those in the control group without tetracycline (Figure 5.4). This suggests that the 
tetracycline was inducing a protective effect at these low concentrations. At higher tetracycline 
concentrations, high levels of cell death were seen regardless of the suramin concentration 
which will be due to the RNAi effect. 
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Figure 5.4. Identifying the tetracycline concentration that affects the growth of 
transgenic T. brucei cells in the presence of suramin. Shown in green:  tetracycline and 
suramin was added to P2T7-TbGEF3 cells at the same time. Blue: P2T7-TbGEF3 cells were 
incubated in tetracycline for 24 hours before addition of suramin. Red: P2T7-TbGEF3 cells 
were incubated without tetracycline for 24 hours before addition of suramin. The concentration 
of tetracycline used is labelled on each graph (n = 3). 
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Figure 5.5. Comparison of IC50 for suramin in transgenic P2T7-TbGEF3 cell line 
incubated +/- tetracycline. Suramin IC50 for samples incubated with (A) 0.1 ng/mL and (B) 
0.15 ng/mL tetracycline (green) was compared to the control group (black) (n = 3). 
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The IC50 for suramin was determined for samples with 0.1 ng/mL and 0.15 ng/mL tetracycline 
and compared to the IC50 for samples without tetracycline (Table 5.4 and Figure 5.5). The 
results show that the IC50 for samples incubated for 24 hours in 0.1 ng/mL tetracycline was 
higher relative to the no tetracycline sample. Samples incubated in 0.1 ng/mL tetracycline had 
an IC50 of 38.65 nM whilst the control group had an IC50 of 30.51 nM. The 95% confidence 
interval for both samples did not overlap (Table 5.4). It is likely that this is due to the induction 
of an endocytosis defect which reduces the uptake of suramin. One-way ANOVA multiple 
comparison showed that the differences in IC50 value compared to the control group were 
highly significant (P ≤ 0.0001). 
The IC50 for samples incubated in 0.15 ng/mL tetracycline did not produce an accurate dose 
response curve (Figure 5.5.B), which meant that the 95% confidence interval for IC50 of 
suramin could not be determined but the IC50 value was similar to that for cells incubated in 
0.1 ng/mL tetracycline. (Table 5.4). Considering the findings, 0.1 ng/mL tetracycline was 
selected for use for further experiments in this chapter. 
 
Sample IC50 of Suramin (nM) 
95% Confidence Interval 
(nM) 
Wild type 30.51 28.69 – 32.63 
0.1 ng/mL tetracycline 38.65 36.71 – 40.84 
0.15 ng/mL tetracycline 39.29 ND 
 
Table 5.4. IC50 of suramin with and without tetracycline in transgenic P2T7-TbGEF3 cell 
line. IC50 for suramin was identified in samples incubated with 0.1 ng/mL and 0.15 ng/mL 
tetracycline for 24 hours and for control sample without tetracycline. The 95% confidence 
interval was also determined. One-way ANOVA multiple comparison was carried out and the 
statistical significance of IC50 shift was calculated (P ≤ 0.0001). 
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5.3.2.2 Validating the effect of tetracycline on transgenic T. brucei growth in suramin 
To confirm the effects of tetracycline in P2T7-TbGEF3 transgenic cells, the experiment was 
repeated with a different range of concentrations of suramin. 
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Figure 5.6. Effects of TbGEF3 RNAi on parasite sensitivity to suramin. Bloodstream form 
T. brucei cells were grown for 24 hours with 0.1 ng/mL and without tetracycline prior to addition 
of different concentration of suramin (n = 6). 2-way ANOVA multiple comparisons was used 
for statistical analysis. **** = P ≤ 0.0001, ** = P ≤ 0.01. 
 
As seen in the previous experiment, there was a significant reduction in sensitivity to suramin 
in cells that had previously been incubated in tetracycline to induce RNAi knockdown of 
TbGEF3. (Figure 5.6). This relationship was observed until the concentration of suramin 
increased to 45.64 nM (log10 = 1.659346) at which point cell viability was very low in all 
samples. 
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5.3.2.3 Using diminazene aceturate to validate endocytosis defect in transgenic cells  
In order to test whether the reduced response to suramin observed in Figure 5.5 and Figure 
5.6 was due to endocytosis being affected and not due to other cellular functions being 
compromised, the experiment was repeated using diminazene aceturate (Figure 5.7). 
Diminazene aceturate is a drug that is taken up into bloodstream form T. brucei via TbAT1/P2 
transporters (Gysin et al., 2018). I predicted that induction of TbGEF3 RNAi would not change 
sensitivity to diminazene aceturate, since uptake of this drug is not believed to be affected by 
endocytosis. 
Figure 5.7 shows that cells incubated in tetracycline were more sensitive to diminazene 
aceturate than the control group. There is a possibility that this increase in sensitivity to 
diminazene aceturate in the tetracycline incubated cells may have been caused by synergy 
between the RNAi of TbGEF3 and either the action or uptake of the drug. 
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Figure 5.7. Effect of diminazene aceturate on cells before and after induction of TbGEF3 
RNAi. Different concentrations of diminazene aceturate was added to bloodstream form T. 
brucei exposed to 0.1 ng/mL tetracycline and control group (n = 6). 2-way ANOVA was used 
for statistical analysis. *** = P ≤ 0.0001, ** = P ≤ 0.01, * = P ≤ 0.05. 
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5.3.3 Pathogen Box (MMV) screening 
In Section 5.3.2 I identified an optimum concentration of tetracycline that can be used to induce 
a partial endocytosis defect in bloodstream form T. brucei, which is sufficient to reduce 
sensitivity to suramin without killing the cells. The next stage was to determine whether this 
system can be used to identify potential drug compounds that are taken up via endocytosis, 
using the Pathogen Box for proof of principle. 
There are 400 compounds in the Pathogen Box that could have potential activity against 
bloodstream form T. brucei. Of these, sufficient quantities of 384 compounds were available 
for screening. The compounds were screened using wild type Lister 427 bloodstream form T. 
brucei. The compounds were screened at two different concentrations, 10 M and 1 M, to 
determine positive hits; defined as any compounds that had less than 5% parasite growth 
compared to an untreated control. The Pathogen Box consists of 5 plates labelled from A to 
E. In this chapter the plates will be referred to by numbers (1 to 5) and the compounds by their 
plate number and well co-ordinates (e.g. 1A11) 
 
5.3.3.1 Pathogen Box screening at a concentration of 10 M 
Figures 5.8 to 5.12 show the results of initial screening the Pathogen Box compounds at a 
single concentration of 10 M on wild type Lister 427 bloodstream form T. brucei. 110 
compounds out of the 384 screened were shown to have reduced the percentage growth 
below 5% against bloodstream form T. brucei at 10 mM concentration.  
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Figure 5.8. Plate 1 of the Pathogen Box compounds screened at 10 M Lister 427 
bloodstream form T. brucei. 
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Figure 5.9. Plate 2 of the Pathogen Box compounds screened at 10 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.10. Plate 3 of the Pathogen Box compounds screened at 10 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.11. Plate 4 of the Pathogen Box compounds screened at 10 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.12. Plate 5 of the Pathogen Box compounds screened at 10 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.13. Plate 1 of Pathogen Box compounds screened at 1 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.14. Plate 2 of Pathogen Box compounds screened at 1 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.15. Plate 3 of Pathogen Box compounds screened at 1 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.16. Plate 4 of Pathogen Box compounds screened at 1 M on Lister 427 
bloodstream form T. brucei. 
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Figure 5.17. Plate 5 of Pathogen Box compounds screened at 1 M on Lister 427 
bloodstream form T. brucei. 
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5.3.3.2 Pathogen Box screening at a concentration of 1 M 
To identify compounds that were effective against bloodstream form T. brucei at a lower 
concentration, drug screening was carried out using 1 M of the compounds from the 
Pathogen Box. Figures 5.13 to 5.17 shows that 20 compounds out of the 384 compounds 
screened from the Pathogen Box library were effective against bloodstream form T. brucei 
(percentage growth below 5% compared to untreated control) at this lower concentration. 
Of the 20 hit compounds, 19 were taken forward for further analysis. More material for 
compound 2A4 could not be obtained in order to carry out further experiments.  A 2-fold serial 
drug dilution was carried out on the remaining 19 hit compounds in order to determine the IC50 
value for bloodstream form T. brucei.  
A lower IC50 signifies higher sensitivity to that particular compound, therefore measuring the 
IC50 of the positive hits will identify which compound is more effective against bloodstream 
form T. brucei (Doldán-Martelli and Míguez, 2018). 
The IC50 value and the 95% confidence interval was obtained for each compound (Table 5.5). 
Out of all the positive hits, five compounds that had the lowest IC50 and smallest 95% 
confidence interval were chosen as potential drug compounds against bloodstream form T. 
brucei (Table 5.5).  
Table 5.6 shows the chemical structures and pathogen screen in which these five compounds 
were identified. The chemical structures and pathogen screen for the other 14 positive hits are 
provided in the Appendix 9. 
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Figure 5.18. IC50 of positive hit compounds from Pathogen Box. IC50 was calculated for 
positive hit compounds using Lister 427 bloodstream form T. brucei. Cells were incubated for 
48 hours and viability was measured using fluorescence.  
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Figure 5.19. IC50 of positive hit compounds from Pathogen Box. IC50 was calculated for 
positive hit compounds using Lister 427 bloodstream form T. brucei. Cells were incubated for 
48 hours and viability was measured using fluorescence. 
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Compound IC50 (nM) 
95% Confidence Interval 
(nM) 
1A6 97.48 64.35 – 147.70 
1E5 64.79 56.54 – 74.24 
1G5 151.70 131 – 175.60 
2B3 53.14 38.68 – 73 
2C2 121.70 24.44 – 605.90 
2D3 12.30 10.03 – 15.09 
2H2 69.29 62.36 – 76.98 
3B10 101.10 88.67 – 115.20 
3B11 4.013 3.441 – 4.679 
3C10 >1000 ND 
3D5 336.30 153.10 – 739.10 
3G6 104.20 81.62 – 133.10 
4B9 2.546 2.256 – 2.872 
4C8 62.18 53.82 – 71.83 
4E10 >1000 ND 
4G8 4.554 4.062 – 5.107 
4H3 >1000 ND 
5B10 167.50 148.60 – 188.80 
5H10 28.10 24.98 – 31.61 
 
Table 5.5. IC50 and 95% confidence interval for all positive hits. 2-fold serial dilution was 
carried out and the IC50 was determined for all positive hits at 1 M. Compounds with the 
lowest IC50 and 95% confidence interval (highlighted in green box) were selected for further 
studies. 
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Compound Structure 
Pathogen 
screened 
2D3 
 
Reference 
compound 
(suramin) 
3B11 
 
Kinetoplastids 
4B9 
 
Kinetoplastids 
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4G8 
 
Kinetoplastids 
5H10 
 
Kinetoplastids 
 
Table 5.6. Chemical structure and pathogen screens of the positive hits. Visualisation of the chemical structure and pathogen screens for 
the five positive hits with the lowest IC50 and 95% confidence interval. Data on chemical structure and pathogen screens are provided by Pathogen 
Box (MMV; https://www.mmv.org/mmv-open/pathogen-box – accessed: Feb 2020). 
  
224 
5.3.3.3 Determining whether endocytosis uptake can be identified in hit compounds 
Five compounds from Pathogen Box (2D3, 3B11, 4B9, 4G8 and 5H10) were selected that had 
the lowest IC50 values and smallest 95% confidence interval. Each compound was diluted in 
HMI-9 in order to obtain 9 different concentrations within the 95% confidence interval. These 
were added to 96 well plates containing clone 6 of the P2T7-TbGEF3 transgenic cell lines that 
had previously been incubated in 0.1 ng/mL tetracycline or in the absence of tetracycline for 
24 hours, as for the suramin assays in section 5.3.2.2. The plates were incubated for 48 hours 
and fluorescence was read 3 hours post addition of PrestoBlue®. 
Figure 5.20 shows that there were no statistical differences between parasite growth in cells 
with or without tetracycline in compounds 4G8, which suggests that compound 4G8 may be 
taken up into bloodstream form T. brucei via a transporter protein mechanism. Similar results 
were observed in compound 2D3, 3B11 and 5H10, however at certain concentrations there 
was significantly more parasite death in the tetracycline positive cells than the tetracycline 
negative cells, in a similar trend to the findings for diminazene aceturate. This statistically 
significant increase in parasite death was not uniform across all concentrations in these 
compounds and was present at the lower range of the diluted concentrations. Regardless of 
the significant increase in tetracycline positive cell death, results suggest that compounds 2D3, 
3B11 and 5H10 are not taken up by endocytosis into bloodstream form T. brucei. 
It should also be noted that although there were no significant differences between the growth 
of transgenic T. brucei cell with or without tetracycline, compounds 3B11 and 4G8 had 90 to 
100% or more viable parasite present (Figure 5.20). This data suggests that the range of 
concentrations used were too low to have any effect on the parasite viability. These 
compounds therefore require re-testing at higher concentrations. 
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Compound 4B9 showed no significant differences in parasite growth from 0 nM to 5 nM 
concentration range. However, an increase in compound 4B9 concentration showed that 
transgenic bloodstream form T. brucei incubated in tetracycline had significantly higher 
parasite growth than the cells that were not incubated in tetracycline (Figure 5.20). The data 
suggests that the first 5 concentrations used were not effective at killing the parasite, and this 
was further shown by the percentage of viable cells – more than 100% viable cells present.  
A wider concentration range is required in order to confirm whether compound 4B9 may be 
taken up by endocytosis.   
 
 
  
226 
 
Figure 5.20. Determining the activity of selected compounds in transgenic P2T7-
TbGEF3 cells. Different concentrations of selected compounds with low IC50 values were 
added to P2T7-TbGEF3 cell lines with (red) and without (blue) tetracycline (n = 3). 2-way 
ANOVA multiple comparisons was used for statistical analysis. * = P ≤ 0.05, ** = P ≤ 0.01, **** 
= P ≤ 0.0001  
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5.4 Discussion 
The current drugs against Human African Trypanosomiasis (HAT) and Animal African 
Trypanosomiasis (nagana) are largely costly, cause severe side effects and there is emerging 
resistance (Thomas et al., 2018, Delespaux and de Koning, 2007).  
The aim of this chapter was to test whether the transgenic P2T7-TbGEF3 RNAi cell lines that 
exhibited an endocytosis defect could be used in a novel drug discovery assay to identify 
compounds that are taken up via endocytosis. An optimal concentration of tetracycline was 
identified through a series of dilutions. The sensitivity of transgenic P2T7-TbGEF3 cell line to 
suramin and diminazene aceturate was also identified. Pathogen Box (MMV) compound 
screening at 1 M identified 20 positive hits against bloodstream form T. brucei with less than 
5% parasite growth after incubation for 48 hours. From the 20, 19 of these compounds were 
further analysed in order to identify their activity in tetracycline induced transgenic T. brucei. 
 
5.4.1 Inducing a partial endocytosis defect in a TbGEF3 RNAi cell line 
Endocytosis in bloodstream form T. brucei is a rapid process that occurs exclusively at the 
flagellar pocket. This process is important for immune evasion and normal cellular functions 
(Allen et al., 2003, Umaer et al., 2018). Disruption of endocytosis in bloodstream form T. brucei 
has been shown to decrease sensitivity to suramin (Zoltner et al., 2015). Reduced sensitivity 
to suramin was demonstrated to be due to disruption in endocytosis of low density lipoproteins 
(LDLs)  (Wiedemar et al., 2019). This principle could be used in conjunction with transgenic 
cell lines exhibiting an endocytosis defect in order to identify compounds from drug libraries 
that are also taken up via endocytosis, since exposure to those compounds would theoretically 
not kill the parasite or have reduced sensitivity. New drug compounds that are taken up via 
endocytosis may have less potential to induce resistance in parasites in the future. 
Indirect immunofluorescent microscopy images in chapter 4 section 4.7.1 identified the 
presence of abnormal morphology in bloodstream form T. brucei from 24 hours post RNAi of 
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TbGEF3 in the transgenic P2T7-TbGEF3 cell lines. Transmission Electron Microscopy images 
in section 4.7.2 showed that the abnormal morphology was due to enlarged flagellar pockets, 
establishing this morphology as the previously described BigEye morphology. Allen et at., 
(2003) and Price et al., (2007) demonstrated that bloodstream form T. brucei with BigEye 
morphology had endocytosis defect (Price et al., 2007b, Allen et al., 2003). This was further 
demonstrated in this thesis (section 4.9), where endocytosis of Concanavalin A (Con A) did 
not occur in bloodstream form T. brucei from 24 hours following RNAi knockdown of TbGEF3.  
A concentration of 1 g/mL of tetracycline was used to induce RNAi in the transgenic cell lines 
in Chapter 4. In addition to an endocytosis defect, RNAi of TbGEF3 also lead to a defect in cell 
cycle progression, eventually leading to increased cell death which is evident from 48 hours 
onwards. If RNAi cell lines were to be used in drug screening assays, I needed to identify a 
concentration of tetracycline which induced a partial endocytosis defect but did not cause 
extensive cell death. The IC50 (the half maximal inhibitory concentration) of tetracycline was 
identified in section 5.3.1. This was found to be between 0.3959 ng/mL to 0.4132 ng/mL, which 
is considerably less than the standard concentration (1 g/mL) used previously (Hashimi et al., 
2016).  
Suramin was used in pilot experiments in this chapter to test if the transgenic P2T7-TbGEF3 
cell lines, in the presence of the optimum concentration of tetracycline, can demonstrate 
reduced sensitivity to the drug, therefore suggesting a reduction in uptake by endocytosis 
(Wiedemar et al., 2019). 
Diminazene aceturate, a therapeutic agent used to treat cattle with nagana (Tsegaye et al., 
2015), was used in this chapter as a control drug. This is because diminazene aceturate is 
taken up into T. brucei via the TbAT1/P2 transporters, meaning that there should still be a 
trypanocidal effect in bloodstream form T. brucei cells that exhibit an endocytosis defect 
(Delespaux and de Koning, 2007). 
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Results from Figure 5.5 show that incubating P2T7-TbGEF3 transgenic cells in 0.1 ng/mL and 
0.15 ng/mL tetracycline for 24 hours prior to addition of suramin had a reduced sensitivity to 
suramin compared to the control group. This observation correlates with the findings in chapter 
4, where a BigEye morphology and endocytosis defect (shown by Con A uptake assay) was 
observed from 24 hours post RNAi of TbGEF3. An increase in IC50 of suramin in the 
tetracycline incubated samples further confirmed the decrease in sensitivity to suramin than 
compared to the control sample without tetracycline incubation.   
The effect of tetracycline on suramin activity in transgenic P2T7-TbGEF3 cell line was validated 
using different concentrations of suramin. Diminazene aceturate was used as a control in order 
to ensure that the differences in suramin sensitivity were due to endocytosis being affected 
and not due to cellular functions being compromised. Figures 5.6 and 5.7 show that cells 
incubated in tetracycline had reduced sensitivity to suramin and increased sensitivity to 
diminazene aceturate.  
A possible reason for the increased sensitivity to diminazene aceturate could be due to the 
bloodstream form T. brucei compensating for lack of endocytosis by increasing uptake of 
molecules via P2 transporters. Future studies are needed to identify if this is the case. Since 
TbAT1/P2 transporters are adenosine/adenine transporters, it may be possible to use 
fluorescent tagged adenosine/adenine and fluorescent cell imaging or flow cytometry to 
determine the intensity of the fluorescence. Fluorescence in normal cells will be used as a 
baseline, and any shift in the baseline fluorescence in the presence of endocytosis defect may 
provide information on P2 transporter activities; thereby identifying if bloodstream form T. 
brucei increases P2 transporter activity in the presence of an endocytosis defect (Munday et 
al., 2014, Bircsak et al., 2013). Interestingly Sykes et al., (2012) identified the IC50 of 
diminazene aceturate to be around 65.4 nM in T. b. brucei (Sykes et al., 2012). This 
concentration is significantly higher than the IC50 observed in section 5.3.1.1 (7.287 – 9.281 
nM), which suggest that either the Lister 427 bloodstream form T. brucei and the transgenic 
cell lines used in the current study may be highly sensitive to diminazene aceturate. 
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5.4.2 Measuring parasite viability  
During the work presented here, cell viability following incubation in test compounds were 
measured using PrestoBlue® - a resazurin based reagent that is reduced into resorufin by 
metabolically active cells. The reduction of resazurin into resorufin occurs due to mitochondrial 
enzymes present in the viable cells accepting electrons from NADPH, FADH, FMNH, NADH 
and cytochromes. Reduction of resazurin into resorufin causes colour change from blue to 
pink, this reduction also causes a shift in fluorescence which is used to assess cell viability (Al-
Nasiry et al., 2007, Xu et al., 2015, Hernandez‐Patlan et al., 2018). However Gould et al., 
(2008) proposed that using propidium iodide to assess drug action against trypanosomes may 
provide more accurate data than use of a resazurin based reagent. This is because resazurin 
based reagent are unable to distinguish between live cells and growth arrested cells, and 
resazurin needs to enter the cell in order to be reduced. Gould et al., (2008) also argued that 
some test compounds have the capability to reduce resazurin, therefore providing false 
positive results (Gould et al., 2008). However adding test compounds to resazurin based 
reagent and measuring changes in fluorescence may help identify compounds that reduce 
resazurin in the absence of live cells. There is also a possibility of compounds exhibiting 
fluorescence, thus providing a false negative reading by suggesting that there is a higher 
percentage of viable cells. Testing compounds without the presence of fluorescent agents may 
help identify any compounds that exhibit fluorescence. 
Another technique that can be used to measure viability is the bioluminescence assay, which 
utilises T. brucei spp. strains expressing Renilla luciferase (RLuc) or other forms of luciferase 
enzyme. The expression of RLuc in T. brucei spp. does not alter their functions or viability in 
vitro or in vivo, therefore this assay could be used to screen drugs (Van Reet et al., 2013, 
Claes et al., 2009). Resazurin based assays require longer incubation period in the reagent in 
order to get a high signal to background reading for detection, whereas luminescence gives a 
much higher signal to background reading regardless of time incubated. The longer incubation 
period can also affect the IC50/EC50 of the compounds that are being tested (Van Reet et al., 
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2013). Van Reet et al., (2013) utilised the RLuc luminescence assay alongside the ATP-
bioluminescence assay; an assay where bioluminescence is generated due to luciferase 
catalysing the transformation of luciferin to oxyluciferin in the presence of cellular ATP, thus 
yielding PPi, AMP and luminescence (Van Reet et al., 2013, Mackey et al., 2006). They noted 
that using RLuc and ATP luminescence assay as a luminescence multiplex viability assay 
resulted in an increase in sensitivity to the assay due to two sensitive and independent viability 
assays being performed, as well as requiring less incubation time than the resazurin based 
assays (Van Reet et al., 2013). NanoLuc-PEST is another luciferase that could be used for 
bioluminescence assays. NanoLuc originates from a deep-sea shrimp and is a small and 
stable enzyme compared to RLuc (19 kDa compared to 36 kDa). Fusion of NanoLuc to PEST 
sequence results in reduced intracellular half-life but increase in enzymatic activity (Berry et 
al., 2018). Comparison of assay performed using NanoLuc-PEST and PrestoBlue® in 
Leishmania mexicana axenic amastigotes found a 50 to 100 fold higher signal to background 
ratio in assays performed using NanoLuc-PEST (Berry et al., 2018). 
 
5.4.3 Pathogen Box screening 
The Medicines for Malaria Ventures (MMV) foundation initially assembled a set of compounds 
that were active against various pathogens, including Plasmodium falciparum, Schistosoma 
mansoni and Toxoplasma gondii. This set of compounds was named the Malaria Box 
(Machicado et al., 2019, Hennessey et al., 2018). Extensive research using the compounds in 
Malaria Box has led to a compilation of screening data (Van Voorhis et al., 2016) that provides 
a wealth of information on the compounds. Data from 236 screens have shown that 135 (34%) 
compounds out of the 400 in the Malaria Box actively kill malaria parasite in multiple life cycle 
stages (Van Voorhis et al., 2016). In addition to compounds killing malaria, research has also 
found 16 compounds that are active against other protozoa, 7 compounds against helminths, 
and 9 compounds against bacterial and mycobacterial species (Van Voorhis et al., 2016). The 
success in generating valuable screening data from the Malaria Box led MMV to release a new 
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set of 400 compounds that have been shown to have inhibitory activities against 
toxoplasmosis, tuberculosis, neosporosis, malaria, leishmaniasis and trypanosomiasis. The 
set of 400 compounds were termed the Pathogen Box (Machicado et al., 2019, Nugraha et al., 
2019). 
Pathogen Box compounds were screened against wild type Lister 427 bloodstream form T. 
brucei in this chapter. Positive hits were confirmed as any compounds that had less than 5% 
parasite growth after 48 hours. A total of 20 compounds out of the 384 were identified as having 
activity on bloodstream form T. brucei. A set of 5 compounds with the lowest IC50 values were 
taken forward for further analysis. Of these, 4 compounds were identified in screens against 
kinetoplastids (Table 5.6); possibly explaining the low IC50 values observed in Table 5.5. While 
assays were performed ‘blind’, later analysis revealed that compound 2D3 is suramin. This 
means that the IC50 value and the possible uptake determination assay carried out in section 
5.3.3.2 and 5.3.3.3 respectively, contradicts the results observed in section 5.3.1 and 5.3.2 
using freshly prepared suramin. The IC50 value in Lister 427 bloodstream form T. brucei using 
a fresh batch of suramin was calculated as 27.12 nM, whilst the IC50 for Pathogen Box provided 
suramin (2D3) was 12.30 nM. Similarly data from Figure 5.6 shows that the lab prepared 
suramin exhibited lower sensitivity in the presence of tetracycline whilst data from Figure 5.20 
shows that suramin (2D3) did not show differences in sensitivity even in the presence of 
tetracycline.   
Several factors could have contributed to the differences in results observed, including the 
preparation and storage of the compounds and potential contaminants. The Pathogen Box 
compounds were shipped as liquid stocks from MMV and may have been exposed to freeze-
thawing, whereas the suramin stock was prepared immediately upon arrival and stored in -
20°C in aliquots before use in the assay. Storage of suramin, as recommended by the 
manufacturer is at +2°C to +8°C for short term use, whilst suramin liquid stocks should be 
stored at -20°C, where they will be stable for up to a month. There is a possibility that the 
suramin stock stored at -20°C may have become unstable or may have been contaminated, 
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thus affecting potency and IC50 values. However Otoguro et al., (2008) identified the IC50 value 
of suramin to be around 37 nM in T. b. rhodesiense (Otoguro et al., 2008), which is closest to 
the T. b. brucei IC50 value for lab prepared suramin (27.12 nM) than the equivalent value from 
the Pathogen Box stock (12.30 nM). Further work with new compound stocks is therefore 
needed to confirm the results.  
Comparison of data obtained in this chapter and previous works on Pathogen Box using Lister 
427 bloodstream form T. brucei found that the same compounds as the ones identified in this 
chapter were also identified as having inhibitory activities against T. b. brucei, however the IC50 
values for the compounds obtained in previous data were higher than the IC50 values obtained 
in this chapter (Veale and Hoppe, 2018, Duffy et al., 2017). The differences in the IC50 
observed may have been due to the methodology differences, as Veale and Hoppe, (2008) 
incubated their cells in resazurin based reagent for 24 hours whilst the cell in this thesis were 
incubated for 3 hours in a similar resazurin based reagent (Veale and Hoppe, 2018). There 
could also be a possibility that the low IC50 values observed in this chapter were due to 
contamination in the Pathogen Box stocks prepared; this also coincides with the low IC50 value 
observed for compound 2D3 (suramin). Future work is required using new suramin stocks and 
Pathogen Box compounds in order to confirm the results found in this chapter. 
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5.5 Conclusions 
The main findings of this chapter are as follows:  
• Transgenic P2T7-TbGEF3 cell lines incubated in 0.1 ng/mL tetracycline for 24 hours to 
induce RNAi had significantly reduced sensitivity to suramin compared to cells grown 
in the absence of tetracycline. 
• Transgenic P2T7-TbGEF3 cell lines incubated in tetracycline for 24 hours had 
increased sensitivity to diminazene aceturate compared to cells grown in the absence 
of tetracycline. 
• Pathogen Box, screening identified that 20 compounds out of 384 had inhibitory 
activities (viability below 5%) against T. brucei. Out of the 20 compounds, 5 of them 
had IC50 values below 30 nM. 
P2T7-TbGEF3 transgenic cells (with and without tetracycline incubation) had increased 
sensitivity to compound 2D3 from the Pathogen Box (suramin) than freshly prepared suramin 
but the latter matched previously published IC50 values. 
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Chapter 6 – Discussion 
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6.1 General Discussion 
In this thesis I studied ARF regulating proteins in bloodstream form T. brucei as potential drug 
targets. Human ARF regulators and their orthologues in bloodstream form T. brucei were 
identified and RNAi constructs were generated. RNAi constructs for knockdown of two GEFs 
and two GAPs were successfully transfected into bloodstream form T. brucei, and the effects 
of tetracycline inducible RNAi were analysed. Tetracycline induced RNAi of TbGEF3 was 
shown to be essential for viability in bloodstream form T. brucei, with knockdown resulting in 
an endocytosis defect  
 
6.1.1 Why study T. brucei drug targets? 
Previous control initiatives and surveillance of HAT resulted in a sharp decrease in the number 
of recorded HAT cases (Legros et al., 2002, Franco et al., 2014). However the number of cases 
always saw a re-emergence when the initiatives were withdrawn (Simarro et al., 2008, 
Kennedy, 2019). The current WHO target for HAT, as highlighted during the London 
Declaration on Neglected Tropical Diseases, is to reduce the number of T. b. gambiense case 
to less than 1 new case/10,000 population at risk globally by 2020 and for zero cases by 2030. 
In 2016, the number of recorded HAT cases had dropped to 2,184; suggesting that elimination 
of HAT by 2030 may be possible and within the set milestones by the WHO (Rock et al., 2015, 
Kennedy, 2019, Franco et al., 2018).  
Since the number of HAT cases per year are based on the recorded data, there is a possibility 
that the actual number of HAT cases may be significantly higher due to high levels of 
unreporting in regions of instability, which may hamper elimination efforts (Legros et al., 2002, 
Chappuis et al., 2005). There is also a risk that non-human infectious T. b. brucei may evolve 
to gain serum-resistance associated (SRA)-like proteins, making them infectious to humans. 
This was observed by Szempruch et al., (2016) who noted that SRA can be transferred from 
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T. b. rhodesiense to T. b. brucei via membranous nanotubes originating from flagellar 
membrane (Szempruch et al., 2016).  
The majority of drugs against HAT were discovered several decades ago, with each drug being 
stage- or species-specific. The rise in resistance to the drugs against HAT, as well as the high 
cost and severe side effects led to new initiatives into drug discovery (Baker and Welburn, 
2018). Through collaborative efforts of Drugs for Neglected Diseases initiative (DNDi) and 
Sanofi, a new drug against HAT was developed. This drug, fexinidazole, has recently been 
registered for use as an oral treatment against late stage T. b. gambiense infection (Mesu et 
al., 2018, Pollastri, 2018, Chappuis, 2018). However studies by Wyllie et al., (2015) have 
shown that there is scope for T. brucei spp. developing resistance to fexinidazole due to 
mutations in nitroreductase (Wyllie et al., 2015). The DNDi strategy for developing new drugs 
against HAT focuses on developing safe, effective and practical drug against second stage 
HAT, and very simple treatment for first stage HAT.  
Control initiatives against African Trypanosomiasis have primarily been focused on HAT; whilst 
nagana is still a prevalent veterinary disease which renders a quarter of Africa unsuitable for 
livestock farming (Giordani et al., 2019, Meyer et al., 2018, Morrison et al., 2016). Nagana kills 
three million animals per years in sub-Saharan Africa, leading to huge socioeconomic burden 
costing billions of US dollars on people living in nagana endemic countries, especially those in 
poorer countries (Morrison et al., 2016, Giordani et al., 2019). The current drugs against 
nagana are toxic, animal specific and there are resistant strains of parasites emerging, thus 
providing opportunities for transmission and re-infection (Giordani et al., 2016). 
Research into novel drug targets against T. brucei ssp., the causative agent of African 
Trypanosomiasis is still urgently need. Such research led to a family of GTPase proteins called 
ADP-ribosylation factors (ARFs). These proteins have been shown previously to have 
important roles in T. brucei. Several ARFs and ARLs are essential for T. brucei viability, with 
RNAi leading to increased cell death, lethal phenotypes (Figure 6.1) and decreased cell 
division (Price et al., 2007b, Price et al., 2005b, Price et al., 2005a).  
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Figure 6.1. Electron Micrograph of lethal phenotype in bloodstream form T. brucei. Price 
et al (2007) identified that RNAi of ARF1 lead to (A) lethal phenotype. B is the enlarged (3.75 
times) view of the boxed area in A. F, flagellum; FP, flagellar pocket; N. nucleus; SM, 
subpellicular microtubules. Bar: A is 1 m and B is 0.2 m. Adapted from (Price et al., 2007b). 
 
Despite previous studies showing ARF1 and several ARLs to be potential drug targets in 
bloodstream form T. brucei, the human and T. brucei proteins have a high level of sequence 
identity, especially at the GDP/GTP binding sites, which is required for activation and 
inactivation of these small GTPase proteins (Price et al., 2007b, Price et al., 2005b). This would 
mean that targeting T. brucei ARF/ARL functions via inhibitors binding to the highly conserved 
sites, may lead to binding of the inhibitors to the human proteins. Several of the members of 
the ARF family of proteins are known to be essential in a range of eukaryotes. For example, 
gene knockdown of ARL2 in a mouse model was shown to cause aggressive proliferation of 
breast cancer tumours, whilst knockdown of ARF1 in mice was shown to be lethal for 
embryogenesis and no viable pups were born (Beghin et al., 2009, Hayakawa et al., 2014). 
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The functions of ARF are regulated by two types of regulatory proteins: guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs), activating and inactivating 
by binding of GTP or hydrolysis of GTP respectively (Bhatt et al., 2016, Sztul et al., 2019). 
ARF/ARLs, the ARF GEFs and GAPs are highly divergent overall at the protein sequence level 
(Xu and Scheres, 2005, Mandiyan et al., 1999); meaning that the functions of ARF/ARLs could 
be targeted by targeting their regulators. 
I hypothesised that ARF GEFs are more likely to be essential in bloodstream form T. brucei 
than the ARF GAPs. This is because GEFs are required for the activation of ARF/ARLs: 
knockdown of the GEFs could lead to a decrease in the level of active ARF proteins; thus 
potentially having a similar effect as ARF RNAi (Bhatt et al., 2016, Sztul et al., 2019). This 
thesis aimed to identify ARF regulating proteins that are present in bloodstream form T. brucei; 
and generate and use RNAi expressing cell lines to identify which ARF regulating proteins are 
essential for T. brucei viability. Finally, studies were performed to evaluate if transgenic cell 
lines with an endocytosis defect could be used in drug discovery to predict the mechanism of 
hit compound uptake. 
 
6.1.2 ARF GEFs and GAPs are conserved at the catalytic domains 
Protein BLAST search using human GEF and GAP sequences identified four T. brucei GAPs 
and three T. brucei GEFs. The level of similarities between the human and T. brucei ARF 
regulators was determined using bioinformatics tools. Multiple sequence alignment showed 
that the identified T. brucei ARF regulators were very diverse at the amino acid sequence level, 
except for their catalytic Sec7 and ARFGAP domains. Out of the three identified T. brucei 
GEFs, TbGEF3 appears to share the lowest sequence identity with other ARF GEFs, even at 
the conserved binding motifs found in the catalytic Sec7 domain. All four identified T. brucei 
GAPs shared a similar Cys4 zinc finger motives of CX2CX16CX2C with the human orthologues. 
Targeting the catalytic domain in GEFs and GAPs using specific chemical inhibitors such as 
brefeldin A has the potential of disrupting ARF functions by preventing their activation or 
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inactivation (Jackson and Casanova, 2000). The high level of amino acid sequence similarities 
in TbGAPs and TbGEF2 suggest that these T. brucei ARF regulators may not be ideal drug 
targets against T. brucei (Ilari et al., 2018). The lower level of sequence identity at the Sec7 
domain seen in TbGEF3 suggests that specific inhibition of this protein by small molecules 
may be possible. 
Domain analysis revealed that the identified T. brucei ARF regulators only had their respective 
catalytic domains present, lacking other protein-protein interaction domains that were present 
in most subfamilies of human ARF regulators. The T. brucei GEFs had similar domain 
composition to the high molecular weight ARFGEF and GBF subfamilies of human GEFs, 
suggesting that these regulators may have similar mechanisms of interaction with the ARFs. 
Interestingly the identified T. brucei GEFs had a molecular weight of above 100 kDa, a criterion 
that is used to classify high molecular vs low molecular weight GEFs in humans (Shinotsuka 
et al., 2002b). This suggests that the T. brucei GEFs may be true orthologues of the ARFGEF 
and GBF subfamilies. The T. brucei GAPs were similar in domain composition to the ARFGAP 
and SMAP subfamilies, lacking any protein-protein interaction domains. Like the T. brucei 
GEFs, this similarities amongst GAPs suggest that they may share a similar mechanism of 
interaction with ARFs.  
No previous data on T. brucei GEF and GAP structures exist, which meant that the protein 
structures in Chapter 3 were predicted using Phyre2 predictive software and pre-existing 
templates of homologous structures (Kelley et al., 2015). The predicted structures of T. brucei 
GEFs and GAPs matched the description of Sec7 and ARFGAP domains as stated in previous 
studies (Mandiyan et al., 1999, Mossessova et al., 1998). This was expected since the catalytic 
domains have been shown to be highly conserved at the amino acid sequence level across all 
species (Pocognoni et al., 2018, Arakel et al., 2020). Structural alignment showed that the 
predicted T. brucei GEF Sec7 domains were structurally similar to CTYH1 and CYTH2 but not 
CYTH3 (which was later identified as CYTH3 PH complex), or to the other human ARF GEFs. 
Although the Sec7 domain has been reported to be highly conserved at the amino acid level, 
  
241 
the differences in structural similarities suggest that a high level of amino acid sequence 
identity may not necessarily equate to secondary structure similarity. The potential differences 
in secondary structure of the Sec7 domain could be exploited in drug design. The ARFGAP 
domains in both human and T. brucei GAPs were shown to be relatively similar structurally, 
however unlike the T. brucei GEFs, the ARF GAPs did not all show similarity to one particular 
subfamily of proteins in humans. Each of the T. brucei GAPs was shown to be structurally 
similar to a different ARF GAP subfamily. This suggests that there may be a higher secondary 
structure diversity amongst the T. brucei ARF GAPs that could be taken into consideration 
when designing specific inhibitor molecules. 
 
6.1.3 TbGEF3 is essential for viability in T. brucei 
Tetracycline induced RNAi knockdown of T. brucei GEFs and GAPs in Chapter 4 showed that 
TbGEF3 is essential for bloodstream form T. brucei viability. A decrease in cell growth, 
increase in cells with BigEye morphology and defect in cell cycle progression was observed 
from 24 hours post RNAi of TbGEF3, with increased cell death occurring from 48 hours post 
RNAi. The BigEye phenotype suggests that TbGEF3 may be implicated in endocytic pathways. 
This was further confirmed when endocytosis assay in section 4.3.7 showed that uptake of 
Con A was compromised from 24 hours post RNAi of TbGEF3. Data from Chapter 5 further 
shows that TbGEF3 is required for endocytosis since sensitivity to suramin decreased in cells 
following the induction of TbGEF3 RNAi. 
The RNAi effect of TbGEF3 data from Chapter 4 and the low level of amino acid sequence 
identity at the ARF binding regions of the Sec7 domain shown in Chapter 3 suggests that 
TbGEF3 is the most promising of the 4 studied proteins as a novel drug target against T. brucei. 
An ideal drug target is defined by several rules that identify and prioritise drug targets, and 
TbGEF3 meets the 3 main rules for drug targets against parasites. These rules are: 1) the drug 
target should be sufficiently different from the host or be absent in host for specific targeting – 
TbGEF3 has low level of overall amino acid sequence identity and at the essential ARF binding 
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sites. 2) the drug target should be essential for the host-stage parasite – RNAi knockdown of 
TbGEF3 led to cell cycle defect and increased death in bloodstream form T. brucei. 3) the 
target should be ‘druggable’ – inhibitors have previously been designed to target the catalytic 
Sec7 domain of ARF GEFs (Ilari et al., 2018, Kandoi et al., 2015).  
Previous work by Demmel et al., (2016) have shown that reductions in phosphatidylinositol 
(4,5)-bisphosphate via knockdown of TbPIPKA, located at the neck of flagellar pocket, led to 
an enlarged flagellar pocket and endocytosis defect (Demmel et al., 2016). This is similar to 
the observed phenotype following RNAi of TbGEF3. Since phosphatidylinositol (4,5)-
bisphosphate is required for the interactions of GEFs to ARF/ARLs (Meissner et al., 2018), it 
could be hypothesised that the results observed by Demmel et al., (2016) may have been due 
to lack of T. brucei GEFs (TbGEF3) interacting with ARF/ARLs; thus further highlighting the 
potential use of TbGEF3 as a novel drug target 
RNAi of TbGAP1, TbGAP4 and TbGEF2 did not affect the cellular functions or morphology in 
bloodstream form T. brucei, suggesting that these ARF regulators may not be essential for 
bloodstream form T. brucei viability. However, measuring the changes in gene expression 
across all clones in all of the ARF regulator cell lines is needed to provide information on 
whether RNAi knockdown was sufficient, thus confirming whether TbGAP1, TbGAP4 and 
TbGEF2 are truly not essential in the cells. 
 
6.2 Future work 
The work done in this thesis identified T. brucei ARF regulators and the effect of tetracycline 
induced RNAi knockdown of these regulators in bloodstream form T. brucei. Further work is 
now required in order to develop a clear understanding of the ARF regulators and their 
functions within bloodstream form T. brucei. Proposed work is described below. 
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6.2.1 Identification of ARF regulator structures 
The structures of the identified ARFs were predicted in this thesis using Phyre2 software 
(described in Chapter 3). However, this prediction software uses homologous templates in 
order to predict secondary structures. This meant that the predicted structures in Chapter 3 
were of the highly conserved Sec7 and ARFGAP domains, and not the overall structure of the 
GEFs and GAPs. Identifying the three-dimensional structure of ARF regulators may provide a 
better understanding of their subcellular functions.   
Mandiyan et al., (1999) and Mossessova et al., (1998) described the catalytic domains of ARF 
GAPs and GEFs using X-ray crystallography (Mandiyan et al., 1999, Mossessova et al., 1998). 
The first step of X-ray crystallography requires a crystal of the protein of interest. This is usually 
the limiting factor since crystallization of proteins are not uniform and require specific 
conditions depending on their tertiary and quaternary structures present, as well as amino 
acids present that may affect polarity (Smyth and Martin, 2000). Once the crystals have been 
obtained, a beam of X-ray is used to strike the crystals. Some of the X-ray beam is scattered 
when the beam hits the protein present in the crystal. The diffraction (scatter) of the X-ray 
beam is used to determine the structure of the protein (Smyth and Martin, 2000).  
Prior to X-ray crystallography, the protein of interest needs to be expressed and purified. A 
technique that can be used to purify T. brucei proteins is the overexpression of histidine tagged 
(His-tagged) protein of interest in E. coli. The His-tagged proteins can then be isolated using 
nickel-nitrilotriacetic acid (Ni-NTA) agarose and purified for X-ray crystallography (Wang et al., 
2017). The same technique could be used to express and purify the identified ARF GEFs and 
GAPs, however purification of the entire length of GEFs have been shown to be difficult due 
to the size of these ARF regulators being approximately 2000 amino acids in length. Therefore 
expression and purification of the essential function retaining fragments (Sec7 catalytic 
domain) may be more feasible (Richardson et al., 2012). 
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6.2.2 Identifying ARF and ARF-regulator interactions 
With the current data it is difficult to determine which ARFs and ARLs are regulated by each 
of the T. brucei GEFs and GAPs. Protein-protein interaction studies may give a wealth of 
information regarding the ARF regulator interactions, localisation and associated cellular 
pathways the regulators might be implicated in. A mutated version of E. coli biotin ligase (BirA*) 
could be used to determine the interactions of T. brucei GEFs and GAPs. In E. coli, the BirA 
is required for the regulation of acetyl-CoA carboxylase through biotinylation. The BirA* binds 
biotin and ATP, this generates reactive bioAMP, these bioAMP covalently interact with primary 
amines present in proximity to BirA* fused proteins. The biotinylated proteins can then be 
isolated via streptavidin affinity purification and identified through mass spectrometry (Khan et 
al., 2018, Oostdyk et al., 2019). The use of BirA* in T. brucei was successfully demonstrated 
by Morriswood et al., (2013), therefore the T. brucei GEFs and GAPs could be expressed as 
BirA* fused proteins in future studies (Morriswood et al., 2013).   
The Yeast 2 Hybrid (Y2H) protein-protein interaction technique has been used widely and 
could be applied to study specific interactions of T. brucei GEFs and GAPs. The Y2H utilises 
two interacting proteins, the protein of interest – “bait”, and a predicted protein that interacts 
with the protein of interest – “prey”. The bait is fused to DNA binding domain (DBD), whilst the 
prey is fused to the activation domain (AD) of a transcription factor. The hypothetical binding 
of prey to bait results in the reconstitution of the transcription factor and expression of a reporter 
gene (Erffelinck et al., 2018, Brückner et al., 2009). Y2H technique was used in Lister 427 
bloodstream form T. brucei with N-terminal fused GAL4 on both BDB and AD, positive 
interactions were determined using selective medium (quadruple drop-out medium) and colour 
change (Singh et al., 2014). Other protein-protein interaction techniques include split luciferase 
assay, a technique where luciferase is split and the inactive C-terminal and N-terminal of the 
luciferase is fused to protein of interest and hypothetical interacting protein. The C-terminus 
and N-terminus luciferase fuse together when the protein of interest binds to the hypothetical 
interacting protein, thus producing a detectable bioluminescence signal (Hatzios et al., 2012). 
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6.2.3 Different systems of gene targeting 
The P2T7Ti vector was used for the RNAi system in this thesis to induce knockdown of T. 
brucei GEFs and GAPs. However the P2T7Ti vector is known to cause leaky expression in 
uninduced cells (LaCount et al., 2002). This would mean that T. brucei transfected with an 
essential ARF regulator could have been killed prior to being induced (e.g. GEF1), thus this 
particular gene transfection would then be determined as unsuccessful. Other methods of 
targeting genes of interest have been studied in T. brucei, which include the pTbFIX vectors 
consists of two transcription units and eliminated the need for pre-existing transgenic cell lines 
(Niemirowicz et al., 2018). There is also the glmS ribozyme based inducible gene expression 
system which worked as effectively as the conventional RNAi system but without the leaky 
expression (Cruz‐Bustos et al., 2018).  
The clustered regularly interspaced short palindromic repeats (CRISPR) is a gene editing 
technique that has gained popularity over the last 5 years. CRISPR utilises an RNA guided 
DNA endonuclease, Cas-9, and a synthetic guide RNA (gRNA) (Beneke et al., 2017). The 
gRNA matches the target DNA sequence, which facilitates endonuclease activity on target 
DNA sequence. In order to cut the target DNA, the DNA sequence must lie at the protospacer 
adjacent motif (PAM), which is at the 3’ end of the gRNA (Figure 6.2) (Rico et al., 2018, 
Redman et al., 2016). Vasquez et al., (2018) demonstrated the use of CRISPR/Cas-9 in T. 
brucei. They inserted a C-terminal GFP tag to the suppressor of clathrin deficient 6 (SCD6) 
without changing the UTRs, and targeted two different genes both individually and at the same 
time. This gene editing was done without the use of selective markers, thus demonstrating the 
robustness of the CRISPR/Cas-9 system (Vasquez et al., 2018). 
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Figure 6.2. The CRISPR/Cas-9 gene editing system. CRISPR/Cas-9 gene editing system 
showing the guide RNA that has the same sequence as the target DNA. Target DNA is cleaved 
at the 3’ end of the guide RNA termed protospacer adjacent motif (PAM) (Redman et al., 2016). 
 
6.2.4 Effects of TbGEF3 RNAi on T. brucei in a mouse infection model 
The experiments in this thesis were carried out in in vitro culture in order to observe the effect 
of RNAi of TbGEF3 in bloodstream form T. brucei. However carrying out an RNAi experiment 
in vivo might provide additional information to further validate TbGEF3 as a novel drug target 
against T. brucei. This is because bloodstream form T. brucei interacting with the host 
environment, especially the host’s immune system greatly influences the subcellular functions. 
Immune evasion by bloodstream form T. brucei heavily relies on internalisation of variant 
surface glycoproteins (VSGs) via endocytosis (Natesan et al., 2011). Knockdown of TbGEF3 
has been shown to induce an endocytosis defect in bloodstream form T. brucei in vitro, 
therefore it could be hypothesised that the knockdown of TbGEF3 in vivo may lead to a rapid 
decrease in parasitaemia due to lack of VSG internalisation and cell cycle defect, leading to 
greater levels of parasites being killed by the host immune system. In vivo effect of TbGEF3 
knockdown could be studied in rodent models. Taking inspiration from a study by Price et al., 
(2010), parasitaemia could be measured using  tail-cut blood samples of infected rodents at 
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different time points following induction of RNAi in transgenic P2T7-TbGEF3 cells by the 
addition of doxycycline to drinking water (Price et al., 2010a). 
 
6.2.5 Screening inhibitors against TbGEF3 using compound libraries 
Several studies have identified specific inhibitors of ARF GEFs, which then have effects on 
ARF functions. The most well-known inhibitor is Brefeldin A (BFA). BFA is a hydrophobic 
lactone produced by fungi, which inhibits ARF GEF function by binding to the interface between 
ARF and GEF (Myers and Casanova, 2008, Ohashi et al., 2012). Screening for compounds 
similar to BFA led to the discovery of AMF-26, a BFA-like inhibitor that was shown to inhibit 
the functions of GBF1 (Ohashi et al., 2012). Similar screening also identified LM11, a 
compound that has inhibitory functions on ARFGEF1 and CYTH subfamily  (Viaud et al., 2007). 
GEF assay screening identified a compound that has inhibitory functions against IQSEC and 
CYTH subfamilies; this inhibitor was named NAV-2729 (Yoo et al., 2016). Another inhibitor of 
CYTH subfamily is SecinH3, discovered during in vitro screening using RNA aptamer (Hafner 
et al., 2006). Golgicide A is an inhibitor that targets GBF1 present in the Golgi. Treatment of 
Vero cells (a African green monkey kidney epithelial line) with Golgicide A caused Golgi and 
trans-Golgi network dispersal (Saenz et al., 2009).  
Protein-protein interaction assays such as the ones described in section 6.2.2 can be used 
using TbGEF3 and these inhibitors of ARF GEFs in order to determine if existing inhibitors 
could potentially be used to target TbGEF3, as well as to study the inhibition mechanism in 
TbGEF3. However since many of these inhibitors are known to inhibit human ARF GEFs, they 
are not suitable as potential therapeutic agents against T. brucei. The chemical structures and 
the mode of interactions of these molecules might help identify or design novel inhibitors that 
can be used to inhibit the functions of TbGEF3 in bloodstream form T. brucei. 
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6.3 Conclusion 
The work carried out in this thesis identified 4 putative orthologues of human ARF GAPs and 
3 putative orthologues of human ARF GEFs in T. brucei. Through RNAi induced gene 
knockdown, TbGEF3 was identified as an essential ARF regulator in bloodstream form T. 
brucei. Further analysis on TbGEF3 led to the conclusion that TbGEF3 may be promising as 
a novel drug target against T. brucei. Additional work will need to be carried out in order to 
understand the specific functions of TbGEF3 as the molecular level; and to further validate 
TbGEF3 as a drug target. The data in this thesis shows a promising step into identifying ARF 
regulators as novel drug targets against T. brucei. 
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Appendix 1 
List of identified human ARF GAPs and their localisation. Data obtained from NCBI database 
and The Human Protein Atlas (www.proteinatlas.org). 
Accession 
number  
Gene 
Identified 
Aliases Localisation Function 
Q9NP61 ADP-
ribosylation 
factor 
GTPase-
activating 
protein 3 
ARFGAP3, 
ARFGAP1 
Cytosol and 
Golgi 
apparatus 
GTPase-activating protein (GAP) for 
ADP ribosylation factor 1 (ARF1). 
Hydrolysis of ARF1-bound GTP may 
lead to dissociation of coatomer from 
Golgi-derived membranes to allow 
fusion with target membranes. 
Q8N6T3 ADP-
ribosylation 
factor 
GTPase-
activating 
protein 1 
ARFGAP1, 
ARF1GAP 
Golgi 
apparatus, 
vesicles and 
nuclear 
membrane 
GTPase-activating protein (GAP) for 
the ADP ribosylation factor 1 (ARF1). 
Involved in membrane trafficking and 
/or vesicle transport. Required for the 
dissociation of coat proteins from 
Golgi-derived membranes and 
vesicles 
Q8N6H7 ADP-
ribosylation 
factor 
GTPase-
activating 
protein 2 
ARFGAP2 
ZNF289 
Nbla10535 
Golgi 
apparatus 
GTPase-activating protein (GAP) for 
ADP ribosylation factor 1 (ARF1). 
Implicated in coatomer-mediated 
protein transport between the Golgi 
complex and the endoplasmic 
reticulum. Hydrolysis of ARF1-bound 
GTP may lead to dissociation of 
coatomer from Golgi-derived 
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membranes to allow fusion with 
target membranes. 
O75689 Arf-GAP 
with dual 
PH domain-
containing 
protein 1 
ADAP1 
CENTA1 
Plasma 
membrane 
and cytosol 
GTPase-activating protein for the 
ADP ribosylation factor family 
(Probable). Binds 
phosphatidylinositol 3,4,5-
trisphosphate (PtdInsP3) and inositol 
1,3,4,5-tetrakisphosphate (InsP4) 
Q9NPF8 Arf-GAP 
with dual 
PH domain-
containing 
protein 2 
ADAP2 
CENTA2 
Data not 
available  
GTPase-activating protein for the 
ADP ribosylation factor family 
(Potential). Binds 
phosphatidylinositol 3,4,5-
trisphosphate (PtdInsP3) and inositol 
1,3,4,5-tetrakisphosphate (InsP4). 
Q8IYB5 Stromal 
membrane-
associated 
protein 1 
SMAP1 Plasma 
membrane, 
cytosol and 
golgi 
apparatus 
GTPase activating protein that acts 
on ARF6. Plays a role in clathrin-
dependent endocytosis. May play a 
role in erythropoiesis 
Q8WU79 Stromal 
membrane-
associated 
protein 2 
SMAP2 
SMAP1L 
Data not 
available 
GTPase activating protein that acts 
on ARF1. Can also activate ARF6 (in 
vitro). May play a role in clathrin-
dependent retrograde transport from 
early endosomes to the trans-Golgi 
network. 
Q9Y2X7 ARF 
GTPase-
GIT1 Focal 
adhesion 
May serve as a scaffold to bring 
together molecules to form signaling 
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activating 
protein 
GIT1 
sites and 
cytosol 
modules controlling vesicle 
trafficking, adhesion and cytoskeletal 
organization. Increases the speed of 
cell migration, as well as the size 
and rate of formation of protrusions, 
possibly by targeting PAK1 to 
adhesions and the leading edge of 
lamellipodia. Sequesters inactive 
non-tyrosine-phosphorylated paxillin 
in cytoplasmic complexes. Involved 
in the regulation of cytokinesis. 
Q14161 ARF 
GTPase-
activating 
protein 
GIT2 
GIT2, 
KIAA0148 
Microtubules  GTPase-activating protein for the 
ADP ribosylation factor family. 
Q9ULH1 Arf-GAP 
with SH3 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 1 
ASAP1, 
DDEF1, 
KIAA1249 
Plasma 
membrane, 
centrosome 
and cytosol 
Possesses phosphatidylinositol 4,5-
bisphosphate-dependent GTPase-
activating protein activity for ARF1 
(ADP ribosylation factor 1) and ARF5 
and a lesser activity towards ARF6. 
May coordinate membrane trafficking 
with cell growth or actin cytoskeleton 
remodeling by binding to both SRC 
and PIP2. May function as a signal 
transduction protein involved in the 
differentiation of fibroblasts into 
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adipocytes and possibly other cell 
types (By similarity). Plays a role in 
ciliogenesis. 
O43150 Arf-GAP 
with SH3 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 2 
ASAP2, 
DDEF2, 
KIAA0400 
Cytosol  Activates the small GTPases ARF1, 
ARF5 and ARF6. Regulates the 
formation of post-Golgi vesicles and 
modulates constitutive secretion. 
Modulates phagocytosis mediated by 
Fc gamma receptor and ARF6. 
Modulates PXN recruitment to focal 
contacts and cell migration. 
Q8TDY4 Arf-GAP 
with SH3 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 3 
ASAP3, 
DDEFL1, 
UPLC1 
Vesicles and 
nucleoplasm 
Promotes cell proliferation. 
Q15027 Arf-GAP 
with coiled-
coil, ANK 
repeat and 
PH domain-
containing 
protein 1 
ACAP1, 
CENTB1, 
KIAA0050 
Golgi 
apparatus 
GTPase-activating protein (GAP) for 
ADP ribosylation factor 6 (ARF6) 
required for clathrin-dependent 
export of proteins from recycling 
endosomes to trans-Golgi network 
and cell surface. Required for 
regulated export of ITGB1 from 
recycling endosomes to the cell 
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surface and ITGB1-dependent cell 
migration. 
Q15057 Arf-GAP 
with coiled-
coil, ANK 
repeat and 
PH domain-
containing 
protein 2 
ACAP2, 
CENTB2, 
KIAA0041 
Endosomes  GTPase-activating protein (GAP) for 
ADP ribosylation factor 6 (ARF6). 
Q96P50 Arf-GAP 
with coiled-
coil, ANK 
repeat and 
PH domain-
containing 
protein 3 
ACAP3, 
CENTB5, 
KIAA1716 
Nucleoplasm 
and Golgi 
apparatus 
GTPase-activating protein for the 
ADP ribosylation factor family. 
Q9UPQ3 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 1 
AGAP1, 
CENTG2, 
KIAA1099 
Data not 
available 
GTPase-activating protein for ARF1 
and, to a lesser extent, ARF5. 
Directly and specifically regulates the 
adapter protein 3 (AP-3)-dependent 
trafficking of proteins in the 
endosomal-lysosomal system. 
Q99490 Arf-GAP 
with 
GTPase, 
AGAP2, 
CENTG1, 
KIAA0167 
Nucleoli, 
mitochondria 
and nucleus 
GTPase-activating protein (GAP) for 
ARF1 and ARF5. 
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ANK repeat 
and PH 
domain-
containing 
protein 2 
Q96P47 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 3 
AGAP3, 
CENTG3 
Data not 
available 
GTPase-activating protein for the 
ADP ribosylation factor family 
(Potential). GTPase which may be 
involved in the degradation of 
expanded polyglutamine proteins 
through the ubiquitin-proteasome 
pathway. 
Q96P64 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 4 
AGAP4, 
AGAP8, 
CTGLF1, 
CTGLF5, 
MRIP2 
Data not 
available 
Putative GTPase-activating protein. 
Q5VTM2 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
AGAP9, 
CTGLF6 
Data not 
available 
Putative GTPase-activating protein. 
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containing 
protein 9 
Q5VW22 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 6 
AGAP6, 
CTGLF3 
Data not 
available 
Putative GTPase-activating protein. 
Q8TF27 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 11 
AGAP11, 
KIAA1975 
Data not 
available 
Putative GTPase-activating protein. 
A6NIR3 Arf-GAP 
with 
GTPase, 
ANK repeat 
and PH 
domain-
containing 
protein 5 
AGAP5, 
CTGLF2 
Data not 
available  
Putative GTPase-activating protein. 
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Q96P48 Arf-GAP 
with Rho-
GAP 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 1 
ARAP1, 
CENTD2, 
KIAA0782 
Nucleoplasm, 
plasma 
membrane, 
vesicles and 
cytosol  
Phosphatidylinositol 3,4,5-
trisphosphate-dependent GTPase-
activating protein that modulates 
actin cytoskeleton remodeling by 
regulating ARF and RHO family 
members. Is activated by 
phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) 
binding. Can be activated by 
phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4,5)P2) 
binding, albeit with lower efficiency. 
Has a preference for ARF1 and 
ARF5 (By similarity). 
Q8WZ64 Arf-GAP 
with Rho-
GAP 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 2 
ARAP2, 
CENTD1, 
KIAA0580 
Focal 
adhesion 
sites and 
actin 
filaments 
Phosphatidylinositol 3,4,5-
trisphosphate-dependent GTPase-
activating protein that modulates 
actin cytoskeleton remodeling by 
regulating ARF and RHO family 
members. Is activated by 
phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) 
binding. Can be activated by 
phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4,5)P2) 
binding, albeit with lower efficiency 
(By similarity). 
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Q8WWN8 Arf-GAP 
with Rho-
GAP 
domain, 
ANK repeat 
and PH 
domain-
containing 
protein 3 
ARAP3, 
CENTD3 
Data not 
available 
Phosphatidylinositol 3,4,5-
trisphosphate-dependent GTPase-
activating protein that modulates 
actin cytoskeleton remodeling by 
regulating ARF and RHO family 
members. Is activated by 
phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) 
binding. Can be activated by 
phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4,5)P2) 
binding, albeit with lower efficiency. 
Acts on ARF6, RAC1, RHOA and 
CDC42. Plays a role in the 
internalization of anthrax toxin. 
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Appendix 2 
List of identified human ARF GEFs and their localisation. Data obtained from NCBI database 
and The Human Protein Atlas (www.proteinatlas.org). 
Accession 
number 
Gene 
Identified 
Aliases Localisation Function 
Q15438 Cytohesin-1 CYTH1, 
D17S811E, 
PSCD1 
Nucleus and 
nucleoli 
Promotes guanine-nucleotide 
exchange on ARF1, ARF5 
and ARF6. Plays an 
important role in membrane 
trafficking, during junctional 
remodelling and epithelial 
polarization, through 
regulation of ARF6 activity. 
Q99418 Cytohesin-2 CYTH2, 
ARNO, 
PSCD2, 
PSCD2L 
Cytosol, golgi 
apparatus 
and plasma 
membrane 
GEF, promotes guanine 
nucleotide exchange on 
ARF1, ARF3 and AF6. 
Reqruits ARF6 to plasma 
membrane 
O43739 Cytohesin-3 CYTH2, 
ARNO3, 
GRP1, 
PSCD3 
Cytosol and 
nucleoplasm 
Promotes guanine-nucleotide 
exchange on ARF1 and 
ARF6. Promotes the 
activation of ARF factors 
through replacement of GDP 
with GTP. Play a role in the 
epithelial polarization 
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Q9UIA0 Cytohesin-4 CYTH4, 
CYT4, 
PSCD4 
Data not 
available 
Promotes guanine-nucleotide 
exchange on ARF1 and 
ARF5 
Q92538 Golgi-
specific 
brefeldin A-
resistance 
guanine 
nucleotide 
exchange 
factor 1 
 
GBF1, 
KIAA0248 
Golgi 
apparatus 
Trafficking in the early 
secretory pathway; GEF 
activity initiates the coating of 
nascent vesicles via the 
localized generation of 
activated ARFs. Involved in 
the recruitment of the COPI 
coat complex to the 
endoplasmic reticulum exit 
sites (ERES), and the 
endoplasmic reticulum-Golgi 
intermediate (ERGIC). Has 
GEF activity towards ARF1 
Q9Y6D5 Brefeldin A-
inhibited 
guanine 
nucleotide-
exchange 
protein 2 
 
ARFGEF2, 
ARFGEP2, 
BIG2 
Golgi 
apparatus 
Promotes guanine-nucleotide 
exchange on ARF1 and 
ARF3 and to a lower extent 
on ARF5 and ARF6. 
Regulation of Golgi vesicular 
transport. Required for the 
integrity of the endosomal 
compartment. Involved in 
trafficking from the trans-
Golgi network (TGN) to 
endosomes and is required 
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for membrane association of 
the AP-1 complex and GGA1. 
Q9Y6D6 Brefeldin A-
inhibited 
guanine 
nucleotide-
exchange 
protein 1 
ARFGEF1, 
ARFGEP1, 
BIG1 
Golgi 
apparatus, 
nucleoplasm 
and cytosol 
Promotes guanine-nucleotide 
exchange on ARF1 and 
ARF3. Involved in vesicular 
trafficking. Required for the 
maintenance of Golgi 
structure; the function may be 
independent of its GEF 
activity. Required for the 
maturaion of integrin beta-1 
in the Golgi. Involved in the 
establishment and 
persistence of cell polarity 
during directed cell 
movement in wound healing. 
A5PKW4 PH and 
SEC7 
domain-
containing 
protein 1 
 
PSD, EFA6, 
EFA6A, 
KIAA2011, 
PSD1, TYL 
Nucleoplasm, 
plasma 
membrane 
and cytosol 
Guanine nucleotide 
exchange factor for ARF6. 
Induces cytoskeletal 
remodeling. 
Q8NDX1 PH and 
SEC7 
domain-
containing 
protein 4 
PSD4, 
EFA6B, TIC 
Data not 
available 
Guanine nucleotide 
exchange factor for ARF6 
and ARL14/ARF7. Through 
ARL14 activation, controls 
the movement of MHC class 
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 II-containing vesicles along 
the actin cytoskeleton in 
dendritic cells. Involved in 
membrane recycling. 
Interacts with several 
phosphatidylinositol 
phosphate species, including 
phosphatidylinositol 3,4-
bisphosphate, 
phosphatidylinositol 3,5-
bisphosphate and 
phosphatidylinositol 4,5-
bisphosphate. 
Q9BQI7 PH and 
SEC7 
domain-
containing 
protein 2 
 
PSD2, 
EFA6C 
Data not 
available 
 
Q9NYI0 PH and 
SEC7 
domain-
containing 
protein 3 
 
PSD3, 
EFA6D, 
EFA6R, 
HCA67, 
KIAA0942 
Nucleus and 
vesicles 
Guanine nucleotide 
exchange factor for ARF6. 
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Q5JU85 IQ motif 
and SEC7 
domain-
containing 
protein 2 
 
IQSEC2, 
KIAA0522 
Vesicles Is a guanine nucleotide 
exchange factor for the ARF 
GTP-binding proteins 
Q6DN90 IQ motif 
and SEC7 
domain-
containing 
protein 1 
 
IQSEC1, 
ARFGEP100, 
BRAG2, 
KIAA0763 
Nucleoli and 
vesicles 
Guanine nucleotide 
exchange factor for ARF1 
and ARF6. Guanine 
nucleotide exchange factor 
activity is enhanced by lipid 
binding. Accelerates GTP 
binding by ARFs of all three 
classes. Guanine nucleotide 
exchange protein for ARF6, 
mediating internalisation of 
beta-1 integrin. 
Q9UPP2 IQ motif 
and SEC7 
domain-
containing 
protein 3 
 
IQSEC3, 
KIAA1110 
No data 
available 
Acts as a guanine nucleotide 
exchange factor (GEF) for 
ARF1. 
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Appendix 3 
Amino acid sequence alignment for TbGAP1 (OG5127251) in other kinetoplastids 
T.brucei         1 --------------------VHFVIMPPTLPKDSEEAKAVVREVRQKPDNKVCFDCPQKN 
L.braziliense    1 MPRPHSPHPSIAGASETSDRAMASTGNLKVPETAEEAKELVAMMRQLPDNRVCFDCPQKN 
L.infantum       1 ---------------------MASTGKLKVPETAEEAKELVAVMRQLPDNRVCFDCPQKN 
L.major          1 ---------------------MASTGKLKVPETAEEAKELVAVMRQLPDNRVCFDCPQKN 
L.mexicana       1 ---------------------MASTGNLKVPETAEEAKELVAVMRQLPDNRICFDCPQKN 
T.b.gambiense    1 -------------------------MPPTLPKDSEEAKAVVREVRQKPDNKVCFDCPQKN 
T.congolense     1 -------------------------MQPTLPKNSEEAKNLARSLRQHADNKICFDCPQKN 
T.cruzi          1 -------------------------MTLTLPKDSEEAKALVGSLRSHADNRVCFDCLQKN 
T.vivax          1 -------------------------MGPTLPKDPEEAKALVRTLRQRPENMVCFDCPQKN 
consensus        1                          . ...*.  **** ... .*....*..****.*** 
 
 
T.brucei        41 PSWCSVTYGIFLCMDCCGRHRGMGVHISFMRSADLDAWKPEEALRMALGGNAAAAAFFRQ 
L.braziliense   61 PSWCSVTYGFFLCMDCCGRHRGMGVHITFMKSAELDSWRPQEALRVALGGNSRGKQFLKQ 
L.infantum      40 PSWCSVTYGLFLCMDCCGRHRGMGVHITFMKSAELDSWRPQEALRVALGGNSRAKQFLKQ 
L.major         40 PSWCSVTYGLFLCMDCCGRHRGMGVHITFMKSAELDSWRPQEALRVALGGNSRAKQFLKQ 
L.mexicana      40 PSWCSVTYGLFLCMDCCGRHRGMGVHITFMKSAELDSWRPQEALRVALGGNSRAKQFLKQ 
T.b.gambiense   36 PSWCSVTYGIFLCMDCCGRHRGMGVHISFMRSADLDAWKPEEALRMALGGNAAAAAFFRQ 
T.congolense    36 PTWCSVTYGIFLCMDCCGRHRGMGVHISFMRSADLDSWKPEKALRMALGGNAAAASFFQQ 
T.cruzi         36 PSWCSVTYGIFLCMDCCGRHRGMGVHISFIRSADLDSWRPEEALRMALGGNAAAREFFKQ 
T.vivax         36 PSWCSVTYGIFLCLDCCGRHRGMGVHVSFMRSADLDSWKPEEGLRMAVGGNAAAQQFFKK 
consensus       61 *.*******.***.************..*..**.**.*.*...**.*.***.....*... 
 
 
T.brucei       101 NGSTGDPRQRYTSQAAQMYKRQLDXLVYNCISGSNGTPNELVGSTGEEVEVT---RVTPS 
L.braziliense  121 HG-SMDPKSFYNSPAAALYKRMVDKAVDNFTQNGQLPPASPIPQPAS------------- 
L.infantum     100 HG-NMDPKSFYTSPAAALYKRMVDKAVNDFTLNGQLPSASPVPQLACEASPQSDNCASPT 
L.major        100 HG-NMDPKSFYTSPAAALYKRMVDKAVNGFMDNGQLPSASPVPQLASEASPQPGNCASPT 
L.mexicana     100 HG-NIDPKSFYTSPAAALYKRMVDKAVNDFTQNGQLPPASPVPQLACEPSPQSGKCASPT 
T.b.gambiense   96 NGSTGDPRQRYTSQVAQMYKRQLDRLVYNCISGSNGTPNELVGSTGEEVEVT---RVTPS 
T.congolense    96 HGGAADSRQRYVTAAAQSYKSRLDRLVAERMREGSTMAGATVST-ARRGEGK---CPLPS 
T.cruzi         96 HG-CNDSKMRYTSPAAQLYRRRIDRLMAEYMGGRRMEPPAEGPN-------T---MSAES 
T.vivax         96 HG-CGDPQVHYGSSAAQMYRRHLDRLVAECVGVSTAEPHVEDAS-------S---AQPDA 
consensus      121 .*   *.. .*....*..*.. .*... ...  ... ..  ... . .         ... 
 
 
T.brucei       158 ----SPKRQQLEKE--------DEMKISSPVAQPSVVAISTK-TGV--------KQRTGG 
L.braziliense  167 -----PIPQPASLSPT-SSASPDVTTQDSPVAMAPIVMMSSKATGLGTKKLGG-GATLGA 
L.infantum     159 FIGVAA-PTGSSLSPT-PSASPDVTAQGSPVTVAPIVAISSKPTGLGTKKLGGSGAALGA 
L.major        159 FFGTAA-PAGSSLSPT-PSASPDVTAQGSPVTVASVVAISSKPTGLGTKKLGGSGAALGA 
L.mexicana     159 FFGAAAVAAGSSLSPT-SSASPDVTAQDSPATVAPVVAISSKPTGLGAKKLGGSGAAPGA 
T.b.gambiense  153 ----SPKRQQLEKE--------DEMKISSPVAQPSVVVISTK-TGV--------KQRTGG 
T.congolense   152 ----SPRPQHQEREEDGGAFKDSTTNIGGPAQEPTMVTMS-S-KSV--------RQRAGG 
T.cruzi        145 ----SPVENRKDL---------EPTTTGSPVAQPSVISMAPK-TGK--------K---PG 
T.vivax        145 -----PHEQQK------------EQGCEGSATQRTAVTLQPV-TGK--------R---LG 
consensus      181      .  .   .         . .   ...   ... .... ...        .   .. 
 
 
T.brucei       197 GLKKKGFGGAMKVEGELTETMQPVPRSLICDVVESDESHNHNYNYNYSYYRNKKDSDHNN 
L.braziliense  220 KGKKKGFGGIARVEGTIEESTQPVPEELLYDREAEQRKAAEAEME-----RR-CQADLAA 
L.infantum     217 KGKKKGFGGIARVEGIIEESTRPVPEELLYDREAEHRKAAEAEME-----RQ-RQADLAA 
L.major        217 KGRKKGFGGIARVEGTIEESTRPVPEELLYDREAEQRKAAEAEME-----RQ-RQADLAA 
L.mexicana     218 KGKKKGFGGIARVEGTIEESTRPVPEELLYDREAEQRKAAEAETE-----RQ-RQADLAA 
T.b.gambiense  192 GLKKKGFGGAMKVEGELTETMQPVPRSLICDVVESDESHNHNYNYNYSYYRNKKDSDHNN 
T.congolense   198 SLKKKGFGGALKVEGHLTESSRKVPQGLMCDVASPHVDGDGC------------------ 
T.cruzi        180 AAKRKGFGGAQKVEGNIKESSDPVPHSLLHDESKLEDEDDAE-RK--------------- 
T.vivax        176 TTKKKGFGGAQKVDGV-RETTGPVPEFLMRDDPSPVSTLNAGGGS--------------- 
consensus      241  ...*****. .*.* . *.. .**. *. *       .  .        .. .  .    
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T.brucei       257 --NNNDDDDNNNNNNNN---SNISSDIARLRGCMSNHNH--NHNSDSTTDGAWKRGIDAG 
L.braziliense  274 -AARAVDPDVLRRSEPNTP---KVPQAPRQTGFIGKSAE--NVNGDLFDETSVPVSS--P 
L.infantum     271 AAARAVDPSMLGRGEPHAPKAPKVTQAPRQTGFIGKNAE--NVNGDLFDDTNVPATA--P 
L.major        271 AAARAVDPSMLGRGEPHAPK---VPQAPRQTGFIGKSAE--NVNGDLFDDTNVPTTT--P 
L.mexicana     272 AAARAVDPTMLGRGEPHAPK---VPQAPRQTGFIGKSAE--NVNGDLFDDTNVPATT--P 
T.b.gambiense  252 --NNNNDDDNDDNNNNN---SNISSDIARLRGCMSNHNHNHNHNSDSTTDGAWKRGIDAG 
T.congolense   240 ----------------N---DNIT--GAKFGSCGSRCAGN------------------AG 
T.cruzi        224 ----------------------T------------------------FVPGAFS-----P 
T.vivax        220 ----------------------M------------------------DTDTEFQ-----S 
consensus      301       .                   . .  . . . .   . . . . ..        . 
 
 
T.brucei       310 GNGEGGVEGEGNKNNNKNKSNNYDNRNVT-GVLDAYADNCTSRVPDFSGMGSQPYDPREA 
L.braziliense  326 APLMSQPYGARSNSATCASRFAAAASSAGPTTAPKPAPAASRAGPDFRGLGSQAYVPETI 
L.infantum     327 APPTRQPCGVGGNNTTNVSASAATARSATPTLPPMSVSAAPRAGPDFRGLGNQAYVPEDT 
L.major        324 APPTRQPYGVGGNKATNVSAFAATARSTTPTPPPMSASAAPRAGPDFRGLGNQAYVPEDT 
L.mexicana     325 APLTHQPYGAGGNNPTNVSASAATARSATPTPLSMSASAAPRAGPDFRGLGNQAYVPEDT 
T.b.gambiense  307 GNGEGGVEGEGNKNNNKNKSNNYDNRNVT-GVLDAYADNCTSRVPDFSGMGSQPYDPREA 
T.congolense   261 DNATGGKKK-----TE----RCVDGSLKDGSIRKSNTGPPEDRVPDFSGMGSQPYDPHEA 
T.cruzi        233 VNPADRFRGVGNP-----------------AFQAEAPSCDRMNGPDFTGLGSRPYQPQAT 
T.vivax        229 RGASGCFRGTGNT-----------------HNMSGAQGGCTRSGPDFSGLGSEPYQPEVS 
consensus      361 .  .    . .             ..  . .     . .  . .***.*.*...* *... 
 
 
T.brucei       369 DSDTSNR------YFNSVGLQDTLWQVSEAWDSFREKASRSGERLGNKVKEFLDDL 
L.braziliense  386 HSADGGPQNSSGGMATSITASDALWHVTEAARSLQQSAAQATGALGEAVKNFLDDL 
L.infantum     387 YCASGGPRGSSGGMGAPGTASDALWHVTEAARSLQQSAAQATGALGEAVKNFLDDL 
L.major        384 YSS-------SSGMGAPRTASDALWHVTEAARSLQQSAAQATGALGEAVKNFLDDL 
L.mexicana     385 YCASGGPRVSSGGMGAPGTASDALWHVTEAARSLQQSAAQATGAFGEAVKNFLDDL 
T.b.gambiense  366 DSDTSNR------YFNSVGLQDTLWQVSEAWDSFREKASRSGERLGNKVKEFLDDL 
T.congolense   312 VADADGA------YFNTNL------------------------------------- 
T.cruzi        276 RT-------------EAGGFQDTLWQVTEAWDSFKESANRSRKEWGNRVREFLDDL 
T.vivax        272 SDG----------DRLNTSIQETLWQVAEAWDSLKEKAGRSSERWGSKVKRFLDDL 
consensus      421  .                .  . .. ....  ..  ...  .  ..  .. ..... 
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Appendix 4 
Amino acid alignment of TbGAP2 (OG5_127190) orthologues in other kinetoplastids 
T.brucei         1 ---------------MTE----KE----NGNKD----KRRKEKHRKHHRDRRESCNGVVN 
L.braziliense    1 ---------------MSVLDRSKEKQHRKSKEHSVGDGRHHHHHHSH--DKKKSRKNTAN 
L.infantum       1 MSCPASEKAQLTAAAMPVADKSKERRHKKSKEASTECGH-HHHHRAH--EK-KKGKSAAN 
L.major          1 MSCPASQRPQLTAAAMPVADKPKERRHRKSKEASTEGGH--HHHRSH--EK-KKGKSAAT 
L.mexicana       1 MSCPASEKTQLTTAAMPIADTSKERRHRKSKEPSTEGDH-DHHHRSH--EKKKKRKSAAN 
T.b.gambiense    1 ------------------------------------------------------------ 
T.congolense     1 ------------------------------------------------------------ 
T.cruzi          1 --------------------------------------------------MFDACT-LLN 
T.vivax          1 ---------------MVG----DDVDHVEGKGE-----KRHRRHRHKDRNKKHEGPSVID 
consensus        1                .      ..  .   .       .  .... .  .. .      . 
 
 
T.brucei        34 SSAA-KTRPE-----TAVAIE---GADEEVENWDENRTRVDQLCQTYPNNMCNDCNNAGT 
L.braziliense   44 ADSS-TSLITTLPA-HQHCGI---DVDEDDEDWEENRVAVERLCAQYPNNICADCGETGT 
L.infantum      57 ADAS-TSLPITLSEPPKHRGT---KADEDDEDWEANRAAVERLCSQYPNNVCADCGETGT 
L.major         56 ADAS-TSSTMTLSA-PKRRGT---EADEDDEDWEENRAAVERLCSQYPNNVCADCGETGT 
L.mexicana      58 ADAS-TSLARTLSA-PKHCGT---ETGEEDEDWEENRAAVERLCSQYPNSVCADCGERGT 
T.b.gambiense    1 ----------------------------MSNANAAQKRRIDALLRLPENKVCFECLENQP 
T.congolense     1 ----------------------------MSQANAAQKRRLDALLRIPENKVCFECLENQP 
T.cruzi         10 TCAYFASIASREGFSTRICTRMQPRAVPTGRKPMTQKLLLEKLLHLPENRECFECSAKQP 
T.vivax         37 G----------------SGRI---EDDGDAEDWDANRTRIEHLCQTYPNNVCSDCSRSGT 
consensus       61 . .   .                   ... .... ..  ...*.  ..*..* .* . .. 
 
 
T.brucei        85 RWASVNHGVFLCIRCSGIHRSLGVHVSKVKSANMDKWSAAEVHLMELIGNQRAKLLYEAH 
L.braziliense   99 RWASVNHGVFVCIRCSGVHRSLGVHISKIKSTNMDRWSLAEVRLMKAIGNVAAKALYEAH 
L.infantum     113 RWTSVNHGVFVCIRCSGVHRSLGVHISKVKSTNMDRWSLAEVRLMEAIGNAKAKTLYEAR 
L.major        111 RWASVNYGVFVCIRCSGVHRSLGVHISKVKSTNMDRWSLAEVRLMEAIGNAKAKTLYEAR 
L.mexicana     113 RWASVNHGVFVCIRCSGVHRSLGVHISKVKSTNMDRWSLAEVRLMEAIGNAKAKTLYEVR 
T.b.gambiense   33 RWASTNLGVFLCLRCAGLHRSAGTHVSKVRSATMDTWEEEMIRCCENIGNARGRVLYEYN 
T.congolense    33 RWASTNLGVFLCLRCAGLHRSAGTHVSKVRSATMDTWEEDMIRRCERIGNARGRLLYEYN 
T.cruzi         70 RWASTNLGIFLCLRCAGIHRAMGTHVSKVRSTNMDTWEDPMIECCECIGNKRGRVLYEHG 
T.vivax         78 RWASVNHGVFICIRCSGIHRSMGVHVSRIKSTNMDKWTTAEVNLMESIGNQRGKLLYESR 
consensus      121 **.*.*.*.*.*.**.*.**..*.*.*...*..**.*. ....... ***.....*** . 
 
 
T.brucei       145 LPKDMKPMTFAE--SDATLQTFIQRKYQEKAFSVEAVDEKLRQYHKEARYGKKPKRNSS- 
L.braziliense  159 LPAGARPSSGAGATADEAVKLFIERKYAQREFAMHNLKDVLERHYKDTGYRRSKTAFKS- 
L.infantum     173 LPTGARPSGGADAAADDAVRSFIQRKYEQREFAMHNLKDVLGRLYKDTGYGRPKMGSKP- 
L.major        171 LPTGVRPSGRADAAADDAVRSFIQRKYEQREFAMRNLQDVLGRLYKDTGYGRPKMASKP- 
L.mexicana     173 LPAGARPSGGADAAADDAVRSFIQRKYEQREFAMHNLKDVLGRLYKDTGYGRPKMASKS- 
T.b.gambiense   93 MPDSARPNASTN---GALAERLIREKYEQRRYFNVEYDSLLKKFMSEGASQGSSTPKDEK 
T.congolense    93 MPDSARPNASTN---GAVAERLIREKYEHKRYFNVQYEALLRSFMSEAPPPASESSKDEK 
T.cruzi        130 MDPQLRPTAATD---NISVDRFIRDKYERKMYYNPQYETLLKQFFDAGTSVNEEKCSGLV 
T.vivax        138 LPKETKTTAFAD--SDAALATFIRQKYQKREFASDDVAEKLKHFYKQARYRKKPKNDSK- 
consensus      181 ..  ..... ..   . .. ..* .**....... .. ..*......... .         
 
 
T.brucei       202 --------AS----------RKKKANDG-----ANDKAERSLKGEDTIKALYGSNAEVIS 
L.braziliense  218 --------RAVVDGVVSLPTGESRAAAV-----SVDRDVMTGKRGDTMRALYGDAAAEMQ 
L.infantum     232 --------GAAAEGTVTSPTRGSSSDAV-----PIDRAVATGKRGDTMRALYGDAAAEMQ 
L.major        230 --------GAAAEGTVTSSTRGSSSAAV-----PTDRAAATGKRGDTMRALYGDAAAEMQ 
L.mexicana     232 --------GAAAEGTVTSPTRGSSSTAV-----PIDRAAATGKRGDTMRALYGDAAAAMQ 
T.b.gambiense  150 RDVVASVS------APPSLWVGNSQQTAQPTLTAGQTKQSASANGISIDDLFSTPNAKTN 
T.congolense   150 YSAETPMQRSGVQPSFPSPLLENPSNGARAAPGAASSKPNQSGSGISIDDLFGSSASAPQ 
T.cruzi        187 -LSKPSEQTGGTSASMPMLWGGSPATAMEAPA--SLEGNTNTKNGIDINELFTTTTSTVT 
T.vivax        195 --------RS----------VSPER-GA-----VRDRSAEARQREETVKALYGPNAEVLS 
consensus      241          ..  ... .   ..   ..       ...  . ........*..  .. .. 
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T.brucei       239 KMSK-------------RTGPIRGT-FGV-VNVGPEAYDERRKTLLEQFGFS-------- 
L.braziliense  265 RGLSRRTKNAASQTQGPMPKLTYGT-FGI-VNVPPEEYEARWQRTVAVFTFVEAPPAAVA 
L.infantum     279 RGSSRRKD-AARLSAASAPKPTYGT-FGM-VNVPVEEYEARWQRTLAVFSSVEALPAAAA 
L.major        277 RGSTRRKD-AARLSAALAPKPTYGT-FGM-VNVPGEEYEARWQRTLAVFSSVEPLPAAAA 
L.mexicana     279 RGSSRRKG-AARLSAASAPKPTYGT-FGM-VNVPVEEYEARWKRTLAVFSSVEALPAAVA 
T.b.gambiense  204 P---NVGTPVSPQPVGVVPQGQFQQTSGMFHPAGMTPFGMEVRG-----------P--SQ 
T.congolense   210 WAPLRMGTSPAQSGQGHPPQGLGA----SPPPLGPDGFGTPVPV---------------- 
T.cruzi        244 SAPMQHQQ-----------QQIFWT---QMAGNGMVGYHQYYQQ----QSQC---P--SS 
T.vivax        231 KKES-------------KTKPLRGT-FGL-VNVAADCYDKRRQAILAHFNFC-------- 
consensus      301 .. ...    .    .  ... ... ... .... . .. ...  .. ..     .     
 
 
T.brucei           -------------------------------------------------------- 
L.braziliense  323 APAEEAPRGDEGEKETRTAAPTPLTEPTAAL--ADRPQMDGVETTPATVSSPSLPV 
L.infantum     336 APAGEMLSADERGKEGDATTATPLTDPNDTV--AERPQMGGAEATPAAASATSFVV 
L.major        334 APAGEMLSADERGKKGGTTIVTPLTDPSDTT--AERPQMGGAEATPAAASASSVVV 
L.mexicana     336 VPAGEMLSADEGGKEGGATAVTPLTDPSDTV--AERPQMSGTEATPTVAAGTSFTV 
T.b.gambiense  248 G-NFQAPAVDAKQEIMSLFTPSN-QGPPHVYS-AWAPSGSSKCFSPQ--------- 
T.congolense   250 --HSQSPAAGAKGGRLCPFLPPPLCRDPRPCTAHGVPQVPVADFS----------- 
T.cruzi        281 APSQAGHQVDVKTEIMSLFSTPPNCSPNHVYS-AWQPQ------------------ 
T.vivax            -------------------------------------------------------- 
consensus      361 ..      .. .         ...  .      .  ...   . ..           
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Appendix 5 
Amino acid sequence alignment for TbGAP3 (OG5_127813) in other kinetoplastids 
T.brucei         1 --------MSHTAEDARVFREILQRDEECKHCFECGALSPQWCDVNHGVFVCLDCSGVHR 
L.braziliense    1 ----MTNHTYVSPEDERAFMAILAKDPECSRCFECGAPSPQWCDVMHGTFICLNCSGQHR 
L_infantum       1 ----MAGRNYVSPEDERAFVAILAKDPECNQCFECGAPSPQWCDVMHGTFICLNCSGQHR 
L.major          1 ----MAGRSYVSPKDERAFVAILAKDPECSQCFECGAPSPQWCDVMHGTFICLNCSGQHR 
L.mexicana       1 ----MAGRHYVSPEDERAFVSIFAKDPECSECFECGAPSPQWCDVMHGTFICLNCSGQHR 
T.b.gambiense    1 --------MSHTAEDARVFREILQRDEECKHCFECGALSPQWCDVNHGVFVCLDCSGVHR 
T.congolense     1 --------MSHSVEDTRAFREILERDSECKRCFECDALNPQWCDVNHGIFICLDCSGVHR 
T.vivax          1 FSGEKDHVMSHTQEDVKAFAEILANDNECRNCFDCGALNPQWCDVNHGIFICLDCSGLHR 
consensus        1     .  ..  ...*...*..*...*.**..**.*.* .****** **.*.** ***.** 
 
 
T.brucei        53 SLGVHLSFVRSPTMDGWTNWRPEKLRQMQIGGNRRAREYFERNGVPKAPIRERYQSLGAL 
L.braziliense   57 GLGVHLSFVRSSTMDGWMNWKPEKLRQMELGGNRRARLYFEAHNVPKAPFRNRYESLPAL 
L_infantum      57 GLGVHLSFVRSSTMDGWVKWKPEKLRQMELGGNRRARLYFEAHKVPKTPLKARYESLPAL 
L.major         57 GLGVHLSFVRSSTMDGWVDWKPEKLRQMELGGNRRARLYFEEHKVPNTPLKARYESLPAL 
L.mexicana      57 GLGVHLSFVRSSTMDGWMKWKPEKLRQMELGGNRRARLYFEAHKVPKTPLKARYESLPAL 
T.b.gambiense   53 SLGVHLSFVRSPTMDGWTNWRPEKLRQMQIGGNRRAREYFERNGVPKAPIRERYQSLGAL 
T.congolense    53 SLGVHLSFVRSSTMDGWTNWRPEKLKQMKIGGNRRAREYFERSGVPKAPIAVRYKSLGAL 
T.vivax         61 GLGVHISFVRSATMDGWSNWRPEKLRQMQIGGNRRAREYFERNNVPRTPIRDRYESLGAL 
consensus       61 .****.*****.***** .*.****.**..******* ***.. **. *.. **.** ** 
 
 
T.brucei       113 RYGAMLEAEALGQPFDESSWTPPEWYERMVQSERNRPNGEGMPPQAPQQHRP--INGMWG 
L.braziliense  117 RYADMLESEALDKPFSEAAWQPPAWYARLKAAASPSEG---SPTSAYPQTNPTRFAGHGS 
L_infantum     117 RYADMLESEALGKPFNEASWQPPAWYTRLKAAASLAGP---SPTSSYPQTDPNRFAGVGS 
L.major        117 RYADMLESEALGKPFSEASWQPPAWYTRLQAAASLAGP---FPTSSYPQTDLNRFAGVGS 
L.mexicana     117 RYADMLESEALGRPFNEASWQPPAWYTRLKAAASLSGP---SPTSSYPQTDPSRFAGVGS 
T.b.gambiense  113 RYGAMLEAEALGQPFDESSWTPPEWYERMVQSERNRPNGEGMPPQAPQQHRP--INGMWG 
T.congolense   113 RYASMLEAEALGQPFDEDAWQPPEWYDRMIQNDLKQNEFGGTPPPAPQQHHP--ISGMRG 
T.vivax        121 RYAAMLEAEALGRPFEESSWQPPEWYERMKQTSQ--GGGAVAAPQAPQQHNP--IRGMGP 
consensus      121 **..*** ***..**.*..*.** **.*.. ...  .    .. ..  *  . . .*... 
 
 
T.brucei       171 --EGHGSTGS--GGGKEWLDTLSGGWSVFSKKTKEIAETAGAQARSLITETNVEGVKGTL 
L.braziliense  174 NGQPHAMSG-NSGGGSEWYSALYSGWSTVSQKATELAQHAT----KAVQSADVEGVRTSL 
L_infantum     174 NGQPHVMSG-SSRGDSEWYSALYSGWSAVSQKTAELAQHAT----KAVQSADVEGMRSSL 
L.major        174 NGQPHVMSD-NSEGDREWYSALYSGWSAVSQKTAELAQHAT----KAVQGADVEGMRSSL 
L.mexicana     174 NGHPHVMPG-SGGGDSEWYSALYSGWSAVSQKTAELAQHAT----KAVQSADVEGMRSTL 
T.b.gambiense  171 --EGHGSTGS--GGGKEWLDTLSGGWSVFSKKTKEIAETAGAQARSLITETNVEGVKGTL 
T.congolense   171 --QRDDDIGN--VT-GQWLNKLSDGFSTLSKKTKEMAESAGTQARSLMNEADVSDVKSKL 
T.vivax        177 --DGQQWTGASTEGPSQWLSTIAGGFATLSRKTTELAGAATTQARTLIQETDVEEVKNKL 
consensus      181 ..... ...  ... ..* .....*.. .*.*. *.*..*. .... .....*......* 
 
 
T.brucei       227 ASGWGAISGFATQMSSKLL----NKN------QEDDLSVLSDMTQHVKTAVQDDNQGLVX 
L.braziliense  229 AQRWAGVSATVSTYATDLQQRMAESGRDMNVPGGDEDDGLAHMLHNVRQVQTENGVDNTP 
L_infantum     229 AQKWAGVSATVSTYAADLQQRIAEGG------GRDKDDGLDRMLQNARQAQTESGVDNRA 
L.major        229 AQTWAGVSATVSAYAADLQQRIAEGG------GRDKDDGLDRMLQNAREAQTESSVDNRA 
L.mexicana     229 AQKWAGVSATVSTYAADLQQRIAQGS------ARDNDDGLDRMIQNARQAQRESGVDSSA 
T.b.gambiense  227 ASGWGAISGFATQMSSKLL----NKN------QEDDLSVLSDMTQHVKTAVQDDNQGLVG 
T.congolense   226 ASGWGALTGLATQVSSKLL----NTT------TEDELSVLSDMTQNAKMATEEGTASIDS 
T.vivax        235 ASGWDSVTTFASQLSSKVL----NKG------INESIGNLTEMAQRARRAEQESLNDISQ 
consensus      241 * .*...... ... . . ..... .      . .....*. *..... .. .. ... . 
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T.brucei       277 RNMT-----QSHSEVGNA---AFKGQANP-----------YDGDFQSKKD---------- 
L.braziliense  289 GGQSRYGPVESSSSSSYGPGSRASVQARPIGPTSPESSKVYQGRILMQSACESAPTASVA 
L_infantum     283 AGQTRYGHIEGSS--GDGQGSRVAVQAKPVGPASPESSPVCQGRVLWQSVSASSPAESVT 
L.major        283 AGQTRYGHIEGSR--GNGPGSRIAVQARPVGAASPESSTVYQGRVLRQSASESSPTESVT 
L.mexicana     283 AVQRRYGHIQGSS--GDGPGLGVAVQAKPVGAASLESSTVYQGRVLWQSASASSPTESAT 
T.b.gambiense  277 RNMT-----QSHSEVGNA---AFKGQANP-----------YDGDFQSKKD---------- 
T.congolense   276 NSRF-----ESQ--------------------------------LSSRKA---------- 
T.vivax        285 GRSE-----QANTN---------------------------------------------- 
consensus      301 . ..... . ...  . . .    .......  . ... ....... ...  . .  .   
 
 
T.brucei           ------------------------------------------------------------ 
L.braziliense  349 SSMSPGWGSPARLNHNVTLPPTELKANRPVNPLGGDDGS----APSAAPQLPAKDNCSWE 
L_infantum     341 ASVSSGWGSPTRASPSTALPQTQPTSSRPVNPLGGGGAGGGVSASPPAPQ-STKDEWAWD 
L.major        341 ASASSGWDSPSRASPSAALPQTQPTSSRPVNPLGGDAGGGG--ASPPASQSTKKDEWSWD 
L.mexicana     341 ASVSSGWGSPTRASPSTALPQIQPTTSRPVNPLGGGGGGGGGSSSPPASQLTKKDEWAWD 
T.b.gambiense      ------------------------------------------------------------ 
T.congolense       ------------------------------------------------------------ 
T.vivax            ------------------------------------------------------------ 
consensus      361  . . .. .. .      ..       ........  .         . .   ..   .. 
 
 
T.brucei           ---- 
L.braziliense  405 DENF 
L_infantum     400 NEYF 
L.major        399 NENF 
L.mexicana     401 DENI 
T.b.gambiense      ---- 
T.congolense       ---- 
T.vivax            ---- 
consensus      421  .   
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Appendix 6 
Amino acid sequence alignment of TbGEF1 (OG5_150051) in other kinetoplastids 
T.brucei         1 MQLAPNKTVVDLENRATFMVQLHAFLLQARHVV-----SGTPKGKLQEVXRNVDEWIKEV 
L.braziliense    1 ------------------------------------------------------------ 
L.infantum       1 -MAHHQPTNVEVENKVAFFVQLNALLTRISSVVSSDALSSAQKAKLSDVRSATEAWLKDV 
L.major          1 -MAHHQPTNVEVENKVAFFVQLNALLTRVSSVVSSDALSSAQKAKLSDVRSATEAWLKDV 
T.b.gambiense    1 MQLAPNKTVVDLENRATFMVQLHAFLLQARHVV-----SGTPKGKLQEVLRNVDEWIKEV 
T.congolense     1 MQF-KGQNSADLENRRTFMVQLHAFLLQARHIV-----SGTPKGKLRDILGSIDEWIKEV 
T.cruzi          1 MQRFSQKLAADLENRTAFLVQLRALLTQAQKIL-----QGNQRGKLQELQVGIEEWVREV 
T.vivax          1 MQNREQKAVADVENLDAFLVQLRALLLQARQVA-----RGNQKGRLPELLSGIDNWLKEV 
consensus        1 ..   ... ...... .................     .. ..... ..  ......... 
 
 
T.brucei        56 SLGDATTSSGSASGN--AS-V-------TERT--GGEASGP------LRQGASE-ADTGA 
L.braziliense    1 --------------------------------------------------------MAAS 
L.infantum      60 GVISAPRPFIAAAPPPPPPPT-PLRSSVTETPAAAAPLSETVAASKQQDEEQAEAALTQA 
L.major         60 GIIGAPRPFIAASPPP------PLRSSVTETPAAAAPLSETVAASEQQDEEQAEAALTQA 
T.b.gambiense   56 SLGDATTSSGSASGN--AS-V-------TERT--GGEASGP------LRQGASE-ADTGA 
T.congolense    55 STAEVATPSTTASTH--TS-V-------TEVT--ADETSKT------LQPGAVG-ADETA 
T.cruzi         56 DEVGTPGTSICNPNLEASIELSHNQEQLQE--------GGPVDTNGGVDDNKKNGTP-RS 
T.vivax         56 KQLVGQRRSISEDRADTASGV-ENQEQENERS--KKEVNTCVSKNTSISDGQLCLTDTSH 
consensus       61  .. .   .....     . .       .. .  ... .  .     . ..  . ... . 
 
 
T.brucei        97 AEDPKP-----PPNSSPS--ASPCEDPSPATAVAA--EGDERGQLVHPRPQCGLL-QLSK 
L.braziliense    5 PSTGEGEAISV---VTPSAADDPALAPSSTAAL--GGPSS------STADVTATHELADG 
L.infantum     119 PEAPAAEQATA---TTSSAADGPARASASPATP--GGSST------ATAAVTSTHERADA 
L.major        114 PEAPAAEQATA---TTSSAADGPARASASPATP--GGSST------TTAALTSTHERADG 
T.b.gambiense   97 AEDPKP-----PPNSSPS--ASPCEDPSPATAVAA--EGDERGQLVHPDPNAGFSSDLSK 
T.congolense    96 AAPEATSSESSRLPSKPQ--VEDCSPPTAAAAGSA--EVDGVDRQKGPETIANYSSDLSE 
T.cruzi        107 PLNPTVEASPSPLTTAPPTAQTPHGDELSCSTVGMGNSVSNAAFRGSASSFSAFSSDFEL 
T.vivax        113 ALEPAGA-----VSSSAL--RRPSTDPPSTSAVETTGGTDNAGITEQFGCDSTFSSSLGG 
consensus      121  . ....  .    .... .  .  .... ...  .. ..  .     . ...... ... 
 
 
T.brucei       147 RNLEDLARFLATLFVGTSSENGKLRNIARNAARIVXTRCFSIIDNTLRQVLREVYDDPTA 
L.braziliense   54 RNLVDLVSYLRLLFDSDVPERAKLQAFGKSLVRLLMVRCCSTIIASLQHVVHHTYAGTTT 
L.infantum     168 RKLVGLVSYLRLLFDSDVPERAKLQEFGKSLVRLLMVRCCSTIMASLQHVVHHTYIGTTT 
L.major        163 RKLVGLVSYLRLLFDSDVPERAKLQEFGKSLVRLLMVRCCSTIMASLQHVVHHTYTSTTT 
T.b.gambiense  148 RNLEDLARFLATLFVGTSSENGKLRNIARNAARIVITRCFSIIDNTLRQVLREVYDDPTA 
T.congolense   152 RNVEDLARFIASLFVGAASEDVKLRNVGRNAARITITRCFSILDNVLLQVVDELYNSQTQ 
T.cruzi        167 RNLEDFAEFLSMFFPSGLQELVKLRSIGRNAARLVIVRCFSIITCSLQQVLCQVYGEMHH 
T.vivax        166 NNIEDLAKFLSSLFISGVAESVPLRNVGRNSVRLVGIRSLSIIDNVLQRVVRELYNDSPK 
consensus      181 ..........  .*.. . * ..*....... *....*..*.....*..*....* ...  
 
 
T.brucei       207 NNGGEAGGNGAARRKESNPLFVSLGHDINVCRNTIGICVDTLSGS---TDFPSVRFAVQV 
L.braziliense  114 AEE-------DDAGAALSALFVQLAKEIDVATRALLGCVQLVTASAVSSDAASTRFPVQL 
L.infantum     228 AAEE-----EGDAEAALSALFVQLAKEIDVATKALLGCVRLITSSAVLSEAASARFPVQL 
L.major        223 TAEE-----GDDAEAALSALFVQLAKEIDVATKALLGCVQLITSSAVLSEAASARFPLQL 
T.b.gambiense  208 NNGGEAGGNGAARRKESNPLFVSLGHDINVCRNTIGICVDTLSGS---TDFPSVRFAVQV 
T.congolense   212 EVDVGARDIATERRSERAALFVSFAHDITSCVNAIGSCVNTLTKP---SDFQSVRFATQV 
T.cruzi        227 VAESTMATNGEDNGLPSASFFVPLARDIRVSTNAVMKCLELLTAH---CDVLSMRFAAQV 
T.vivax        226 AGEKKLE--DNEIPKNHSPVFTHLSHDITVATQAILVCLETLAGA---PDFSSVRFAAQV 
consensus      241  ..      . .     ...*. ....* ....... *.. ....   ... *.**..*. 
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T.brucei       264 CIDILKQLRQCVVHFERQFASREIGHIQDMVEATGNGHNGEVRA-AD------------D 
L.braziliense  167 CVDVVKQTRRAQAYLQSRVEREELRQLRAFVMSSGSAARWVEESLEDVDAAQGTIEGKSR 
L.infantum     283 CVDVVKQTRRAQVYFQSRVEREEYHLLRTFVTSSDTAAKSAEGSLEDVDAVHDALESVSP 
L.major        278 CVDVVKQTRRAQVYFQSRVEREEIYLLRTFVTSSDTAAKSAEGLLEDVDAVHDALESVSP 
T.b.gambiense  265 CIDILKQLRQCVVHFERQFASREIGHIQDMVEATGNGHNGEVRA-AD------------D 
T.congolense   269 CIDVLKQLRHTAVHFERRFMSQELRHTREVIGGTAA-HCDNVAH-DT------------R 
T.cruzi        284 CVDILKQLRQCVTLFVYRALRGELRRLRTMGID----AKDRDALLLD------------A 
T.vivax        281 SLDVLKQLRQSAINFEQSLFRREYEYLQSNADLSG--HSGEDMKDVD------------V 
consensus      301 ..*..**.*.  . .. .. . *........  .. . .  .. ...              
 
 
T.brucei       311 EEDRCMAEQRVEELKRLLGPTLLESITHLVGLVRPVVGYLFSIVSVKSXTASEDERTTKS 
L.braziliense  227 DHIAAHVQRRVEVLRQQWGPSLVHSVGNIGDVIEPSVKFLASVAAVRAEGAPAPLVALKK 
L.infantum     343 ERVAAHVLRRVEALRRRWGPSLVHSVRNIGDVIEPSVKFLATVAAVRAEVAPAPLVALKK 
L.major        338 ERVAAHVLRRVEALRRRWGPSLVHSVRKIGDVIEPSVKFLAAVAAVRAEGAPAPLVALKK 
T.b.gambiense  312 EEDRCMAEQRVEELKRLLGPTLLESITHLVGLVRPVVGYLFSIVSVKSATASEDERTTKS 
T.congolense   315 GEARHSAERRAEDLKQRLGPAFLGSITHLMGLLRPVVGFLINVVSIKPSATSEEEKTTKN 
T.cruzi        328 SRVRQSAKTRAKELQLLLGPSLLISIEHLMGIVRPTVRYLMSVVSFKNTVSSQEQQVLKN 
T.vivax        327 ELAERCAKERSTALRSRLGPPFLNSITCLMRLVRHAIQYLVSIISQRVPAPSQEERMLKN 
consensus      361 ....  . .*...*....**... *..............* ......  ... ... .*  
 
 
T.brucei       371 DVVSNLFGFAKWYGRTSHLSRCGDASVDDSV-TLSR------------------S-TEFD 
L.braziliense  287 DAAQDLFSLCEPLTTAA-ATG------GQAGLSKSLSTD----NLA-------AVEETPV 
L.infantum     403 DAAHDLFSLCEPVTVATTAAG------GQPCLAKSLSTC----DSP-------SVVAAPV 
L.major        398 DAAHDLFSLCEPVTA--AAAG------GQASLAKSLSTC----DSP-------SVVAAPV 
T.b.gambiense  372 DVVSNLFGLAKWYGRTSHLSRCGDASVDDSV-TLSR------------------S-TEFD 
T.congolense   375 DAVTNLFGFARWQWRASHLKRHGDPPLDSQS-EASR------------------S-TEVV 
T.cruzi        388 DVCANLFTLAQWVTPALLLRRRRQQSSSEDNLAKEREGDFASGRSPKTVFSLSGSLPELD 
T.vivax        387 DVSANLCVFPQWFSHATHSKQLQSESGGEL----NM------------------S-SSPE 
consensus      421 *   .*.... ........ .    . ..  . ...                  . .... 
 
 
T.brucei       411 DNVPIHSRSHRILCCVLESVLATSFSPEYTACVAQHCGDRAEGQFLAVRLLKDTVSELCE 
L.braziliense  329 SGSSGTPLTWRAAAGEVLTHLGSSFSADYLAAVAGCCGDSNEGQLLATRLLTDMLQRVAA 
L.infantum     446 SASSATPLAWRAAAGEVLIRLGSSFSADYLAAVAACCGDSNEGELLATRLLTDMLKCVAA 
L.major        439 SASSATPLARRAAAGEVLIRLGSSFSADYLAAVAACCGDNNEGELLATRLLTDMLKCVAA 
T.b.gambiense  412 DNVPIHSRSHRILCCVLESVLATSFSPEYTACVAQHCGDRAEGQFLAVRLLKDTVSELCE 
T.congolense   415 DGTDVSQQSYRVVCRVVESVLLTSFSPEFMACMAQHCGDNSEGRILAVRLLRDMVSELVD 
T.cruzi        448 GIEATHTFYYQFVCFVMDSVFPVVFSPEYTACVAQHCGDQNEGQLLAVRVLNDTIVQLAE 
T.vivax        424 QTVSFVPVVEYVASIVVESVLPSSFFPEYISCIAQHCGDRNEGQHLAVHVLQDIVSLLVE 
consensus      481  ... ......... .........*........*..*** .**..**...* *... ... 
 
 
T.brucei       471 GSAAELEYVLRHDNWRKRILDGIFNCVMSLRPSVLDAGLETLRRVVTSCPDCLSTEVGSI 
L.braziliense  389 HDLPLLQCVLQNSRWYRALYNGILNCVASIQPAVLAAGLDALRLLTTTCPEEVGQEVGFL 
L.infantum     506 HDLPLLRCVLLDGRWYRALYGGILNCVSSSQPAVLAAGLDALGLLTTACPVVIGREVGLL 
L.major        499 HDLPLLRCVLLDGRWYRALYDGILNCVSSSQPAVLAAGLDALGLLTTACPVVIGREVGLL 
T.b.gambiense  472 GSAAELEYVLRHDNWRKRILDGIFNCVMSLRPSVLDAGLETLRRVVTSCPDCLSTEVGSI 
T.congolense   475 KDVTEMEYVLRHARWRKRVADGILNCVVSVRASVLDVGLEILQRIVVSCPHHLGTEVGFL 
T.cruzi        508 REMEEFRHLLGCSAWRKRITEGILNCLVSLQPVVLEAGLETLQRIVVGCPESLGSEVGFV 
T.vivax        484 NNIRGLERLLKHARWRKNIVEGILGCILSVNPVVLDTGLDILKKIVVACPNYLGTEIGFL 
consensus      541 ... ... .*....*.... .**..*..*... **..**. *..... **. ...*.*.. 
 
 
T.brucei       531 YCNGIFGLLGSDSTPPFMQRSFLHHIIDTFFQGSA------VSGEAPLLLRCYRRFDLNV 
L.braziliense  449 YSNVVLRLLESPNSPHYVKRTIVLHFITTFMGNSSTLSAGGSRSAIPLTLHMYRLYDLNV 
L.infantum     566 YSNVVLRLLESSNTPQYVKRTIVLHFVTTFMGSGSTLPADGGGGAIPLILHLYRLYDLNV 
L.major        559 YSNVVLRLLESSNTPRYVKRTIVLHFVTTFMGSGSTLPADGGGAAVPLILHLYRLYDLNV 
T.b.gambiense  532 YCNGIFGLLGSDSTPPFMQRSFLHHIIDTFFQGSA------VSGEAPLLLRCYRRFDLNV 
T.congolense   535 YSNGIFGLLESDSTPPFVRRALLHHIIDTFFIKSN------LPGESPL-FQCYRRFDLNI 
T.cruzi        568 YTSGVFGLLESESTPPVMRRSLLRHVISTFFKPTS------VPDEPSLLLRLYRHFDLNV 
T.vivax        544 YTRGVFGLLESDSTPPAVRRSLLHHVNDTLLEVND------TKSEIPLLLHFYHCFDLNI 
consensus      601 *......**.*...*....*....*...*..  ..      . ....*....*...***. 
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T.brucei       585 HWHQLNLIQKVVTVLSRAVCTARPEEFVDIEGPKPRASGTASGSAAGNAEASNESIVYAE 
L.braziliense  509 HAHQLNFIQQLTSALSRIVRAAPKEEFTQDAVVQEQLRLQQEAAV-ALAS---------- 
L.infantum     626 HAHQLNIMQQLTSALSRIVRAAPKEELMQDAVVREQLQIQQEAAPSAVMT---------- 
L.major        619 HAHQLNLMQQLTSALSRIVRAAPKEEFMQDAVVQEQLRIQQEAAPSAVMT---------- 
T.b.gambiense  586 HWHQLNLIQKVVTVLSRAVCTARPEEFVDIEGPKPRASGTASGSAAGNAEASNESIVYAE 
T.congolense   588 HWHQLNIIQQTVVSLAKVVRCAAPDEFDDVEGPKPRKSVTLSGGGVTGSSNE-------R 
T.cruzi        622 QWHQLNVVQQAVATLSKTVRCAAPEDFADEKEVKNDS----------------------- 
T.vivax        598 HWHQLNVVQRAIATLSRAVRCATAEEFVDVDVPNKGATDA-------------------- 
consensus      661 ..****..*.... *...*. * ...... .. .   ..   ..  .  .           
 
 
T.brucei       645 TGGGDSANVTQ--------TVNCAS--FVDDGTVMMQRSVPFLALHGLALVVEILTKQIP 
L.braziliense  558 -AVTTQLDRTQHRPGVVNGTTPSESFSSPGAALNLASLSLPAMALHGLVRIVELLMTQTP 
L.infantum     676 -APAAQLDGAQHRAEVANGTTSSEPSSLVAAALNPASLSLPAMALHGLVRIVELLTTQTP 
L.major        669 -APAAQLDGAQHRTGVGNGTTSSEPSSSTAATLNPASLSLPAIALHGLVRIVELLTTQTP 
T.b.gambiense  646 TGGGDSANVTQ--------TVNCAS--FVDDGTVMMQRSMPFLALHGLALVVEILTKQIP 
T.congolense   641 GGEGGSQNNTQTADGVSKGQPANAG--GLDDGTITMQRSLPFLALHGLSTMVELLAKQIP 
T.cruzi        659 ------------------------------QEITAPRKSLPFLALQGLSLAVELLAVHIP 
T.vivax        638 ---------------------------AATDGGTTARRSLPFLALKGLAAFVEILTQKIP 
consensus      721  . .     ..    .  ..        . ...  . .*.*..**.**  .**.*. ..* 
 
 
T.brucei       695 QN--TGLSNWKPLPRLLNRKKKIEQLRFVEAINSSPIKGLRKLFNIRDEEWQTEADRAIA 
L.braziliense  617 PEEESGRDVLAELPVMTCRESKLKEQQEVDRFNDSPKKAIYKLFSVSAEENAIPDSHADF 
L.infantum     735 PEEESGKDVLASLPAMTCRESKLKEQQEVDRFNAAPKKAIYKLFNVTAEENAIPASHADF 
L.major        728 PEEESGKDVLASLPAMTCRESKLKEQQEVDRFNAAPKKAIYKLFNVTAEDNAIPASHADF 
T.b.gambiense  696 QN--TGLSNWKPLPRLLNRKKKIEQLHFVEAINSSPIKGLRKLFNIRDEEWQTEADRAIA 
T.congolense   699 HN--TGLSNWKPLPRLLNRKRKMEQERIIEAINSSPVKGIRRLFNIKDDEWQTESDSVIA 
T.cruzi        689 RD--GDAVGGKSYPMLRNRDDKMEEQRAVDIINSSPLKGIKKLFGVTDDEMNPGGHMNLA 
T.vivax        671 QS--SNLSCWRPLPRLLNREKKMDEQRTVEIINSSPIKGVRKLFNVTNEEFKTDSDAIMH 
consensus      781  .  .... ....*....*..*..... .. .*..*.*....**................ 
 
 
T.brucei       753 ENNWSHRHIPEPATPQAEEKVQHIAQFLMETPSLNSDAVAEILSYPAVISLQVCRAFMDL 
L.braziliense  677 SSQWEHTLLPPLPSAASAQKVEAVADFLTQISSLNPEAVAEFLTTPEVFPLHVCAAYLRR 
L.infantum     795 SSQWEHTLLPPLTSAA-AAKVEAVADFLNQVSSLNPEAVSEFLTTPEVFPLQVCRTYLRR 
L.major        788 SSQWEHTLLPPLTSTA-AAKVEAVADFLNQVSSLNPEAVAEFLTTPEVFPLQVCRAYLRR 
T.b.gambiense  754 ENNWSHRHIPEPATPQAEEKVQHIAQFLMETPSLNSDAVAEILSYPAVISLQVCRAFMDL 
T.congolense   757 ENNWSHRHIPYPSTPEAEERVRRIAQFLKETPSLSSEAVSDFLSYPAVIPLQVCRAFMDS 
T.cruzi        747 GKNWAHQHIPLPASPAIEEKVRRIVQFLMETPSLNPESVAEFLSHPAVFPLQVCRVFMEA 
T.vivax        729 EKNWSHKHLPSPSTPEIEEKVHRIAQFLLMTPSLNLEAVAEFLSYPAVLPLQVCQVFMDS 
consensus      841 . .*.*...* ..... ...* ....**....**....*...*..*.*..*.**.....  
 
 
T.brucei       813 LPLAGKTLINGLRELFRVVKLPKEGQRIERLIEFFCSAYYKAGSRSCVDTDVFPFASEDA 
L.braziliense  737 LPLAGCSVLEAISELLMRVHLPKEGQRIERLLEYFSAAYYEANRGHGINTDVFPFKSDTA 
L.infantum     854 LPLAGFSVLEAISELLMRVQLPKEGQRIERLLEYFSAAYYEANRGHGIDSDIFPFKSDTA 
L.major        847 LPLAGCSVLEAISELLMCVQLPKEGQRIERLLEYFSAAYYEANRGHGIDSDIFPFKSDTA 
T.b.gambiense  814 LPLAGKTLINGLRELFRVVKLPKEGQRIERLIEFFCSAYYKAGSRSCVDTDVFPFASEDA 
T.congolense   817 LPLAGKSLLQGFQELFSTVKLPKEGQRIERLIEFFCSSYYKAGTEGAVDTDNFPFVSEDA 
T.cruzi        807 LPIAGRSLVEGLRKLFSVVQLPKEGQRIERLIEFFCSAYFKANSVDGIDIETFPFESENA 
T.vivax        789 LPLAGKTLVDGLKELLQVVQLPKEGQRIERLIEFFCSAYYKAGSIEYPDLDIFPFRSEES 
consensus      901 **.**.........*  .*.***********.*.*...*..* .  ......***.*... 
 
 
T.brucei       873 CFIAGIGIIMLNTNLHNPNVSTTKMTAASFYAQMRGCNDNKDFPRRFTDSVFEEVSTRSL 
L.braziliense  797 VFIVVVATVMLNTNIHNPSAG-MRLDVKAFRGQLHRCNEDESFADNFVDDIFYRISRRPL 
L.infantum     914 VFIVVVATVMLNTNIHNPSAG-MRLDVKAFRGQLRRCNDDESFADSFVDDIFDRISTHPL 
L.major        907 VFIVVVATVMLNTNIHNPSAG-MRLDAKTFRGQLCRCNNDESFAGSFVDDIFDRISRHPL 
T.b.gambiense  874 CFIAGIGIIMLNTNLHNPNVSTTKMTAASFYAQMRGCNDNKDFPRRFTDSVFEEVSTRSL 
T.congolense   877 CFIAGIGIIMLNTNLHNPNASSVKMTADSFYSQMRECNNNKGFSRRFTDGIFEEISTRSL 
T.cruzi        867 CFIMGVAIIMLNTNLHNPHAASTKMTDSSFCAQLRGCNEGKDFPERFAKNIFNEIHLHSL 
T.vivax        849 CFIAAIAVIMLNTNLHNPNVSSNKMTAATFHAQLRGCNEGTDFPHHFTSKIFEEISSHSL 
consensus      961 .**......*****.***......... .*..*...**. ..*...*.. .*.......* 
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T.brucei       933 SNVHESMLTE---AKRRGSVVSHMRMDAFFFTSEDRKEAEFNVVRRRLTDETRELLFRSS 
L.braziliense  856 ESIKRIAIDA----TASTEGASRGSFDIFFVSQEEKRQLAFGVEQQRMVSETRQLLKLRT 
L.infantum     973 ESIKSVAADA----NASTDSTSRGPFDMFFVSQEEKRQLAFGVERQRMVSETRQLLKLRT 
L.major        966 ESIKSIAADA----NASTDSTNRGSFDMFFVSQEEKRQLAFGLERQRMVRETQQLLKLRT 
T.b.gambiense  934 SNVHESMLTE---AKRRGSVVSHMRMDAFFFTSEDRKEAEFNVVRRRLTDETRELLFRSS 
T.congolense   937 SNLLDATAVN---AKRCDSMAPHGRMDSLFFTSDDRKEMAFNVARQRIADETRELVFRCS 
T.cruzi        927 SSMKGFWSAGMSSGVRYASVPFPRKMDSIFFSSEERRELAFGVVRQRLLSETRELVYRHS 
T.vivax        909 SSLQALWTGG---GARQGAPSTLGKFDALFFSNDDRRSGENNAVRHRLASETIELIMRYS 
consensus     1021 .... .   .   . . ... .... * .*........... ....*...**..*..... 
 
 
T.brucei       990 RLCED-DGEIREGGDTEQEYWTSVTQDLFLSTWPSLNAVFGAAVDG--NQIPEDALLLYA 
L.braziliense  912 QQDP--------PAPAPDGWWYAVAKDFLLSIWSSVCAVFGPAMYEGATSAPSDVLLQCV 
L.infantum    1029 QQEP--------LAPAPEGWWCAVAKDFFLSTWSSVCAVFGPAMYEGTTAAPSDVLLQCV 
L.major       1022 QQES--------LAPAPEGWWCAVAKDFFLSTWSSVCAVFGPAMYEGTTAAPSDVLLQCV 
T.b.gambiense  991 RLCED-DGEIREGGDTEQEYWTSVTQDLFLSTWPSLNAVFGAAVDG--NQIPEDALLLYA 
T.congolense   994 RLEAGDDGLDLAEGESAQEYWTSVTQDLFLSTWPSLSAVFGAEVEG--HQLPNDALLLYV 
T.cruzi        987 NIIQTQLEE------MKLRDWCCVTRDLFFSTWPSLCAVFGVAGHG--AKVPEEALTLCV 
T.vivax        966 TLETTQDGQ-------TDEFWMSITQDLFLSSWPMLSAAFGTAVQG--EQMPESALLLYI 
consensus     1081 ...   ..     .   ...* ....*...*.*....*.** .. .   ..*...*.. . 
 
 
T.brucei      1047 TGLRSSLLLSAAFGLHTECDAAQMALVRLSAFDSLRDVCHGCLLEVASSRHSVHFSSRCW 
L.braziliense  964 RGLQSLLCTAAAFDLPTECTVTLLTLLRMADATPVRAHCLRAVLAVAATTYAINFPVRCW 
L.infantum    1081 RGLQSLLCMAAAFDLPTECTVTLLTLLRMADATPVREHCRRAVLVVAATTYAVNFPVRCW 
L.major       1074 RGLQSLLCMAAAFDLPTECTVTLLTLLRMADATPVREHCRRAVLVVAATTYAVNFPVRCW 
T.b.gambiense 1048 TGLRSSLLLSAAFGLHTECDAAQMALVRLSAFDSLRDVCHGCLLEVASSRHSVHFSSRCW 
T.congolense  1052 SGLRSSLFLSAAFGLHTECDTSQSALMHLSTFESVRDVCHSCLLEVASSHHSVHFSSRCW 
T.cruzi       1039 MGLRSSFLVATAFGLQTECGVSQLALLRMATFEPMRDVCHKSILEVASSPYSVSFSAPCW 
T.vivax       1017 KGLRSSLLVSAAFGLHNECGVSQAALLRLASIEQLRDLCHSCVLEIASSLHSVHFSSRCW 
consensus     1141 .**.*.... .**.*..** .....*.... ....*..*....*..*..  ...*...** 
 
 
T.brucei      1107 LPVVELLVTIRKEQSQTQXQQSYQQQSQSQQQQRRAILVQMESLFGHLEEITREYCNMSV 
L.braziliense 1024 VAVYQLILEVRCTAAGTAP-------------------PLTEDVFTRIEAITRLSVEAEG 
L.infantum    1141 VAVCQIILEVRRTAAAATP-------------------PLVEDVFTRIEGITRLSVETEE 
L.major       1134 VAVCQIILEVRRTAAAATP-------------------PLVEDVFTRIEGITRLSVETEA 
T.b.gambiense 1108 LPVVELLVTIRKEQSQTQSQQSYQQQSQSQQQQRRAILVQMESLFGHLEEITREYCNMSV 
T.congolense  1112 VPVVELLVSIRKEQNQTQPH-------QMQSQQRRAILVQMESLFAHLEEITREYCNMNV 
T.cruzi       1099 VPVVELLVAIRKQQQ----------------QQQQTMVVESESVFGRVEEFTRESCENDG 
T.vivax       1077 MPVVELLIFVRKEQHQM-------------QQQKRPILVEVESLFTRLEEVTREYCTVSV 
consensus     1201 ..*..... .*... .. .            .... ... .*..*...*..**. ..... 
 
 
 
 
T.brucei      1167 HEAPPVI-------VVAVRELLQGVAALL-RDQGMDFPTLTAALYVVRRVLSYSVISHDQ 
L.braziliense 1065 RRAADASLPKTDRPTEAIHRAIEGIMTTISGYAVGDVANLSSALAVLRRVLEYTRIVHLK 
L.infantum    1182 RRAADDSAPKTDRPTEAIHRAMEGVMTTISGYAVGDVANLSSALAVLRRALEYTRIVHAN 
L.major       1175 RRAADDSAPKTDRPTEAIHRAMEGITTTISGYAVGDVANLSSALAVLRRALEYTRIVHAK 
T.b.gambiense 1168 HEAPPVI-------VVAVRELLQGVAALL-RDQGMDFPTLTAALYVVRRVLSYSVISHDQ 
T.congolense  1165 HEAPPVI-------VVAVRELLQGVSMLL-RDTSGDCPSLTAALYVVRRLLSYSVISHDQ 
T.cruzi       1143 KKATPAVT---SVCKNAVREVLQGISTVL-QDTSVDGETLSAAFYVLRRFLGYSLISHEQ 
T.vivax       1124 QEAPPVI-------AVAVRELLQGIATVL-RDSNVDTASLGAALYVLRRALSYSLLSHDQ 
consensus     1261 ..*....        .*......*. ... ..  .* ..*..*..*.**.*.*....*.. 
 
 
T.brucei      1219 ELGPVVTNLINVRDLSGIVMPALVDVVEARREKGDECLHAVTSFVVDVLSVVWNSCVRDA 
L.braziliense 1125 RTAD-VVYFVNVRDFTAVVVPAYVGLMQKH-SSSDDGLQVLCESLVDLLCTMWASYSTCR 
L.infantum    1242 RRTD-IVYFVNVRDFTAVVAPAYVELMKKH-SSSDDGLQVLFECLVDLLCTMWVSYSTSR 
L.major       1235 RRTD-IVYFVNVRDFTAVVAPAYVELMKKH-SSSDDGLQALFECLVDLLCTMWVSYSTSR 
T.b.gambiense 1220 ELGPVVTNLINVRDLSGIVMPALVDVVEARREKGDECLHAVTSFVVDVLSVVWNSCVRDA 
T.congolense  1217 EMGAVVTNLINARDLSGFIIPALVDVVEAWCDKGDEGLQAITGFAVDVLSVVWNSCVRDA 
T.cruzi       1199 EQGAVVTNFINVRDFSNFIVPTLVDIVEARNGNGDGYMHLVVEFVVDILNTMWGSCICET 
T.vivax       1176 QQGPVVTNFINVRDMCGIVVPALVDVVDMRREAGDDCLQSIMGFAVDVLSIVWNSSVRDG 
consensus     1321 . . ......*.**......*..*...... . .*...... ...**.*...*.*..... 
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T.brucei      1279 N------------CSHQA------VKLTELANCFCFFQMCHERC------VNSSVVQMHM 
L.braziliense 1183 VTVSAPAT--ETGKAETTATLTVDTAPAGFVQSFRCLRSIYEVTLASASDGSATLLQMHI 
L.infantum    1300 VMVPAPAAA-AAGKAETAETPTVDTAPAEFVQSFRFLRSVYDVTLASASEGAATLLQMHT 
L.major       1293 VMVAGPGPAAAGGKAETAETLTVDTAPADFAQSFRFLRSVYDVTLASASDGTATLLQMHT 
T.b.gambiense 1280 N------------CSHQA------VKLTELANCFCFFQMCHERC------VNSSVVQMHM 
T.congolense  1277 N------------STQQV------VSITELTDCFSFFQLCRERC------ANSPVAQMHM 
T.cruzi       1259 K------------L-EGV------ERHSELIKCFTFFQTCYDRY------GASAEVRMHV 
T.vivax       1236 G------------STQQV------IEHRELMECFGFFQVCYVRC------ARSLPVHMHV 
consensus     1381               ....      .  ......* ... .....      . .....**. 
 
 
T.brucei      1315 LQGVKELVSCTVLAESSVKQRTTRGVQTRVSFTMALVWERLLHSVAHALSGKSTVGTETC 
L.braziliense 1241 LQAVKEVLSRTVRAAEVTS-----ADQHLSLYTMMASWQEVLYPLAMALCDRSSTAIEAG 
L.infantum    1359 LQAIKEVLSRTVRTAEMTA-----AGQHLSLYTMMASWQEVLYPLAVALCDRNSTAVEAG 
L.major       1353 LQAIKEVLSRTVRMAEMTP-----AGQHLSLYTMMASWQEMLYPLAVALCDRNSTAVEAG 
T.b.gambiense 1316 LQGVKELVSCTVLAESSVKQRTTRGVQTRVSFTMALVWERLLHSVAHALSGKSTVGTETC 
T.congolense  1313 LQGVKELVACTAFAESSIKSRASRGVSSRTLFDMALVWERLLHSVAHAVSSKSTVDTEMC 
T.cruzi       1294 LQGVKELVARTLHKVGSKKKRAM-GFPSHTLFIMALIWAQLLQPVARALSEKDSLGTETC 
T.vivax       1272 LRGIKELVSRTVLAEGSVRARPH-AIPSDELRTMTLIWQRLLQPVAFALSPKGSADTEAC 
consensus     1441 *...**....*.... ... .   .........*...*...* ..*.*.........*.. 
 
 
T.brucei      1375 SLAVHVLQKLVLICCGAGSVPPSVQMRQEPLNVLLSLLCNVAYVGGMCSDVESAQSCLAQ 
L.braziliense 1296 SLALLVLRKLVALCGGTGTA-SSDQLPGLVRATLLWLLAQLAYMGGMCGDTDSAQVCVAL 
L.infantum    1414 SLALLVLRKLVALCGGTGTA-SSDRLPGPVRAALLWLLAQLAYMGGMCGDADSAQVCVAL 
L.major       1408 SLALLVLRKLVALCGGTGTA-SSDRLPGPVRAALLWLLAQLAYMGGMCGDADSAQVCVAL 
T.b.gambiense 1376 SLAVHVLQKLVLICCGAGSVPPSVQMRQEPLNVLLSLLCNVAYVGGMCSDVESAQSCLAQ 
T.congolense  1373 SLAVHILQKLICISCGTGSSLPSARMRQEPLKVLLSILSNVAYVGGMCSGMESAQSCLSQ 
T.cruzi       1353 SLAVHILRKLVDLCCGTGGTTIGIHLQKKVRSVPLLLLMNVAYIGGMCSDVDSAQSCLAQ 
T.vivax       1331 NLAIHVVRGLVSLSCGTVSSPATIQVRNDVLHVLLLKLMNLAFIGGLCGSVENAQMCLAQ 
consensus     1501 .**......*. ...*...   ........  ..* .* ..*..**.* ....**.*... 
 
 
T.brucei      1435 LSCVCTAALNREVTTSLEAT--------AVT--SDEDDYEVDGLNEVQVQLTRRLLQGIQ 
L.braziliense 1355 LSSICTSTVAMSATAVSSSSPGSSPGGPASPVIAVEDPSTFARRMEQRNALTQQVVASIE 
L.infantum    1473 LSSICTTTVAMSVTAASSSSPGCSTAGPASPVTAVADPSTAARLMEQRNALTQQVVTSIE 
L.major       1467 LSSICTTTVAMSVTAASSSSPWCGAAGPASPVTAVADPSTVARLMEQRNALTQQVVTSIE 
T.b.gambiense 1436 LSCVCTAALNREVTTSLEAT--------AVT--SDEDDYEVDGLNEVQVQLTRRLLQGIQ 
T.congolense  1433 LSFLCTSALSHEPVPLSEGV--------EVT--SDGGDLEVSGANTTQARLTRCLIQNMQ 
T.cruzi       1413 FSTICTSALSQEETVSPEDE--------LPL-LDAADVAEFDPVRESSKFLLQRLIENVR 
T.vivax       1391 FPAISAAAVKQNGIRHTEKN--------CASKEEVGGKYE---PNKPHLKLIEQILEGVQ 
consensus     1561 .........  ...  .. .        . .   ...  ..  ... .  *.....  .. 
 
 
T.brucei      1485 GQDDFTVLHALERICMLLGCHTQETRTEAIGVLXAVSKQLXVRDQKQHLAVQLADTVLQV 
L.braziliense 1415 ENPHYVVHSTLARLCLLLRCEREQTRAEVVRQLRTLSLQLR-PAQLCPMVLDLAEVVLEG 
L.infantum    1533 ENPHYVVQCTLARLCLLLQCEREQTRAEVMHQLRTLSLQMR-PAQLCPMALDLAEVVLEG 
L.major       1527 ENPHYVVQCTLARLCLLLRCEREQTRAEVMHQLRTLSLQMR-PAQLCPMALDLAEVVLEG 
T.b.gambiense 1486 GQDDFTVLHALERICMLLGCHTQETRTEAIGVLRAVSKQLCVRDQKQHLAVQLADTVLQV 
T.congolense  1483 AREDFVVLHVVERMCMMLCCQAQETRAEVISALRVLCRQLKGRDQRQHLVVHMADTILEA 
T.cruzi       1464 QKPDVLVLHALERMSLLLCCHVQQTRTDVITALRALVVQLG-PSQLQHLAVHLSDAVLKA 
T.vivax       1440 SRPNFVLFHLLERLCIMLRCHHQQTRAEVVTVLRTVVKQLKDEEYRQHLAVHVADAVLEC 
consensus     1621  ........ ..*....* *....**....  *.... *.. ......... ... .*.. 
 
 
T.brucei      1545 LLGHTAPGSKSSAN--TPEAAEDVGRVSFAILNLRTPPTMRKCPAVAFHATLPQLLNFMS 
L.braziliense 1474 TIGYAAHHHTTPI--------THSSLTPFLFFELPVPASLRRCFRTSFRTTVPSVLGFLA 
L.infantum    1592 TIGHAAHHRQAPR--------TQSSLIPFLFFQMPVPASMRRCSRTSFRATVPAALGFLA 
L.major       1586 TIGHDACHRDAPH--------TQSSLIPFLFFQMPVPASMRRCSRTSFRATVPAALGFLA 
T.b.gambiense 1546 LLGHTAPGSKSSAN--TPEAAEDVGRVSFAILNLRTPPTMRKCPAVAFHATLPQLLNFMS 
T.congolense  1543 SLDRTTLESNSSVAAVGPAAEVSSWATSFALLNLPTPPTMRKCSAAAFRTTLPQLLNFIS 
T.cruzi       1523 SLGHATPENTSPM--------ADSSFVAHALFSLKTPFNMRRCSPTSFRATLPLVLSFMS 
T.vivax       1500 SIGEAIVPDKEE--------ATFREHLSFLLFEVSAPPTVHKCSPSAFRTTLSPLLNFVL 
consensus     1681 ......    ..         . .. ... ......*.....*. . *..*.. .*.*.. 
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T.brucei      1603 HELIVDASLEDVASLGAVVMERCLLPLAVSPKSSSHVRPLAVRSMMQCATLCVAALGKLS 
L.braziliense 1526 NELLTGLSGDDLATAAESVMRRCLLPIFLSPNSSYQCRFLAVRSLSQCVAVCLPQNNEAP 
L.infantum    1644 NELLTGLSGDDLAMAAESVMRRCLLPILLSPNSPHQCRFIAVRSLSQCVSVCLPQNSAAR 
L.major       1638 NELLTGLSGDDLATAAESVMRRCLLPILLSRNSPHQSRFIAVRSLSQCISVCLPQNSTAP 
T.b.gambiense 1604 HELIVDASLEDVASLGAVVMERCLLPLAVSPKSSSHVRPLAVRSMMQCATLCVAALGKLS 
T.congolense  1603 HDLLADASVEELASLAVIVMERCLLPLAVSRHSSSHMRPLAVRSIMQCAALCVSAVSRLS 
T.cruzi       1575 QEFLTEVPLEYLDSVAAIVMKHCLVPLVVSPRSAFQFRATAVRFLMHCALLCVTRQTIDG 
T.vivax       1552 HDFLLEAPPSCLSALAKVIITRCLLPLTVSPRTPAQTRLLAVRYFTQCADLCIATSLKH- 
consensus     1741 ................ .....**.*. .*.... . * .***....*...*.  ...   
 
 
T.brucei      1663 ESSAARE--------KAAGDRCLNAIINSVSLVLLDTHLFKQSIVPHNAQYVGSRWDAG- 
L.braziliense 1586 LP------------------KLAQCVLDCLAMALYAVRVPLTAVMSPDSSFVGRRWLDQP 
L.infantum    1704 SP------------------QLAQCVLDCLAMALYAVRVPLTSVVSPDTSFVGRRWLDAP 
L.major       1698 SP------------------QLAQCVLDCLAMALYGVRVPLTSVVSPDTSFVGRRWLDAP 
T.b.gambiense 1664 ESSAARE--------KAAGDRCLNAIINSVSLVLLDTHLFKQSIVPHNAQYVGSRWDAG- 
T.congolense  1663 EPLTETE--------KEAVGACLSSITGSVGLVLLSAYIPRELIVPHNTQYVGNQWGTS- 
T.cruzi       1635 RDSCGSKTGSSSSSIISISSSSSNTIAECVSLLLFALRVPVRFIVPDGADHAGRRWVKEE 
T.vivax       1611 -----AL--------DDERRACFSIVLDSIGFILFASHIPMRHVVPQSSDYCGRRWITE- 
consensus     1801  .                   . . ... ....*....... ....  . ..*..*. .  
 
 
T.brucei      1714 LSQML---GAYSKAGRSAIRALSASDXCNITGSRGCVTLSMRMLHEEQVS-EHSKVAP-- 
L.braziliense 1628 TTSAGSGWAVYCAQAAYTMELMDRAEPPWLM--------RGAAAEA---ALST--FGP-- 
L.infantum    1746 AISSASGWAAYCAQATHTVELMDRAEPQWLV--------RGAAAAAAQVALST--LAA-- 
L.major       1740 ATSSASGWAAYCAQATHTVELMDRAEPQWLV--------RGATPAAADAALST--LAA-- 
T.b.gambiense 1715 LSQML---GAYSKAGRSAIRALSASDPCNITGSRGCVTLSMRMLHEEQVS-EHSKVAP-- 
T.congolense  1714 ASPEL---AAYVEAGWGTIEFFSTKEPHDITGSCLCATMRIVGERSEGSSYESRGVAA-- 
T.cruzi       1695 KSAAL---SEYMRKGADAIQALWTAEAYEVTGSRRSATLSGTGKTEANVEP--------- 
T.vivax       1657 KSVQM---AEYAAVGANALNALSSARAFEVTESRSYFTLCIDADE---VKMKHSGIDEMK 
consensus     1861  .  .   ..* . .   ..... ...  .....   .... .    .. . .  ..    
 
 
T.brucei      1768 -----NDLPGKKQGTV-------AGCEEG-----LSSGTDSTVLSDEQLVEYCNLMAPLL 
L.braziliense 1673 ------LPTEELNGVAATQTASRSDCAAS--EEARRT-GGTALFSDDLLIEYVNLLAQVL 
L.infantum    1794 ------TATEERDGAAATPTSSRGGCATS--EETHRAD-GAAFVPDEALIEYVNLLAQML 
L.major       1788 ------TATEERDGAAATPTSSHGGCATS--DETHRARGGAAFVPDEALIEYVNLLAQML 
T.b.gambiense 1769 -----NDLPGKKQGTV-------AGCEEG-----LSSGTDSTVLSDEQLVEYCNLMAPLL 
T.congolense  1769 -----GDPAEDKPGMT-------ADGEAD-----SSTHAEVAVVSDERLIEYCNLMVQLL 
T.cruzi       1743 ---------EEIARTM----------------RSSWSSPFGEVATDEQLVEYCSLMALLL 
T.vivax       1711 CSAAVAEDGEKIVGAM-------DAEQLDYPSANDRDSVAFSAVDDDTLVEYYTLMAQLL 
consensus     1921       .  ... . .       ...         ..  . ....*. *.**..*....* 
 
 
T.brucei      1811 SPLPKVLAAITPAMYTRSERPFS-----GDEGASTTEGCEQPVWWSPPPCNYKLMAELLL 
L.braziliense 1724 AGVPKELQGVVSSAAT-ATGSTAPSAS------AAEVAGASTDDWELPRASAMVLLQLSL 
L.infantum    1845 AGVPKELQGVVASAA-AAAGSATPSAG------AVAVPDMNTDDWKLPRASVTVLLQLCL 
L.major       1840 AGVPKELQGVVANAAAAAAGSATPSAG------AVAVPDMHTDDWKLPRASVMVLLQLCL 
T.b.gambiense 1812 SPLPKVLAAITPAMYTRSERPFS-----GDEGAGTTEGCEQPVWWSPPPCNYKLMAELLL 
T.congolense  1812 PALPKVLDVIVPLLHMGISERQG-------------GQARDQGWWSLPSCNYKVLGDLLL 
T.cruzi       1778 SPLPKVLGAFPPQVFRAKNGDPTPHHSQQQQQQQEEEKLFDAVVWAPPPADHKLLKELVL 
T.vivax       1764 SPLPKMLSDMSNCVLDSDDCASQ-----NPKILEAGNGVQYSENWAPPACNYRLVGELLL 
consensus     1981 ...**.* .... .  .  .  ..         .   .   .. *  *  .......*.* 
 
 
T.brucei      1866 DAEGAFFAVLWRVNHASEMDQFVMQSVTKGREATPLSKSSALLPHTAVRGGLNAYLSLAL 
L.braziliense 1777 QAAGTLFAVLWRINHPHEVEQYALQSVEMRREAQALTRNSGLLPHAAIRNVLQCYLELAM 
L.infantum    1898 QAGGTLFAVLWRVNHPHEVEQYAMQSVESRREALAFTRNSGLLPHAAIRSVLQCYLKLAV 
L.major       1894 QAGGTLFAVLWRVNHPHEVEQYALQSVESRREALAFTRKSGLLPHAAIRSVLQCYLKLAV 
T.b.gambiense 1867 DAEGAFFAVLWRVNHASEMDQFVMQSVTKGREATPLSKSSALLPHTAVRGGLNAYLSLAL 
T.congolense  1859 NASSIFFAAYWRVNHTAEMEHFVTQSVTKGRVAAPINKGSALLPHSAVRGALNAYFSLAL 
T.cruzi       1838 ETTGIFFSILWRVNNVAEMEKFMTRATQKGRDAPSICKSSALLPHAAIRGGLNAFLTLAL 
T.vivax       1819 EAVGTLLCTLWRVNYAMEVGEFVAQPALKGRDASALNRGNVLGPHSGIRGGLNSYLTIVL 
consensus     2041  . .. ....**.*.  *......... ..*.* .... ..*.**...*..*........ 
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T.brucei      1926 QMD---FSHLRHVLVEILEEVAFVQSLSSGSR------------------KPRRTGDSMS 
L.braziliense 1837 LSTEYPSGELLTVTTDIIEGIRQVQAATHAAAPSPPKPSVAVGGGTGAATEATGESSLAA 
L.infantum    1958 LSTEYPSAELLEVTTDIIEGIRQVQAATHAAAPSPSPPSLAVGGGAGAVTAGASSTSLAA 
L.major       1954 LSTEYPSAELLEVTTDIIEGIRQVQAATHAAAPMPSPPSLAVGGGAGAVTAGASNTSLAA 
T.b.gambiense 1927 QMD---FSHLRHVLVEILEEVAFVQSLSSGSR------------------KPRRTGDSMS 
T.congolense  1919 LMD---SARLREVLVEVLRGTALAQSLSSSAR------------------RPRYAGDTLP 
T.cruzi       1898 WVD---IPELRDVFVEILRITATVQKLTLSMR------------------EAQKMVEGAA 
T.vivax       1879 HGD---ISCIRGVLVEILRATATVQAFCLGSR------------------KNQRSTESVT 
consensus     2101 ...   ......*......... .*... ...                  .. ....... 
 
 
T.brucei      1965 DSPVGQQLSPREQQHVRSCNVGMYQELTSVVVHWVKNLMYQLXPET-SALTGQRQSELAD 
L.braziliense 1897 DTASLQRLSPQEQQHVRTCNSGMYQQLAFVLGYLVRLLTGPPTLTAPVAGWARRQEAFKA 
L.infantum    2018 DGASLQRLPPQEQQHVRTCNSGMYQQLSVVLGYLVRLLTGQSTSMASVAGWARRQEAFEA 
L.major       2014 DSASLQRLPPQEQQHVRTCNSGMYQQLSVVLGYLVRLLTGQSTSMASVAGWARRQEAFEA 
T.b.gambiense 1966 DSPVGQQLSPREQQHVRSCNVGMYQELTSVVVHWVKNLMYQLAPET-SALTGQRQSELAD 
T.congolense  1958 DGTASPQLSPRGQQFVRACNVGMYQELSAVVIHWTKNLMSQVQPDT-STLAGEQQKGLAM 
T.cruzi       1937 ETAAMQRPSPLEQQHIRSCNVGMYQELSSVVAHWIRTVVHQTDDMT-SSLAATQRDELRS 
T.vivax       1918 DSVAVQQLSPQEQQLVRNYNMSMYQELTFVVSHWVKCLTFPAGATPLTTRESKRHAELAI 
consensus     2161 ... .. ..*..**..*..*..***.*. *...... .. .    . ... ........  
 
 
T.brucei      2024 VVRDPEVFKGLVQLLTAAGGSIVSTVRDYLTWYIEAQQR--------------------- 
L.braziliense 1957 MALHPQFFASLVSLLTPTAGTLVITVRDYFTWYIAHAQPLQQASGISGTVAGRGSAAGSG 
L.infantum    2078 MALHPQFFSSLVSLLTPTAGMLIITVRDYFAWYIAHAQLPHQASEIAGPVTVSGGAACSG 
L.major       2074 MALHPQFFSSLVSLLTPTAGTLIITVRDYFAWYIAHAQLPHQASEIAGPVTVSGGAACSG 
T.b.gambiense 2025 VVRDPEVFKGLVQLLTAAGGSIVSTVRDYLTWYIEAQQR--------------------- 
T.congolense  2017 VMREPIVFKGLVELLTAAGGDIVTTVHDYLAWYIADHQPQ-------------------- 
T.cruzi       1996 VAGDPEVFSGVVQLLTVAAGAVIVAVRDYLVWYIAAQEHETKQTTE--TFDPDT------ 
T.vivax       1978 VAHHAEVFMGLVRLLVNNAGNIITTIRDYLAWYIDVQQRVNGSQDRGDGYPTDGFHT--- 
consensus     2221 .......* ..* **. ..*... ...**..***. ...    .         .       
 
 
T.brucei           ------------------------------------------------------------ 
L.braziliense 2017 EVVPTSAAQNDEVGAPSAKVTVVNGTHDGNGRALSNYDIKGS------------------ 
L.infantum    2138 EATSTWAAESDEEGPSSSQLTALNGTHDGKGSAFGSYSVNGGGSVKLSYVKAARTLSPKP 
L.major       2134 EVTPTSAAESNEEGPSSSQLTALNGTQDGKGSAIGSYSVNGGGSVKRSDAKAATV-SPVA 
T.b.gambiense      ------------------------------------------------------------ 
T.congolense       ------------------------------------------------------------ 
T.cruzi            ------------------------------------------------------------ 
T.vivax       2035 ----------------SILTTIMQGVNERDGANE-------------------------- 
consensus     2281                 .   . ...  .  .                              
 
 
T.brucei           ---------------------------- 
L.braziliense      ---------------------------- 
L.infantum    2198 STVGMERMCMTEVVSDVAAKSTRNFNSE 
L.major       2193 GR-------------------------- 
T.b.gambiense      ---------------------------- 
T.congolense       ---------------------------- 
T.cruzi            ---------------------------- 
T.vivax            ---------------------------- 
consensus     2341                              
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Appendix 7 
Amino acid sequence of TbGEF2 (OG5_150255) in other kinetoplastids 
T.brucei         1 -----MIGSSAT-------TVSCSNDVCS---RANERWDEDRLAVATHVQSLLVAIRSNE 
L.braziliense    1 ---------------MM----TSSLLAQDLHAALPDGGETERQIVLIHVDNTLLAMRTKN 
L.infantum       1 ---------------MA----SLCASACDVHESLNDSGETDRQMVLIHVDNTLLAMRTSN 
L.major          1 ---------------MA----SLCASACDLHAVLSDSGETDRQMVLIHVDNTLLAMRTSN 
L.mexicana       1 ---------------MA----SVCASACDLHASLSDIGETDRQMVLIHVDNTLLAMRTSK 
T.b.gambiense    1 -----MIGSSAT-------TVSCSNDVCS---RANERWDEDRLAVATHVQSLLVAIRSNE 
T.congolense     1 MGEAFLNGSRSMPQSVEPDGLGLDVVASD---YSAERWGEDRLVIATQVQNLQVTIRSTE 
T.cruzi          1 ---------------MEENG-QVSSLSSS---DGAECWRRDCLVLSNQTQNLLVAIRSNG 
T.vivax          1 ---------------MSPPTT-PTSSMAG---HHVEQWEEDRLILANQVQNLLVTIRSNE 
consensus        1                .     ...  ...      . .. .....  .........*.   
 
 
T.brucei        46 RFGAKARFLGSSDVVEHVLLRRLRALQRKIVTPC-------------------------- 
L.braziliense   42 RINYHSGAVNGRDASDSATTQRLFDLQRRLFAGAVPVPGRISSSSPVHPAPSSKNFPACA 
L.infantum      42 RLNYRSSPLKEKEASEYAVAQELLDLQRRLFAGAVPVPGRTSSSSSVHPSPQGKSNPACA 
L.major         42 RLNYRSGPLKEKEASEYAAAQELLDLQRCLFAGAVPASDRASSSSSVHPTPQGKSNPACA 
L.mexicana      42 RLNYRSGPRKEKEASEYAVAQELHGLQRRLFAGALPVSSRTPSLSSVHPTPQGDSNPACG 
T.b.gambiense   46 RFGAKARFLGSSDVVEHVLLRRLRALQRKIVTPC-------------------------- 
T.congolense    58 RFGAKARFLGSSDVVEHPLLRQLRELERKIMVPS-------------------------- 
T.cruzi         42 KFGANARFANAGRITEHPLLRQLKALQREIMTPA-------------------------- 
T.vivax         42 RFEAKARFLGTSNVQEHPLLRSLEAFQRNIMVPS-------------------------- 
consensus       61 .. ......   ..... ... *....*... ..                           
 
 
T.brucei        80 -------------------LVRPITEEAILLPFCDIWISEEMSYTIIGTAMTSLSNLIDL 
L.braziliense  102 FSAEALPDPMTFDLQDNYATYCEVSEWAILSTFAAVCRSPSTSAVVTGVALTALIDILEF 
L.infantum     102 CSTEALPDLVPLALPDSYSKHGEVSEVAILSAFANVCRSPNTSAVVTGVALTALVDMLDL 
L.major        102 FTTEALPDLVPFFLQDSCAKHAEVSEVAILSAFANVCRSPNTSAVVTGVALTALVDILDL 
L.mexicana     102 FSTEALPGLVPLTLQDNHANHSEVSEVAILSAFANVCRSPNTSAVVTGVALTALVDMLDL 
T.b.gambiense   80 -------------------LVRPITEEAILLPFCDIWISEEMSYTIIGTAMTSLSNLIDL 
T.congolense    92 -------------------LVRPVEEEMILQPFCDIWMSEEMSETVIGVAMMSLSNIIDL 
T.cruzi         76 -------------------LVRYISEEAILRPFCDLYSSEEMGDTIVGVALASLSNLIDL 
T.vivax         76 -------------------TVRCLSEEAIFQPFCDVWMCEDMNDTVIGMGMMSLSSIIDQ 
consensus      121                     .. ..*..*. .*.... ..... ...*.....*. .... 
 
 
T.brucei       121 RCTFITVKGIQRVLELAQRSVGGSEDDLTYEDLLLRKLKLCVSCVKHPCARALPETFFVD 
L.braziliense  162 PCAFVSIDGVYAAIEAASETRAEVHDNASHEMLLSRIFNVYAAALNHPAAVMADGDVHVR 
L.infantum     162 PCAFVSMYGVYAAIEAASETRAEVHDSASHEVLLSRIFSVYVAALNHPAAVMADGGVHVR 
L.major        162 PCAFVSMYGVYAAIEAASETRAEVHDSASHEVLLSRIFSVYVAALNHPAAVMADGGVHVR 
L.mexicana     162 PCAFVSIYGVYAAIEAASETRAEVHDSASHEVLLSRIFSVYVAALNHPAAVMADGDVHVR 
T.b.gambiense  121 RCTFITVKGIQRVLELAQRSVGGSEDDLTYEDLLLRKLKLCVSCVKHPCARALPETFFVD 
T.congolense   133 KCSFITMGGLEKLLLLAQRPVGVSFSDITCEDLLFKKLKMCLSCVRHPRASELPESLFIG 
T.cruzi        117 RCSFITRNGLEMILKIVHGKKGEASDISTYEVVLARTLQLYVSCAGHPCARGLPEDLFIR 
T.vivax        117 RCSFITEKGLGKVLSLAKRSIACAGDEHSYEVLQDRRMQICVSCADHPRAHAVPEGLFVE 
consensus      181 .*.*... *.  .....  ....  .  . *... . . ...... ** *  ... .... 
 
 
 
T.brucei       181 VVRLAFVIAMHPDTSLLLRCIAKEAMKDTATAMYGFIIENISSYNLGQGST-DGVENFQA 
L.braziliense  222 ALGRMIMLATDPEASQLLKRTVEKSMQLIVMTLFRRLLYLPA------------------ 
L.infantum     222 ALGRMMVLATHPEASQLLKRTVEKSMRLIVMTLFRRLLHLPA------------------ 
L.major        222 ALGRMMVLATHPEASQLLKRTVEKSMRLIVMTLFRRLLHLPA------------------ 
L.mexicana     222 ALGRMMVLATHPEASQLLKRTVEKSMQLIVMTLFRRLLHLPV------------------ 
T.b.gambiense  181 VVRLAFVIAMHPDTSLLLRCIAKEAMKDTATAMYGFIIENISSYNLGQGST-DGVENFQA 
T.congolense   193 VLRRAFIITLCPETSLLLRRFAEEVMKETVTVMYRFIVADDLERTAGGASKVVDDDRLKR 
T.cruzi        177 ILRRACKVALHPMVSPLLRRTAEQAMKSIVTSLYTFVVKNRPHSSPLEEKNET---AVNN 
T.vivax        177 AVQRAFMIAVHPRTSLLLRRTTEAAMKKIVTSVYKAVVECNSNKSK---CKYDSLGNYEN 
consensus      241 .. .. .....*. * **... .  *. ....... ..                       
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T.brucei       240 HESCV-DFQLTGVPMLRYVCSLIDGTVSETKE-------------------GRFSPGMFX 
L.braziliense  264 DEAAHGALVAAGVKVLGFISRLISGDIACFDSDGCEVASTVAFGSSEGSAGASASGGNSA 
L.infantum     264 DEDARGALVAAGVTVLRFISRLISGDIACFDNDGHEVASTVAFGGSEGLAGTSASGGSGD 
L.major        264 DEDARGALVAAGVTVLRFISRLISGEIACFDSDGREVASTVAFGGSEGLAGTSASGGSGD 
L.mexicana     264 DEGARGALVAAGVTVLRFISRLISGEIACFDNDGREVASTVALSGSEGLGGTSASGGSGN 
T.b.gambiense  240 HESCV-DFQLTGVPMLRYVCSLIDGTVSETKE-------------------GRFSLGMFV 
T.congolense   253 RERCSKPPPLTGLPMLRYVCGLITGDLSGERE-------------------DESVAGLSL 
T.cruzi        234 EAGEEEESFLTGANMLRYICTLIMGSDNERGS-------------------NSDI----Q 
T.vivax        234 GREPSQEYVPTGVPMLRYMCCLITGAFSEKSG-------------------P-LSKGSNN 
consensus      301 ..      . .*. .*.... **.*..                         . ...    
 
 
T.brucei       280 S--AADSSLIRKVQLEGLHLAQSILFVVKDHLCMPECGNLLYSVQHNLCRALLVAGVGTE 
L.braziliense  324 DKASPVENTIALIQLEGLALVQDCLLLLQHFLSKPLCAPLLDTVQNQLCRALLIAGVGTK 
L.infantum     324 DKTSPLENTITLIQLEGLALAQDCLLLLRCSLSKPLFAPLLDTVQNQLCRALLIAGVGTM 
L.major        324 DKTSPWENTITLIQLEGLALAQDCLLLLRCSLSKPLFAPLLDTVQNQLCRALLIAGVGAT 
L.mexicana     324 DKTLPLENTITLIQLEGLALAQDCLLLLRCSLSKPLFAPLLDTVQNQLCRALLIAGVGTT 
T.b.gambiense  280 S--AADSSLIRKVQLEGLHLAQSILFVVKDHLCMPECGNLLYSVQHNLCRALLVAGVGTE 
T.congolense   294 Q--SGEPSLVAAVQLGGLCLVQCILFVVKDHLCSPRCGDLLFGVRHHLCRALLLAGVSTD 
T.cruzi        271 RSVNKSSPKAAAVQLEGLWLVQAMLLVVNDCLCEPGWEELLHSVQQDLCRALLVTGVSTE 
T.vivax        274 SDLVTASARSAAVQLVGLWLVQAMLFVVKDHLLQPGLRQLLHSVQHDLCRALLVAGVSTD 
consensus      361          .  .**.** *.* .*..... *  *  . ** .*...******..**... 
 
 
T.brucei       338 DIXLLSQIFPTVHTVVKVASFHLLPQTYSFLKVLHLDPLVRIGSDLNTNSTSSRVGS--- 
L.braziliense  384 RTIVLAQALRAIHLVIQGSSKHLIPQIYNFIRVLHLIPLEALTKELADAGASQQGSPADP 
L.infantum     384 RTIVLAQTLRTVHLVMQGSSVHLIPQIYNFIRVLHLNPLEALANELADAGAVQPGSPVGR 
L.major        384 RTIVLAQVLRTVHLVMQGFSEHLIPQIYNFIRVLHLNPLEALANELADAGAAQPRSPVGH 
L.mexicana     384 RIIVLAQALRTVHLVMQGNSEHLIPQIYNFIRVLHLNPLEALANELADAGAGQPGSPVGS 
T.b.gambiense  338 DIALLSQIFPTVHTVVKVASFHLLPQTYSFLKVLHLDPLVRIGSDLNTNSTSSRVGS--- 
T.congolense   352 NIIILSQIFPTVHAVVKMASHHLLPQVFMFIKVLHLDPLARIGNDLNTSSSVSQHAH--- 
T.cruzi        331 NIIVLSLILRTVHIVVKIASIHVVPQTFSFIRVLHLDPIMRMTEELRSGPSSPGRNI--- 
T.vivax        334 NAIVLSQILPTVHIVVKTASTRLLPQTFSFLKALHLDPLIRIANDLRVACSSGGQGQ--- 
consensus      421  ...*.......*.*.. .* ...**.. *...***.*. .....*  . ..         
 
 
T.brucei       395 -----VT--------TSSQRPSPAAQMSVSKMLDLCEKRELILESLVGFCTDANFAVFCY 
L.braziliense  444 SGSPNTGRGSRSLVSSASSGLGNSGRLSVPQLQRMQERRDILLGSLAEFCSDPHFGRFCF 
L.infantum     444 SGSPVASRPPASPVSTASSGHGNSGRLSAQQLQRKQERRDILLESLAEFCSDPRFGSFCF 
L.major        444 SGSPVASRSPASPVSAASTGHGNSGRLSVQQLQRKQEWRDILLESLAEFCSDPRFGSFCF 
L.mexicana     444 SGSPGASRSPASPVSNTSSGHGNTGRLSVQQLQRKQERRDIILESLAEFCSDPRFGIFCF 
T.b.gambiense  395 -----VT--------TSSQRPSPAAQMSVSKMLDLCEKRELILESLVGFCTDANFAVFCY 
T.congolense   409 -----SS--------IPPKQSVSAAQMSVSKMLDLCEKRELILESLVGFCTDASFAAFCY 
T.cruzi        388 -----SS-PSM--ATSPSMPTGSQAHRSITQVMDLYERRELLLESLVEFCGDADFSTFCY 
T.vivax        391 -----VLRSSV--FPLPTIRSTSASQMSLSKILELCERREIILGSLLVFSTDVNFAIFCY 
consensus      481       ..      .. .   .  ...*....... *.*...*.**..*..*  *. **. 
 
 
T.brucei       442 AQYDLSRRFLPLLEHMCSLLVENCFNITNSNVPL---EGXKPGHNGLTNDVEVGTPLTRM 
L.braziliense  504 IHYDLSWRYASLLPQLSQVLADHAYPVFHGDPEEAATATWMQRRGGMAKDRKAAVQRRQQ 
L.infantum     504 IHYDLSWRYASLLPQLYQVLANHVYPVFHGDPEEVATAAWSQRRSGMAGDRKAAAQRRQR 
L.major        504 IHYDLSWRYASLLPQLCQVLASHAYPVFHGDSEEVATAAGSQRRGGMAGDRKAAAQRRQR 
L.mexicana     504 IHYDLSWRYASLLPQLYQVLANHAYPVFHGDPEEVATAAWSQRRGGMAGDRKAAAHRRQR 
T.b.gambiense  442 AQYDLSRRFLPLLEHMCSLLVENCFNITNSNVPL---EGGKPGHNGLTNDVEVGTPLTRM 
T.congolense   456 AQYDLSPHFPPLLEQVCTLLVENCFNISNANMPL---EEGKNDHGAYTADVEVGTSLTRM 
T.cruzi        440 AQYDLSRRFPPLFDRLCAVLVENCFYVVDEDSSS---ALRREERTGVSFDFGAEGFLTQM 
T.vivax        444 TQYDLSRCFLPLLEHICEVLVENCFSMAEDHVGE---GRAGGVRDGFASDPDVTCSLRRA 
consensus      541  .**** .. .*..... .*..... .  ..  .   ..  . . ... *  ..  ...  
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T.brucei       499 DAL-------------------------ALEAIKGLLWQVSQ------------------ 
L.braziliense  564 ATVAADYRRDRRQLSMAARRLSRSTQQTALDGMMNMMFGITLPVIAAGASSSRLSEPDVT 
L.infantum     564 AAAAVDYRRDRRQRSMAARRLPRSTQRTALDATTNMVSGIAIRAIASGALPSTAAESDTT 
L.major        564 AAAAVDYRRDRRQRSMAARRLPRSTQRTALDATTNMVSGIAIRAIASGTLPSRAAESDTT 
L.mexicana     564 AAAAVDYRRDRRQRSMAARRLPRSTQRTSLDATTNMVSGIAIRAIASGALPSRAAESDTT 
T.b.gambiense  499 DAL-------------------------ALEAIKGLLWQVSQ------------------ 
T.congolense   513 DAL-------------------------ALEAIKGLLWQTMN------------------ 
T.cruzi        497 DAL-------------------------ALEAMIGLLRQTSL------------------ 
T.vivax        501 DAL-------------------------ALEIIRGLLWQTSL------------------ 
consensus      601 ...                         .*... ........                   
 
 
T.brucei       516 VAPPQRFHGDSNMAAMINARITEKNMLVELASLFRTNALKSGIPFLLEKAIRLPAGSLKG 
L.braziliense  624 MSAGTASLSSAEVSHLLQHAQKMKDVLNQFAALFEESPIKKGIPFLLEHAIRVPAGAEEE 
L.infantum     624 ICAGSPSTSLAELQRLIQHAQKEKDKLNYFASLFEDSPIKKGIPFLLEHAIRVPAGAEEE 
L.major        624 MGAGSPSTSLAELHRLIQHAQKEKDKLSHFASLFEDSPMKKGIPFLLEHAIRVPAGTEEA 
L.mexicana     624 MGAGSASTSLTELHRLIEHAQKEKDKLNHFASLFEHSPIKKGIPFLLEHAIRVPPGAEEE 
T.b.gambiense  516 VAPPQRFHGDSNMAAMINARITEKNMLVELASLFRTNALKSGIPFLLEKAIRLPAGSLKG 
T.congolense   530 STLHVPVTAQPSLAEAIRSRLAQKRLVLEFASLFRDNAVKCGIPFLLQKAAHVPVGFFKQ 
T.cruzi        514 AVSH-PLPPPAELTSLILSRLEQKKLLMEFASLFRRNAIKEGIPFLLGNATRVPAGSSYR 
T.vivax        518 NVTKSPSASTTSLLPLIESLVERKNQLMEFVSLFRSDAAKHGIPFLLQNALRVPAGSLKN 
consensus      661 .   ... .  ..  ...  . .* .......**.  ..*.******..*...*.*.    
 
 
T.brucei       576 VETGSIGCDVPMLILEEPAGGREVGACLYRLSGLLDKRALGDYLGELGREPPEPDPDEGE 
L.braziliense  684 GSL----KHCTKLVLAEPAGGRELGEALYRLSIVLNKRVLGDYIGEQGRNNPEDAGAA-E 
L.infantum     684 TSL----KHCTKLVLAEPAGGRELGEALYRLSIVLNKRVLGDYIGEQGRNQPEDVAAA-E 
L.major        684 SSL----KHCTKLVLAEPAGGRELGAALYRLSIVLNKRVLGDYIGEQGRNKPENVATA-E 
L.mexicana     684 SSL----KHCTKLVLAEPAGGRELGEALYRLSIVLNKRVLGDYIGEQGRNKPEDVAAA-E 
T.b.gambiense  576 VETGSIGCDVPMLILEEPAGGREVGACLYRLSGLLDKRALGDYLGELGREPPEPDPDEGE 
T.congolense   590 FNFKKPCVDAPLLAIEEPFGGREVGACLHRLSYMLDKRALGDYLGELGREPPPPDPGSGV 
T.cruzi        573 NIFGSGVADTPAFVLVEPAGGREVGACLYYLSDVLDKRALGEYLGELGRELPAPASGEGE 
T.vivax        578 RKNGSA-SSVPPLVLEDPAGGREVGACLQRLSRLLDKRALGEYLGELGREPAAPDAGD-P 
consensus      721           . ... .*.****.*..*..** .*.**.**.*.**.**. ... ..  . 
 
 
T.brucei       636 HYQAALAAWMEDRKDDHLKLGTVRYHQEQLKGFLQSFDFRGKSLLSSIRETAYHMCMPGE 
L.braziliense  739 ------------DATKPPALFSVRFFERQLDGFIHQFVFHNKPLLEAIREMVYLLCLPGE 
L.infantum     739 ------------DATRPAALFSVRFFEEQLDGFIHQFEFHNKPLLDSIREMVFLLCLPGE 
L.major        739 ------------DATVPAALFSVRFFEEQLNGFIHQFEFRNKRLLESIREMVFLLCLPGE 
L.mexicana     739 ------------DATRPAALFSVRFFEEQLDGFIHQFEFHNKPLLESIREMVFLLCLPGE 
T.b.gambiense  636 HYQAALAAWMEDRKDDHLKLGTVRYHQEQLKGFLQSFDFRGKSLLSSIRETAYHMCMPGE 
T.congolense   650 ESQHALAVWADERRNDHMKPGTQRFHEELLEGFLHEFDFRGKSLLSSIREAAFHMCMPGE 
T.cruzi        633 EGAAALAAWESEREKSHLQAGTVRFYEEQLKGFLQEFDYRNKSLLSCIRETAYRMCMPGE 
T.vivax        636 NYATMLAEWEDERSRDHLRPGTERFFKELLYGFLEEFDFRGKSLLSCIRETSYCMCMPGE 
consensus      781      .. .  ..   .. ....*.....* **.. *....*.**..***  . .*.*** 
 
 
T.brucei       696 AQKIDRVMEVFSRTWLEANRGE--------GKDINPFQSEQGPFILGFSLIMLNTDQHSG 
L.braziliense  787 SQKIDRVMESFARHWYQQNVTYREDGTVVKDETINPFHSESGAFVLSFAIIMLNTDQHSG 
L.infantum     787 SQKIDRVMESFAKHWYQQNVTYREDGTLVKDETLNPFHSDSGAFVLSFAIIMLNTDQHSG 
L.major        787 SQKIDRVMESFAKHWYQQNVAYREDGTVIKDETVNPFHSDSGAFVLSFAIIMLNTDQHSG 
L.mexicana     787 SQKIDRVMESFAKHWYQQNLTYREDGTVVKDETINPFHSESGAFVLSFAIIMLNTDQHSG 
T.b.gambiense  696 AQKIDRVMEVFSRTWLEANRGE--------GKDINPFQSEQGPFILGFSLIMLNTDQHSG 
T.congolense   710 AQKIDRVMEAFSKTWLEANRDA--------EKSINPFRSDNGPFILGFSLIMLNTDQHSG 
T.cruzi        693 AQKIDRVMEAFAKIWAKSNFDA--------GKEINPFCSEQGPFILAFSLIMLNTDQHSG 
T.vivax        696 AQKIDRVMEAFSAVWMRANRDA--------GSDVNPFCSEKGPFILSFSLIMLNTDQHSG 
consensus      841 .******** *.. *   *           . ..***.*. *.*.*.*..********** 
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T.brucei       748 KMSKPMTQEDFRRMHRDSDGGSSLPEEYLRAVFEDVKAHPIIMAEMMDXGFSNDVTWRLE 
L.braziliense  847 KVAHQMTKEDFARMNRGIDDGKDIPAAYLGSVYDDVRQHEVVMADMMDRGFANNTTWRLE 
L.infantum     847 KVAQQMKREDFVKMNRGIDDGKDIPAAYLGSIYDDVRQHEVVMAEMMDRGFANDTTWRLE 
L.major        847 KVAQQMKREDFVKMNRGIDDGKDIPAAYLGSIYDDVRQHEVVMAEMMDRGFANDTTWRLE 
L.mexicana     847 KVAQQMKREDFVKMNRGIDDGKDIPVAYLRSIYDDVRQHEVVMAEMMDRGFANSTTWRLE 
T.b.gambiense  748 KMSKPMTQEDFRRMHRDSDGGSSLPEEYLRAVFEDVKAHPIIMAEMMDVGFSNDVTWRLE 
T.congolense   762 KMMTPMTKEDFRRMHRDSDGGNSLPEDFLNAVFDDIRAHPLTMADMMAAGIRNDVTWALE 
T.cruzi        745 KMMKPMKKEDFRRVHRDSDGGNKLPDEFLDRLYDDVKAHPIIMAEMIDAGFSNDVTWALE 
T.vivax        748 KLTTPMTQEDFRRMLRGSDGGNDFPDEFLNLLFDDVKAHPIIMAEMIDVGFTNDVTWALE 
consensus      901 *.  .*..***... *..*.* ..*...*  ...*...*...**.*.. *. *..**.** 
 
 
T.brucei       808 MRPSEAV-E-----------SRKSDPFTRVSMQAVS-----------------PNALESC 
L.braziliense  907 MQPCVSFVHHVLSTKAVLKGAEAMEALSSISSHEPSTAAAAAATVSSTDAAARACDTKSV 
L.infantum     907 MQPCLNFVHHALSAAAEVEKAEAVKALTTISSHELGAATA-AATAGSTVATARMRDPESG 
L.major        907 MQPCLSFVHHALSAAAEAEKAEAVKAPANIPSHELGAATA-AATAGSTVATTRIRDPESG 
L.mexicana     907 MQPCLSFVHHGLSAAAELEKAEPVKTLANIS-YELGAATA-TSTAGSTVGTARILDTKSG 
T.b.gambiense  808 MRPSEAV-E-----------SRKSDPFTRVSMQAVS-----------------PNALESC 
T.congolense   822 IRDRGAH-G-----------GSNMEPFNTLSMRHYL-----------------PDGPTLN 
T.cruzi        805 MRELALSKD-----------VISKDALMRCSMQVTG-----------------SNPKDQA 
T.vivax        808 MQMSLHD-A-----------ADTLETMSRFSMQLSS-----------------MGTEVDG 
consensus      961 ... .               .. .. .. ...  .                      ... 
 
 
T.brucei       839 EVEALRPFILRMIWSYCLTAFGNTLVGC-------------------------------- 
L.braziliense  967 VLQTFDLFLFQSLWKRSLLVFD-------------------------------------- 
L.infantum     966 VLQIFDLLLFQSLWKRSLLVLD-------------------------------------- 
L.major        966 VLQIVDLFLFQSLWKRSLLVFD-------------------------------------- 
L.mexicana     965 VLQIFDLFLFQSLWKRSLLVFD-------------------------------------- 
T.b.gambiense  839 EVEALRPFILRMIWSYCLTAFGNTLVGC-------------------------------- 
T.congolense   853 ASASVQPFIFNMLWMHCLTAFGNTLVVC-------------------------------- 
T.cruzi        837 VAQALHAFVFSSLWNNCLTAFSNTIYMCGISLEQ-------------------------- 
T.vivax        839 YAETLQPFVFRAIWRHCLTAFANALEAHVKLADLAFPVAYVTNGSNANDATDAPRLSDPM 
consensus     1021 ... .  ......*...*... . .                                    
 
 
T.brucei       867 ------------------------------------------------------TKSLFA 
L.braziliense  989 ------------------------------------------------GMLELAVDEVSR 
L.infantum     988 ------------------------------------------------GMLASAVDEVSL 
L.major        988 ------------------------------------------------GMLSSAVDEVSL 
L.mexicana     987 ------------------------------------------------GMLASAVDEVSL 
T.b.gambiense  867 ------------------------------------------------------TKSLFA 
T.congolense   881 ------------------------------------------------------SKTLSS 
T.cruzi        871 --------------------------Y--------------------------------- 
T.vivax        899 HDAADTLETMSRFSMQLSSMGTEVDGYAETLQPFVFRAIWRHCLTAFANALEAHVKLADL 
consensus     1081                                                   .   .  ..  
 
 
T.brucei       873 TQ--KDSTQETGAEGG-DVIPQLATPEYAYNCALDGLCLLAKAARDRGMASVVDRVILTI 
L.braziliense 1001 SI---VATGATVARAVEAAQQQLPAEMATLQSSLRGVCVLARAAHALGLPAVADQCFIGL 
L.infantum    1000 SI---VATGDTIARAVEEAEQQLPAEMAILQSSLRGVCLLARAAHALSLPVVADQCFMGL 
L.major       1000 SI---VATGDTIARAIEEAEQQLPTEMAILQSSLRGVCLLVRAAHALPLPVVADQCFMGL 
L.mexicana     999 SI---VATGDTVARAVEEAEQQLPAEMAILQLSLRGVCLLARAAHALSLPVVADQCFMGL 
T.b.gambiense  873 TQ--KDSTQETGAEGG-DVIPQLATPEYAYNCALDGLCLLAKAARDRGMASVVDRVILTI 
T.congolense   887 SS--LEPTPAVGTEGG-DLTTQLTTPEYAYNCALDGLCLLAKTAKRYCVTPAVDRVLLTI 
T.cruzi        872 ----LMAEGDVELEST-KLDSSLTPAEEAYNVALDGLCFLAKTATMFGVVSAVNHVVLVL 
T.vivax        959 AFPVAYVTNGSNANDA-TDAPRLSDPIYVCNTALAGFCLIAKTSARHGVVNAVDHVILAL 
consensus     1141 .    ...... . .  .   .*   .   . .* *.*.......  ..  ......... 
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T.brucei       930 LSQLPL-DLENVGSTIPQLSTQPSALLCLEKVFRVLDECVHDVLDAWEKLGRLFSNFFLL 
L.braziliense 1058 LKYVVLDDLTNAEEEVRTLYHSVPKLLCMREIFALFVDLYSSLVDSWLPLSRLILDMRLI 
L.infantum    1057 LKYVVMSDLTNAEEEVRALYRSVPKLLCMREIFALLVDIYSSLEDSWLPLSRLILDMQLV 
L.major       1057 LKYVVMSDLTNPEEEVRALYRSVPKLLCMREVFALLVDIHSSLEDSWLPLSRLILDMQFL 
L.mexicana    1056 LKYVVMSDLTNAEEEVRALYRSVPKLLCMREVFALFVDIHSSLADSWLPLSRLILDMQLM 
T.b.gambiense  930 LSQLPL-DLENVGSTIPQLSTQPSALLCLEKVFRVLDECVHDVLDAWEKLGRLFSNFFLL 
T.congolense   944 LSQLPF-DMASVESATLHFAAQPSALLCFEKVIQLVNECTDCVLDAWEKLGHLFANFFLL 
T.cruzi        927 LSQLPL-DMQDANGSLVRLGNQRFSLHCLEKLFCVLHDCMPMVIDAWGELGNFFSKSFLL 
T.vivax       1018 LSQLPL-DAKRSQGLVQRFGHYPFSALCLRGIFDLLRECTQDVMDAWEELGHLLSELFLL 
consensus     1201 *..... *. . .  .  . .    ..*.. .. .. ..   ..*.*  *.... ..... 
 
 
T.brucei       989 GMFSRDVVD------SPETV----------------------TLWAELYANPC------- 
L.braziliense 1118 GLFVEPAQEVGRRGKAKLCGTGRGYSEAVEDSAAEGSLSAPAEPPHALLENTGICADVFA 
L.infantum    1117 GLFAEPAQAAA-RGRPKPRGADDGDAEASDSRAAQRSVSAPTEPLHVLLQDPGIYANVFA 
L.major       1117 GLFVEPAQEAA-RCRPQPRGAGDGDAEASVSRAAQRSVSAPTEPLHVLLQDPGICANVFA 
L.mexicana    1116 GLFVEPAQEAA-RRRSKPCEAGDGDAEASESRAAQRSVSTPAGPLHVLLQDPGICANVFA 
T.b.gambiense  989 GMFSRDVVD------SPETV----------------------TLWAELYANPC------- 
T.congolense  1003 GLFAKGERT------LPQGG----------------------APCAELYVNPG------- 
T.cruzi        986 GVFAKEPNVTSSTSSSTDCT----------------------EVWEELRHNPR------- 
T.vivax       1077 GMFTRDTQA------GSEEG----------------------AIWSELHVRPR------- 
consensus     1261 *.* .  ..          .                       .  .*  ...        
 
 
T.brucei      1014 --------AGAEEIGDTQXDGGWLSTLWGSPNTQNRTKELRLQREQETMERVKALLPTLE 
L.braziliense 1178 PLMAASATESADAERKAPSERSWFSSLFRGSGAPQVSA-VQLSELRDAQGRIGSCIPNMR 
L.infantum    1176 PLSAASAAGDIAAEQKAASERGWFSSLFGGSGALQVST-VQLSELRDALGRIGSCIPNMR 
L.major       1176 PLSAAPAAGDVAAEQKAASERGWFSSLFGGSGAPQVSA-VQLSELRDALGRIVSCIPNMR 
L.mexicana    1175 PLTTASTAGDIAAEQKAASERGWFSSLFGGSGALQVSA-VQLSELRDALGRIGSCIPNMR 
T.b.gambiense 1014 --------AGAEEIGDTQTDGGWLSTLWGSPNTQNRTKELRLQREQETMERVKALLPTLE 
T.congolense  1028 --------AERDEVKDTESDTGWLSALWRAPSNPNRTRELRQQKGQEVLERVKALLPSME 
T.cruzi       1017 --------IVVAGAKRATSEGGWFAALWGSSISSERAK-AQEGEERRAMERVKMLFPTME 
T.vivax       1102 --------SSSFGTKRASSESGWLSALWGSSNPDSARE--QEEEEQRITTHIKAFLPSME 
consensus     1321         .   .  .. .. .*...*....   . .  ... . .... ...  .*... 
 
 
T.brucei      1066 ELLNMIDGLDVDSHGRFFSVLCEEV-----RHKLRQK----------------------- 
L.braziliense 1237 EMLAILQRVVADSHAGH-QFVYSLSAVSSIEEDAAGGGISGGSPAPAEEEGKRGNGHTSG 
L.infantum    1235 RLLSILQRVSADPNAAQ-RCLCSLSAVSSIEEDIAGSSGNGVNSAPAEGEGKKGNGHPSG 
L.major       1235 RLLMILQRVSTDPNAAQ-RCLCSLSAVSSIEEDVAGSGGNDVSSASTEGEGKKENGHPSG 
L.mexicana    1234 RLLTILQRVSADPNAAQ-RCVCSLSAVSSIEEDVAGGGGNGVSPVSAEEEGKKGNGHPSD 
T.b.gambiense 1066 ELLNMIDGLDVDSHGRFFSVLCEEV-----RHKLRQK----------------------- 
T.congolense  1080 ELLEMIDSLKPPSHERVFSALCGEV-----KRKLHGA----------------------- 
T.cruzi       1068 EFLRMIDKLEDKAHLQFFRALCETG-----RMKSKGA----------------------- 
T.vivax       1152 ELLCIIDSISSAGHRMVFRSLCNEV-----KAAISSG----------------------- 
consensus     1381 ..* .....  . ..  .. ..        .  . ..                        
 
 
T.brucei      1098 ---DGGRLSTHLLVLITEIAVRRPAEQTILDRYIKLCQQTASHYFTAHEHLDDADLYRN- 
L.braziliense 1296 LDEASAYAASYELAFICAVVGGAST--------------------PTVLQPEHFAPLTT- 
L.infantum    1294 LDEASAYAASYELAFICAVVGGAAT--------------------TAVLQPAHFASLTT- 
L.major       1294 LDEASAYAASYELAFICAVVGGAAT--------------------TAVLQPAHFASFTT- 
L.mexicana    1293 LDEASAYAASYELAFICAVVGGAST--------------------AAVLQPANVALLTT- 
T.b.gambiense 1098 ---DGGRLSTHLLVLITEIAVRRPAEQTILDRYIKLCQQTASHYFTAHEHLDDADLYRN- 
T.congolense  1112 ---TESTLASHLLVFVTEIVVRRTNEDAEMERFTNLCQQLTSHCFAAVNHTKNCDLRCK- 
T.cruzi       1100 ---ADSYAASYMMLLVTEVAIRRSTDNVVLECYMKLCQQVTSSIFATINQPKNLRSQQSN 
T.vivax       1184 ---SC-SAASCLMILITELAVRRCTEEDILERYGRLCQHVASHFFKVLEELSNSNSSGSN 
consensus     1441    . .................. ..   .. .  ...   .  . .. ..       .  
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T.brucei      1154 N-ISEDGES--SSRLYAP---TTERFGVSFGAGASPASFDFFEEWLTSTTRVVKAVLRAL 
L.braziliense 1335 -------------------RINGLLREVDLHLHDSRASDGVRAYWCTLGNRVVCASLQLM 
L.infantum    1333 -------------------RVSRLLREVDVYLHDTRASDGVRAYWCTLGNRVVCASLQLM 
L.major       1333 -------------------RVSRLLREVDVYLRDTRASDGVRAYWCTLGNRVVCASLQLM 
L.mexicana    1332 -------------------RVSRLLREVDVYLRDTRASDGVRAYWCTLGNRVVCASLQLM 
T.b.gambiense 1154 N-ISEDGGS--SSRLYAP---TTERFGVSFGAGASPASFDFFEEWLTSTTRVVKAVLRAL 
T.congolense  1168 S-VVERGNGAGSGSGYGH---PDEVVGSPLTAVDNPTTDVPDDKWLTATRRVVRAVLRAV 
T.cruzi       1157 NNSCNDGSGSGCNSNKNNTTSAAIEYESSLTEPSQPIRPEAHEYWLSLAIRVVKALLRAF 
T.vivax       1240 N-ITNTGGSS---NI--------QALDISQVELSHQTSRRVFRGWTPATMRLVRAMMRAV 
consensus     1501       .              . .. .. .   .. ... .. .* ... *.*.*..... 
 
 
T.brucei      1208 VCFASNAESRHVFSPLLDLLMAAPPNVFKVAVAADLSLTLLELTQE---A---------- 
L.braziliense 1376 AVHWRGQHGAVAMEQLWACWMRATPSIFALVVAQPVAAFLYDQVVGVGDTENSAGTGEGE 
L.infantum    1374 AVHWRGQHGAVAMEQLWACWMRAAPSTFAFVVARPVAAFLYDQVVVLDEAEKGAGPGEKE 
L.major       1374 AVHWRGQHGAVAMEQLWACWMRAAPSTFAIVVARPVAAFLYDQVVALGEAESGSGSGE-E 
L.mexicana    1373 AVHWRGQHGAVAMEQLWACWMRAAPSTFAVVVARPVAAFLYDQVV-LGEAENGTGPGERE 
T.b.gambiense 1208 VCFASNAESRHVFSPLLDLLMAAPPNVFKVAVAADLSLTLLELTQE---A---------- 
T.congolense  1224 ISFSQGASSRCASLPLFNMLMGASPDVFSVAVAPELSFTLLELAVE---A---------- 
T.cruzi       1217 KHFICHYLQQEVGPQVLDLLTNAPSKVFTSVVAPLLSSTLLELLSE---P---------- 
T.vivax       1288 SRFLRNAESRDASSYVLRTLMTATPSVFGAFVAAELTSGTLELLSW---P---------- 
consensus     1561   . ..     .  ...  .. * ...*...**  ..  ......    .           
 
 
T.brucei      1255 -PRLVNPPYNLSLNGVLSALSLSFTTCPSPVVQKRVQSALSFVVREALYDSLSESDDIVN 
L.braziliense 1436 RDAMQPWACGSEVLVLLAPFAVHATAVSDVAVQRQIGSLLLHVVQQRLYSVADDTESIVS 
L.infantum    1434 RDAMQPWASGSEVLVLLAPFAVHAAAVSDVVVQRQIGSLLLHVVQQRRYSVSDDTESIVS 
L.major       1433 RDAMQPWASGSEVLVLLAPFAVHAAAVSDVVVQRQIGSLLLHVVQQRRYSVLDDTESIVS 
L.mexicana    1432 RDAMAPWASGSEVLVLLAPFAVHAVAVSDAVVQRQIGCLLLHVVQPRRYSVSDDTESIVS 
T.b.gambiense 1255 -PRLVNPPYNLSLNGVLSALSLSFTTCPSPVVQKRVQSALSFVVREALYDSLSESDDIVN 
T.congolense  1271 -PRYFTLG-ALPLSVVISALSQISALCSDAVVQERTQQAFSYIVRQMPYDLSGDNDGIVD 
T.cruzi       1264 -QYLPHVPTHSILVRLLNTLCMMATACSHPLVQWRTRKALTIMVKEEHYDILRDGEDVIN 
T.vivax       1335 -QLFPEVLNSSLLSTVLESLTLAFTTCYKPPVQQNAQKALSIIVKRGLYDALASSEDIVN 
consensus     1621    .   . .. .....  . . ...... .**... .... .*.   *... ... ..  
 
 
T.brucei      1314 VLVTCALQSSRMQEE-YPASA-DTTWPRTNVKPSDVPEQGEL----VESFIGSLVTVCHR 
L.braziliense 1496 LCLSFSVWVRHSRAAGSNAAAGDTPENSATPNTTSKCGSAAATTLPSGASVLEVLTLCGR 
L.infantum    1494 LCLSFSVWMRHSRAAGSSTAVGDTPESNEAALTKAKCGAVATTSLPSGASVAEVLGLCGR 
L.major       1493 LCLLFSVWTRHGRAAGSSTAVGDKPESNEAAFTKAKCGAVATTSLPSGASMAEVLGLCGR 
L.mexicana    1492 LCLSFSVWMRHGRAAGSSTAVGDTPESHEAALTKADCGTVETASLPSGVSVAEVLGLCGR 
T.b.gambiense 1314 VLVTCALQSSRMQEE-YPASA-DTTWPRTNVKPSDVPEQGEL----VEGFIGSLVTVCHR 
T.congolense  1329 ALVACALESSKPKDV-RRYIT-GTPHSSSIAKFPDECADVET----RGTFTDSLAVVCHR 
T.cruzi       1323 ALVTYALESYSEDEE-AVGC----------VANASEVDQGEN----LESIADDVTTICRR 
T.vivax       1394 ALVVCALKLSEIDTG-DTVAGSSVSNPTPLTKSLEASMTDAT----LETFPGILTHVCHR 
consensus     1681 ....... . . . .    .  ...       .   ..  ..     .  ..... .*.* 
 
 
T.brucei      1368 FAINH----ALIDAPADNAKGPAVWIIALKGLSNLVVMSRHSRDRNMALLCLQRCLLDLE 
L.braziliense 1556 NVLLDNTDAAAAGAGGKRGEWCNLWVLVLRSLGALVLCSPDARDSSEAIFCLQRALLDSE 
L.infantum    1554 NVLLDNAGTAAGGAGAERGEWCSLWVFVLRSLGALALCSSDARDGSEAILCLQRALLDSE 
L.major       1553 NVLLDNAGAAAGGAGAKRGEWCSLWVFVLRSLAALALCSTDARDGSEAILCLQRALLDSE 
L.mexicana    1552 NVLLDNADAAPGGTDGGRGEWCRLWVFVLRSLGALALCSSDARDGSEAILCLQRALLDSE 
T.b.gambiense 1368 FAINH----ALIDAPADNAKGPAVWIIALKGLSNLVVMSRHSRDRNMALLCLQRCLLDLE 
T.congolense  1383 LAVEF----ASGGEAGRSACVPQAWATALDGLSTLVVESHQNRHRITALLCLQRCLLDLE 
T.cruzi       1368 LVAAH----DLGSTDNENTEWHRVWIASLRGLCALVVLSRQYRDRSEALLCLQHCLLDSD 
T.vivax       1449 LAAVY----NTHVDESNSLKWRQAWVSSLRGFSALVIMSRQYRDRCSALSEMQCCLLSPE 
consensus     1741  ...     . ... .  ...  .*.  *... .*.. *.  *....*....*..**... 
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T.brucei      1424 IGSLSADTVVLVYENVIFPLVEQTCASPSDSPATLGERCDQNDECQGGHATDKVLPQILP 
L.braziliense 1616 AHSLPFSAVVAVYEDILIPLTERLCVPNARVQTGLRWAGG-NKVALGEKSGAASSFSRGV 
L.infantum    1614 AHDLPSSAVMAVYEDILIPLTERLCAPKARLQTGLQWAGA-RKAALRENSGAAASFSRSV 
L.major       1613 AHDLPSSAVMAVYEDILIPLTERLCAPKARLQTGLQWTGA-RKAASGENSVAAASFSQSV 
L.mexicana    1612 AHDLPSSAVVAVYEDILIPLTERLCAPKARLQTGLQWTGA-RKAASGENNGALASFSGSV 
T.b.gambiense 1424 IGSLSADTVVLVYENVIFPLVEQTCASPSDSPATLGERCDQNDECQGGHATDKVLPQILP 
T.congolense  1439 IELFSEDALMQVYERAIFLLMEKVCALSLDSPATQGHGDTQESVDQVRNPADEIGSTGLP 
T.cruzi       1424 IKRLPVASISLLYEDVVFPLTEQICAPSSAADPAPSRSTK---------TPADTAVNPTS 
T.vivax       1505 NGVLSADTVASLYEEVLFPFTDRLCTSLNGSPVQSSEPLGTERGSEAGFSSADVST-KPV 
consensus     1801  . ..  ... .**..........*..      ..    .  .   .  . .  . .  . 
 
 
T.brucei      1484 KQFSVTSILSSLAPAPPSRRAAQSAAAAAAQRSQGGRDKHREVVDLKCRVVSLLSKVFLH 
L.braziliense 1675 LGGFFRSLLSPASPECGEHGAPTTSVAGTSATSRQSTLSTLVFTEVKCRLLSLVPKVLLR 
L.infantum    1673 LGSLVNSLVSPVSPERNGQGESMASVVGASALSRRSAPPTLVFTEVKCRLLSLVPKVLLR 
L.major       1672 LGSLFNSLVSPASPERNGHGESMAYVGGASALSRRSAPPTLVFTEVKCRLLSLVPKVLLR 
L.mexicana    1671 LGSLFNSLLSPASPERNGHGELMAYVAGASPASRRSTPPTLVFTEVKCRLLSLVPKVLLR 
T.b.gambiense 1484 KQFSVTSILSSLAPAPPSRRAAQSAAAAAAQRSQGGRDKHREVVDLKCRVVSLLSKVFLH 
T.congolense  1499 RQFSVTSILSSLAPAPPPRRALRSGIANGSL--KDANNRRREVLDLRCRVVSLLSSVFLH 
T.cruzi       1475 TQTFVTSLLSSFSPRPTAKVATKNSADPSS---AARERNQIVAIDLKCRVVGLLPKVLLH 
T.vivax       1564 TQSLVTSLFNSLVSAPRSQKAVKGHSVAHL--ERPERFQHHLVIDLRCRLVSLLSKVFLY 
consensus     1861  .. ..*....... .  . .    .....  ..      .. ....**...*...*.*. 
 
 
T.brucei      1544 YAKLMGENPVVLRDLWQRVLGTLCALYTSLSEESGTGLPGGEAATLDVPASNGPRRIGAM 
L.braziliense 1735 YTAALATQPDLLVSLWRQVLGTLYAVYSAYLVIEDAAR-------------DDMGGSIPS 
L.infantum    1733 YTAALTTQPDLLLSLWRRVLGTLYAVHSAYPVIEDAAG-------------HGMGGGSTS 
L.major       1732 YTAALTTQPDLLLSLWRRVLGTFYAVYSAYPVIEDAAG-------------RDMSGGSTF 
L.mexicana    1731 YTAPLTTQPDLLLSLWRRVLGTLYAVYSAYPVMEDAAG-------------RDMGGGSTS 
T.b.gambiense 1544 YAKLMGENPVVLRDLWQRVLGTLCALYTSLSEESGTGLPGGEAATLDVPASNGPRRIGAM 
T.congolense  1557 HAGLL-EEPVVLRRLWQRVLESLSAFYSSVSVRPAESTINGQ------VNSDGASKEDVM 
T.cruzi       1532 YVKSLGETPEVLQELWQRILGTLYALYTAPTESSCNTVT------ADAQDARELRRCNAL 
T.vivax       1622 YVKTLRDKPDVLRELWQRVLGTFSALYAVAPVGRRENN----------NSSGGVSVEHDS 
consensus     1921 . . . ..*..*  **...*....*....  .    .               ..       
 
 
T.brucei      1604 AEDNAVLREAIQEAVKNMIYVLASILVGTGSTLE-------AVEAQQFWTSTKNLLRTFD 
L.braziliense 1782 HDDAMLVQEAVEETVKNMIYVVVSTWNGSSSSIVSGAAGTEQRHAEAFWVAIVQLLQPFA 
L.infantum    1780 HDDAMLVQEAVEETVKNMIYVVASTWQCSSSSTVGSVAGTQQQHAAAFWAAIVRFLQPFS 
L.major       1779 HDDAMLVQEAVEETVKNMIYVVASTWHGSSPSTVGGVTGTQQEHAAAFWAAIVGFLQPFA 
L.mexicana    1778 HDDAMLVQEAVEETVKNMIYVVASTWNGPSLPTVGGATGTQQQHAAAFWAAIVRFLQPFA 
T.b.gambiense 1604 AEDNAVLREAIQEAVKNMIYVLASILVGTGSTLE-------AVEAQQFWTSTKNLLRTFD 
T.congolense  1610 TEEVAVLREAIQESIKNMIHVLVTLTMEPESAMA-------SGDMSLFWATTKSSLSSFD 
T.cruzi       1586 TEEENVLREAIQETIKNMIYVLSATLSEPECEEV-------MQQTPYFWTSTKNLLRTFD 
T.vivax       1672 QEDFVALQEAIQESVKNMIFVLAAVLNESESAVL-------SQHASSIWEHTRSSLHAFN 
consensus     1981  .. ....**..*..****.*....  .. ....         ..  .*  ..  *  *  
 
 
T.brucei      1657 FAEQLLVFIDNLEGT------------------- 
L.braziliense 1842 FSAPLIDFMVQAGLARIEAAADAATALGTVASAG 
L.infantum    1840 FSAPLVDFMVQAGLVRIEAGAEAAIAPDAAAPAG 
L.major       1839 FSAPLVDFMVQAGLVRVEACAEAATAPDTAAPAG 
L.mexicana    1838 FSAPLIDFMVQAGLVRVEAGAEAATAPDTVAPAG 
T.b.gambiense 1657 FAEQLLVFIDNLEGT------------------- 
T.congolense  1663 FVQQLLDYIDTIEEK------------------- 
T.cruzi       1639 FAGPLLAHIDALDG-------------------- 
T.vivax       1725 IEESSLAVVVSLISAQDKECIQASEV-------- 
consensus     2041 . ..........          .            
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Appendix 8 
Amino acid sequence of TbGEF3 (OG5_154690) in other kinetoplastids 
T.brucei         1 ------------------------------------------------------------ 
L.braziliense    1 ------------MGPAPPPELVRRTIEACRVALQEVRRSVDSTVTNAAVKAELRRGVRAA 
L.infantum       1 -MLWPPTTLASRTGPEPPPELVHRALGACRVVLHEVCRRVESTVANAAAKAELRHGVKAA 
L.major          1 ------------MEPEPPPELVQRALAACRVVLHEVSRRVESTVPNAAAKAELLDGVKAA 
L.mexicana       1 MMLLSPTTLAARTGSEPPPELVHRALEACRAVLHEVCRRVESTVENAAVKAELRHGVKAA 
T.b.gambiense    1 ------------------------------------------------------------ 
T.congolense     1 ------------------------------------------------------------ 
T.vivax          1 ------------------------------------------------------------ 
consensus        1                 ...... . . ...  . .. . ..... ... ....  ..... 
 
 
T.brucei         1 ------------------------------------------------------------ 
L.braziliense   49 ESALNTAEQLLTASLHRSGASRRTSA---------------------------------- 
L.infantum      60 ESAVARSERLFAVPPHRKGS-STSGASAGAPPLSNLETQDHAGSGVSSVSAAPHHAKCAR 
L.major         49 ESAVARSERLFAVPPHRKGGSSTKGASAGAPPLSNLETQDHAAAGVSSVSPAPHHTKGAR 
L.mexicana      61 ESAVARSERLLTVPPRRKGA-SASGASAAATPPSNLETQDRARSGRSSVSSVPNHVIGAR 
T.b.gambiense    1 ------------------------------------------------------------ 
T.congolense     1 ------------------------------------------------------------ 
T.vivax          1 ------------------------------------------------------------ 
consensus       61 ....   . .     .. .      .                                   
 
 
T.brucei         1 --------------------------------------MEALLRSLDSLLALVSRGDGGS 
L.braziliense   75 -------------------------------SAPTLHVREDTATLSATTVAQLATNAVGS 
L.infantum     119 STQHAQKSHDAAGRRESMPGATVGASGGTSASAPPHPTKEVIVKRRKTTVALSPTNAVGS 
L.major        109 PTQLTQKSHDAADRRESMPGATVGASGGTSAAAPPLLAKEVIAKGQKTTVALPPTNAVGS 
L.mexicana     120 PTQLTQRSHDAAGRRESMPSATVGASGSTSASAPSLRAKEVIVKRRKTAAELSSTNAVGS 
T.b.gambiense    1 --------------------------------------MEALLRSLDSLLALVSRGDGGS 
T.congolense     1 --------------------------------------MEALLRSVEKLLEQMYRGDSGN 
T.vivax          1 --------------------------------------MESLMRALDSLLKLIGRGD--- 
consensus      121                                 ..    .* ... ........    ... 
 
 
T.brucei        23 FVI----DPEFKQALKQAQSSVGRWR-GGA------------WKSERI----RFVTDSVM 
L.braziliense  104 PVLQSSIASRDDNTSREERHLSNSSLRGGGTVSATRPVGTAMDPAGSPQLCTTLQDAVIW 
L.infantum     179 TALQSSTGAETDDASRAEQHLSNSSLSGGATPSAMRPARTVMYTTDRLPFCTALQSAVVW 
L.major        169 TALQSSTDAEADAASRAGQHLSNTSLSGGATASAMRLVGTAVHTTDRLPFCTELQSAVVW 
L.mexicana     180 TTLQSSTGAEADDASRAEQHISNPSLSGGATASALRPAGTAKYSTDRVTFSTALQSAVVW 
T.b.gambiense   23 FVI----DPEFKQALKQAQSSVGRWR-GGA------------WKSERI----RFVTDSVM 
T.congolense    23 VGV----GHEFKQKIKRTQTSVSKWS-SGA------------WVSERM----RVVNADVM 
T.vivax         20 VSL----DTEFKQALRCAEGCVAKSL-ACV------------ARGHQP----TVTDIPVV 
consensus      181   .... . .. .... .... .... .... .. .   .  . ....   . ....... 
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T.brucei        62 SSVLGALYIKKTRVTEAALPLLQRMIHNNCIQYTTSI-------VLYRAN-GSNSV---- 
L.braziliense  164 SYLLSTFFWKRRKLTKCSITALELLLRVVPVPSEAVTLIVDLAAMGPEGNVGGDGVLEGG 
L.infantum     239 GYVLSAIFWKRRKLTEYTITALELLLRVMPVPSDIVTLIVDPAALSYEGVAGEDGAFKGR 
L.major        229 GYVLSAIFWKRRKLTEYTITALELLLRVMPVPSHIVTLIVDPAALSYEGATGGDGAFKGR 
L.mexicana     240 GYVLSAIFWKRRKLTEYTITALELLLRVMPVPSDIVTLIVDPAALSYEGAARGDGALKGR 
T.b.gambiense   62 SSVLGALYIKKTRVTEAALPLLQRMIHNNCIQYTTSI-------VLYRAN-GSNSV---- 
T.congolense    62 SVVLSALYFKKTRVVEAALPVIQGMLHKSCIPFSAQV-------VLHRGN-GGNIT---- 
T.vivax         59 SVILSALYLKKNRIVDAVLPVLLQLVQSGLIPYDKEV-------ILYQAQ-GNSNV---- 
consensus      241 ...*.....*......... .............. ...... ........ .....  .  
 
 
T.brucei       110 ----------LSCGAAVFEALGDV-LARITDAGLQLTSVEILHD---------------- 
L.braziliense  224 PVSRRSSHVRLYVAAGVYYALSECVLQSFSEPAVQIRALRLLSELITRIPGSPRWSGVGA 
L.infantum     299 RAPRRSGHMLVSVAMGVYCALSECIMQSFSEPAVQTRALRLVTELITSSLVPPRRSEAEA 
L.major        289 CAPRRSGRMLVSVSMGVYCALSECILHSFSEPAVQTRALRLITELITSSLVPPRRSAAGA 
L.mexicana     300 RAPRRSGRVLVSVAMGVYCALSECILQSFSEPAVQTRALRLVTVLITSSPVPPRRSGAGE 
T.b.gambiense  110 ----------LSCGAAVFEALGDV-LARITDAGLQLTSVEILHD---------------- 
T.congolense   110 ----------LPCGAALFEALRDL-LLRVTDSGLQLSSVEILHD---------------- 
T.vivax        107 ----------MVCGCALFQTLCDF-LTRTTDPSAQLTGVEILHD---------------- 
consensus      301    ... .. .. ..... .*.....  ......*.... .......     .. .     
 
 
T.brucei       143 ------------------LVSDDSFPSFTGKCVTRCIQTCCRVALLGASEGARGISRDLL 
L.braziliense  284 GSAGHEVEANGSIVRSSESVTVDMVTCFRGRIAMRVVESCFKAAAEGMQDSVRCEGRVAL 
L.infantum     359 CCAGREGETNSFIARRSDNGTVDVAACFHGDTAVRVIESCLKVAARGMQETARREALLAL 
L.major        349 CCAGREREANTFIARRCNNGTVDVAACFHGHTAIGVIKSCLKVAALGMQETARREALLAL 
L.mexicana     360 CCSGRKGERNSFIAPHPDNGTVDMAACFHGHTAVQVIESCFKVAAGGAQETVRCEALLAL 
T.b.gambiense  143 ------------------LVSDDSFPSFTGKCVTRCIQTCCRVALLGASEGARGISRDLL 
T.congolense   143 ------------------LVSDDTFPSFTGRCVTRCVQTCCRMVLHGLDDGARAISSDLL 
T.vivax        140 ------------------LVSNDGCSSFTGKCVTRCVQVCCQVALQSANEGARAISRDLI 
consensus      361    ..  . .  .     ....*.   *.*.. .. ...*....  ......*. ... . 
 
 
T.brucei       185 PLCVLRVTRTFLESAPT----------DSRSCTFTSLTPLDDYVHDVEPDSKHLPISVEN 
L.braziliense  344 HAAVQRVVYNFVKMRMYKGKVSDPDGCAEARAAFSTDTILSDYTVDVDSNEPYTRINFVP 
L.infantum     419 RAAVQRVVHTFVTMRTYDEVVGGTDGRAQAHSAFSTDTVLADYTTDVDNNEPYTWIHVVL 
L.major        409 RAAVKRVVHTFVTMRTYNEVVGGTDGRAQAHSAFSTDTILADYTTDVDNTEPYTWIHVMP 
L.mexicana     420 RAAMKRVVHTFVTMQAYDEVVVGTDGRAQAHSTFSTDTILADYITDVDSNEPYTWIHVVP 
T.b.gambiense  185 PLCVLRVTRTFLESAPT----------DSRSCTFTSLTPLDDYVHDVEPDSKHLPISVEN 
T.congolense   185 PLCILRVTRAFLESAQS----------DSDACTFTSSTLLDDYMHDVERGAKHVPIKVEG 
T.vivax        182 PLCVFRVTRAFAESAPS----------SDRPCTFASSTLMDDCVSDVEPDAKYTPIVVHD 
consensus      421 .  . ** ..*.. . .   .   .. . ....*...*...*...**.  . ...*...  
 
 
T.brucei       235 NTDPFV--------------EA-------SLGETTGDERA-------------------- 
L.braziliense  404 SDKAEVRLPTGVLTGTLPIVPAATAATLHVGGQTCSVAATQLQRDEEGGSKSGREPTAAP 
L.infantum     479 SDKAEVPLPAPRCTGFSPLEPAATAAAPRSGGEPGGNPATQPPQYREGRSELVSAPAVGT 
L.major        469 SNKAEVSLPASRRTGFSPLEPAATAAAPRSGGEPGGDLATQPPQHTEGPSELVSAPVAAT 
L.mexicana     480 SDKAEVPLPASQRTSLLPLDSAATAVAPRSAGEPGRNAATQPQQHREGRSELVSAPAAAT 
T.b.gambiense  235 NTDPFV--------------EA-------SLGETTGDERA-------------------- 
T.congolense   235 VSDCLM--------------DA-------SLRELPLDDKT-------------------- 
T.vivax        232 IASSLR--------------AS-------TAGSLSDTLAS-------------------- 
consensus      481 . .... ..    .   ..  ....   .....  .. ...     .. .     .  .  
 
 
T.brucei       254 ------------------------------------------AQSLS---H--------- 
L.braziliense  464 SPLSVEQLRCSGDENSG-VVCVSDAQAPSPMHLVSRETPTLSAQLISEGSCLNEGDSGLL 
L.infantum     539 SPQIMKHALRTGDASSSASEQVSNAPAPSPKRPVFREARWPSAQRGHAVPRRNEGSSHVA 
L.major        529 SPQIVKHALHRGDASSSASEQVSNAPAPSPKHPVLGAARWSSAQLEHEAPRRNEGGSHVA 
L.mexicana     540 SPPIMKPVLCTGDRSSSASGQVSSAQAPSPEHPVLGEARRSSTQLGIDAPRCNEGNSHFA 
T.b.gambiense  254 ------------------------------------------AQSLS---H--------- 
T.congolense   254 ------------------------------------------VQFFS---Q--------- 
T.vivax        251 ------------------------------------------QQDGE---L--------- 
consensus      541 ..  .      ..  .     .. . .... . .       ..*  .   . ... .    
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T.brucei       260 -----------------------NSECELFAETTFSSFDYFRSTLNGQIIGSALSSMK-- 
L.braziliense  523 QSPARSQPPGTAAANIATSSLLDVPPSPPPLNLSFDPHKFFPNSVDESLVLDALSTLNAA 
L.infantum     599 HTLARSQPSATAAASAAAATRLDVNPSPSSVNLSFDPHTFFRNSVDESLVLDALSTLSTS 
L.major        589 PTLPRSQPSATAAASAAAATPLRVNPSPSSLNLSFDPHTFFRNSVDESLVLGALSTLNTS 
L.mexicana     600 QTLARSQPSATAAASAAAATPPDVDPSPSSLNLSFDPQALFRKSVDESLVLDALSTLNTS 
T.b.gambiense  260 -----------------------NSECELFAETTFSSFDYFRSTLNGQIIGSALSSMK-- 
T.congolense   260 -----------------------TADGD-TTLSTFSSFDYFRSTLNDQIMRSALSSMR-- 
T.vivax        257 -----------------------TTEELSASKGPFQPLDYFRSSLNEHMIQSALLSMK-E 
consensus      601  .  .... .....  .  .   . .........*.. ..*.... ......**....   
 
 
T.brucei       295 MGRFPDAMKDLLLLIKHTCSLGARTVSGSGSTGEGGPEARARQLALDMLEAVFQALPMAN 
L.braziliense  583 DGALPSSLKDLLMVLRRMCRHASHPCSGT--LSDASNDVRARDLGLWVLECVLDGLPVAN 
L.infantum     659 DGALPSPLKDLLIVLRRMCRYASRPCSGT--PTNANRDVRERDVGLWALECVLDGLPVAN 
L.major        649 DGALPSPLKDLLIVLRRMCRYASRQCSGM--PTHANSDVRKRDVGLWALECVLDGLPVAN 
L.mexicana     660 DGALPSPLKDLLIVLRRMCRHASRPCSGT--PTNANSDVRERDVGLWALECVLDGLPVAN 
T.b.gambiense  295 MGRFPDAMKDLLLLIKHTCSLGARTVSGSGSTGEGGPEARARQLALDMLEAVFQALPMAN 
T.congolense   294 MGKFPDAMRDLLLLIKHTCDLGSRSV------NEGSLEVRARQLALNMLLVVFEALPVAN 
T.vivax        293 KGRFPDPMKDLLLLIKHTCKLGTRSPSASSSTNEANLEIRARQLALEILEKIFQALPEAN 
consensus      661 .*. * ...***..... *..........   .... ..*.* ..*..*... ..**.** 
 
 
T.brucei       355 CCAEHHCATWLSLVITATKYDLTRCLARNLTAVAPASFFASAVRIISLLLQKCHYHLARE 
L.braziliense  641 CEREHRCAKWMSLVLHACKYELLGCIVKNLAMATPFTLFERAVHLLGMLLRKLHYHMARE 
L.infantum     717 CEREHRCATWLSLVLNACKYELLGCIAKNLAMATPFTLFERAVHLLGMLLRKLHYHMARE 
L.major        707 CEQEHRCATWLSLVLNACKYELLGCIAKNLAIATPFKLFERAVHLLGMMLRKLHYHMARE 
L.mexicana     718 CEQEHRCATWVSLVLNACKYELLGCIAKNLAMATPFKLFERAVHLLGMILRKLHYHMARE 
T.b.gambiense  355 CCVEHHCATWLSLVITATKYDLTRCLARNLTAVAPASFFASAVRIISLLLQKCHYHLARE 
T.congolense   348 CSREHPCATWLSLVITASKYDLIRCIGRNLTTVSPASFFTSAVRILSLLLQKCHYHLARE 
T.vivax        353 CNFEHNCATWLSLVLAATKYDLIHCIARNISTVVPASFFTTCVRILTLIMRKCHYHIARE 
consensus      721 *. **.**.*.***. *.**.*..*...*... .* . *...*........* ***.*** 
 
 
T.brucei       415 LHTVLAVMLFPLALSRYSSFSQKHAVVDMVRELLSVPHLCVSLFINYDCNPTFDAGGKYG 
L.braziliense  701 LHTLLGAFLLPLMASQYAGFRQKYVVLSMIKQLFAVPHLCIAFFINYDCSPAFDPGAEYG 
L.infantum     777 LHTLLGAFLLPLMVSQYAGFRQKHAVLSMIRQLFTVPHLCVSFFVNYDCNPAFDPGAEYG 
L.major        767 LHTLLGAFLLPLMVSQYAGFRQKHAVLSMIRQLFTVPHLCVSFFVNYDCNPAFDSGAEYG 
L.mexicana     778 LHTLLGAFLLPLMVSPYAGFRQKHAVLSMIRQLFAVPHLCVSFFVNYDCNPAFDPGAEYG 
T.b.gambiense  415 LHTVLAVMLFPLALSRYSSFSQKHAVVDMVRELLSVPHLCVSLFINYDCNPTFDAGGKYG 
T.congolense   408 LHTLLAVVVFPLAQSRYSSFSQKHAVVDMVRELLDVPHLCISFFINYDCNPTFDAAGKYG 
T.vivax        413 LHTLLAVMVFPLALSKYSSFHQKHAVLNMVRELLNIPHLCISYFINYDCNPAFDASGKYG 
consensus      781 ***.*. .. ** .*.*  *.**..*..*.. * ..****...*.****.*.**... ** 
 
 
T.brucei       475 GMLELMVNFVAEMTFTHLIEP-----DWLSDDQQQLLRSGCASAIHNLVHSLQRWIAEDP 
L.braziliense  761 GMLELLVEYVVKMTFLDHVDENGDVYPWLSFDQQQLLRSECVVVICTLMASLYRWIAEDP 
L.infantum     837 GMLELLVEHVVEMTFLDHVDGNGDAYPWLSSDQQQLLRSECVVVIHTLMTSLYRWIAEDP 
L.major        827 GMLELLVEHVVEMTFLDHVDGNGDAYPWLSSDQQQLLRSECVVVIHTMMTSLYRWIAEDP 
L.mexicana     838 GMLELLVEHVVEMTFLDHVDGNGDAYPWLSSDQQQLLRSECVVVIHTLMTSLYRWIAEDP 
T.b.gambiense  475 GMLELMVNFVAEMTFTHLIEP-----DWLSDDQQQLLRSGCASAIHNLVHSLQRWIAEDP 
T.congolense   468 GMLELIVNFIAEMTYTRLIEP-----DWLTDDQQQLLRSGCASAIHNLVQSLQRWITEDP 
T.vivax        473 GMLEMLVRFVARIMLADHVDT-----EWLSVDQLQLLRGDCVRAIHSVMQSMQRWIAEDP 
consensus      841 ****..*... ......... ... ..**. **.****..*.. *.... *. ***.*** 
 
 
T.brucei       530 DDYSHQQTREVVGQV---LSRLPGDTVSDNRWYDVYRNYSERDVKDG------------- 
L.braziliense  821 REYAESLLCNTQKDAPQRQQQGGGGTIGATESSELYVVNLEADAGVDPHPPLTGDHSATA 
L.infantum     897 RDYAASLQRDHQKGAQQGQQQEGGGTIGATESTELCLDSWESDEVVDPNPLLTASHSATA 
L.major        887 REYAANLQRDHRKGAQRRQQQEGGATIGANKLTELCLESWESDEVANPNPPLKARHSATA 
L.mexicana     898 REYAEGLQRDYQKDAQQGQQQEGGSTIGTTASTELCLNSWESDEVVDPNPLLTVSHSATA 
T.b.gambiense  530 DDYSHQQTREVVGQV---LSRLPGDTVSDNRWYDVYRNYSERDVKDG------------- 
T.congolense   523 EEYSHQQTREVMSQV---LTRLSGDKVVGSHWCEVYRNCWGKDVKDR------------- 
T.vivax        528 KDYSHQQTREYAGQT---IRRLDGIGKDSSQWHEVYHDCWGVSDRGQ------------- 
consensus      901 ..* .. ...  ...   .. ..* ........... . .. ...  . . .   ..... 
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T.brucei       574 -------HRVSERVT---GNNMPVSPIVTDESLFEQQGVERRWSVGYHWKHIHYLLHSKR 
L.braziliense  881 AANGKEGKEGSDNPGESEFDNRKVALTLSAFSGMTLPHWNKRHNVMYHWKHIHYLLHDKR 
L.infantum     957 AASRKEDHKGSNNSGESEVHGRDVALPLDAVSGKALSHWRKNSNVNYHWKHIHYLLHNKR 
L.major        947 PASRKEDHKGSSNSGESEVHGCNVALSLDAVAGMPLPQWGKNGNINYHWKHIHYLLHNKR 
L.mexicana     958 TASRKEDHKGSSNSGENEIHGRNVALPLDAASGTALPHWSKDNNANYHWKHIHYLLHNKR 
T.b.gambiense  574 -------HRVSERVT---GNNMPVSPIVTDESLFEQQGVERRWSVGYHWKHIHYLLHSKR 
T.congolense   567 -------YRSSDKCA---SSQTPVTPVVIDESLLDQPDFERYWGVGYHWKHIHYLLHSKH 
T.vivax        572 -------HRASADRS---SSNAVFSMGAKNELGSGPLRAKKRGSVGYHWKHIHFLLHGKR 
consensus      961  .  .. ...*.. .. .  .  ... . ....  .... .. ...*******.*** *. 
 
 
T.brucei       624 TAQLAVGLINKGQWRQAMSFLKERDYIPAEG---------------EEGWSAFALFLKTY 
L.braziliense  941 IFQEAVQRINAGRWREAKEFLESRGLTTALAPSAGERADPTSVVTGTSSYSLFARFLFEY 
L.infantum    1017 IVQEAVQSINSGHWREAKEFLESRGFMAAVAPSETERADPSSVAPGTSSYALFARFLFEY 
L.major       1007 ILQEAVQGINSGHWREAKAFLESRGFMAAVVPSETERADPASVAPGTSSYALFARFLFEY 
L.mexicana    1018 IVQEAVQSINSGHWREAKEFLESRGFMAAGAPSEAERADPTSVAPGASSYTLFARFLFEY 
T.b.gambiense  624 TAQLAVGLINKGQWRQAMSFLKERDYIPAEG---------------EEGWSAFALFLKTY 
T.congolense   617 MAQHAARLINKGKWRDAMKFLKEREYIPSTNE--------------NECWSAFALFLKTH 
T.vivax        622 TAQAALRLINTGKWRDGMSLLQRRGYIPPEGD--------------DKTWPAFARFLKTY 
consensus     1021 ..*.*...**.*.**..  .*..*..... ...  ..... ..  . .... **.**  . 
 
 
T.brucei       669 EGVERGALCGIFERVLKDKDCDR-VLREYLQHFSYRNVPIDIALRDTTCEFMSWDRPTFE 
L.braziliense 1001 PGISREALSAIFEKVNQKDGASRMLLLEYLHCFDYKDVPIDVALRDTTCKFMSWERPTFE 
L.infantum    1077 PGISRGALCSIFEKVNQKDGVSRMLLQEYLHCFNYTDIPIDVAMRDTTCKFMSWDRPMFE 
L.major       1067 PGISRGALSSIFEKVNREDGVSRMLLQEYLHCFNYTDIPIDVAMRDTTCKFMSWDRPMFE 
L.mexicana    1078 PGISRGALSSIFEKVNQKDGVSRMLLQEYLHCFSYKDIPIDVAMRDTTCKFMSWDRPMFE 
T.b.gambiense  669 EGVERGALCGIFERVLKDKDCDR-ILREYLQHFSYRNVPIDIALRDTTCEFMSWDRPTFE 
T.congolense   663 EGVERGALCGIFERILKDKDCDR-VLKEYLQHFFYKDVPIDIALRDTTCEFMSWDRPTFE 
T.vivax        668 SGVERSALCGIFERVIQKEDCDR-VLREYLQLFSYRNVPIDIALRDTTCEFMSWDRPTFE 
consensus     1081 .*. *.**..***...... . *..*.*** .*.*...***.*.***** ****.**.** 
 
 
T.brucei       728 AQVWVVIQQRFGEVYAAQNPRSISPDDANAMAGVLLFLHTSLHNANVRSSRMTMKDFVRN 
L.braziliense 1061 AKVWETIQECFGNEYANQNPHSITARDADAMAGVLLFLHSNLHNVLMKNERMQMSQFVRD 
L.infantum    1137 AKVWETIQQCFGNEYAKQNPGSITARDADVMAGVLLFLHSNLHNCLVKSSRMQASQFVRD 
L.major       1127 AKVWETIQKCFGNEYARQNPDSITARDADVMAGVLLFLHSNLHNSLVKGSRMQASQFVRD 
L.mexicana    1138 AKVWETIQQCFGNEYARQNPSSITARDADVMAGVLLFLHSNLHNALVKNNRMQVSQFVRD 
T.b.gambiense  728 AQVWVVIQQRFGEVYAAQNPRSISPDDANAMAGVLLFLHTSLHNANVRSSRMTMKDFVRN 
T.congolense   722 AQVWVMIQQRFGEVYASQNPRNITAEDANAMAGVLLFLHTSLHNAHVRSSRMTMKDFVRN 
T.vivax        727 AQVWGMIQQRFGEVYAMHNPHSITPEDANAMAGVLLFLHTSLHNANARTSRMTMKDFVRN 
consensus     1141 * **..**. **  ** .**..*...** .*********. ***......** .  ***  
 
 
T.brucei       788 GNECVAVPFPEDVMCEMYTRVARSKWELDRFQRTPRQAEMEFSSPGLARMLDIYNQQRQQ 
L.braziliense 1121 ANDCLEFPMMVEDLQAIFNRVLQCKWELDTYGRTPQEAGREQTLVRLSTKIKMVRAAQQR 
L.infantum    1197 ANACLEFPMMEEDLQAMFNRVLNCKWELDMYGRTPQQAEKERTLVRLSTKIQMEQAAQQR 
L.major       1187 ANACLEFPMMEEDLQAMFNRVLNCKWELDMYGRTPQQAEKERTLVRLSTKIQMERAAQQR 
L.mexicana    1198 ANACLEFPMMEEDLQAMFNRVLSCKWELDIYGRTPQQAEKERTLVRLSTKIQMERAAQQR 
T.b.gambiense  788 GNECVAVPFPEDVMCEMYTRVARSKWELDRFQRTPRQAEMEFSSPGLARMLDICNQQRQQ 
T.congolense   782 GNECVSVPFPEDVMREMYTRVAQQKWELDKFHRTPRQVELEMATPGIAKIVCMYQQQKQQ 
T.vivax        787 GNECVSVPFPEDVMRDMYNRIAQRKWELDEFQRTPRQIEKDLTAPSFATMVNLYHQQQQQ 
consensus     1201 .*.*.. *  .. ......*. ..***** ..*** ..... .. .. .....    .*  
 
 
T.brucei       848 HVL---SSEQLA------------------PADAV-GETVDAA-----G----------- 
L.braziliense 1181 RQSTANNNTSITNSKGSTVSRGLSPGGG-GGAGAV------ATAATTSKGSLIVDADPEV 
L.infantum    1257 RQSVARNNSSIVNSETTAVP----ASAAAAGSGAVATASVAETHATTCKGYLMFDTDPAA 
L.major       1247 RQSVSNNNSFIVNSDKMAGPAGLSASAAAAGSGAVATASAAETHATTCKEYLILDTDPAA 
L.mexicana    1258 RQSVTNSNSFIVNSEKTAVSAGVSASAAAAGSGAVATASAAETHATTCKDYLMLGTEPAA 
T.b.gambiense  848 HVL---SSEQLA------------------PADAV-GETVDAA-----G----------- 
T.congolense   842 LAS---SGDQAS------------------TAGETTTDVADTT-----A----------- 
T.vivax        847 QEQ---QLSMSA-----------------NGCDETVNDILTSN-----QHF--------- 
consensus     1261 ...   ... . ..            .. ...... ....  . ... . ...   ..   
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T.brucei       870 ------LSHSGS-----------GT---RDASL----EN--------FVGSSGHSDSSLL 
L.braziliense 1234 LYDVLQGTEENDDNLRHTFFSVPGSTAARMIPKAAAVPSPSASLDGRTLQMWSSDDMALL 
L.infantum    1313 LEDVLQGADESDGISGHSPSRAPGTAATTATPKAEIAQNPNASMDSSTLQVWMSDDMGLL 
L.major       1307 LEDALQSEDESDGISGHSPSRAPGTAAATATPKLETAQNPNASMDSSTLQVWMSDDMGLL 
L.mexicana    1318 LADVLQ----SDGISGHSPPRAPGTAAATATRKAEAAQNPNASMDSRTLQVWMSDDMGLL 
T.b.gambiense  870 ------LSHSGS-----------GT---RDASL----EN--------FVGSSGHSDSSLL 
T.congolense   865 ------MSYSYN-----------SH---KTAAL----QS--------SVPLDGDGDSSLL 
T.vivax        873 ----VQSTWASE-----------GA----EQPK----GE--------SNASDISSDTFLL 
consensus     1321 . . .. .  ..    ..    ... . .  ..    ... ....  ........*..** 
 
 
T.brucei       898 DASMLPYTEELETIKSREPYHQRYAELALQCLQRLEREHRVLCGDRGGV--QPYAIPHYA 
L.braziliense 1294 DNTIPAYAEMKDGLKTKEPQHHAFHEAAAVYLQKLESVHRVYCIEGGVYRPQPYISPYYA 
L.infantum    1373 DNTIPTYADNKDTLKTKEEQHHAFREVSAMYLHKLESVHRLYCVEDEAYRPQPYIMPCYA 
L.major       1367 DNMIPTYADSKDTLKTKEEQHHAYREVSAMYLHKLESVHRLYCVEEEAYRPQPYIMPCYA 
L.mexicana    1374 DNTIPTYVDNKDTLKTKEEQHHASREVSAMYLHKLESVHRLYCVEAEAYRPQPYIMPCYA 
T.b.gambiense  898 DASMLPYTEELETIKSREPYHQRYAELALQCLQRLEREHRVLCGDRGGV--QPYAIPHYA 
T.congolense   893 DAPMLPYTEGSDVVKCRESYHQRYLDLALRLLQRLECEHRVLYADRGGV--QPYAVPHYA 
T.vivax        902 DAQLLPYSTQPEGFKLRELYHQRYVELSIKHLHRLEQEHRWLQIEPGVF--QPYIVPHYA 
consensus     1381 * .. .*.. ....*..*  *  .... ...* .**. **. ... .....***..*.** 
 
 
T.brucei       956 QHVRPMLLSLYPQIAATIYKGLRVLEVQPILRLLHDTYSMLDDLVAAFAVNLTGMHVAVE 
L.braziliense 1354 EHVRQILLLTYPHVMSCVYMGFRVLKEAPISRKLLDTVQVTYDIAAAFVLNLHDLRPAME 
L.infantum    1433 EHVRQMLLLTYPHVMSCVYMGFRVLEEAPIARKLLDTVQITYDIAAAFVLNLRDLRPVME 
L.major       1427 EHVRQMLLLTYPHVMSSVYMGFRVLEEAPIARKLLDTVQITYDIAAAFVLSLHDLRPVME 
L.mexicana    1434 EHVRQMLLLTYPHVMSCVYMGFRVLEEAPIARTLLETVQITYDVAAAFVLNLCDLHPLME 
T.b.gambiense  956 QHVRPMLLSLYPQIAATIYKGLRVLEVQPILRLLHDTYSMLDDLVAAFAVNLTGMHVAVE 
T.congolense   951 QHVRPMLLNLYPQILATVYKGFRVVEVQPILRLLHDTYRMLDDLVAAFAVDLMGLHAEAE 
T.vivax        960 QHVRPMLLMLYPTIAAAAYMGFRVQDGQPILRLLHDTYRILFDVAAALQLSLVGMQTEVV 
consensus     1441  *** .**. **... ..*.*.**... **.*.* .* .. .*..**....*  ... .. 
 
 
T.brucei      1016 KRIQYYMLRGGTRHLPPPTRATFALPLMNLV 
L.braziliense 1414 EALQRYLDDKRVYRLLPQSRATFVPFFLNVL 
L.infantum    1493 EALQRYLDDERAYRLLPSSRATFVPFLLNVL 
L.major       1487 EALQRYLNDERAYRLLPSSRSTFVSFLLNVM 
L.mexicana    1494 EVLQRYLDDERAYRLLPSSRATFVPFLLNVL 
T.b.gambiense 1016 KRIQYYMLRGGTRHLPPPTRATFALPLMNLV 
T.congolense  1011 KMIQHYM-KGETQRFSPPTRASFTLPLMNMI 
T.vivax       1020 QEIERCMLEEGSKELPPPGRAAFVLPLMSLV 
consensus     1501 . ..... ........*..*..*.. ..... 
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Appendix 9 
List of compounds, their structure and the pathogen screened for that showed inhibitory effect 
in bloodstream form T. brucei at 1 M. Data obtained from Pathogen Box 
(www.pathogenbox.org/) 
Compound Structure 
Pathogen 
screened 
1A6 
 
Kinetoplastids 
1E5 
 
Kinetoplastids 
1G5 
 
Kinetoplastids 
2B3 
 
Kinetoplastids 
2C2 
 
Kinetoplastids 
2D3 
 
Reference 
compound 
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2H2 
 
Kinetoplastids 
3B10 
 
Kinetoplastids 
3B11 
 
Kinetoplastids 
3C10 
 
Kinetoplastids 
3D5 
 
Tuberculosis 
3G6 
 
Tuberculosis 
4B9 
 
Kinetoplastids 
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4C8 
 
Kinetoplastids 
4E10 
 
Kinetoplastids 
4G8 
 
Kinetoplastids 
4H3 
 
Malaria 
5B10 
 
Kinetoplastids 
5H10 
 
Kinetoplastids 
 
 
 
